Sentence,class,file
"2012, 8    http://www.biolsci.org  1209  stroma.",Non-OADS,/arxiv_data1/oa_pdf/b0/c6/ijbsv08p1206.PMC3491428.pdf
"2012, 8    http://www.biolsci.org  1210    Figure 2.",Non-OADS,/arxiv_data1/oa_pdf/b0/c6/ijbsv08p1206.PMC3491428.pdf
"2012, 8    http://www.biolsci.org  1211    Figure 3: Plasma membrane conjunction of CK -19-positive cells and elongated cells with D2 -40 expression.",Non-OADS,/arxiv_data1/oa_pdf/b0/c6/ijbsv08p1206.PMC3491428.pdf
"2012, 8    http://www.biolsci.org  1212    Figure 5.",Non-OADS,/arxiv_data1/oa_pdf/b0/c6/ijbsv08p1206.PMC3491428.pdf
"2012, 8    http://www.biolsci.org  1213    Figure 6.",Non-OADS,/arxiv_data1/oa_pdf/b0/c6/ijbsv08p1206.PMC3491428.pdf
"2012, 8    http://www.biolsci.org  1214    Figure 7.",Non-OADS,/arxiv_data1/oa_pdf/b0/c6/ijbsv08p1206.PMC3491428.pdf
"2012, 8    http://www.biolsci.org  1215  node -positive cases, the presence or absence of these  structures within the primary tumor may represent a  reliable predictor for the metastatic potential of a  given CRC.",Non-OADS,/arxiv_data1/oa_pdf/b0/c6/ijbsv08p1206.PMC3491428.pdf
"2012, 8    http://www.biolsci.org  1216  38.",Non-OADS,/arxiv_data1/oa_pdf/b0/c6/ijbsv08p1206.PMC3491428.pdf
"2012, 8      http://www.biolsci.org  1217  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(8):1217-1224. doi: 10.7150/ ijbs.5109   Review  Thyroid Hormone Regulation of Adult Intestinal Stem Cell Development:  Mechanisms and Evolutionary Conservations    Guihong Sun1, Yun- Bo Shi2  1.",Non-OADS,/arxiv_data1/oa_pdf/71/e5/ijbsv08p1217.PMC3491429.pdf
"2012, 8    http://www.biolsci.org  1218  self-renewed every 2 weeks or so [4].",Non-OADS,/arxiv_data1/oa_pdf/71/e5/ijbsv08p1217.PMC3491429.pdf
"2012, 8    http://www.biolsci.org  1219    Fig.",Non-OADS,/arxiv_data1/oa_pdf/71/e5/ijbsv08p1217.PMC3491429.pdf
"2012, 8    http://www.biolsci.org  1220  transgenic frog line expressing GFP ubiquitously.",Non-OADS,/arxiv_data1/oa_pdf/71/e5/ijbsv08p1217.PMC3491429.pdf
"2012, 8      http://www.biolsci.org  1221    Fig.",Non-OADS,/arxiv_data1/oa_pdf/71/e5/ijbsv08p1217.PMC3491429.pdf
"2012, 8    http://www.biolsci.org  1222  villus.",Non-OADS,/arxiv_data1/oa_pdf/71/e5/ijbsv08p1217.PMC3491429.pdf
"2012, 8    http://www.biolsci.org  1223  13.",Non-OADS,/arxiv_data1/oa_pdf/71/e5/ijbsv08p1217.PMC3491429.pdf
"2012, 8    http://www.biolsci.org  1224  64.",Non-OADS,/arxiv_data1/oa_pdf/71/e5/ijbsv08p1217.PMC3491429.pdf
"2012, 9      http://www.medsci.org  738  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):738-742. doi: 10.7150/ ijms.5042   Research Paper   Clinical Efficacy of C ervical Length and Volume for P rediction of L abor  Onset in VBAC C andidates   Yun Sung Jo, Gui Se Ra Lee,  Narinay Kim, Dong Gyu Jang, Sa Jin Kim, and Young Lee   Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Korea .",Non-OADS,/arxiv_data1/oa_pdf/1e/08/ijmsv09p0738.PMC3491431.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/1e/08/ijmsv09p0738.PMC3491431.pdf
"2012, 9    http://www.medsci.org  739  sonographic evaluations of women’s cervixes were  performed between 36 –  40 gesta tional weeks.",Non-OADS,/arxiv_data1/oa_pdf/1e/08/ijmsv09p0738.PMC3491431.pdf
"2012, 9    http://www.medsci.org  740    Figure 2.",Non-OADS,/arxiv_data1/oa_pdf/1e/08/ijmsv09p0738.PMC3491431.pdf
"2012, 9    http://www.medsci.org  741    Figure  3.",Non-OADS,/arxiv_data1/oa_pdf/1e/08/ijmsv09p0738.PMC3491431.pdf
"2012, 9    http://www.medsci.org  742  3.",Non-OADS,/arxiv_data1/oa_pdf/1e/08/ijmsv09p0738.PMC3491431.pdf
"2012, 9      http://www.medsci.org  743  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):743-747. doi: 10.7150/ ijms.4862   Research Paper   A Two-Step Control of Secondary Splenic Pedicles Using Ligasure during  Laparoscopic Splenectomy   Bai Ji,  Yahui Liu, Ping Zhang, Yingchao Wang, Guangyi Wang  Department of Hepatobiliary and Pancreatic Surgery, the First Bethune Hospital, Jilin University, Jili n 130021, China.",Non-OADS,/arxiv_data1/oa_pdf/33/87/ijmsv09p0743.PMC3491432.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/33/87/ijmsv09p0743.PMC3491432.pdf
"2012, 9    http://www.medsci.org  744  den compared to conventional ligation method , which  compromise the otherwise intrinsic superiorities of  LS8.",Non-OADS,/arxiv_data1/oa_pdf/33/87/ijmsv09p0743.PMC3491432.pdf
"2012, 9    http://www.medsci.org  745  Laparoscopic Mobilization of Spleen    Laparoscopy was performed through the ant e- rior approach.",Non-OADS,/arxiv_data1/oa_pdf/33/87/ijmsv09p0743.PMC3491432.pdf
"2012, 9      http://www.medsci.org  746  Results    Out of 105 patients, 103 (98.1%) underwent  successful LS.",Non-OADS,/arxiv_data1/oa_pdf/33/87/ijmsv09p0743.PMC3491432.pdf
"2012, 9    http://www.medsci.org  747  6.",Non-OADS,/arxiv_data1/oa_pdf/33/87/ijmsv09p0743.PMC3491432.pdf
"2012, 9      http://www.medsci.org  748  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):748-756. doi: 10.7150/ ijms.5081   Research Paper   THRB  Genetic Polymorphisms Can Predict Severe Myelotoxicity after D e- finitive Chemoradiotherapy in P atients with E sophageal Squamous Cell  Carcinoma   Ikuya Miki1,2, Tsutomu Nakamura3,4, Akiko Kuwahara3,5, Motohiro Yamamori3,5, Kohshi Nishiguchi3,6,       Takao Tamura1, Tatsuya Okuno1, Hideaki Omatsu3, Shigeto Mizuno2, Midori Hirai3, Takeshi Azuma1, and  Toshiyuki Sakaeda3,7  1.",Non-OADS,/arxiv_data1/oa_pdf/5b/05/ijmsv09p0748.PMC3491433.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/5b/05/ijmsv09p0748.PMC3491433.pdf
"2012, 9    http://www.medsci.org  749  Introduction   Esophageal cancer is a common gastrointestinal  malignancy that continues to remain virulent.",Non-OADS,/arxiv_data1/oa_pdf/5b/05/ijmsv09p0748.PMC3491433.pdf
"2012, 9    http://www.medsci.org  750  International Union Against Cancer t u- mor-node -metastasis (TNM) classification; 2) age less  than 85 years; 3) an Eastern Cooperative Oncology  Group performance status of 0 to 2; 4) adequate bone  marrow, renal, and hepatic function; 5) no prior  chemotherapy; 6) no severe medical complications; 7)  no other active malignancies (except early cancer) and  8) availability of written informed consent, as d e- scribed above.",Non-OADS,/arxiv_data1/oa_pdf/5b/05/ijmsv09p0748.PMC3491433.pdf
"2012, 9      http://www.medsci.org  751  SNP selection    The human THRB  gene expresses 2  isoforms,  TRβ1 and TRβ2, in developmental and tissue -specific  patterns by alternative splicing [12].",Non-OADS,/arxiv_data1/oa_pdf/5b/05/ijmsv09p0748.PMC3491433.pdf
"2012, 9      http://www.medsci.org  752  Results   Patient characteristics    Patient characteristics are presented in Table 1.",Non-OADS,/arxiv_data1/oa_pdf/5b/05/ijmsv09p0748.PMC3491433.pdf
"2012, 9    http://www.medsci.org  753  Table 3.",Non-OADS,/arxiv_data1/oa_pdf/5b/05/ijmsv09p0748.PMC3491433.pdf
"2012, 9      http://www.medsci.org  754  Discussion    Administration of chemotherapy without severe  toxici ties is of great importance to medical oncol o- gists.",Non-OADS,/arxiv_data1/oa_pdf/5b/05/ijmsv09p0748.PMC3491433.pdf
"2012, 9    http://www.medsci.org  755  of transcription factors, in these mechanisms.",Non-OADS,/arxiv_data1/oa_pdf/5b/05/ijmsv09p0748.PMC3491433.pdf
http://www.ncbi.nlm.nih.gov/projects/SNP/.,Non-OADS,/arxiv_data1/oa_pdf/5b/05/ijmsv09p0748.PMC3491433.pdf
"2012, 9    http://www.medsci.org  756  35.",Non-OADS,/arxiv_data1/oa_pdf/5b/05/ijmsv09p0748.PMC3491433.pdf
"2012, 9      http://www.medsci.org  757  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):757-765. doi: 10.7150/ ijms.4916   Research Paper   Multiple -, But Not  Single -, Dose of Parecoxib Reduces Shoulder Pain after  Gynecologic Laparoscopy   Hufei Zhang1, Haihua Shu1, Lu Yang1, Minghui Cao2, Jingjun Zhang1, Kexuan Liu1, Liangcan Xiao1, Xuyu  Zhang1  1.",Non-OADS,/arxiv_data1/oa_pdf/46/5d/ijmsv09p0757.PMC3491434.pdf
This is an open -access article distributed under the terms of the C reative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/46/5d/ijmsv09p0757.PMC3491434.pdf
"2012, 9    http://www.medsci.org  758  cholecystectomy  [6], 66% after  laparoscopic adjustable  gastric band surgery [7], 65.5% after laparoscopic  ap- pendectomy  [8] and 83%  after gynecological lapar o- scopic surgeries [5].",Non-OADS,/arxiv_data1/oa_pdf/46/5d/ijmsv09p0757.PMC3491434.pdf
"2012, 9    http://www.medsci.org  759  (Dynastat , Pharmacia Limited ) and the rest time of  patients.",Non-OADS,/arxiv_data1/oa_pdf/46/5d/ijmsv09p0757.PMC3491434.pdf
"2012, 9      http://www.medsci.org  760    Figure 1 .",Non-OADS,/arxiv_data1/oa_pdf/46/5d/ijmsv09p0757.PMC3491434.pdf
"2012, 9    http://www.medsci.org  761  and mood (RD= -18.7%; 95% CI: - 34.3~ -3.1%; P=0.019),  respectively .",OADS,/arxiv_data1/oa_pdf/46/5d/ijmsv09p0757.PMC3491434.pdf
"2012, 9    http://www.medsci.org  762  Table 3.",Non-OADS,/arxiv_data1/oa_pdf/46/5d/ijmsv09p0757.PMC3491434.pdf
"2012, 9    http://www.medsci.org  763  Table 5.",Non-OADS,/arxiv_data1/oa_pdf/46/5d/ijmsv09p0757.PMC3491434.pdf
"2012, 9    http://www.medsci.org  764  performance after laparoscopy.",Non-OADS,/arxiv_data1/oa_pdf/46/5d/ijmsv09p0757.PMC3491434.pdf
"2012, 9    http://www.medsci.org  765  5.",Non-OADS,/arxiv_data1/oa_pdf/46/5d/ijmsv09p0757.PMC3491434.pdf
"2012, 9      http://www.medsci.org  766  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):766-771. doi: 10.7150/ ijms.5007   Research Paper   Non-Stimulation Needle with External Indwelling Cannula for Brachial  Plexus Block and Pain Management in 62 Patients Undergoing Upper -Limb  Surgery   Bin Yu, Xiaoqing Zhang, Peili Sun, Shuqi Xie, Qiying Pang   Department  of Anesthesiology , Tongji Hospital of Tongji University , Shanghai 200065, C hina .",Non-OADS,/arxiv_data1/oa_pdf/23/c5/ijmsv09p0766.PMC3491435.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/23/c5/ijmsv09p0766.PMC3491435.pdf
"2012, 9    http://www.medsci.org  767  the procedure more complicated.",Non-OADS,/arxiv_data1/oa_pdf/23/c5/ijmsv09p0766.PMC3491435.pdf
"2012, 9    http://www.medsci.org  768  follo wed by continuous infusion at a rate of 4 ml/h  and a bolus injection  of 3 ml with in 20 min.",Non-OADS,/arxiv_data1/oa_pdf/23/c5/ijmsv09p0766.PMC3491435.pdf
"2012, 9    http://www.medsci.org  769    Figure 3  Brachial plexus block  of axillary sheath cannulation .",Non-OADS,/arxiv_data1/oa_pdf/23/c5/ijmsv09p0766.PMC3491435.pdf
"2012, 9    http://www.medsci.org  770  esthesia  were excluded because of the change s in  medical conditions.",Non-OADS,/arxiv_data1/oa_pdf/23/c5/ijmsv09p0766.PMC3491435.pdf
"2012, 9    http://www.medsci.org  771  degrees, and the sensation of breaking through the  intermuscular sheath and axillary sheath is very o b- vious; thus, nerves are not easily damaged; further- more, there are many l ateral apertures in the anterior  ends of cannula, which ensures the continuous inf u- sion of local anaesthetics post surgery.",Non-OADS,/arxiv_data1/oa_pdf/23/c5/ijmsv09p0766.PMC3491435.pdf
"2012, 9      http://www.medsci.org  772  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):772-777. doi: 10.7150/ ijms.5063   Research Paper   Plasma Brain -derived Neurotrophic  Factor in Hemodialysis Patients   Seok Joon Shin1, Hye Eun Yoon1, Sungjin Chung1, Yong Gu Kim2, Dai -Jin Kim3  1.",Non-OADS,/arxiv_data1/oa_pdf/5f/52/ijmsv09p0772.PMC3491436.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/5f/52/ijmsv09p0772.PMC3491436.pdf
"2012, 9    http://www.medsci.org  773  several inflammatory or metabolic derangement co n- ditions (2 -4).",Non-OADS,/arxiv_data1/oa_pdf/5f/52/ijmsv09p0772.PMC3491436.pdf
"2012, 9    http://www.medsci.org  774  (43.3%) had  diabetes.",Non-OADS,/arxiv_data1/oa_pdf/5f/52/ijmsv09p0772.PMC3491436.pdf
"2012, 9    http://www.medsci.org  775  Table 1.",Non-OADS,/arxiv_data1/oa_pdf/5f/52/ijmsv09p0772.PMC3491436.pdf
"2012, 9    http://www.medsci.org  776  Previous animal research  demonstrated that subc u- taneous administration of BDNF reduced food intake  and ameliorated impaired glucose tolerance in d i- et-induced obesity mice (9).",Non-OADS,/arxiv_data1/oa_pdf/5f/52/ijmsv09p0772.PMC3491436.pdf
"2012, 9    http://www.medsci.org  777  this is a cross sectional study, therefore, longitudinal  observation is needed to assess the relationship b e- tween this peptide with uremic inflammatory cond i- tions and clinical outcomes .",Non-OADS,/arxiv_data1/oa_pdf/5f/52/ijmsv09p0772.PMC3491436.pdf
"2012, 9      http://www.medsci.org  778  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):778-785. doi: 10.7150/ ijms.5129   Research Paper   Peri-Operative Treatment of Giant Nodular  Goiter   Bo Gao*, Wuguo Tian*, Yan Jiang, Xiaohua Zhang, Jianjie Zhao, Shu Zhang, Jinping Chen, Donglin Luo  Department of Surgery for Breast and Thyroid, Institute of Surgery Research,  Daping Hospital, Third Military Medical  University, Chongqing 400042, C hina .",Non-OADS,/arxiv_data1/oa_pdf/cf/30/ijmsv09p0778.PMC3491437.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/cf/30/ijmsv09p0778.PMC3491437.pdf
"2012, 9    http://www.medsci.org  779  mans et al performed r adioactive Iodine I -131 therapy  in patients with nodular goiter achieving favorable  therapeutic effectiveness [ 7].",Non-OADS,/arxiv_data1/oa_pdf/cf/30/ijmsv09p0778.PMC3491437.pdf
"2012, 9    http://www.medsci.org  780    Figure 2 Ultrasonography of giant nodular goiter.",Non-OADS,/arxiv_data1/oa_pdf/cf/30/ijmsv09p0778.PMC3491437.pdf
"2012, 9    http://www.medsci.org  781  goiter.",Non-OADS,/arxiv_data1/oa_pdf/cf/30/ijmsv09p0778.PMC3491437.pdf
"2012, 9    http://www.medsci.org  782    Figure 6  A T incision  was made at the neck and chest: Intra- operative findings of giant nodular goiter at the posterior mediastinum .",Non-OADS,/arxiv_data1/oa_pdf/cf/30/ijmsv09p0778.PMC3491437.pdf
"2012, 9    http://www.medsci.org  783  tion; 4) The nodular goiter is giant and affect the  beauty.",Non-OADS,/arxiv_data1/oa_pdf/cf/30/ijmsv09p0778.PMC3491437.pdf
"2012, 9    http://www.medsci.org  784  On the thyroid, the veins and arteries are giant and  have some branches.",Non-OADS,/arxiv_data1/oa_pdf/cf/30/ijmsv09p0778.PMC3491437.pdf
"2012, 9    http://www.medsci.org  785  When the thyroid is adherent to the muscle or su r- rounding major blood vessels, frozen pathology is  required.",Non-OADS,/arxiv_data1/oa_pdf/cf/30/ijmsv09p0778.PMC3491437.pdf
"2012, 9      http://www.medsci.org  786  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):786-792. doi: 10.7150/ ijms.4563   Research Paper   Effects of Smokeless Tobacco “Maras Powder” Use on Nitric Oxide and  Cardiovascular Risk Parameters   Aytekin Guven1 , Fatma Tolun2  1.",Non-OADS,/arxiv_data1/oa_pdf/8d/74/ijmsv09p0786.PMC3491438.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/8d/74/ijmsv09p0786.PMC3491438.pdf
"2012, 9    http://www.medsci.org  787  range from ground tobacco mixed with spices and  sugars (Chimo in Venezuela) to sodium bicarbonate  (Toombak in Sudan) to areca and betel nuts (Mawa or  Gutkha in India).",Non-OADS,/arxiv_data1/oa_pdf/8d/74/ijmsv09p0786.PMC3491438.pdf
"2012, 9    http://www.medsci.org  788  assayed.",Non-OADS,/arxiv_data1/oa_pdf/8d/74/ijmsv09p0786.PMC3491438.pdf
"2012, 9      http://www.medsci.org  789  Table 1.",Non-OADS,/arxiv_data1/oa_pdf/8d/74/ijmsv09p0786.PMC3491438.pdf
"2012, 9    http://www.medsci.org  790  Maras powder is a different form of the smok e- less tobacco (2 0).",Non-OADS,/arxiv_data1/oa_pdf/8d/74/ijmsv09p0786.PMC3491438.pdf
"2012, 9    http://www.medsci.org  791  chemic heart disease, peripheral vascular disease,  gastrointestinal disease.",Non-OADS,/arxiv_data1/oa_pdf/8d/74/ijmsv09p0786.PMC3491438.pdf
"2012, 9    http://www.medsci.org  792  39.",Non-OADS,/arxiv_data1/oa_pdf/8d/74/ijmsv09p0786.PMC3491438.pdf
"2012, 9      http://www.medsci.org  793  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):793-800. doi: 10.7150/ ijms.4722   Research Paper   Synergistic Effects of Honey and Propolis toward Drug Multi-Resistant  Staphylococcus Aureus,  Escherichia Coli and Candida Albicans  Isolates in  Single and Polymicrobial Cultures   Noori AL -Waili, Ahmad Al -Ghamdi , Mohammad Javed Ansari, Y. Al -Attal, Khelod Salom   Departme nt of Plant Protection, College of Food and Agricultural Sciences, King Saud University - Riyadh, 11543, KSA; Waili  Foundation for Science, Queens, NY 11418, NY, USA  .",Non-OADS,/arxiv_data1/oa_pdf/5d/5c/ijmsv09p0793.PMC3491439.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/5d/5c/ijmsv09p0793.PMC3491439.pdf
"2012, 9    http://www.medsci.org  794  sources, and the collection season.",Non-OADS,/arxiv_data1/oa_pdf/5d/5c/ijmsv09p0793.PMC3491439.pdf
"2012, 9    http://www.medsci.org  795  mentation.",Non-OADS,/arxiv_data1/oa_pdf/5d/5c/ijmsv09p0793.PMC3491439.pdf
"2012, 9    http://www.medsci.org  796  at 37° C, and inspected after 24 h for microbial growth.",Non-OADS,/arxiv_data1/oa_pdf/5d/5c/ijmsv09p0793.PMC3491439.pdf
"2012, 9    http://www.medsci.org  797  Table 3 .",Non-OADS,/arxiv_data1/oa_pdf/5d/5c/ijmsv09p0793.PMC3491439.pdf
"2012, 9    http://www.medsci.org  798  In one study by Stepanovic et al ., the MIC of  propolis against Gram -positive bacteria was  0.078% -1.25% and against yeasts was 0.16% -1.25%,  while against Gram -negative bacteria was less, 1.25% -  5%.",OADS,/arxiv_data1/oa_pdf/5d/5c/ijmsv09p0793.PMC3491439.pdf
"2012, 9    http://www.medsci.org  799  fluids and decreased prostaglandin concentration  (47-49).",Non-OADS,/arxiv_data1/oa_pdf/5d/5c/ijmsv09p0793.PMC3491439.pdf
"2012, 9    http://www.medsci.org  800  26. Cooper R, Molan P, Harding K. Antibacterial activity of honey against  strains of Staphylococcus aureus from infected wounds.",Non-OADS,/arxiv_data1/oa_pdf/5d/5c/ijmsv09p0793.PMC3491439.pdf
http://www.cdc.gov/drugresistance/about.html.,Non-OADS,/arxiv_data1/oa_pdf/5d/5c/ijmsv09p0793.PMC3491439.pdf
"2012, 9      http://www.medsci.org  801  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):801-807. doi: 10.7150/ ijms.4838   Research Paper   Low-Magnitude High-Frequency Vibration Inhibits RANKL-Induced Oste o- clast Differentiation of RAW264 .7 Cells   Song- Hui Wu*, Zhao- Ming Zhong*, Jian -Ting Chen  Department of Orthopedic and Spinal Surgery, Nanfang Hospital, Southern Medical University, China.",Non-OADS,/arxiv_data1/oa_pdf/7a/b3/ijmsv09p0801.PMC3491440.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/7a/b3/ijmsv09p0801.PMC3491440.pdf
"2012, 9    http://www.medsci.org  802  demonstrated that LMHFV did not enhance the o s- teogenic differentiation of bone marrow mesenchymal  stromal cells (8).",Non-OADS,/arxiv_data1/oa_pdf/7a/b3/ijmsv09p0801.PMC3491440.pdf
"2012, 9    http://www.medsci.org  803  5′-GCC CTG GAA CTC ACA CGA CA -3′ and ant i- sense 5′ -TTG GAA ACT CAC ACG CCA GAA G -3′,  TRAP sense 5′ -CTA CCT GTG TGG ACA TGA  CCA -3′ and antisense 5′ -GCA CAT AGC CCA CAC  CGT TC- 3′, glyceraldehyde 3 -phosphate dehydr o- genase (GAPDH)  sense 5′ -AAA TGG TGA AGG TCG  GTG TG- 3′ and antisense 5′ -TGA AGG GGT CGT  TGA TGG- 3′.",Non-OADS,/arxiv_data1/oa_pdf/7a/b3/ijmsv09p0801.PMC3491440.pdf
"2012, 9      http://www.medsci.org  804  Statistical analysis    Results were represented as mean ± standard  deviation (SD) for three separate experiments.",OADS,/arxiv_data1/oa_pdf/7a/b3/ijmsv09p0801.PMC3491440.pdf
"2012, 9    http://www.medsci.org  805    Figure  3: LMHFV inhibited RANKL- induced the actin rings formation.",Non-OADS,/arxiv_data1/oa_pdf/7a/b3/ijmsv09p0801.PMC3491440.pdf
"2012, 9      http://www.medsci.org  806  Disc ussion   Osteoporosis results from the rate of bone re- sorption by osteoclast outpacing the rate of bone  formation by osteoblast.",Non-OADS,/arxiv_data1/oa_pdf/7a/b3/ijmsv09p0801.PMC3491440.pdf
"2012, 9    http://www.medsci.org  807  11.",Non-OADS,/arxiv_data1/oa_pdf/7a/b3/ijmsv09p0801.PMC3491440.pdf
"2012, 9      http://www.medsci.org  808  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):808-815. doi: 10.7150/ ijms.4910   Research Paper   How the Duration Period of Erythropoietin Treatment Influences the Ox i- dative Status of Hemodialysis  Patients   Zorica M. Dimitrijevic1, Tatjana P. Cvetkovic1,2, Vidojko M. Djordjevic1, Dusica D. Pavlovic2, Nikola Z.  Stefanovic3, Ivana R. Stojanovic2, Goran J. Paunovic1, Radmila M. Velickovic -Radov anovic1   1.",Non-OADS,/arxiv_data1/oa_pdf/c3/dc/ijmsv09p0808.PMC3491441.pdf
This is an open -access article  distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/c3/dc/ijmsv09p0808.PMC3491441.pdf
"2012, 9    http://www.medsci.org  809  ESRD patients.",Non-OADS,/arxiv_data1/oa_pdf/c3/dc/ijmsv09p0808.PMC3491441.pdf
"2012, 9    http://www.medsci.org  810  Estimation of erythrocyte MDA products   The MDA content of erythrocytes was estimated  by the production of thiobarbituric acid reacting su b- stances by the spectrophotometric method (at 532 nm)  as described by Jain et al.",OADS,/arxiv_data1/oa_pdf/c3/dc/ijmsv09p0808.PMC3491441.pdf
"2012, 9    http://www.medsci.org  811  All HD patients showed lower hemoglobin and  albumin levels ( p<0.001) as well as higher uric acid  and triglycerides levels (p<0.001) compared to healthy  controls.",Non-OADS,/arxiv_data1/oa_pdf/c3/dc/ijmsv09p0808.PMC3491441.pdf
"2012, 9    http://www.medsci.org  812    Fig.1 .",Non-OADS,/arxiv_data1/oa_pdf/c3/dc/ijmsv09p0808.PMC3491441.pdf
"2012, 9    http://www.medsci.org  813    Fig.",Non-OADS,/arxiv_data1/oa_pdf/c3/dc/ijmsv09p0808.PMC3491441.pdf
"2012, 9      http://www.medsci.org  814  DISCUSSION   Oxidative stress results from the imbalance of  ROS and defense mechanisms, which results in cell  damage.",Non-OADS,/arxiv_data1/oa_pdf/c3/dc/ijmsv09p0808.PMC3491441.pdf
"2012, 9    http://www.medsci.org  815  were also verified in the group with the longest dur a- tion of EPO treatment (group IIc) but without any  concomitant changes in the urate or albumin levels  which represent valuable extracellular a ntioxidants.",Non-OADS,/arxiv_data1/oa_pdf/c3/dc/ijmsv09p0808.PMC3491441.pdf
"2012, 9      http://www.medsci.org  816  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):816-824. doi: 10.7150/ ijms.4882   Research Paper   Development of a Clinically Relevant Animal Model for the Talar Osteon e- crosis in Sheep   Chao -Fan Yuan1,*, Jun- Lin Wang2,*, Yong- Quan Zhang1, Xiao -Kang Li1, Yi Li1, Su-Hua Wu1, Zhi-Yong  Zhang3, Zheng Guo1  1.",Non-OADS,/arxiv_data1/oa_pdf/13/55/ijmsv09p0816.PMC3491442.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/13/55/ijmsv09p0816.PMC3491442.pdf
"2012, 9    http://www.medsci.org  817  ONTs have generally experienced a phase of ischemic  injury after the disturbance of blood circulation, alt- hough the detailed pathophysiological process r e- mained unknown [ 6-8].",Non-OADS,/arxiv_data1/oa_pdf/13/55/ijmsv09p0816.PMC3491442.pdf
"2012, 9    http://www.medsci.org  818  Anesthesia and surgical procedures   The sheep were fasted 24 hrs before surgery.",Non-OADS,/arxiv_data1/oa_pdf/13/55/ijmsv09p0816.PMC3491442.pdf
"2012, 9    http://www.medsci.org  819  the talar head samples at week four postoperatively  (Figure 3C).",Non-OADS,/arxiv_data1/oa_pdf/13/55/ijmsv09p0816.PMC3491442.pdf
"2012, 9      http://www.medsci.org  820    Figure 4.",Non-OADS,/arxiv_data1/oa_pdf/13/55/ijmsv09p0816.PMC3491442.pdf
"2012, 9    http://www.medsci.org  821    Figure 6.",Non-OADS,/arxiv_data1/oa_pdf/13/55/ijmsv09p0816.PMC3491442.pdf
"2012, 9      http://www.medsci.org  822  At the end of the fourth week, there were i n- creasing numbers of empty lacunae (black arrow  head, Figure 6 C) in most bone trabecula e with r e- duced number o f osteocytes, disordered trabecular  structure and enlarged gaps.",Non-OADS,/arxiv_data1/oa_pdf/13/55/ijmsv09p0816.PMC3491442.pdf
"2012, 9    http://www.medsci.org  823  veloped by J. Manggold et al.",OADS,/arxiv_data1/oa_pdf/13/55/ijmsv09p0816.PMC3491442.pdf
"2012, 9    http://www.medsci.org  824  human being [27 -28].",Non-OADS,/arxiv_data1/oa_pdf/13/55/ijmsv09p0816.PMC3491442.pdf
"2012, 9      http://www.medsci.org  825  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2012; 9(9):825-832. doi: 10.7150/ ijms.5180   Review  Immune Regulation o f Osteoclast  Function in Postmenopausal Osteopor o- sis: A Critical Interdisciplinary Perspective   Renqing Zhao   College of Physical Education and Health Sciences, Zhejiang Normal University, Zhejiang Jinhua, China .",Non-OADS,/arxiv_data1/oa_pdf/57/04/ijmsv09p0825.PMC3491443.pdf
This is an open -access article distribu ted under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/57/04/ijmsv09p0825.PMC3491443.pdf
"2012, 9    http://www.medsci.org  826  regulating bone ce lls have extensively investigated.",Non-OADS,/arxiv_data1/oa_pdf/57/04/ijmsv09p0825.PMC3491443.pdf
"2012, 9    http://www.medsci.org  827  osteoclasts and their precursors.",Non-OADS,/arxiv_data1/oa_pdf/57/04/ijmsv09p0825.PMC3491443.pdf
"2012, 9      http://www.medsci.org  828  Although up regulated T cell activity and cyt o- kine production play a pivotal role in estrogen def i- ciency -induced bone loss, the source and characteri s- tics of T cells remains to be defined.",Non-OADS,/arxiv_data1/oa_pdf/57/04/ijmsv09p0825.PMC3491443.pdf
"2012, 9    http://www.medsci.org  829  pausal women with normal BMD[61].",Non-OADS,/arxiv_data1/oa_pdf/57/04/ijmsv09p0825.PMC3491443.pdf
"2012, 9    http://www.medsci.org  830  IL-6[76].",Non-OADS,/arxiv_data1/oa_pdf/57/04/ijmsv09p0825.PMC3491443.pdf
"2012, 9      http://www.medsci.org  831  Acknowledgements   This study was based upon work funded by  Zhejiang Provincial Natural Science Foundation of  China under Grant (No.",Non-OADS,/arxiv_data1/oa_pdf/57/04/ijmsv09p0825.PMC3491443.pdf
"2012, 9    http://www.medsci.org  832  51.",Non-OADS,/arxiv_data1/oa_pdf/57/04/ijmsv09p0825.PMC3491443.pdf
"Genomic aspects of cigarette smoke 885 © 2012 Informa Healthcare USA, Inc.   Programs such as NexGen (http://www.epa.gov/risk/nex - gen/index.htm) from the US Environmental Protection  Agency guide the community in this direction.",Non-OADS,/arxiv_data1/oa_pdf/72/45/TXC-042-0877.PMC3491444.pdf
"2012, 8      http://www.biolsci.org  1225  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(9):1225-1226.  doi: 10.7150/ ijbs.8.1225  Editorial   Special issue on  Interleukin-6 (IL-6)   Mercedes Rincon  Department of Medicine, Immunobiology Division, University of Vermont, Burlington, VT 05405, USA     Corresponding author : Mercedes Rincon, Ph.D., Professor, Department of Medicine/Immunobiology, Given C331, University of  Vermont, 89 Beaumont Ave., Burlington, VT 05405.",Non-OADS,/arxiv_data1/oa_pdf/e2/31/ijbsv08p1225.PMC3491445.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licens es/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/e2/31/ijbsv08p1225.PMC3491445.pdf
"2012, 8    http://www.biolsci.org  1226  coworkers describes the results from clinical studies  and experimental mouse models that support the  contribution of IL -6 to the pathogenesis of sporadic  colorectal cancer (CRC) [5].",Non-OADS,/arxiv_data1/oa_pdf/e2/31/ijbsv08p1225.PMC3491445.pdf
"2012, 8      http://www.biolsci.org  1227  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(9):1227-1236. doi: 10.7150/ ijbs.4666   Review  Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflamm a- tory Diseases    Toshio Tanaka1,2,3 and Tadamitsu Kishimoto4  1.",Non-OADS,/arxiv_data1/oa_pdf/97/d8/ijbsv08p1227.PMC3491446.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/97/d8/ijbsv08p1227.PMC3491446.pdf
"2012, 8      http://www.biolsci.org  1228    Figure 1.",Non-OADS,/arxiv_data1/oa_pdf/97/d8/ijbsv08p1227.PMC3491446.pdf
"2012, 8    http://www.biolsci.org  1229  stem cells [17].",Non-OADS,/arxiv_data1/oa_pdf/97/d8/ijbsv08p1227.PMC3491446.pdf
"2012, 8    http://www.biolsci.org  1230  studies, case series or case studies have suggested that  tocilizumab may have broad application for other  diseases.",Non-OADS,/arxiv_data1/oa_pdf/97/d8/ijbsv08p1227.PMC3491446.pdf
"2012, 8    http://www.biolsci.org  1231  Table 2.",OADS,/arxiv_data1/oa_pdf/97/d8/ijbsv08p1227.PMC3491446.pdf
"2012, 8    http://www.biolsci.org  1232  motes the differentiation of naïve T cells into Th17,  but inhibits TGF- β-induced Treg differentiation, i n- dicating that IL -6 is a very important factor for d e- termining the Th17/Treg balance [14].",Non-OADS,/arxiv_data1/oa_pdf/97/d8/ijbsv08p1227.PMC3491446.pdf
"2012, 8    http://www.biolsci.org  1233  25.",Non-OADS,/arxiv_data1/oa_pdf/97/d8/ijbsv08p1227.PMC3491446.pdf
"2012, 8    http://www.biolsci.org  1234  71.",Non-OADS,/arxiv_data1/oa_pdf/97/d8/ijbsv08p1227.PMC3491446.pdf
"2012, 8    http://www.biolsci.org  1235  119.",Non-OADS,/arxiv_data1/oa_pdf/97/d8/ijbsv08p1227.PMC3491446.pdf
"2012, 8    http://www.biolsci.org  1236  168.",Non-OADS,/arxiv_data1/oa_pdf/97/d8/ijbsv08p1227.PMC3491446.pdf
"2012, 8      http://www.biolsci.org  1237  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(9):1237-1247. doi: 10.7150/ ijbs.4989   Review  IL-6 Trans -Signaling via the Soluble IL -6 Receptor: Importance for the  Pro-Inflammatory Activities of IL -6   Stefan Rose- John   Institute of Biochemistry, Christian -Albrechts -University of Kiel, Kiel, Germany .",Non-OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
"2012, 8    http://www.biolsci.org  1238  thritis patients IL -6 mediated STAT3 activation will  play a key role in the disease [9].",Non-OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
"2012, 8    http://www.biolsci.org  1239  On CD4 -T-cells, IL -6 has been shown to strongly  influence the balance between regulatory T -cells and  TH 17-cells [28].",Non-OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
"2012, 8      http://www.biolsci.org  1240  Protein tools to study IL -6 trans -signaling:  Hyper -IL-6, sgp130Fc, L -gp130  When together with Joachim Grötzinger we built  a molecular model of the IL -6/sIL -6R prot ein complex  [12] we realized that the C -terminus of the sIL -6R and  the N -terminus of IL -6 were about 40Å apart.",OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
"2012, 8      http://www.biolsci.org  1241  So far it is unclear how binding of the IL -6/IL -6R  or IL -6/sIL-6R complexes to gp130 leads to the  transmission of the signal into the cell.",Non-OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
"2012, 8    http://www.biolsci.org  1242  trans -signaling could be blocked with the help of the  sgp130Fc protein.",Non-OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
"2012, 8    http://www.biolsci.org  1243      Fig.",Non-OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
"2012, 8    http://www.biolsci.org  1244  patients was at least as high as the benefit from  blocking TNF α activity.",Non-OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
"2012, 8    http://www.biolsci.org  1245  10.",Non-OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
"2012, 8    http://www.biolsci.org  1246  55.",Non-OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
"2012, 8    http://www.biolsci.org  1247  101.",Non-OADS,/arxiv_data1/oa_pdf/b6/83/ijbsv08p1237.PMC3491447.pdf
"2012, 8      http://www.biolsci.org  1248  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(9):1248-1253. doi: 10.7150/ ijbs.4614   Review  Interleukin-6 – A Key Regulator of  Colorectal Cancer Development    Maximilian J. Waldner, Sebastian Foersch, Markus F. Neurath  Department of Medicine 1, University of Erlangen -Nuremberg, Erlangen, Germany .",Non-OADS,/arxiv_data1/oa_pdf/56/7b/ijbsv08p1248.PMC3491448.pdf
This is an open -access article distribute d under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/56/7b/ijbsv08p1248.PMC3491448.pdf
"2012, 8    http://www.biolsci.org  1249  which have an increased risk for the development of  colitis- associated CRC depending on the durat ion and  severity of intestinal inflammation [7].",Non-OADS,/arxiv_data1/oa_pdf/56/7b/ijbsv08p1248.PMC3491448.pdf
"2012, 8    http://www.biolsci.org  1250  noma as well as breast, ovarian, pancreatic, prostate,  renal and, of course, colorectal cancer.",Non-OADS,/arxiv_data1/oa_pdf/56/7b/ijbsv08p1248.PMC3491448.pdf
"2012, 8    http://www.biolsci.org  1251  promotes proliferation of tumor cells in the  AOM+DSS mod el of CAC through  VEGFR2 -dependent STAT3 activation [34] .",Non-OADS,/arxiv_data1/oa_pdf/56/7b/ijbsv08p1248.PMC3491448.pdf
"2012, 8    http://www.biolsci.org  1252    Figure 1: IL -6 signaling in colorectal cancer.",Non-OADS,/arxiv_data1/oa_pdf/56/7b/ijbsv08p1248.PMC3491448.pdf
"2012, 8    http://www.biolsci.org  1253  13.",Non-OADS,/arxiv_data1/oa_pdf/56/7b/ijbsv08p1248.PMC3491448.pdf
"2012, 8      http://www.biolsci.org  1254  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(9):1254-1266. doi: 10.7150/ ijbs.4679   Review  Interleukin-6, a Major Cytokine in  the Central Nervous System    María Erta1, Albert Quintana2, and Juan Hidalgo1  1.",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1255  neuropoietic fa mily, for its effects on hematopoietic  and nervous system).",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1256  [28], of adult rats.",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1257  GFAP -IL6 mice, indeed, show a diminished hipp o- campal neurogenesis [82] , and moreover, in vitro IL- 6  clearly decreases the differentiat ion of neural  stem/progenitor cells into neurons [83, 84] .",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1258  CNS IL -6 is upregulated whenever neuroi n- flammation is expected, such as following CNS infe c- tion or injury or in a number of CNS dise ases (Figures  2 and 3).",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1259    Figure 3.",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1260  stress [166]  and angiogenesis [165]  are among the a t- tributed functions of IL -6 during stroke.",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1261  levels in the CSF of PD patients are elevated [215] ,  although an inverse correlation between severity of  PD and IL -6 levels is observed [216] .",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1262  11.",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1263  60.",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1264  106.",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1265  brain injury and its impact on the cortical transcriptome.",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8    http://www.biolsci.org  1266  not associated with susceptibility to multiple sclerosis.",Non-OADS,/arxiv_data1/oa_pdf/ac/48/ijbsv08p1254.PMC3491449.pdf
"2012, 8       http://www.biolsci.org  1267  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(9):1267-1280. doi: 10.7150/ ijbs.4828   Review  The Pathological and Physiological Roles of IL -6 Amplifier Activation    Masaaki Murakami1, and Toshio Hirano2  1.",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8    http://www.biolsci.org  1268  rheumatoid arthritis -like tissue specific disease, ind i- cating that constitutive activation of IL -6 signaling is  involved in the development of autoimmune symp- toms  [19] (see Figure 1) .",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8       http://www.biolsci.org  1269  What is the IL -6 amplifier?",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8    http://www.biolsci.org  1270    Figure 3.",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8    http://www.biolsci.org  1271  method [33] enhanced it (Figure 6).",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8    http://www.biolsci.org  1272    Figure 7 .",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8       http://www.biolsci.org  1273    Figure 8 .",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8    http://www.biolsci.org  1274    Figure 10.",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8    http://www.biolsci.org  1275  lar, pathogenic CD4+ T cells migrated to the 5th lum- bar cord (L5) from the blood vessels of the dorsal side  (Figure 11) .",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8       http://www.biolsci.org  1276  Additionally, we have shown that CCL20, which  binds to CCR6, induces the accumulation of Th17 cells  [21].",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8       http://www.biolsci.org  1277  (iii) Chemokine expression in dorsal blood vessels of the 5th  lumbar cord is dependent on IL -6 amplifier activation via  regional neural activation in response to anti -gravity.",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8       http://www.biolsci.org  1278    Figure 18.",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8       http://www.biolsci.org  1279  Future direction   (i) Role of antigen recognition for the acc u- mulation of pathogenic CD4+  T cells in the 5th  lumbar cord.",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8    http://www.biolsci.org  1280  8.",Non-OADS,/arxiv_data1/oa_pdf/15/88/ijbsv08p1267.PMC3491450.pdf
"2012, 8      http://www.biolsci.org  1281  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(9):1281-1290. doi: 10.7150/ ijbs.4874   Review  Role of IL-6 in Asthma and Other Inflammatory Pulmonary Diseases    Mercedes Rincon1 and Charles G. Irvin2   1.",Non-OADS,/arxiv_data1/oa_pdf/c4/64/ijbsv08p1281.PMC3491451.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/c4/64/ijbsv08p1281.PMC3491451.pdf
"2012, 8    http://www.biolsci.org  1282  have provided some conflictive conclusions in part  due to the presence of several members of the IL- 17  family and a common IL -17R, together with human  studies, it a ppears that IL -17 also contributes to the  pathogenesis of asthma, primarily severe and ste r- oid-resistant asthma (6).",Non-OADS,/arxiv_data1/oa_pdf/c4/64/ijbsv08p1281.PMC3491451.pdf
"2012, 8    http://www.biolsci.org  1283  and the subsequent association of this complex with  gp130.",OADS,/arxiv_data1/oa_pdf/c4/64/ijbsv08p1281.PMC3491451.pdf
"2012, 8    http://www.biolsci.org  1284  istrations cause allergic airway inflammation chara c- terized by an accumulation of eosinophils and Th2  cytokines in the airways, IgE production and airway  hyperresponsiveness (41).",Non-OADS,/arxiv_data1/oa_pdf/c4/64/ijbsv08p1281.PMC3491451.pdf
"2012, 8    http://www.biolsci.org  1285  COPD, including mucus hypersecretion, emphysema,  airway obstruction.",Non-OADS,/arxiv_data1/oa_pdf/c4/64/ijbsv08p1281.PMC3491451.pdf
"2012, 8    http://www.biolsci.org  1286  terized (14).",OADS,/arxiv_data1/oa_pdf/c4/64/ijbsv08p1281.PMC3491451.pdf
"2012, 8    http://www.biolsci.org  1287  muscle cells, fibroblasts).",Non-OADS,/arxiv_data1/oa_pdf/c4/64/ijbsv08p1281.PMC3491451.pdf
"2012, 8    http://www.biolsci.org  1288  blocking Ab) in certain human inflammatory diseases  and its recent approval for treatment of rheumatoid  arthritis reveals the contribution of IL- 6 in disease  pathogenesis.",Non-OADS,/arxiv_data1/oa_pdf/c4/64/ijbsv08p1281.PMC3491451.pdf
"2012, 8    http://www.biolsci.org  1289  Uncoupling of airway inflammation and bronchial hyperreactivity.",Non-OADS,/arxiv_data1/oa_pdf/c4/64/ijbsv08p1281.PMC3491451.pdf
"2012, 8    http://www.biolsci.org  1290  85. van den Berg A, Kuiper M, Snoek M, Timens W, Postma DS, Jansen HM,  et al.",OADS,/arxiv_data1/oa_pdf/c4/64/ijbsv08p1281.PMC3491451.pdf
"To view acopy of this license, visit http://creativecommons.org/licenses/by-nc- nd/3.0/Notch and TGF- bSignaling During HBV Infection Trehanpati et al.",Non-OADS,/arxiv_data1/oa_pdf/5d/0b/ctg201217a.PMC3491533.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/Endoscopic Features of Colon Tuberculosis Before and After Anti-TB Treatment Mukewar et al.",Non-OADS,/arxiv_data1/oa_pdf/5f/e9/ctg201219a.PMC3491534.pdf
The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/3.0/ >.,Non-OADS,/arxiv_data1/oa_pdf/f7/cb/S0029665111003338a.PMC3491641.pdf
"Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests W.Y., N.E., A.K., A.H., T.E., T.S., M.K.",Non-OADS,/arxiv_data1/oa_pdf/88/1b/srep00783.PMC3491666.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Yoshioka, W. et al.",Non-OADS,/arxiv_data1/oa_pdf/88/1b/srep00783.PMC3491666.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Xu, H., Wang, X., Yu, T., Sun, H. & Zhang, B. Radiation-Suppressed plasmonic open resonators designed by nonmagnetic transformation optics.",Non-OADS,/arxiv_data1/oa_pdf/dd/2d/srep00784.PMC3491667.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.doi:10.1093/cercor/bhr353 Advance Access publication December 15, 2011Cerebral Cortex December 2012;22:2769– 2783",Non-OADS,/arxiv_data1/oa_pdf/9a/c8/bhr353.PMC3491764.pdf
Supplementary Material Supplementary material can be found at: http://www.cercor.,Non-OADS,/arxiv_data1/oa_pdf/9a/c8/bhr353.PMC3491764.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/36/9e/IJOrtho-46-505.PMC3491782.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/17/33/IJOrtho-46-556.PMC3491790.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free  applications.,Non-OADS,/arxiv_data1/oa_pdf/17/33/IJOrtho-46-556.PMC3491790.pdf
Available from: http://www.rheumatology.org [Last cited on 2011 Sep 07].,Non-OADS,/arxiv_data1/oa_pdf/ba/e4/IJOrtho-46-589.PMC3491797.pdf
Available from: http://www.fda.gov/Drugs/DrugSafety/ucm229009.,Non-OADS,/arxiv_data1/oa_pdf/ba/e4/IJOrtho-46-589.PMC3491797.pdf
The application can be downloaded from https://market.android.com/details?id=comm.app.medknow.,Non-OADS,/arxiv_data1/oa_pdf/ba/e4/IJOrtho-46-589.PMC3491797.pdf
The application can be downloaded from http://itunes.apple.com/us/app/medknow-journals/ id458064375?ls=1&mt=8.,Non-OADS,/arxiv_data1/oa_pdf/66/dd/IJOrtho-46-596.PMC3491799.pdf
100http://dx.doi.org/10.4046/trd.2012.73.2.100 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:100-106 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/a6/01/trd-73-100.PMC3492373.pdf
"16, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   There are so many literatures showing that a high-in- tensity intensive care unit (ICU) physician staffing is as- sociated with a reduced ICU mortality1-10.",Non-OADS,/arxiv_data1/oa_pdf/a6/01/trd-73-100.PMC3492373.pdf
107http://dx.doi.org/10.4046/trd.2012.73.2.107 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:107-114 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/ac/aa/trd-73-107.PMC3492374.pdf
"27, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Hemoptysis is the expectoration of blood from the  airways.",Non-OADS,/arxiv_data1/oa_pdf/ac/aa/trd-73-107.PMC3492374.pdf
115http://dx.doi.org/10.4046/trd.2012.73.2.115 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:115-121 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/a4/99/trd-73-115.PMC3492375.pdf
"26, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   There are various lymphoproliferative disorders which  affect the lung parenchyme.",Non-OADS,/arxiv_data1/oa_pdf/a4/99/trd-73-115.PMC3492375.pdf
122http://dx.doi.org/10.4046/trd.2012.73.2.122 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:122-126 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/7d/da/trd-73-122.PMC3492376.pdf
"25, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   P l a s t i c  b r o n c h i t i s  i s  a  r a r e  d i s e a s e  c h a r a c t e r i z e d  b y   the formation of large gelatinous or rigid airway cast.",Non-OADS,/arxiv_data1/oa_pdf/7d/da/trd-73-122.PMC3492376.pdf
77http://dx.doi.org/10.4046/trd.2012.73.2.77 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:77-83 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/94/0d/trd-73-77.PMC3492377.pdf
"6, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Pneumonia is still the leading disease of infectious  cause despite many efforts in diminishing of morbidity and mortality.",Non-OADS,/arxiv_data1/oa_pdf/94/0d/trd-73-77.PMC3492377.pdf
Available from:  http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667htm.,Non-OADS,/arxiv_data1/oa_pdf/94/0d/trd-73-77.PMC3492377.pdf
84http://dx.doi.org/10.4046/trd.2012.73.2.84 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:84-92 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/7f/cd/trd-73-84.PMC3492378.pdf
"17, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Fibrosis is an important process in the development  of several pulmonary diseases.",Non-OADS,/arxiv_data1/oa_pdf/7f/cd/trd-73-84.PMC3492378.pdf
93http://dx.doi.org/10.4046/trd.2012.73.2.93 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:93-99 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/78/61/trd-73-93.PMC3492379.pdf
"26, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Glucocorticoids are the most potent and reliable of  the available agents among the anti-inflammatory drugs, and have assumed a major role in the management of  asthma 1.",Non-OADS,/arxiv_data1/oa_pdf/78/61/trd-73-93.PMC3492379.pdf
137http://dx.doi.org/10.4046/trd.2012.73.3.137 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:137-142 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/10/6b/trd-73-137.PMC3492398.pdf
"14, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Lung cancer is the leading cause of cancer-related  mortality in the developed world, accounting for 26 ∼ 29% of all cancer deaths1.",Non-OADS,/arxiv_data1/oa_pdf/10/6b/trd-73-137.PMC3492398.pdf
143http://dx.doi.org/10.4046/trd.2012.73.3.143 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:143-150 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/3f/ca/trd-73-143.PMC3492399.pdf
"M a r y ' s   Hospital, The Catholic University of Korea College of Medicine, 62, Yeouido-dong, Yeongdeungpo-gu, Seoul  150-713, Korea Phone: 82-2-3779-1102, Fax: 82-2-786-1518 E-mail: jssong@catholic.ac.kr Received: Dec. 8, 2011 Revised: Jan. 30, 2012Accepted: Aug. 2, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Tuberculous pleurisy is a common extrapulmonary  form of tuberculosis (TB) worldwide and also is the most common manifestation in South Korea 1.",Non-OADS,/arxiv_data1/oa_pdf/3f/ca/trd-73-143.PMC3492399.pdf
151http://dx.doi.org/10.4046/trd.2012.73.3.151 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:151-161 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/22/de/trd-73-151.PMC3492400.pdf
"30, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Adequate use of sedatives is crucial in maintaining  mechanical ventilation1.",Non-OADS,/arxiv_data1/oa_pdf/22/de/trd-73-151.PMC3492400.pdf
162http://dx.doi.org/10.4046/trd.2012.73.3.162 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:162-168 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/f4/eb/trd-73-162.PMC3492401.pdf
"13, 2012 Revised: May 14, 2012Accepted: Aug. 29, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Idiopathic pulmonary fibrosis (IPF) is the most com- mon type of idiopathic interstitial lung diseases.",Non-OADS,/arxiv_data1/oa_pdf/f4/eb/trd-73-162.PMC3492401.pdf
169http://dx.doi.org/10.4046/trd.2012.73.3.169 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:169-173 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/c7/fd/trd-73-169.PMC3492402.pdf
"10, 2012Accepted: Aug. 29, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Spontaneous pneumomediastinum (SPM) is a con- dition in which air is present in the mediastinum with- out any definite precipitating causes.",Non-OADS,/arxiv_data1/oa_pdf/c7/fd/trd-73-169.PMC3492402.pdf
174http://dx.doi.org/10.4046/trd.2012.73.3.174 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:174-177 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/bb/9b/trd-73-174.PMC3492403.pdf
"30, 2012Accepted: May 10, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Primary endobronchial schwannomas are extremely  uncommon, constituting approximately 2% of benign  tracheobronchial tumors1.",Non-OADS,/arxiv_data1/oa_pdf/bb/9b/trd-73-174.PMC3492403.pdf
178http://dx.doi.org/10.4046/trd.2012.73.3.178 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:178-181 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/f2/a4/trd-73-178.PMC3492404.pdf
"10, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Streptococcus suis is a swine pathogen that causes  meningitis, sepsis, pneumonia and endocarditis1.",Non-OADS,/arxiv_data1/oa_pdf/f2/a4/trd-73-178.PMC3492404.pdf
182http://dx.doi.org/10.4046/trd.2012.73.3.182 ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:182-186 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/ab/62/trd-73-182.PMC3492405.pdf
"27, 2012 Revised: Aug. 6, 2012Accepted: Aug. 30, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Case Report   A 74-year-old woman was admitted to the hospital  for the evaluation of abnormal chest radiograph taken at the private clinic for the routine check-up for her gen- eral weakness.",Non-OADS,/arxiv_data1/oa_pdf/ab/62/trd-73-182.PMC3492405.pdf
197http://dx.doi.org/10.4046/trd.2012.73.4.197   ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:197-203 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/fc/55/trd-73-197.PMC3492419.pdf
"Key Words:  Bronchoscopy; Ultrasonography; Bronchoscopy; Pulmonary Surgica l Procedures Address for correspondence: Bin Hwangbo, M.D., Ph.D. Center for Lung Cancer, National Cancer Center, 323,  Ilsan-ro, Ilsandong-gu, Goyang 410-769, Korea Phone: 82-31-920-1115, Fax: 82-31-920-1298E-mail: hbb@ncc.re.kr  Received: Sep. 7, 2012 Revised: Sep. 10, 2012Accepted: Sep. 13, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Bronchoscopy is used in the diagnosis and therapy  of pulmonary diseases.",Non-OADS,/arxiv_data1/oa_pdf/fc/55/trd-73-197.PMC3492419.pdf
http://dx.doi.org/10.1378/chest.,Non-OADS,/arxiv_data1/oa_pdf/fc/55/trd-73-197.PMC3492419.pdf
http://dx.doi.org/10.1183/09031936.00015312.,Non-OADS,/arxiv_data1/oa_pdf/fc/55/trd-73-197.PMC3492419.pdf
204http://dx.doi.org/10.4046/trd.2012.73.4.204   ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:204-209 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/e9/e9/trd-73-204.PMC3492420.pdf
"31, 2012 Revised: Aug. 16, 2012Accepted: Sep. 13, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Mucus in the airway is very important in defense  against airborne chemicals, particles and pathogenic microorganisms.",Non-OADS,/arxiv_data1/oa_pdf/e9/e9/trd-73-204.PMC3492420.pdf
210http://dx.doi.org/10.4046/trd.2012.73.4.210   ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:210-218 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/ab/0e/trd-73-210.PMC3492421.pdf
"31, 2012 Revised: Sep. 3, 2012Accepted: Sep. 26, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Smoking, which includes second-hand smoke, is a  significant risk factor for various diseases such as can- cers, respiratory diseases, heart problems and various forms of stroke1-3.",Non-OADS,/arxiv_data1/oa_pdf/ab/0e/trd-73-210.PMC3492421.pdf
219http://dx.doi.org/10.4046/trd.2012.73.4.219   ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:219-223 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/35/97/trd-73-219.PMC3492422.pdf
"Received: Aug. 17, 2012 Revised: Sep. 8, 2012Accepted: Sep. 27, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Tuberculosis (TB) still remains a serious health threat  in South Korea, an intermediated TB-burden country.",Non-OADS,/arxiv_data1/oa_pdf/35/97/trd-73-219.PMC3492422.pdf
Available from: http://www.cdc.go.kr/CDC/in-fo/CdcKrInfo0301.jsp?menuIds=HOME001-MNU0001-M NU0036-MNU0037&q_type=A&q_value=2012&cid=  12798&pageNum.,OADS,/arxiv_data1/oa_pdf/35/97/trd-73-219.PMC3492422.pdf
224http://dx.doi.org/10.4046/trd.2012.73.4.224   ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:224-230 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/53/2c/trd-73-224.PMC3492423.pdf
"31, 2012Accepted: Sep. 27, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Advances in critical care have enabled more patients  to survive from an acute catastrophic ill state; however  these also created a population of patients who were dependent on continuous ventilator care and unable to  recover rapidly to a point at which they were fully in- dependent of life support 1.",Non-OADS,/arxiv_data1/oa_pdf/53/2c/trd-73-224.PMC3492423.pdf
231http://dx.doi.org/10.4046/trd.2012.73.4.231   ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:231-233 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/66/98/trd-73-231.PMC3492424.pdf
"10, 2012 Revised: May 2, 2012Accepted: May 24, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   Phosphodiesterase-5 inhibitors (PDE5Is)-sildenafil and  tadalafil-have been prescribed worldwide to treat male erectile dysfunction 1,2.",Non-OADS,/arxiv_data1/oa_pdf/66/98/trd-73-231.PMC3492424.pdf
234http://dx.doi.org/10.4046/trd.2012.73.4.234   ISSN: 1738-3536(Print)/2005-6184(Online)Tuberc Respir Dis 2012;73:234-238 Copyright Ⓒ2012.,Non-OADS,/arxiv_data1/oa_pdf/7e/40/trd-73-234.PMC3492425.pdf
"16, 2012 CCIt is identical to the Creative Commons Attribution Non-Commerc ial  License (http://creativecommons.org/licenses/by-nc/3.0/).Introduction   The tumor necrosis factor (TNF) blocker is known to  be a promising treatment modality among patients with  rheumatoid arthritis (RA) showing poor response to  conventional therapy including disease modifying an-ti-rh e u m a tic d ru g s (D M A R D s) 1.",Non-OADS,/arxiv_data1/oa_pdf/7e/40/trd-73-234.PMC3492425.pdf
"G&I    Genomics & InformaticspISSN 1598-866X eISSN 2234-0742 Genomics Inform  2012;10(3):133-144 http://dx.doi.org/10.5808/GI.2012.10.3.133 REVIEW ARTICLE Received August 3, 2012; Revised August 22, 2012; Accepted August 24, 2012 *Corresponding author: Tel: +86-21-54920479, Fax: +86-21-54920451, E-mail: xushua@picb.ac.cn Copyright © 2012 by The Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Human Population Admixture in Asia Shuhua Xu* Max Planck Independent Research Group on Population Genomics, Chinese Academy of Sciences and Max Planck Society  (CAS-MPG) Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences,  Chinese Academy of Sciences, Shanghai 200031, China Genetic admixture in human, the result of inter-marriage among  people from different well-differentiated populations, has  been extensively studied in the New World, where European  colonization brought contact between peoples of Europe,  Africa, and Asia and the Amerindian populations.",Non-OADS,/arxiv_data1/oa_pdf/d3/1e/gni-10-133.PMC3492649.pdf
"G&I    Genomics & InformaticspISSN 1598-866X  eISSN 2234-0742 Genomics Inform  2012;10(3):145-152 http://dx.doi.org/10.5808/GI.2012.10.3.145 ORIGINAL ARTICLE Received August 1, 2012; Revised August 22, 2012; Accepted August 24, 2012 *Corresponding author:  Tel: +82-54-279-2350, Fax: +82-54-279-2199, E-mail: tyroh@postech.edu Copyright © 2012 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Characterization of Chromatin Structure-associated  Histone Modifications in Breast Cancer Cells Chang Pyo Hong1,2, Moon Kyung Choe1, Tae-Young Roh1,3* 1Division of Molecular and Life Sciences, Pohang University of Science and T echnology, Pohang 790-784, Korea,  2Theragen Etex Bio Institute, Suwon 443-270, Korea, 3Division of Integrative Biosciences and Biotechnology,  Pohang University of Science and T echnology, Pohang 790-784, Korea Chromatin structure and dynamics that are influenced by epigenetic marks, such as histone modification and DNA  methylation, play a crucial role in modulating gene tr anscription.",Non-OADS,/arxiv_data1/oa_pdf/4d/72/gni-10-145.PMC3492650.pdf
"G&I    Genomics & InformaticspISSN 1598-866X eISSN 2234-0742 Genomics Inform  2012;10(3):153-166 http://dx.doi.org/10.5808/GI.2012.10.3.153 ORIGINAL ARTICLE Received May 25, 2012; Revised July 14, 2012; Accepted July 20, 2012 *Corresponding author: Tel:  ＋82-31-219-2600, Fax: ＋82-31-219-1615, E-mail: sangdunchoi@ajou.ac.kr Copyright © 2012 by The Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Systems Biological Approach es Reveal Non-additive  Responses and Multiple Crosstalk Mechanisms  between TLR and GPCR Signaling Jayalakshmi Krishnan, Sangdun Choi* Department of Molecular Science and T echnology, Ajou University, Suwon 443-749, Korea A variety of ligands differ in their capacity to bind the recept or, elicit gene expression, and modulate physiological response s.  Such receptors include Toll-like receptors (TLRs), which recogn ize various patterns of pathogens and lead to primary innate  immune activation against invaders, and G- protein coupled receptors (GPCRs), whose interaction with their cognate ligands  activates heterotrimeric G proteins and regulates specific down stream effectors, including immuno-stimulating molecules.",Non-OADS,/arxiv_data1/oa_pdf/c8/f4/gni-10-153.PMC3492651.pdf
"The list of genes is available through the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) under  accession number GPL254.",Non-OADS,/arxiv_data1/oa_pdf/c8/f4/gni-10-153.PMC3492651.pdf
"Data selection, analysis, and visualization Features that were differentially expressed in response to  ligand stimulation were identified with Linear Models for Microarray Data (LIMMA, http://bioinf.wehi.edu.au/  limma).",OADS,/arxiv_data1/oa_pdf/c8/f4/gni-10-153.PMC3492651.pdf
"We next hypothesized that the co-downregulated genes  may have common transcription factor binding sites; there- fore, we examined their promoter regions using TOUCAN(http://homes.esat.kuleuven.be/~saerts/software/toucan.",Non-OADS,/arxiv_data1/oa_pdf/c8/f4/gni-10-153.PMC3492651.pdf
php) and analyzed the genes downregulated by 8-Br using  MotifMogul (http://xerad.systemsbiology.net/MotifMogul-Server).,OADS,/arxiv_data1/oa_pdf/c8/f4/gni-10-153.PMC3492651.pdf
"For CREB, we searched in the website developed  by Marc Montminy, which takes advantage of CHIP-on-chip  data (http://natural.salk.edu/CREB).",OADS,/arxiv_data1/oa_pdf/c8/f4/gni-10-153.PMC3492651.pdf
"For potent NF- κB  sites, we looked in the website http://www.bu.edu/nf-kb.",OADS,/arxiv_data1/oa_pdf/c8/f4/gni-10-153.PMC3492651.pdf
Supplementary materials Supplementary data including six tables can be found with  this article online at http://www.genominfo.org/src/sm/ gni-10-153-s001.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c8/f4/gni-10-153.PMC3492651.pdf
"G&I   Genomics & InformaticspISSN 1598-866X eISSN 2234-0742 Genomics Inform  2012;10(3):167-174 http://dx.doi.org/10.5808/GI.2012.10.3.167 ORIGINAL ARTICLE Received May 5, 2012; Revised August 3, 2012; Accepted August 4, 2012 *Corresponding author: Tel: +82-2-920-5569, Fax: +82-2-926-4534, E-mail: yhk0215@korea.ac.kr  Copyright © 2012 by The Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Discovery and Evaluation of Polymorphisms in  the AKT2  and AKT3  Promoter Regions for Risk of  Korean Lung Cancer Jae Sook Sung1,2, Kyong Hwa Park3, Seung Tae Kim3, Yeul Hong Kim1,2,3* 1Genomic Research Center for Lung and Breast/Ovarian Cancers, Korea University Anam Hospital, Seoul 136-705, Korea,  2Division of Brain Korea 21 Program for Biomedical Science, Korea University College of Medicine, Seoul 136-701, Korea,  3Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital,  Korea University College of Medicine, Seoul 136-701, Korea AKT is a signal transduction protein that plays a central role in the tumorigenesis.",Non-OADS,/arxiv_data1/oa_pdf/23/07/gni-10-167.PMC3492652.pdf
"G&I    Genomics & InformaticspISSN 1598-866X eISSN 2234-0742 Genomics Inform 2012;10(3):175-183 http://dx.doi.org/10.5808/GI.2012.10.3.175 ORIGINAL ARTICLE Received July 31, 2012; Revised August 21, 2012; Accepted August 23, 2012 *Corresponding author: Tel: +82-2-2228-1523, Fax: +82-2-365-5118, E-mail: jsunha@yuhs.ac  Copyright © 2012 by The Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Prediction of Colorectal Cancer Risk Using a Genetic  Risk Score: The Korean Cancer Prevention Study-II  (KCPS-II) Jaeseong Jo1,2, Chung Mo Nam2,3, Jae Woong Sull4, Ji Eun Yun1, Sang Yeun Kim5, Sun Ju Lee5,  Yoon Nam Kim2, Eun Jung Park2,5, Heejin Kimm1,5, Sun Ha Jee1,5* 1Institute for Health Promotion and Department  of Epidemiology and Health Promotion,  Graduate School of Public Health, Yonsei University, Seoul 120-752, Korea, 2Department of Public Health,  Graduate School of Yonsei University, Seoul 120-752, Korea, 3Department of Preventive Medicine, Yonsei University College of  Medicine, Seoul 120-752, Korea, 4Metabolic Syndrome Research Initiatives, Seoul 120-752, Korea, 5Department of Biomedical  Laboratory Science, College of Health Sciences, Eulji University, Seongnam 461-713, Korea Colorectal cancer (CRC) is among the leading causes of cancer de aths and can be caused by environmental factors as well as  genetic factors.",Non-OADS,/arxiv_data1/oa_pdf/ad/16/gni-10-175.PMC3492653.pdf
Supplementary materials Supplemetary data including four tables can be found with  this article online at http://www.genominfo.org/src/sm/  gni-10-175-s001.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ad/16/gni-10-175.PMC3492653.pdf
Available from: http://www.cancer.gov/cancertopics/wyntk/colon-and-  rectal.,Non-OADS,/arxiv_data1/oa_pdf/ad/16/gni-10-175.PMC3492653.pdf
"G&I   Genomics & InformaticspISSN 1598-866X eISSN 2234-0742 Genomics Inform  2012;10(3):184-193 http://dx.doi.org/10.5808/GI.2012.10.3.184 ORIGINAL ARTICLE Received July 31, 2012; Revised August 23, 2012; Accepted August 24, 2012 *Corresponding author 1: Tel: +82-31-920-2282, Fax: +82-31-920-2542, E-mail: cij1224@ncc.re.kr  **Corresponding author 2: Tel: +82-31-920-2551, Fax: +82-31-920-2542, E-mail: yslee2@ncc.re.kr  †These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/b2/7b/gni-10-184.PMC3492654.pdf
"Copyright © 2012 by The Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Association Study between Folate Pathway Gene  Single Nucleotide Polymorphisms and Gastric Cancer  in Koreans Jae-Young Yoo1†, Sook-Young Kim1†, Jung-Ah Hwang1, Seung-Hyun Hong1,  Aesun Shin2, Il Ju Choi3*, Yeon-Su Lee1** 1Cancer Genomics Branch, National Cancer Center, Goyang 410-769, Korea, 2Molecular Epidemiology Branch, National Cancer  Center, Goyang 410-769, Korea, 3Gastric Cancer Branch, Research Institute, National Cancer Center, Goyang 410-769, Korea Gastric cancer is ranked as the most common cancer in Korea ns.",Non-OADS,/arxiv_data1/oa_pdf/b2/7b/gni-10-184.PMC3492654.pdf
"The SNP information,  including nucleic acid sequences, was collected from dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/; Build 136).",OADS,/arxiv_data1/oa_pdf/b2/7b/gni-10-184.PMC3492654.pdf
http://dx.doi.org/10.1007/s10620- 012-  2095-6.,Non-OADS,/arxiv_data1/oa_pdf/b2/7b/gni-10-184.PMC3492654.pdf
"G&I    Genomics & InformaticspISSN 1598-866X eISSN 2234-0742 Genomics Inform 2012;10(3):194-199 http://dx.doi.org/10.5808/GI.2012.10.3.194 ORIGINAL ARTICLE Received August 10, 2012; Revised August 20, 2012; Accepted August 23, 2012 *Corresponding author: Tel:  ＋82-2-2258-7343, Fax: ＋82-2-537-0572, E-mail: yejun@catholic.ac.kr Copyright © 2012 by The Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Effect of Combining Multiple CNV Defining  Algorithms on the Reliability of CNV Calls from SNP  Genotyping Data Soon-Young Kim1,2, Ji-Hong Kim1,2, Yeun-Jun Chung1,2* 1Integrated Research Center for Genome Polymorphism, The Catholic University of Korea School of Medicine, Seoul 137-701,  Korea, 2Department of Microbiology, The Catholic University of Korea School of Medicine, Seoul 137-701, Korea In addition to single-nucleotide polymorp hisms (SNP), copy number va riation (CNV) is a major component of human genetic  diversity.",Non-OADS,/arxiv_data1/oa_pdf/37/51/gni-10-194.PMC3492655.pdf
The PCR primers used in this study were designed using the  PrimerQuest program (http://www.idtdna.com/Scitools/  Applications/Primerquest).,OADS,/arxiv_data1/oa_pdf/37/51/gni-10-194.PMC3492655.pdf
"G&I    Genomics & InformaticspISSN 1598-866X eISSN 2234-0742 Genomics Inform  2012;10(3):200-205 http://dx.doi.org/10.5808/GI.2012.10.3.200 ORIGINAL ARTICLE Received July 7, 2012; Revised August 17, 2012; Accepted August 20, 2012 *Corresponding author: Tel:  ＋82-43-261-2547, Fax: ＋82-43-273-2240, E-mail: kwanskim@chungbuk.ac.kr Copyright © 2012 by The Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Comparison of SNP Variation and Distribution in  Indigenous Ethiopian and Korean Cattle (Hanwoo)  Populations Zewdu Edea1,2, Hailu Dadi3, Sang Wook Kim2, Tadelle Dessie1, Kwan-Suk Kim2* 1International Livestock Research Institute (ILRI), P .O.",Non-OADS,/arxiv_data1/oa_pdf/bb/70/gni-10-200.PMC3492656.pdf
Available from: http://dagris.ilri.cgiar.org.,Non-OADS,/arxiv_data1/oa_pdf/bb/70/gni-10-200.PMC3492656.pdf
"G&I    Genomics & InformaticspISSN 1598-866X  eISSN 2234-0742 Genomics Inform  2012;10(3):206-211 http://dx.doi.org/10.5808/GI.2012.10.3.206 ORIGINAL ARTICLE Received July 17, 2012; Revised August 8, 2012; Accepted August 13, 2012 *Corresponding author 1:  Tel: +82-42-601-7989, Fax: +82-42-601-7819, E-mail: paekwk@mest.go.kr **Corresponding author 2:  Tel: +82-10-8482-2091, Fax: +82-53-813-4620, E-mail: jeongheuilim@gmail.com †These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/0f/b1/gni-10-206.PMC3492657.pdf
"Copyright © 2012 by the Korea Genome Organization CC It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).DNA Barcoding of Fish, Insects, and Shellfish in Korea Dae-Won Kim1†, Won Gi Yoo2†, Hyun Chul Park3,4, Hye Sook Yoo5, Dong Won Kang6,  Seon Deok Jin6, Hong Ki Min7, Woon Kee Paek6*, Jeongheui Lim8** 1Division of Malaria and Parasitic Diseases, Korea National Institute of Health, Osong 363-951, Korea, 2Codes Division,  Insilicogen Inc., Suwon 441-813, Korea, 3Forensic DNA Center, National Forensic Service, Seoul 158-707, Korea, 4School of  Biological Sciences, Seoul National University, Seoul 151-744, Korea, 5Korea Biobank, Center for Genome Science, Korea National  Institute of Health, Osong 363-951, Korea, 6Division of Natural History, National Science Museum, Daejeon 305-705, Korea,  7Natural History Museum, Hannam University, Daejeon 306-791, Korea, 8School of Biotechnology, Yeungnam University,  Gyeongsan 712-749, Korea DNA barcoding has been widely used in species identificati on and biodiversity research.",Non-OADS,/arxiv_data1/oa_pdf/0f/b1/gni-10-206.PMC3492657.pdf
Supplementary data  including one table can be found with this article online at  http://www.genominfo.org/src/sm/gni-10-206-s001.pdf.,OADS,/arxiv_data1/oa_pdf/0f/b1/gni-10-206.PMC3492657.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 EDITORIAL   Occupation & Environmental Medicine Health Care Plan for Hydrogen Fluoride Spill, Gumi, Korea Hyun-Sul Lim and Kwan Lee Department of Preventive Medicine, Dongguk Univeristy College of Medicine, Gyeongju, Koreahttp://dx.doi.org/10.3346/jkms.2012.27.11.1283   •  J Korean Med Sci 2012; 27: 1283-1284 At 3:43 p.m. on September 27, 2012, leakage of anhydrous hy - drofluoric acid occurred in a chemical plant in the Gumi indus - trial complex, Gyeongsangbuk-do, Korea.",Non-OADS,/arxiv_data1/oa_pdf/9e/36/jkms-27-1283.PMC3492659.pdf
"• Hydrogen Fluoride Spill 1284   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1283tions, including chronic lung disease, blindness, burn scars,  and esophageal stricture.",Non-OADS,/arxiv_data1/oa_pdf/9e/36/jkms-27-1283.PMC3492659.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Effect of Aditional Brief Counselling after Periodic Health  Examination on Motivation for Health Behavior Change This study was to evaluate the effect of additional brief counseling by a primary care  physician on lifestyle modification of examinees after a periodic health examination.",Non-OADS,/arxiv_data1/oa_pdf/d1/97/jkms-27-1285.PMC3492660.pdf
"Received: 20 June 2012 Accepted: 5 September 2012 Address for Correspondence: BeLong Cho, MD Department of Family Medicine, Seoul National University  College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul   1 10-744, Korea Tel: +82.2-2072-2195, Fax: +82.2-766-3276 E-mail: belong@snu.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.11.1285   •  J Korean Med Sci 2012; 27: 1285-1291ORIGINAL ARTICLE  Medicine General & Social Medicine INTRODUCTION A periodic health examination (PHE) is a proven strategy for en - hancing the delivery of many preventive health services at the  population level (1).",Non-OADS,/arxiv_data1/oa_pdf/d1/97/jkms-27-1285.PMC3492660.pdf
• Addition of Brief Counseling on PHE 1286   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1285the Transitional Ages in Korea in April 2007 to tailor program  according to age and gender and strengthen post-examination - al follow up.,Non-OADS,/arxiv_data1/oa_pdf/d1/97/jkms-27-1285.PMC3492660.pdf
• Addition of Brief Counseling on PHE http://jkms.org   1287  http://dx.doi.org/10.3346/jkms.2012.27.11.1285derstanding contents of counseling (for additional group).,Non-OADS,/arxiv_data1/oa_pdf/d1/97/jkms-27-1285.PMC3492660.pdf
"• Addition of Brief Counseling on PHE 1288   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1285were hypertensive, they were less likely to be positive changer  (P= 0.047).",Non-OADS,/arxiv_data1/oa_pdf/d1/97/jkms-27-1285.PMC3492660.pdf
"• Addition of Brief Counseling on PHE http://jkms.org   1289  http://dx.doi.org/10.3346/jkms.2012.27.11.1285cant difference in the adjusted proportion of 66-yr-old positive  changers (adjusted proportion 0.114, 95% CI 0.070-0.179 vs ad - justed proportion 0.274, 95% CI 0.200-0.362; P< 0.001) between  the basic and the additional program groups.",Non-OADS,/arxiv_data1/oa_pdf/d1/97/jkms-27-1285.PMC3492660.pdf
"• Addition of Brief Counseling on PHE 1290   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1285additional program group, especially in older age group.",Non-OADS,/arxiv_data1/oa_pdf/d1/97/jkms-27-1285.PMC3492660.pdf
• Addition of Brief Counseling on PHE http://jkms.org   1291  http://dx.doi.org/10.3346/jkms.2012.27.11.1285REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/d1/97/jkms-27-1285.PMC3492660.pdf
Available in:  http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide  2005/guide.pdf.,Non-OADS,/arxiv_data1/oa_pdf/d1/97/jkms-27-1285.PMC3492660.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Identifying Genetic Susceptibility to Sensitization to  Cephalosporins in Health Care Workers Exposure to cephalosporins could cause occupational allergic diseases in health care  workers (HCWs).",Non-OADS,/arxiv_data1/oa_pdf/7a/f9/jkms-27-1292.PMC3492661.pdf
http://dx.doi.org/10.3346/jkms.2012.27.11.1292   •  J Korean Med Sci 2012; 27: 1292-1299ORIGINAL ARTICLE   Occupation & Environmental Medicine INTRODUCTION Occupational allergies caused by medicines in the hospital   environment are becoming a problem for health care workers  (HCWs).,Non-OADS,/arxiv_data1/oa_pdf/7a/f9/jkms-27-1292.PMC3492661.pdf
"• Sensitization to Cephalosporins in Health Care Workers http://jkms.org   1293  http://dx.doi.org/10.3346/jkms.2012.27.11.1292589T > C, and IL-4-33C > T.   The present study was performed to evaluate the prevalence  of IgE and IgG sensitization to commonly used cephalosporins  in exposed HCWs and possible associations with these four can - didate SNPs.",Non-OADS,/arxiv_data1/oa_pdf/7a/f9/jkms-27-1292.PMC3492661.pdf
"• Sensitization to Cephalosporins in Health Care Workers 1294   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1292their mean age was 22.7 ±3.28 yr, which was significantly younger  than the HCWs ( P< 0.001).",OADS,/arxiv_data1/oa_pdf/7a/f9/jkms-27-1292.PMC3492661.pdf
"• Sensitization to Cephalosporins in Health Care Workers http://jkms.org   1295  http://dx.doi.org/10.3346/jkms.2012.27.11.1292Skin-prick test and serum-specific IgE and IgG antibodies  to cephalosporins SPT with cephalosporins identified a single positive response  in one (0.7%) HCW, who had a positive response to ceftriaxone.",Non-OADS,/arxiv_data1/oa_pdf/7a/f9/jkms-27-1292.PMC3492661.pdf
"• Sensitization to Cephalosporins in Health Care Workers 1296   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1292conjugate significantly more often than did those carrying the CC  or CT genotype (OR = 3.553; CI, 1.324-9.532) in multiple logistic  regression controlling for age, atopy, and occupation.",Non-OADS,/arxiv_data1/oa_pdf/7a/f9/jkms-27-1292.PMC3492661.pdf
• Sensitization to Cephalosporins in Health Care Workers http://jkms.org   1297  http://dx.doi.org/10.3346/jkms.2012.27.11.1292significantly associated with the intensity of wheat flour expo - sure and also WRS (23).,Non-OADS,/arxiv_data1/oa_pdf/7a/f9/jkms-27-1292.PMC3492661.pdf
• Sensitization to Cephalosporins in Health Care Workers 1298   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1292IgE sensitization to antibiotic exposure in the workplace.,Non-OADS,/arxiv_data1/oa_pdf/7a/f9/jkms-27-1292.PMC3492661.pdf
• Sensitization to Cephalosporins in Health Care Workers http://jkms.org   1299  http://dx.doi.org/10.3346/jkms.2012.27.11.1292236-9.,Non-OADS,/arxiv_data1/oa_pdf/7a/f9/jkms-27-1292.PMC3492661.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Human Amniotic Fluid Stem Cell-derived Muscle Progenitor Cell  Therapy for Stress Urinary Incontinence The most promising treatment for stress urinary incontinence can be a cell therapy.",Non-OADS,/arxiv_data1/oa_pdf/7c/c0/jkms-27-1300.PMC3492662.pdf
"Received: 24 April 2012 Accepted: 10 August 2012 Address for Correspondence: Tae Gyun Kwon, MD Department of Urology, Chilgok Kyungpook National University  Hospital, 807 Hoguk-ro, Buk-gu, Daegu 702-210, Korea Tel: +82.53-420-5843, Fax: +82.53-427-5447 E-mail: tgkwon@knu.ac.kr This study was supported by a grant of the Korea Healthcare  Technology R&D Project, Ministry for Health, Welfare & Family  Affairs, Republic of Korea (A091224).http://dx.doi.org/10.3346/jkms.2012.27.11.1300   •  J Korean Med Sci 2012; 27: 1300-1307ORIGINAL ARTICLE  Cell Therapy & Organ Transplantation INTRODUCTION Stress urinary incontinence (SUI) is the involuntary leakage of  urine that can occur during coughing, laughing, sneezing, or  jogging (1).",Non-OADS,/arxiv_data1/oa_pdf/7c/c0/jkms-27-1300.PMC3492662.pdf
• Muscle Progenitor Cell Therapy for Urinary Incontinence http://jkms.org   1301  http://dx.doi.org/10.3346/jkms.2012.27.11.1300urinary incontinence has been demonstrated.,Non-OADS,/arxiv_data1/oa_pdf/7c/c0/jkms-27-1300.PMC3492662.pdf
"• Muscle Progenitor Cell Therapy for Urinary Incontinence 1302   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1300Muscle progenitor cell growth assay The growth rate of the muscle progenitor cells in CM was evalu - ated using Cell Counting Kit-8 (CCK-8, Dojindo, Japan).",OADS,/arxiv_data1/oa_pdf/7c/c0/jkms-27-1300.PMC3492662.pdf
"• Muscle Progenitor Cell Therapy for Urinary Incontinence http://jkms.org   1303  http://dx.doi.org/10.3346/jkms.2012.27.11.1300Immunogenicity and tumorigenicity of muscle progenitor  cells The presence, migration and duration of injected human cells  in situ were analyzed with IHC using anti-human nuclear anti - body (Cell Signaling Technology, Danvers, MA, USA) at 1 and 2  weeks after the injection.",OADS,/arxiv_data1/oa_pdf/7c/c0/jkms-27-1300.PMC3492662.pdf
"• Muscle Progenitor Cell Therapy for Urinary Incontinence 1304   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1300progenitor and Ctrl (+) groups at week 2 was 10.98 ±2.46,  12.42 ±1.50, 21.84 ±1.13, and 22.68 ±3.03 cmH 2O, respectively.",Non-OADS,/arxiv_data1/oa_pdf/7c/c0/jkms-27-1300.PMC3492662.pdf
• Muscle Progenitor Cell Therapy for Urinary Incontinence http://jkms.org   1305  http://dx.doi.org/10.3346/jkms.2012.27.11.1300 Relative change fold to GAPDHPAX7  C- AF M C+ C- AF M C+100 80 60 40 20 0 2 w 4 wMyoD  C- AF M C+ C- AF M C+100 80 60 40 20 0 2 w 4 wMyf5  C- AF M C+ C- AF M C+120 90 60 30 0 2 w 4 wMyogenin  C- AF M C+ C- AF M C+80 60 40 20 0 2 w 4 w CACmH 2O CmH 2OLPP CP  2 w 4 w  2 w 4 w40 30 20 10 030 20 10 0† §† § * ‡*‡Ctrl (-) MusclehAFSC Ctrl (+) B DH&ECtrl (-) hAFSC Muscle Ctrl (+) MyoD SM actin HuNu   DAPICtrl (-) hAFSC Muscle CD8 DAPI Tumorigenicity Ctrl (+)Fig.,Non-OADS,/arxiv_data1/oa_pdf/7c/c0/jkms-27-1300.PMC3492662.pdf
• Muscle Progenitor Cell Therapy for Urinary Incontinence 1306   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1300progenitor cell injection with normal-appearing circular mus - cle mass regeneration at the urethral sphincter at week 4.,Non-OADS,/arxiv_data1/oa_pdf/7c/c0/jkms-27-1300.PMC3492662.pdf
"• Muscle Progenitor Cell Therapy for Urinary Incontinence http://jkms.org   1307  http://dx.doi.org/10.3346/jkms.2012.27.11.1300muscle region, which was proved by IHC analyses using hu - man nuclei-specific antibodies.",Non-OADS,/arxiv_data1/oa_pdf/7c/c0/jkms-27-1300.PMC3492662.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Epidemiological and Clinical Characteristics of Community- Acquired Severe Sepsis and Septic Shock: A Prospective  Observational Study in 12 University Hospitals in Korea A prospective multicenter observational study was performed to investigate the  epidemiology and outcomes of community-acquired severe sepsis and septic shock.",Non-OADS,/arxiv_data1/oa_pdf/e1/2d/jkms-27-1308.PMC3492663.pdf
"http://dx.doi.org/10.3346/jkms.2012.27.11.1308   •  J Korean Med Sci 2012; 27: 1308-1314ORIGINAL ARTICLE   Infectious Diseases, Microbiology & Parasitology INTRODUCTION Severe sepsis is a syndrome triggered by systemic inflammation,  coagulopathy, and acute organ dysfunction in response to in - fection (1).",Non-OADS,/arxiv_data1/oa_pdf/e1/2d/jkms-27-1308.PMC3492663.pdf
• Epidemiology of Community-Acquired Severe Sepsis  http://jkms.org   1309  http://dx.doi.org/10.3346/jkms.2012.27.11.1308past few decades.,Non-OADS,/arxiv_data1/oa_pdf/e1/2d/jkms-27-1308.PMC3492663.pdf
"• Epidemiology of Community-Acquired Severe Sepsis  1310   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1308registration at each center, and all data were checked to be with - in acceptable ranges.",OADS,/arxiv_data1/oa_pdf/e1/2d/jkms-27-1308.PMC3492663.pdf
"• Epidemiology of Community-Acquired Severe Sepsis  http://jkms.org   131 1  http://dx.doi.org/10.3346/jkms.2012.27.11.1308ples for the bacterial isolates, Streptococcus pneumoniae , S. au - reus and Klebsiella  species were more frequently isolated from  respiratory samples.",Non-OADS,/arxiv_data1/oa_pdf/e1/2d/jkms-27-1308.PMC3492663.pdf
"• Epidemiology of Community-Acquired Severe Sepsis  1312   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1308the 28-day mortality were urinary tract infection (OR, 0.33; 95%  CI, 0.17-0.59), APACHE II score (1.06; 1.02-1.09), SOFA score on  day 1 (1.11; 1.04-1.18) and metabolic dysfunction (2.09; 1.36- 3.22).",Non-OADS,/arxiv_data1/oa_pdf/e1/2d/jkms-27-1308.PMC3492663.pdf
• Epidemiology of Community-Acquired Severe Sepsis  http://jkms.org   1313  http://dx.doi.org/10.3346/jkms.2012.27.11.1308and that of 27.6% from sepsis and septic shock patients admit - ted through emergency departments in Australia and New Zea - land (17).,Non-OADS,/arxiv_data1/oa_pdf/e1/2d/jkms-27-1308.PMC3492663.pdf
• Epidemiology of Community-Acquired Severe Sepsis  1314   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1308Korean J Med 2010; 79: 526-35.,Non-OADS,/arxiv_data1/oa_pdf/e1/2d/jkms-27-1308.PMC3492663.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Phylogenetic Analysis of the 56-kDa Type-Specific Protein Genes  of Orientia tsutsugamushi  in Central Korea There are several antigenic variants of Orientia tsutsugamushi .",Non-OADS,/arxiv_data1/oa_pdf/bc/7e/jkms-27-1315.PMC3492664.pdf
"Key Words:  Orientia tsutsugamushi ; 56-kDa Type-Specific Antigen; Boryong Genotype;  Kawasaki GenotypeHye Won Jeong1, Young Ki Choi2,  Yun Hee Baek2, and Mun Hyuk Seong3 Departments of 1Internal Medicine, 2Microbiology,  Chungbuk National University College of Medicine,  Cheongju; 3Department of Internal Medicine, Seoul  National University Bundang Hospital, Seongnam,  Korea Received: 3 February 2012 Accepted: 22 August 2012 Address for Correspondence: Hye Won Jeong, MD Department of Internal Medicine, Chungbuk National University  College of Medicine, 410 Seongbong-ro, Heungdeok-gu,  Cheongju 361-71 1, Korea Tel: +82.43-269-6302, Fax: +82.43-273-3252 E-mail: hwjeong@chungbuk.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.11.1315   •  J Korean Med Sci 2012; 27: 1315-1319ORIGINAL ARTICLE   Infectious Diseases, Microbiology & Parasitology INTRODUCTION Tsutsugamushi disease (scrub typhus) occurs throughout Korea  on a yearly basis and the number of the reported cases has in - creased recently.",Non-OADS,/arxiv_data1/oa_pdf/bc/7e/jkms-27-1315.PMC3492664.pdf
"• Genotypes of Orientia tsutsugamushi in Korea 1316   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1315on the presence of an eschar or maculopapular skin rash with  at least two of the following symptoms: fever, myalgia, nausea,  cough, headache, generalized weakness and abdominal dis - comfort.",Non-OADS,/arxiv_data1/oa_pdf/bc/7e/jkms-27-1315.PMC3492664.pdf
• Genotypes of Orientia tsutsugamushi in Korea http://jkms.org   1317  http://dx.doi.org/10.3346/jkms.2012.27.11.1315phylogenetically (Fig.,Non-OADS,/arxiv_data1/oa_pdf/bc/7e/jkms-27-1315.PMC3492664.pdf
"• Genotypes of Orientia tsutsugamushi in Korea 1318   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1315performed on the 37 patients using an IFA based upon the 56- kDa type-specific antigen from the Gilliam, Karp and Boryong  serotypes.",Non-OADS,/arxiv_data1/oa_pdf/bc/7e/jkms-27-1315.PMC3492664.pdf
"• Genotypes of Orientia tsutsugamushi in Korea http://jkms.org   1319  http://dx.doi.org/10.3346/jkms.2012.27.11.1315Karp and Boryong strains, the sensitivity of the diagnostic test  was significantly lower for the Kawasaki strain than for the Bo - ryong strain (16).",OADS,/arxiv_data1/oa_pdf/bc/7e/jkms-27-1315.PMC3492664.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Cord Blood Cellular Proliferative Response as a Predictive Factor  for Atopic Dermatitis at 12 Months  Since the risk of developing allergic disease increases in individuals exposed to  allergens previously, even during the neonatal period, the immunologic status of a  fetus may be important in the subsequent development of allergy.",Non-OADS,/arxiv_data1/oa_pdf/39/30/jkms-27-1320.PMC3492665.pdf
"Key Words:  Atopic Dermatitis; Cohort; Cord Blood; Cellular Proliferative Response;  Cytokine; Risk FactorHyo-Bin Kim1, Kang Mo Ahn2,  Kyung Won Kim3, Youn Ho Shin4, Jinho Yu5,  Ju-Hee Seo5, Hyung Young Kim5,  Ji-Won Kwon6, Byoung-Ju Kim7,  Ja-Young Kwon8, Suk-Joo Choi9,  Kyung-Ju Lee10, Hee Jin Park10,  Hye-Sung Won1 1, and Soo-Jong Hong5 1Department of Pediatrics, Inje University Sanggye Paik  Hospital, Seoul; 2Department of Pediatrics, Samsung  Medical Center, Sungkyunkwan University School of  Medicine, Seoul; 3Department of Pediatrics, Yonsei  University College of Medicine, Seoul; 4Department of  Pediatrics, CHA Medical Center, CHA University College  of Medicine, Seoul; 5Department of Pediatrics, Childhood  Asthma Atopy Center, Research Center for  Standardization of Allergic Diseases, Asan Medical  Center, University of Ulsan College of Medicine, Seoul;  6Department of Pediatrics, Seoul National University  Bundang Hospital, Seongnam; 7Department of Pediatrics,  Inje University Haeundae Paik Hospital, Busan;  8Department of Obstetrics and Gynecology, Yonsei  University College of Medicine, Seoul; 9Department of  Obstetrics and Gynecology, Samsung Medical Center,  Sungkyunkwan University School of Medicine, Seoul;  10Department of Obstetrics and Gynecology, CHA  University College of Medicine, Seoul; 1 1Department of  Obstetrics and Gynecology, Asan Medical Center,  University of Ulsan College of Medicine, Seoul, Korea Received: 8 June 2012 Accepted: 25 September 2012 Address for Correspondence: Soo-Jong Hong, MD Department of Pediatrics, Childhood Asthma Atopy Center, Research  Center for Standardization of Allergic Diseases, University of Ulsan  College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul   138-736, Korea  Tel: +82.2-3010-3379, Fax: +82.2-473-3725 E-mail: sjhong@amc.seoul.kr This study was supported by a fund (2008-E33030-00, 2009-E33033- 00, 201 1-E33021-00) from the Research of Korea Centers for Disease  Control and Prevention.http://dx.doi.org/10.3346/jkms.2012.27.11.1320   •  J Korean Med Sci 2012; 27: 1320-1326ORIGINAL ARTICLE Immunology, Allergic Disorders & Rheumatology INTRODUCTION Although allergic diseases are increasing recently both world - wide and in Korea (1-4), the reason for these increases, their  risk factors and the onset period for allergic disease have not  been determined.",Non-OADS,/arxiv_data1/oa_pdf/39/30/jkms-27-1320.PMC3492665.pdf
"• Cord Blood Cell Proliferation as a Predictor of AD http://jkms.org   1321  http://dx.doi.org/10.3346/jkms.2012.27.11.1320munological bias toward atopy and asthma may be established  in utero during the development of the fetal immune system (6,  10) and may be detected by assays of cord blood.",Non-OADS,/arxiv_data1/oa_pdf/39/30/jkms-27-1320.PMC3492665.pdf
• Cord Blood Cell Proliferation as a Predictor of AD 1322   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1320Ethics statement The study protocol was approved by the institutional review  board of Asan Medical Center (IRB No.,Non-OADS,/arxiv_data1/oa_pdf/39/30/jkms-27-1320.PMC3492665.pdf
"• Cord Blood Cell Proliferation as a Predictor of AD http://jkms.org   1323  http://dx.doi.org/10.3346/jkms.2012.27.11.1320However, maternal education level was not associated with the  development of AD at 12 months ( P= 0.101).",Non-OADS,/arxiv_data1/oa_pdf/39/30/jkms-27-1320.PMC3492665.pdf
• Cord Blood Cell Proliferation as a Predictor of AD 1324   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1320to PHA stimulation may be a predictor of AD during infancy.,Non-OADS,/arxiv_data1/oa_pdf/39/30/jkms-27-1320.PMC3492665.pdf
"• Cord Blood Cell Proliferation as a Predictor of AD http://jkms.org   1325  http://dx.doi.org/10.3346/jkms.2012.27.11.1320the latter may be more accurate, the small number of patients  can be limitation of our study.",Non-OADS,/arxiv_data1/oa_pdf/39/30/jkms-27-1320.PMC3492665.pdf
• Cord Blood Cell Proliferation as a Predictor of AD 1326   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.132017.,Non-OADS,/arxiv_data1/oa_pdf/39/30/jkms-27-1320.PMC3492665.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Quality of Life and Disease Severity Are Correlated in Patients  with Atopic Dermatitis Quantification of quality of life (QOL) related to disease severity is important in patients  with atopic dermatitis (AD), because the assessment provides additional information to the  traditional objective clinical scoring systems.",Non-OADS,/arxiv_data1/oa_pdf/4c/65/jkms-27-1327.PMC3492666.pdf
"Key Words:  Atopic Dermatitis; Disease Severity; Quality of LifeDong Ha Kim1, Kapsok Li1,  Seong Jun Seo1, Sun Jin Jo2,  Hyeon Woo Yim2, Churl Min Kim3,  Kyu Han Kim4, Do Won Kim5,  Moon-Bum Kim6, Jin Woo Kim7,  Young Suck Ro8, Young Lip Park9,  Chun Wook Park10, Seung-Chul Lee1 1,  and Sang Hyun Cho7 1Department of Dermatology, Chung-Ang University  College of Medicine, Seoul; Departments of  2Preventive Medicine, 3Family Medicine, The Catholic  University of Korea College of Medicine, Seoul;  4Department of Dermatology, Seoul National  University College of Medicine, Seoul; 5Department  of Dermatology, Kyungpook National University  College of Medicine, Daegu; 6Department of  Dermatology, Pusan National University College of  Medicine, Busan; 7Department of Dermatology, The  Catholic University of Korea College of Medicine,  Seoul; 8Department of Dermatology, Hanyang  University College of Medicine, Seoul; 9Department  of Dermatology, Soonchunhyang University College  of Medicine, Cheonan; 10Department of Dermatology,  Hallym University College of Medicine, Seoul;  1 1Department of Dermatology, Chonnam National  University College of Medicine, Gwangju, Korea Received: 8 October 201 1 Accepted: 27 August 2012 Address for Correspondence: Seong Jun Seo, MD Department of Dermatology, Chung-Ang University Hospital,   29 Heukseok-ro, Dongjak-gu, Seoul 156-755, Korea Tel: +82.2-6299-1538, Fax: +82.2-823-1049 E-mail: drseo@hanafos.comhttp://dx.doi.org/10.3346/jkms.2012.27.11.1327   •  J Korean Med Sci 2012; 27: 1327-1332ORIGINAL ARTICLE     Immunology, Allergic Disorders & Rheumatology INTRODUCTION Atopic dermatitis (AD) is a pruritic, chronic, relapsing, inflam - matory skin condition that affects between 2% and 7% of adults  worldwide (1), with the overall prevalence of AD reported to  have increased over the last 3 decades.",Non-OADS,/arxiv_data1/oa_pdf/4c/65/jkms-27-1327.PMC3492666.pdf
• Quality of Life and Disease Severity in Atopic Dermatitis 1328   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1327ease severity or if it substantially differs from the QOL of the gen - eral public (7).,Non-OADS,/arxiv_data1/oa_pdf/4c/65/jkms-27-1327.PMC3492666.pdf
• Quality of Life and Disease Severity in Atopic Dermatitis http://jkms.org   1329  http://dx.doi.org/10.3346/jkms.2012.27.11.1327used for all analyses.,Non-OADS,/arxiv_data1/oa_pdf/4c/65/jkms-27-1327.PMC3492666.pdf
• Quality of Life and Disease Severity in Atopic Dermatitis 1330   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1327The 10 detailed dimensions of the IDQOL can be seen in Table 3.,Non-OADS,/arxiv_data1/oa_pdf/4c/65/jkms-27-1327.PMC3492666.pdf
• Quality of Life and Disease Severity in Atopic Dermatitis http://jkms.org   1331  http://dx.doi.org/10.3346/jkms.2012.27.11.1327general practices.,Non-OADS,/arxiv_data1/oa_pdf/4c/65/jkms-27-1327.PMC3492666.pdf
• Quality of Life and Disease Severity in Atopic Dermatitis 1332   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1327dermatitis in Korea: analysis by using national statistics.,Non-OADS,/arxiv_data1/oa_pdf/4c/65/jkms-27-1327.PMC3492666.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Association of Toll-Like Receptor 2 Polymorphisms with Papillary  Thyroid Cancer and Clinicopathologic Features in a Korean  Population Toll-like receptors (TLRs) single nucleotide polymorphisms (SNPs) were analyzed in patients  with papillary thyroid cancer (PTC; n = 133) and their clinicopathologic features and age- matched controls (n = 321) using direct sequencing.",Non-OADS,/arxiv_data1/oa_pdf/51/77/jkms-27-1333.PMC3492667.pdf
"Key Words:  Papillary Thyroid Cancer; Single Nucleotide Polymorphisms; Clinicopathologic  Characteristics; Toll-Like Receptors Mi Kyeong Kim1, Sung Wook Park1,  Su Kang Kim2, Hae Jeong Park2,  Young Gyu Eun3, Kee Hwan Kwon4,  and Jinju Kim2,5 1Department of Anesthesiology and Pain Medicine,  Kyung Hee University School of Medicine, Seoul;   2Kohwang Medical Research Institute, Kyung Hee  University School of Medicine, Seoul; 3Department  of Otolaryngology-Head and Neck Surgery, Kyung  Hee University School of Medicine, Seoul;  4Department of Otorhinolaryngology-Head and  Neck Surgery, Ilsong Memorial Institute of Head and  Neck Cancer, Hallym University College of Medicine,  Anyang; 5Department of Oriental Physiology, Kyung  Hee University College of Pharmacy, Seoul, Korea Received: 4 January 2012 Accepted: 27 August 2012 Address for Correspondence: Jinju Kim, PhD Department of Oriental Physiology, College of Pharmacy,   School of Medicine and Kohwang Medical Research Institute,   Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu,  Seoul 130-701, Korea Tel: +82.2-961-9437, Fax: +82.2-968-0560 E-mail: shdwer@khu.ac.kr This research was supported by the Kyung Hee University  Research Fund in 2010 (KHU-20101889).http://dx.doi.org/10.3346/jkms.2012.27.11.1333   •  J Korean Med Sci 2012; 27: 1333-1338ORIGINAL ARTICLE    Oncology & Hematology INTRODUTION Thyroid cancer is characterized by the most common endocrine  malignant carcinoma and is one of the fastest growing cancer  diagnoses worldwide.",Non-OADS,/arxiv_data1/oa_pdf/51/77/jkms-27-1333.PMC3492667.pdf
"The TLR2  gene is located in the  chromosome 4p32 protein coding gene, and is expressed most  abundantly in peripheral blood leukocytes, and mediates host  response (http://www.ncbi.nlm.nih.gov/gene).",Non-OADS,/arxiv_data1/oa_pdf/51/77/jkms-27-1333.PMC3492667.pdf
• Association of TLR2 Polymorphism with Papillary Thyroid Cancer  1334   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1333TLR2  contribute to the development of PTC.,Non-OADS,/arxiv_data1/oa_pdf/51/77/jkms-27-1333.PMC3492667.pdf
"SNP selection and genotyping For the selection among TLR2  SNPs, we searched the synony - mous SNPs of the TLR2  gene in the SNP database of the National  Center for Biotechnology Information (http://www.ncbi.nlm.",OADS,/arxiv_data1/oa_pdf/51/77/jkms-27-1333.PMC3492667.pdf
Statistical analysis Hardy–Weinberg equilibrium (HWE) was estimated using SNP- Stats (http://bioinfo.iconcologia.net/index.php?module = Snp-  stats) in both the patient and control groups.,OADS,/arxiv_data1/oa_pdf/51/77/jkms-27-1333.PMC3492667.pdf
"• Association of TLR2 Polymorphism with Papillary Thyroid Cancer  http://jkms.org   1335  http://dx.doi.org/10.3346/jkms.2012.27.11.1333ter, Seoul, Korea (20040915).",Non-OADS,/arxiv_data1/oa_pdf/51/77/jkms-27-1333.PMC3492667.pdf
"• Association of TLR2 Polymorphism with Papillary Thyroid Cancer  1336   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1333[reference T/T vs T/C]; P= 0.018, OR, 0.42, 95% CI, 0.21-0.87 in  dominant model [reference T/T vs T/C + C/C]; P= 0.011, OR,  0.46; 95% CI, 0.25-0.85 in log-additive model [reference T/T vs  T/C vs C/C], respectively) and allele distributions ( P= 0.019,  OR, 0.52; 95% CI, 0.30-0.90, reference T vs C) (Table 4).",Non-OADS,/arxiv_data1/oa_pdf/51/77/jkms-27-1333.PMC3492667.pdf
We calculated sample  power to verify our data (http://pngu.mgh.harvard.edu/~pur-  cell/gpc/cc2.html).,OADS,/arxiv_data1/oa_pdf/51/77/jkms-27-1333.PMC3492667.pdf
"• Association of TLR2 Polymorphism with Papillary Thyroid Cancer  http://jkms.org   1337  http://dx.doi.org/10.3346/jkms.2012.27.11.1333cutaneous manifestations in a Japanese population (18), and  rs3804099 was suggested as a relevant risk estimate for the de - velopment of sepsis and multiple organ dysfunction in Chinese  patients with major trauma (19).",Non-OADS,/arxiv_data1/oa_pdf/51/77/jkms-27-1333.PMC3492667.pdf
• Association of TLR2 Polymorphism with Papillary Thyroid Cancer  1338   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1333nation and timing: the signal integration model of dendritic cell activa - tion.,Non-OADS,/arxiv_data1/oa_pdf/51/77/jkms-27-1333.PMC3492667.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Safety and Efficacy of Overlapping Homogenous Drug-Eluting  Stents in Patients with Acute Myocardial Infarction: Results from  Korea Acute Myocardial Infarction Registry  The aim of this study was to compare safety and efficacy of 4 homogenous overlapping  drug-eluting stents (DES) in acute myocardial infarction (AMI) patients.",Non-OADS,/arxiv_data1/oa_pdf/20/54/jkms-27-1339.PMC3492668.pdf
"Key Words:  Drug-Eluting Stents; Myocardial Infarction; Coronary Angioplasty  Khurshid Ahmed1,2, Myung Ho Jeong1,  Rabin Chakraborty2, Young Joon Hong1,  Doo Sun Sim1, Sumera Ahmed2,  Seung Hwan Hwang1, Min Goo Lee1,  Keun Ho Park1, Ju Han Kim1,  Youngkeun Ahn1, Myeong Chan Cho3,  Chong Jin Kim4, Young Jo Kim5,  Jong Chun Park1, Jung Chaee Kang1,  and The Korea Acute Myocardial  Infarction Registry Investigators 1The Heart Center of Chonnam National University  Hospital, Chonnam National University Research  Institute of Medical Sciences, Gwangju, Korea;  2Department of Cardiology, Apollo Gleneagles  Hospital, Kolkata, India; 3Department of Cardiology,  Chungbuk National University Hospital, Cheongju,  Korea; 4Department of Cardiology, East West Neo  Medical Center, Seoul, Korea; 5Department of  Cardiology, Yeungnam University Hospital, Daegu,  Korea Received: 1 1 March 2012 Accepted: 5 September 2012 Address for Correspondence: Myung Ho Jeong, MD Principal Investigator of Korea Acute Myocardial Infarction  Registry, Director of Heart Research Center Nominated by Korea  Ministry of Health & Welfare, Director of Department of  Education and Research, Chonnam National University Hospital,  671 Jaebong-ro, Dong-gu, Gwangju 501-757, Korea Tel: +82.62-220-6243, Fax: +82.62-228-7174 E-mail: myungho@chollian.net This study was performed with the support of the Korean  Society of Circulation in the memorandum of the 50th  Anniversary of the Korean Society of Circulation and Korea  Ministry of Health and Welfare (A084869), Republic of Korea.http://dx.doi.org/10.3346/jkms.2012.27.11.1339   •  J Korean Med Sci 2012; 27: 1339-1346ORIGINAL ARTICLE Cardiovascular Disorders INTRODUCTION Drug-eluting stents (DES) substantially reduce the risk of reste - nosis and target lesion revascularization (TLR) compared with  bare metal stents (BMS), particularly in complex coronary dis - ease (1).",Non-OADS,/arxiv_data1/oa_pdf/20/54/jkms-27-1339.PMC3492668.pdf
"• Overlapping DES in AMI 1340   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1339regarding the safety and efficacy of overlapping DES because of  the increased density of polymer, drug, and stent material (10,  11).",Non-OADS,/arxiv_data1/oa_pdf/20/54/jkms-27-1339.PMC3492668.pdf
"• Overlapping DES in AMI http://jkms.org   1341  http://dx.doi.org/10.3346/jkms.2012.27.11.1339cedure, aspirin 100-200 mg (1 time per day) was prescribed in - definitely.",Non-OADS,/arxiv_data1/oa_pdf/20/54/jkms-27-1339.PMC3492668.pdf
• Overlapping DES in AMI 1342   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1339highest in EES ( P= 0.019) and nicorandil in ZES ( P= 0.033)  group.,OADS,/arxiv_data1/oa_pdf/20/54/jkms-27-1339.PMC3492668.pdf
"• Overlapping DES in AMI http://jkms.org   1343  http://dx.doi.org/10.3346/jkms.2012.27.11.1339P= 0.032, respectively).",OADS,/arxiv_data1/oa_pdf/20/54/jkms-27-1339.PMC3492668.pdf
• Overlapping DES in AMI 1344   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1339vantage of DES is that they allow higher local drug concentra - tions at lesion sites while avoiding systemic toxicity.,Non-OADS,/arxiv_data1/oa_pdf/20/54/jkms-27-1339.PMC3492668.pdf
"• Overlapping DES in AMI http://jkms.org   1345  http://dx.doi.org/10.3346/jkms.2012.27.11.1339 In conclusion this study demonstrates that any of the 4 types  of overlapping homogenous DES (PES, SES, ZES, or EES) is ac - ceptable to treat AMI patients and there are no significant dif - ferences in their 12-month MACEs.",Non-OADS,/arxiv_data1/oa_pdf/20/54/jkms-27-1339.PMC3492668.pdf
• Overlapping DES in AMI 1346   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1339layed healing and persistent inflammation at sites of overlapping siroli - mus- or paclitaxel-eluting stents.,Non-OADS,/arxiv_data1/oa_pdf/20/54/jkms-27-1339.PMC3492668.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Comparison of Clinical and Imaging Characteristics and  Outcomes between Provoked and Unprovoked Acute Pulmonary  Embolism in Koreans This study was performed to compare clinical and imaging parameters and prognosis of  unprovoked pulmonary embolism (PE), provoked PE with reversible risk factors (provoked- rRF), and provoked PE with irreversible risk factors (provoked-iRF) in Koreans.",Non-OADS,/arxiv_data1/oa_pdf/0d/f0/jkms-27-1347.PMC3492669.pdf
"Key Words:  CT Obstruction Index; Provoked; Pulmonary Embolism; Unprovoked Jae-Sun Uhm, Hae-Ok Jung,   Chan-Joon Kim, Tae-Hoon Kim,   Ho-Joong Youn, Sang Hong Baek,   Wook-Sung Chung, and Ki Bae Seung Division of Cardiology, Department of Internal  Medicine, The Catholic University of Korea College  of Medicine, Seoul, Korea Received: 23 April 2012 Accepted: 14 August 2012 Address for Correspondence: Hae-Ok Jung, MD Cardiovascular Center, Seoul St. Mary’s Hospital, The Catholic  University of Korea, 222 Banpo-daero, Seocho-gu, Seoul   137-701, Korea Tel: +82-2.2258-1 134, Fax: +82.2-2258-1506 E-mail: hojheart@catholic.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.11.1347   •  J Korean Med Sci 2012; 27: 1347-1353ORIGINAL ARTICLE    Cardiovascular Disorders INTRODUCTION Acute pulmonary embolism (PE) is a serious, potentially fatal  disease in Asians as well as Caucasians, although there are ra - cial differences in the prevalence of PE (1-3).",Non-OADS,/arxiv_data1/oa_pdf/0d/f0/jkms-27-1347.PMC3492669.pdf
"• Provoked and Unprovoked Pulmonary Embolism 1348   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1347voked PE was defined as PE not related to risk factors including  cancer, immobilization (due to neurologic sequelae, fracture of  the lower extremities, major surgery, or admission to ICU due  to medical disease) for more than a week, pregnancy, or estro - gen supplement within the past 3 months.",Non-OADS,/arxiv_data1/oa_pdf/0d/f0/jkms-27-1347.PMC3492669.pdf
• Provoked and Unprovoked Pulmonary Embolism http://jkms.org   1349  http://dx.doi.org/10.3346/jkms.2012.27.11.1347sitivity.,Non-OADS,/arxiv_data1/oa_pdf/0d/f0/jkms-27-1347.PMC3492669.pdf
"• Provoked and Unprovoked Pulmonary Embolism 1350   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1347Imaging parameters  The numbers of patients who underwent both CT and echocar - diography were 87, 27, and 80 in the unprovoked, provoked-rRF ,  and provoked-iRF groups, respectively.",Non-OADS,/arxiv_data1/oa_pdf/0d/f0/jkms-27-1347.PMC3492669.pdf
"• Provoked and Unprovoked Pulmonary Embolism http://jkms.org   1351  http://dx.doi.org/10.3346/jkms.2012.27.11.1347Treatment The numbers of patients treated with surgery or thrombolytics  were 10 (3.3%) and 16 (5.3%), respectively.",Non-OADS,/arxiv_data1/oa_pdf/0d/f0/jkms-27-1347.PMC3492669.pdf
• Provoked and Unprovoked Pulmonary Embolism 1352   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1347tality than the unprovoked and provoked-rRF groups.,Non-OADS,/arxiv_data1/oa_pdf/0d/f0/jkms-27-1347.PMC3492669.pdf
"• Provoked and Unprovoked Pulmonary Embolism http://jkms.org   1353  http://dx.doi.org/10.3346/jkms.2012.27.11.1347Prins MH, Girolami A.",Non-OADS,/arxiv_data1/oa_pdf/0d/f0/jkms-27-1347.PMC3492669.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Onodera’s Prognostic Nutritional Index as a Risk Factor for  Mortality in Peritoneal Dialysis Patients The aim of this study was to evaluate the clinical relevance and usefulness of the Onodera’s  prognostic nutritional index (OPNI) as a prognostic and nutritional indicator in peritoneal  dialysis (PD) patients.",Non-OADS,/arxiv_data1/oa_pdf/ae/16/jkms-27-1354.PMC3492670.pdf
"Key Words:  Onodera’s Prognostic Nutritional Index; Peritoneal Dialysis; Nutrition;  Mortality; Albumin; Edema indexSeok Hui Kang, Kyu Hyang Cho,   Jong Won Park, Kyung Woo Yoon,   and Jun Young Do Division of Nephrology, Department of Internal  Medicine, Yeungnam University Hospital, Daegu,  Korea Received: 3 June 2012 Accepted: 27 August 2012 Address for Correspondence: Jun-Young Do, MD Department of Internal Medicine, Yeungnam University Hospital,  170 Hyeonchung-ro, Nam-gu, Daegu 705-717, Korea Tel: +82.53-680-3844, Fax: +82.53-654-8386 E-mail: jydo@med.yu.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.11.1354   •  J Korean Med Sci 2012; 27: 1354-1358ORIGINAL ARTICLE    Nephrology INTRODUCTION Malnutrition is a common unfavorable complication prevalent  in peritoneal dialysis (PD) patients and is associated with mor - bidity and mortality in these patients (1-5).",Non-OADS,/arxiv_data1/oa_pdf/ae/16/jkms-27-1354.PMC3492670.pdf
"• Onodera’s Prognostic Nutritional Index in Dialysis Patients http://jkms.org   1355  http://dx.doi.org/10.3346/jkms.2012.27.11.1354pearance (g/kg/day), C-reactive protein (CRP; mg/dL), serum  albumin (g/dL), total cholesterol (mg/dL), residual renal func - tion (RRF; mL/min/1.73 m2), edema index, PD modality, and  fat mass (kg).",Non-OADS,/arxiv_data1/oa_pdf/ae/16/jkms-27-1354.PMC3492670.pdf
"• Onodera’s Prognostic Nutritional Index in Dialysis Patients 1356   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1354group A, 41.9 (1-181) months in group B, and 37.6 (1-174) months  in group C. Twenty-seven patients (5.2%) had liver or spleen  diseases.",Non-OADS,/arxiv_data1/oa_pdf/ae/16/jkms-27-1354.PMC3492670.pdf
• Onodera’s Prognostic Nutritional Index in Dialysis Patients http://jkms.org   1357  http://dx.doi.org/10.3346/jkms.2012.27.11.1354inflammation or hydration than the nutritional status.,Non-OADS,/arxiv_data1/oa_pdf/ae/16/jkms-27-1354.PMC3492670.pdf
• Onodera’s Prognostic Nutritional Index in Dialysis Patients 1358   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1354prealbumin and other nutritional and metabolic parameters.,Non-OADS,/arxiv_data1/oa_pdf/ae/16/jkms-27-1354.PMC3492670.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Determinants of Brachial-Ankle Pulse Wave Velocity in  Normotensive Young Adults with Type 2 Diabetes Mellitus Brachial–ankle pulse wave velocity (baPWV) is simple, noninvasive method which correlates  well with arterial stiffness.",Non-OADS,/arxiv_data1/oa_pdf/a4/00/jkms-27-1359.PMC3492671.pdf
"Key Words:  Pulse Wave Velocity; Type 2 Diabetes; NormotensionBo Gwang Choi1, Ji Hyun Kang2,  Yun Kyung Jeon3, Sang Soo Kim3,  Chang Won Lee4, In Joo Kim3,5,  Yong Ki Kim1, and Bo Hyun Kim3,5 1Kim Yong Ki Internal Medicine Clinic, Busan;  2Department of Internal Medicine, Dong Eui Medical  Center, Busan; 3Department of Internal Medicine,  Pusan National University School of Medicine,  Busan; 4Department of Internal Medicine, Busan  St. Mary’s Hospital, Busan; 5Biomedical Research  Institute, Pusan National University, Busan, Korea Received: 23 April 2012 Accepted: 14 August 2012 Address for Correspondence: Bo Hyun Kim, MD Division of Endocrinology and Metabolism, Department of  Internal Medicine, Pusan National University School of  Medicine, 305 Gudeok-ro, Seo-gu, Busan 602-739, Korea Tel: +82.51-240-7983, Fax: +82.51-254-3237 E-mail: pons71@hanmail.net This study was supported by a grant of the Korean Health  Technology R&D Project, Ministry of Health and Welfare,  Republic of Korea (A070001).http://dx.doi.org/10.3346/jkms.2012.27.11.1359   •  J Korean Med Sci 2012; 27: 1359-1363ORIGINAL ARTICLE   Endocrinology, Nutrition & Metabolism INTRODUCTION Epidemiological studies have reported that patients with type 2  diabetes mellitus (DM) have increased mortality and morbidity  from cardiovascular diseases, independent of other risk factors  (1, 2).",Non-OADS,/arxiv_data1/oa_pdf/a4/00/jkms-27-1359.PMC3492671.pdf
"• Pulse Wave Velocity Related Factors in Diabetic Patients  1360   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1359MATERIALS AND METHODS Patients We measured baPWV with a noninvasive pulse wave analyzer  (form PWV/ABI, Colin Co., Komaki, Japan) in 2,728 consecu - tive type 2 diabetic patients in Department of Endocrinology  and Metabolism, Pusan National University Hospital, between  January 2008 to January 2011.",OADS,/arxiv_data1/oa_pdf/a4/00/jkms-27-1359.PMC3492671.pdf
• Pulse Wave Velocity Related Factors in Diabetic Patients  http://jkms.org   1361  http://dx.doi.org/10.3346/jkms.2012.27.11.13590.003).,Non-OADS,/arxiv_data1/oa_pdf/a4/00/jkms-27-1359.PMC3492671.pdf
"• Pulse Wave Velocity Related Factors in Diabetic Patients  1362   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1359DISCUSSION In prior studies, arterial stiffness was associated with age, gen - der, mean blood pressure, heart rate, obesity, dyslipidemia and  hyperglycemia (14, 19, 20).",Non-OADS,/arxiv_data1/oa_pdf/a4/00/jkms-27-1359.PMC3492671.pdf
• Pulse Wave Velocity Related Factors in Diabetic Patients  http://jkms.org   1363  http://dx.doi.org/10.3346/jkms.2012.27.11.1359REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/a4/00/jkms-27-1359.PMC3492671.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves  Vascular Endothelial Function in Type 2 Diabetes The vascular endothelial function is impaired in the very early stage of atherosclerosis in  diabetic patients.",Non-OADS,/arxiv_data1/oa_pdf/1c/a2/jkms-27-1364.PMC3492672.pdf
"Key Words:  Endothelial Function; Dipeptidyl Peptidase-4 Inhibitor; Adiponectin; Type 2  Diabetes MellitusYoshiaki Kubota, Masaaki Miyamoto,  Gen Takagi, Takeshi Ikeda,   Sonoko Kirinoki-Ichikawa,   Kotoko Tanaka, and Kyoichi Mizuno Department of Cardiovascular Medicine, Nippon  Medical School, Tokyo, Japan Received: 5 July 2012 Accepted: 27 August 2012 Address for Correspondence: Masaaki Miyamoto, MD Department of Cardiovascular Medicine, Nippon Medical  School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 1 13-8603, Japan Tel: +81.3-3822-2131, Fax: +81.3-5814-6050 E-mail: miyamoto-m@nms.ac.jphttp://dx.doi.org/10.3346/jkms.2012.27.11.1364   •  J Korean Med Sci 2012; 27: 1364-1370ORIGINAL ARTICLE    Endocrinology, Nutrition & Metabolism INTRODUCTION Diabetes mellitus (DM) is one of the most major risk factors for  cardiovascular diseases, primarily as the result of adverse chang - es in arteries.",Non-OADS,/arxiv_data1/oa_pdf/1c/a2/jkms-27-1364.PMC3492672.pdf
• Sitagliptin Improves Endothelial Function http://jkms.org   1365  http://dx.doi.org/10.3346/jkms.2012.27.11.1364type 2 DM and with inadequate glucose control (defined as  6.5% ≤Hemoglobin A1c [HbA1c] < 10%) even after dietary  and exercise therapies for ≥8 weeks.,Non-OADS,/arxiv_data1/oa_pdf/1c/a2/jkms-27-1364.PMC3492672.pdf
• Sitagliptin Improves Endothelial Function 1366   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1364ous Japanese standard substance and measurement methods  and HbA1c (NGSP).,Non-OADS,/arxiv_data1/oa_pdf/1c/a2/jkms-27-1364.PMC3492672.pdf
"• Sitagliptin Improves Endothelial Function http://jkms.org   1367  http://dx.doi.org/10.3346/jkms.2012.27.11.1364sulin resistance, carotid IMT and ba-PWV did not change.",Non-OADS,/arxiv_data1/oa_pdf/1c/a2/jkms-27-1364.PMC3492672.pdf
"• Sitagliptin Improves Endothelial Function 1368   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1364DISCUSSION The current findings were that %FMD was increased, NMD did  not change, HbA1c and ADMA levels were decreased ( P< 0.001),  plasma adiponectin levels were increased ( P< 0.001) after 12  weeks of treatment.",Non-OADS,/arxiv_data1/oa_pdf/1c/a2/jkms-27-1364.PMC3492672.pdf
• Sitagliptin Improves Endothelial Function http://jkms.org   1369  http://dx.doi.org/10.3346/jkms.2012.27.11.13643.,Non-OADS,/arxiv_data1/oa_pdf/1c/a2/jkms-27-1364.PMC3492672.pdf
• Sitagliptin Improves Endothelial Function 1370   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1364tension.,Non-OADS,/arxiv_data1/oa_pdf/1c/a2/jkms-27-1364.PMC3492672.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Behavioral and Healthcare-Associated Risk Factors for Chronic  Hepatitis C Virus Infection in Korea    The risk factors related to hepatitis C virus (HCV) infection showed geographic and temporal  differences.",Non-OADS,/arxiv_data1/oa_pdf/ed/a0/jkms-27-1371.PMC3492673.pdf
"Received: 7 May 2012 Accepted: 27 August 2012 Address for Correspondence: Sook-Hyang Jeong, MD Department of Internal Medicine, Seoul National University  Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundanag-gu,  Seongnam 463-707, Korea Tel: +82.31-787-7034, Fax: +82.31-787-4052 E-mail: jsh@snubh.org   This study was supported by a grant from the Korea Centers for  Disease Control and Prevention (2012-E4-200300).http://dx.doi.org/10.3346/jkms.2012.27.11.1371   •  J Korean Med Sci 2012; 27: 1371-1377ORIGINAL ARTICLE  Gastroenterology & Hepatology INTRODUCTION Hepatitis C virus (HCV) infection is one of the most common  causes of chronic liver disease worldwide, affecting about 170  million people (1).",Non-OADS,/arxiv_data1/oa_pdf/ed/a0/jkms-27-1371.PMC3492673.pdf
"• Risk Factors for Hepatitis C Virus Infection in Korea    1372   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1371Although transfusion before 1992 was a strong factor for HCV  transmission (13, 14), studies of HCV epidemiology with regard  to other risk factors, such as injection drug use, needle stick in - jury, surgery, and tattooing have been limited in Korea (15-17).",Non-OADS,/arxiv_data1/oa_pdf/ed/a0/jkms-27-1371.PMC3492673.pdf
• Risk Factors for Hepatitis C Virus Infection in Korea    http://jkms.org   1373  http://dx.doi.org/10.3346/jkms.2012.27.11.1371Table 1.,Non-OADS,/arxiv_data1/oa_pdf/ed/a0/jkms-27-1371.PMC3492673.pdf
"• Risk Factors for Hepatitis C Virus Infection in Korea    1374   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1371 In the multivariate logistic regression, we excluded smoking  status, marital status, and piercing, because smoking status was  highly correlated with alcohol drinking status (Spearman’s cor - relation coefficient, 0.57; P< 0.001), marital status was highly  correlated with age (Spearman’s correlation coefficient, 0.45;  P< 0.001), and piercing was significantly correlated with tattoo - ing by Spearman’s correlation analysis (Spearman’s correlation  coefficient, 0.44; P< 0.001).",OADS,/arxiv_data1/oa_pdf/ed/a0/jkms-27-1371.PMC3492673.pdf
• Risk Factors for Hepatitis C Virus Infection in Korea    http://jkms.org   1375  http://dx.doi.org/10.3346/jkms.2012.27.11.13713.06).,Non-OADS,/arxiv_data1/oa_pdf/ed/a0/jkms-27-1371.PMC3492673.pdf
"• Risk Factors for Hepatitis C Virus Infection in Korea    1376   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.137120 yr ago was a significant risk factor for HCV infection, com - pared to having it within 20 yr.",Non-OADS,/arxiv_data1/oa_pdf/ed/a0/jkms-27-1371.PMC3492673.pdf
• Risk Factors for Hepatitis C Virus Infection in Korea    http://jkms.org   1377  http://dx.doi.org/10.3346/jkms.2012.27.11.1371lence and risk factors of hepatitis C virus infection among Koreans in ru - ral area of Korea.,Non-OADS,/arxiv_data1/oa_pdf/ed/a0/jkms-27-1371.PMC3492673.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Successful Treatment of Primary Central Nervous System  Lymphoma without Irradiation in Children: Single Center  Experience Primary CNS lymphoma (PCNSL) is a very uncommon disease in children, and usually  treated by chemotherapy, combined with focal or craniospinal radiotherapy (RT).",Non-OADS,/arxiv_data1/oa_pdf/59/19/jkms-27-1378.PMC3492674.pdf
04-2010-0660  from SNUH Research Fund.http://dx.doi.org/10.3346/jkms.2012.27.11.1378   •  J Korean Med Sci 2012; 27: 1378-1384ORIGINAL ARTICLE  Pediatrics INTRODUCTION Primary central nervous system lymphoma (PCNSL) is a very  rare brain tumor in children.,Non-OADS,/arxiv_data1/oa_pdf/59/19/jkms-27-1378.PMC3492674.pdf
"• Childhood Primary CNS Lymphoma Treated without Irradiation http://jkms.org   1379  http://dx.doi.org/10.3346/jkms.2012.27.11.1378in our hospital, and evaluated the efficacy of systemic and in - trathecal (IT) chemotherapy, without cranial or craniospinal  RT, and effects on patient survival.",Non-OADS,/arxiv_data1/oa_pdf/59/19/jkms-27-1378.PMC3492674.pdf
"• Childhood Primary CNS Lymphoma Treated without Irradiation 1380   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1378was treated with the Children’s Cancer Group (CCG)-106B treat - ment protocol (9), and the others were treated with the regimen  for Group C disease of French-American-British (FAB)/LMB96  (CCG-5961) treatment protocol (10), with augmented IT che - motherapy.",Non-OADS,/arxiv_data1/oa_pdf/59/19/jkms-27-1378.PMC3492674.pdf
• Childhood Primary CNS Lymphoma Treated without Irradiation http://jkms.org   1381  http://dx.doi.org/10.3346/jkms.2012.27.11.1378 The median EFS and OS were both 72 months.,Non-OADS,/arxiv_data1/oa_pdf/59/19/jkms-27-1378.PMC3492674.pdf
"• Childhood Primary CNS Lymphoma Treated without Irradiation 1382   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1378that children with PCNSL or CNS-involved NHL were success - fully treated with chemotherapy, not RT (1, 4, 5, 18).",Non-OADS,/arxiv_data1/oa_pdf/59/19/jkms-27-1378.PMC3492674.pdf
• Childhood Primary CNS Lymphoma Treated without Irradiation http://jkms.org   1383  http://dx.doi.org/10.3346/jkms.2012.27.11.1378without RT.,Non-OADS,/arxiv_data1/oa_pdf/59/19/jkms-27-1378.PMC3492674.pdf
• Childhood Primary CNS Lymphoma Treated without Irradiation 1384   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1378ma.,Non-OADS,/arxiv_data1/oa_pdf/59/19/jkms-27-1378.PMC3492674.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Adolescent Build Plotting on Body Composition Chart and   the Type of Diabetes Mellitus Although the prevalence of type 2 diabetes is increasing, there are cases difficult to  categorize into certain type in pediatric diabetic patients.",Non-OADS,/arxiv_data1/oa_pdf/99/79/jkms-27-1385.PMC3492675.pdf
"Key Words:  Diabetes Mellitus; Adolescent; Body Composition; Body Mass IndexHye Won Park1, Yong Hyuk Kim2,  Myunghyun Cho1, Byung Ok Kwak1,  Kyo Sun Kim1, and Sochung Chung1 1Department of Pediatrics, Konkuk University  Medical Center, Konkuk University School of  Medicine, Seoul; 2Department of Pediatrics,  Severance Children’s Hospital, Yonsei University  College of Medicine, Seoul, Korea Received: 8 June 2012 Accepted: 25 September 2012 Address for Correspondence: Sochung Chung, MD Department of Pediatrics, Konkuk University Medical Center,  Konkuk University School of Medicine, 120-1 Neungdong-ro,  Gwangjin-gu, Seoul 143-729, Korea Tel: +82.2-2030-7553, Fax: +82.2-2030-7748  E-mail: scchung@kuh.ac.kr http://dx.doi.org/10.3346/jkms.2012.27.11.1385   •  J Korean Med Sci 2012; 27: 1385-1390ORIGINAL ARTICLE Pediatrics INTRODUCTION The prevalence of type 2 diabetes is increasing along with the  changes in diet pattern and obesity in pediatric population (1-4).",Non-OADS,/arxiv_data1/oa_pdf/99/79/jkms-27-1385.PMC3492675.pdf
• Adolescent Build on Body Composition Chart in Diabetes 1386   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1385index (FFMI) and fat mass index (FMI) (10).,Non-OADS,/arxiv_data1/oa_pdf/99/79/jkms-27-1385.PMC3492675.pdf
• Adolescent Build on Body Composition Chart in Diabetes http://jkms.org   1387  http://dx.doi.org/10.3346/jkms.2012.27.11.1385were not different.,Non-OADS,/arxiv_data1/oa_pdf/99/79/jkms-27-1385.PMC3492675.pdf
• Adolescent Build on Body Composition Chart in Diabetes 1388   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1385and type 1 diabetic subjects were located below the line based  on BMI 23 kg/m2.,Non-OADS,/arxiv_data1/oa_pdf/99/79/jkms-27-1385.PMC3492675.pdf
"• Adolescent Build on Body Composition Chart in Diabetes http://jkms.org   1389  http://dx.doi.org/10.3346/jkms.2012.27.11.1385(FFM) with exercise, and reduce fat (FM) is important to reduce  insulin resistance (26).",Non-OADS,/arxiv_data1/oa_pdf/99/79/jkms-27-1385.PMC3492675.pdf
• Adolescent Build on Body Composition Chart in Diabetes 1390   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.138514.,Non-OADS,/arxiv_data1/oa_pdf/99/79/jkms-27-1385.PMC3492675.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Localization Value of Magnetoencephalography Interictal Spikes  in Adult Nonlesional Neocortical Epilepsy Few studies have included magnetoencephalography (MEG) when assessing the diagnostic  value of presurgical modalities in a nonlesional epilepsy population.",Non-OADS,/arxiv_data1/oa_pdf/e9/be/jkms-27-1391.PMC3492676.pdf
"Key Words:  Magnetoencephalography; Presurgical Evaluation; Nonlesional Epilepsy;  Surgical OutcomeWoorim Jeong1, Chun Kee Chung1,2,3,  and June Sic Kim1,4 1MEG Center, Department of Neurosurgery, Seoul  National University Hospital, Seoul; 2Department of  Neurosurgery, Seoul National University College of  Medicine, Seoul; 3Neuroscience Research Institute,  Seoul National University Medical Research Center,  Seoul; 4Research Center for Sensory Organs, Seoul  National University, Seoul, Korea Received: 25 May 2012 Accepted: 22 August 2012 Address for Correspondence: Chun Kee Chung, MD Department of Neurosurgery, Seoul National University Hospital,  Seoul National University College of Medicine, 101 Daehak-ro,  Jongno-gu, Seoul 1 10-744, Korea Tel: +82.2-2072-2352, Fax: +82.2-2072-0806 E-mail: chungc@snu.ac.kr This research was supported by a grant of the Korean Health  Technology R&D Project, Ministry of Health & Welfare, Republic  of Korea (A1 1 1406).http://dx.doi.org/10.3346/jkms.2012.27.11.1391   •  J Korean Med Sci 2012; 27: 1391-1397ORIGINAL ARTICLE Neuroscience INTRODUCTION It is well known that the presence of a specific lesion predicts a  favorable surgical outcome (1-3).",Non-OADS,/arxiv_data1/oa_pdf/e9/be/jkms-27-1391.PMC3492676.pdf
"• Localization Value of MEG in Nonlesional Epilepsy  1392   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1391sclerosis or tumor, based on pathology examination results,  were excluded.",Non-OADS,/arxiv_data1/oa_pdf/e9/be/jkms-27-1391.PMC3492676.pdf
"• Localization Value of MEG in Nonlesional Epilepsy  http://jkms.org   1393  http://dx.doi.org/10.3346/jkms.2012.27.11.1391tients, class II in 3 (13%), class III in 10 (43%), and class IV in 5  (22%) patients.",Non-OADS,/arxiv_data1/oa_pdf/e9/be/jkms-27-1391.PMC3492676.pdf
• Localization Value of MEG in Nonlesional Epilepsy  1394   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1391MEG ECDs at the hemispheric and lobar levels.,Non-OADS,/arxiv_data1/oa_pdf/e9/be/jkms-27-1391.PMC3492676.pdf
"• Localization Value of MEG in Nonlesional Epilepsy  http://jkms.org   1395  http://dx.doi.org/10.3346/jkms.2012.27.11.1391dences of interictal and ictal SPECT, and PET with the iEEG IOZ  were 25%, 62.5%, and 55.6%, respectively.",OADS,/arxiv_data1/oa_pdf/e9/be/jkms-27-1391.PMC3492676.pdf
"• Localization Value of MEG in Nonlesional Epilepsy  1396   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1391surgery, especially in the absence of a structural lesion, every  presurgical modality showed a high concordance rate with the  IOZ (6).",Non-OADS,/arxiv_data1/oa_pdf/e9/be/jkms-27-1391.PMC3492676.pdf
• Localization Value of MEG in Nonlesional Epilepsy  http://jkms.org   1397  http://dx.doi.org/10.3346/jkms.2012.27.11.1391Surgical outcome and prognostic factors of frontal lobe epilepsy surgery.,Non-OADS,/arxiv_data1/oa_pdf/e9/be/jkms-27-1391.PMC3492676.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Relationship between Irritable Bowel Syndrome, Worry and  Stress in Adolescent Girls The aim of this study is to investigate prevalence of irritable bowel syndrome (IBS) among  adolescents and difference in worry and stress between normal and IBS groups.",Non-OADS,/arxiv_data1/oa_pdf/89/7a/jkms-27-1398.PMC3492677.pdf
"Key Words:  Irritable Bowel Syndrome; Worry; StressSang-Wook Song, Seo-Jin Park,   Se-Hong Kim, and Sung-Goo Kang  Department of Family Medicine, St. Vincent’s  Hospital, The Catholic University of Korea, Suwon,  Korea Received: 29 March 2012 Accepted: 14 August 2012 Address for Correspondence: Sung-Goo Kang, MD Department of Family Medicine, St. Vincent’s Hospital,   The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu,  Suwon 442-723, Korea Tel: +82.31-249-8308, Fax: +82.31-249-8253 E-mail: hippo94@naver.comhttp://dx.doi.org/10.3346/jkms.2012.27.11.1398   •  J Korean Med Sci 2012; 27: 1398-1404ORIGINAL ARTICLE   Psychiatry & Psychology INTRODUCTION Irritable bowel syndrome (IBS) is a common functional gastro - intestinal disorder and its characteristic symptoms are chronic  abdominal pain or discomfort for over three months, abdomi - nal distension and changes in bowel habit.",Non-OADS,/arxiv_data1/oa_pdf/89/7a/jkms-27-1398.PMC3492677.pdf
"• Irritable Bowel Syndrome, Stress and Worry http://jkms.org   1399  http://dx.doi.org/10.3346/jkms.2012.27.11.1398anxiety disorder (13, 14).",Non-OADS,/arxiv_data1/oa_pdf/89/7a/jkms-27-1398.PMC3492677.pdf
"• Irritable Bowel Syndrome, Stress and Worry 1400   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1398Stress Stress was investigated with Korean version Brief Encounter  Psychosocial Instrument (BEPSI).",Non-OADS,/arxiv_data1/oa_pdf/89/7a/jkms-27-1398.PMC3492677.pdf
"• Irritable Bowel Syndrome, Stress and Worry http://jkms.org   1401  http://dx.doi.org/10.3346/jkms.2012.27.11.1398Correlation between IBS and stress According to the average of five questions of BEPSI-K the sub - jects were classified into mild-stress, moderate-stress and se - vere-stress groups with less than 1.7 points, 1.7-2.1 points and  over 2.1 points, respectively (29).",Non-OADS,/arxiv_data1/oa_pdf/89/7a/jkms-27-1398.PMC3492677.pdf
"• Irritable Bowel Syndrome, Stress and Worry 1402   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1398and state anxiety were proved to be good predictors of GI symp - tom severity, accounting for almost 30% of the variance.",Non-OADS,/arxiv_data1/oa_pdf/89/7a/jkms-27-1398.PMC3492677.pdf
"• Irritable Bowel Syndrome, Stress and Worry http://jkms.org   1403  http://dx.doi.org/10.3346/jkms.2012.27.11.1398in middle school students and high school students respective - ly.",Non-OADS,/arxiv_data1/oa_pdf/89/7a/jkms-27-1398.PMC3492677.pdf
"• Irritable Bowel Syndrome, Stress and Worry 1404   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.139821: 9-16.",Non-OADS,/arxiv_data1/oa_pdf/89/7a/jkms-27-1398.PMC3492677.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Inhalation Therapy of Calcitonin Relieves Osteoarthritis of the  Knee This study was conducted to determine if nasal salmon calcitonin has additional beneficial  effects on clinical symptoms, serum NO, IL-1 β, matrix metalloproteinase 3, urinary  C-terminal telopeptide type II collagen (CTX-II) levels and MRI findings in knee  osteoarthritis (OA) when used concomitantly with exercise therapy.",Non-OADS,/arxiv_data1/oa_pdf/34/c5/jkms-27-1405.PMC3492678.pdf
"Key Words:  Nasal Salmon Calcitonin; Knee Osteoarthritis; ExerciseOnur Armagan1, Dilek Kaya Serin2,  Cüneyt Calisir3, Ali Dokumacioglu4,  Merih Ozgen1, Setenay Oner5,  and Ozkan Alatas4 1Department of Physical Therapy and Rehabilitation,  Eskisehir Osmangazi University Faculty of Medicine;  2Department of Physical Therapy and Rehabilitation,  Eskisehir State Hospital; Departments of 3Radiology,  4Biochemistry, and 5Biostatistics,  Eskisehir  Osmangazi University Faculty of Medicine, Eskisehir,  Turkey Received: 8 February 2012 Accepted: 27 August 2012 Address for Correspondence: Onur Armagan, MD Department of Physical Therapy and Rehabilitation, Eskisehir  Osmangazi University Faculty of Medicine, Meselik 26480  Eskisehir, Turkey Tel: +902222392979/2457, Fax: +902222393774 E-mail: dronurarmagan@hotmail.comhttp://dx.doi.org/10.3346/jkms.2012.27.11.1405   •  J Korean Med Sci 2012; 27: 1405-1410ORIGINAL ARTICLE     Musculoskeletal Disorders INTRODUCTION Osteoarthritis (OA) is a chronic degenerative disease character - ized by the loss of cartilage in the joints covered by synovia.",Non-OADS,/arxiv_data1/oa_pdf/34/c5/jkms-27-1405.PMC3492678.pdf
"• Calcitonin Treatment in Knee Osteoarthritis  1406   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1405modality for OA and it was found effective in a vast number of  studies (11, 12).",Non-OADS,/arxiv_data1/oa_pdf/34/c5/jkms-27-1405.PMC3492678.pdf
"• Calcitonin Treatment in Knee Osteoarthritis  http://jkms.org   1407  http://dx.doi.org/10.3346/jkms.2012.27.11.1405An imaging area of 25 cm, a spatial resolution of 1.2 ×  1 mm and  a matrix of 256 ×192 were used to minimize the artifacts from  the contralateral knee.",Non-OADS,/arxiv_data1/oa_pdf/34/c5/jkms-27-1405.PMC3492678.pdf
• Calcitonin Treatment in Knee Osteoarthritis  1408   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1405ment status in patients of the second group (Table 3).,Non-OADS,/arxiv_data1/oa_pdf/34/c5/jkms-27-1405.PMC3492678.pdf
"• Calcitonin Treatment in Knee Osteoarthritis  http://jkms.org   1409  http://dx.doi.org/10.3346/jkms.2012.27.11.1405II, stimulates growth of the cartilage, prevents cartilage erosions,  and decreases the proteolytic and metalloproteinase activities  (7, 21-23).",Non-OADS,/arxiv_data1/oa_pdf/34/c5/jkms-27-1405.PMC3492678.pdf
"• Calcitonin Treatment in Knee Osteoarthritis  1410   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1405P , Tankó LB, Bagger YZ, Christiansen C, Karsdal MA.",Non-OADS,/arxiv_data1/oa_pdf/34/c5/jkms-27-1405.PMC3492678.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Analgesic Effects of Dexmedetomidine in Vincristine-Evoked  Painful Neuropathic Rats Dexmedetomidine, which is a selective α2-adrenoceptor agonist, was recently introduced  into clinical practice for its analgesic properties.",Non-OADS,/arxiv_data1/oa_pdf/0f/2d/jkms-27-1411.PMC3492679.pdf
"Key Words:  Dexmedetomidine; Neuropathy; Pain; VincristineHue Jung Park, Young Hoon Kim,   Hyun Jung Koh, Chul-Soo Park,   Seung-hee Kang, Jong-Ho Choi,   and Dong Eon Moon Department of Anesthesiology and Pain Medicine,  Seoul St. Mary’s Hospital, The Catholic University of  Korea College of Medicine, Seoul, Korea Received: 18 March 2012 Accepted: 12 September 2012 Address for Correspondence: Dong Eon Moon, MD Department of Anesthesiology and Pain Medicine, The Catholic  University of Korea College of Medicine, Seoul St. Mary’s  Hospital, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea Tel: +82.2-2258-2236,6150, Fax: +82.2-537-1951 E-mail: demoon@catholic.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.11.1411   •  J Korean Med Sci 2012; 27: 1411-1417ORIGINAL ARTICLE    Anesthesiology & Pain INTRODUCTION Vincristine-evoked painful neuropathy is one of the major dose- limiting adverse effects by cancer chemotherapy with vincris - tine.",Non-OADS,/arxiv_data1/oa_pdf/0f/2d/jkms-27-1411.PMC3492679.pdf
• Dexmedetomidine and Vincristine-Evoked Painful Neuropathy 1412   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1411Vincristine injection The vincristine-evoked peripheral neuropathic model was used  in this study.,Non-OADS,/arxiv_data1/oa_pdf/0f/2d/jkms-27-1411.PMC3492679.pdf
"• Dexmedetomidine and Vincristine-Evoked Painful Neuropathy http://jkms.org   1413  http://dx.doi.org/10.3346/jkms.2012.27.11.1411at 30 min for 25 µg/kg, from 15 to 60 min for 50 µg/kg, and from  15 to 120 min for 100 µg/kg ( P= 0.004), as compared to the ve - hicle group (Fig.",Non-OADS,/arxiv_data1/oa_pdf/0f/2d/jkms-27-1411.PMC3492679.pdf
"• Dexmedetomidine and Vincristine-Evoked Painful Neuropathy 1414   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1411DISCUSSION In this study, we validated vincristine-induced rat models showed  mechanical and cold allodynia.",Non-OADS,/arxiv_data1/oa_pdf/0f/2d/jkms-27-1411.PMC3492679.pdf
"• Dexmedetomidine and Vincristine-Evoked Painful Neuropathy http://jkms.org   1415  http://dx.doi.org/10.3346/jkms.2012.27.11.1411severe respiratory depression (12, 13), it was expected that dex - medetomidine would have stronger analgesic effects with less  side effects.",Non-OADS,/arxiv_data1/oa_pdf/0f/2d/jkms-27-1411.PMC3492679.pdf
• Dexmedetomidine and Vincristine-Evoked Painful Neuropathy 1416   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1411showed anti-allodynia in vincristine-induced neuropathy.,Non-OADS,/arxiv_data1/oa_pdf/0f/2d/jkms-27-1411.PMC3492679.pdf
• Dexmedetomidine and Vincristine-Evoked Painful Neuropathy http://jkms.org   1417  http://dx.doi.org/10.3346/jkms.2012.27.11.141123.,Non-OADS,/arxiv_data1/oa_pdf/0f/2d/jkms-27-1411.PMC3492679.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 The Incidence, Causes, and Prognostic Significance of New- Onset Thrombocytopenia in Intensive Care Units: A Prospective  Cohort Study in a Korean Hospital  This study was designed to investigate the incidence, causes, and outcomes of new-onset  thrombocytopenia (NOT) in Korean intensive care units (ICUs).",Non-OADS,/arxiv_data1/oa_pdf/80/c5/jkms-27-1418.PMC3492680.pdf
"Key Words:  Heparin; Intensive care units; Korea; Mortality; ThrombocytopeniaSo Yeon Lim1, Eun Ju Jeon1,  Hee-Jin Kim2, Kyeongman Jeon1,  Sang-Won Um1, Won-Jung Koh1,  Man Pyo Chung1, Hojoong Kim1,  O Jung Kwon1, and Gee Young Suh1 1Division of Pulmonary and Critical Care Medicine,  Department of Medicine, 2Department of Laboratory  Medicine & Genetics, Samsung Medical Center,  Sungkyunkwan University School of Medicine,  Seoul, Korea Received: 5 April 2012 Accepted: 20 August 2012 Address for Correspondence: Gee Young Suh, MD Division of Pulmonary and Critical Care Medicine, Department  of Medicine, Samsung Medical Center, Sungkyunkwan  University School of Medicine, 81 Irwon-ro, Gangnam-gu,   Seoul 135-710, Korea Tel: +82.2-3410-3426, Fax: +82.2-3410-6956 E-mail: suhgy@skku.edu This work was supported by a grant from Samsung Medical  Center in 201 1 (CRS1 104521).http://dx.doi.org/10.3346/jkms.2012.27.11.1418   •  J Korean Med Sci 2012; 27: 1418-1423ORIGINAL ARTICLE   Emergency & Critical Care Medicine INTRODUCTION Thrombocytopenia, which is one of the most commonly ob - served laboratory abnormalities in the intensive care units (ICU)  population, has an incidence ranging from 13.0% to 44.1% (1),  depending on the study population, the timing and frequency  of platelet monitoring, and the definition of thrombocytopenia  (2-5).",Non-OADS,/arxiv_data1/oa_pdf/80/c5/jkms-27-1418.PMC3492680.pdf
"• New-Onset Thrombocytopenia in Korean ICUs http://jkms.org   1419  http://dx.doi.org/10.3346/jkms.2012.27.11.1418Definitions Thrombocytopenia was defined as a platelet count < 150,000/µL  or a decrease in platelet count ≥ 50% from the ICU admission  value (9, 12).",Non-OADS,/arxiv_data1/oa_pdf/80/c5/jkms-27-1418.PMC3492680.pdf
• New-Onset Thrombocytopenia in Korean ICUs 1420   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1418yr (Table 1).,Non-OADS,/arxiv_data1/oa_pdf/80/c5/jkms-27-1418.PMC3492680.pdf
"• New-Onset Thrombocytopenia in Korean ICUs http://jkms.org   1421  http://dx.doi.org/10.3346/jkms.2012.27.11.1418nificantly increased the odds ratio of 28-day mortality (4.70, 2.06- 10.70, P< 0.001).",Non-OADS,/arxiv_data1/oa_pdf/80/c5/jkms-27-1418.PMC3492680.pdf
"• New-Onset Thrombocytopenia in Korean ICUs 1422   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.14181.6% of the patients receiving heparin therapy, and thrombosis  occurred in these two patients.",Non-OADS,/arxiv_data1/oa_pdf/80/c5/jkms-27-1418.PMC3492680.pdf
"• New-Onset Thrombocytopenia in Korean ICUs http://jkms.org   1423  http://dx.doi.org/10.3346/jkms.2012.27.11.1418temically look for and treat HIT, even in Asians.",Non-OADS,/arxiv_data1/oa_pdf/80/c5/jkms-27-1418.PMC3492680.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Familial Mediterranean Fever: The First Adult Case in Korea Familial Mediterranean fever (FMF) is known to be a genetic disorder that prevalent among  populations surrounding the Mediterranean Sea.",Non-OADS,/arxiv_data1/oa_pdf/2b/56/jkms-27-1424.PMC3492681.pdf
"Key Words:  Familial Mediterranean Fever; Periodic Fever Syndrome; MEFV GeneAh Leum Lim, Hyun Joo Jang,   Jung Wan Han, Yong Keun Song,   Won Jun Song, Heung Jung Woo,   Young Ok Jung, Sea Hyub Kae,   and Jin Lee Department of Intenal Medicine, Hallym University  College of Medicine, Seoul, Korea Received: 17 April 2012 Accepted: 12 September 2012 Address for Correspondence: Hyun Joo Jang, MD Department of Internal Medicine, Hallym University College of  Medicine, 12 Beodeunaru-ro 7-gil, Yeongdeungpo-gu, Seoul  150-719, Korea Tel: +82.2-2639-5400, Fax: +82.2-2677-9756 E-mail: jhj1229@hallym.or.krhttp://dx.doi.org/10.3346/jkms.2012.27.11.1424   •  J Korean Med Sci 2012; 27: 1424-1427CASE REPORT Human Genetics & Genomics INTRODUCTION Familial Mediterranean fever (FMF) is an autosomal recessive  disease characterized by the manifestation of symptoms such  as recurrent episodes of fever with serosal, synovial, or cutane - ous inflammation (1).",Non-OADS,/arxiv_data1/oa_pdf/2b/56/jkms-27-1424.PMC3492681.pdf
• Familial Mediterranean Fever: The First Adult Case in Korea  http://jkms.org   1425  http://dx.doi.org/10.3346/jkms.2012.27.11.1424doscopy.,Non-OADS,/arxiv_data1/oa_pdf/2b/56/jkms-27-1424.PMC3492681.pdf
"• Familial Mediterranean Fever: The First Adult Case in Korea  1426   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1424with disease onset after 20 yr of age (adult-onset) is 14% and af - ter 40 yr of age (late-onset) is only 0.5% in Turkey (5, 7).",Non-OADS,/arxiv_data1/oa_pdf/2b/56/jkms-27-1424.PMC3492681.pdf
"Among them,  100 gene mutations have been found to be associated with the  manifestation of diseases (An updated list of mutations for FMF  can be found online at http://fmf.igh.cnrs.fr/infevers/).",Non-OADS,/arxiv_data1/oa_pdf/2b/56/jkms-27-1424.PMC3492681.pdf
"• Familial Mediterranean Fever: The First Adult Case in Korea  http://jkms.org   1427  http://dx.doi.org/10.3346/jkms.2012.27.11.1424Yamashita T, Uehara K, Miyazato A, Hatta K, et al.",Non-OADS,/arxiv_data1/oa_pdf/2b/56/jkms-27-1424.PMC3492681.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 The Return of an Old Worm: Cerebral Paragonimiasis Presenting  with Intracerebral Hemorrhage Paragonimiasis is caused by ingesting crustaceans, which are the intermediate hosts of  Paragonimus .",Non-OADS,/arxiv_data1/oa_pdf/23/3d/jkms-27-1428.PMC3492682.pdf
"Key Words:  Cerebral Paragonimiasis; Intracerebral Hemorrhage; DiagnosisEun Jung Koh1, Seung-Ki Kim1,  Kyu-Chang Wang1, Jong-Yil Chai2,  Sangjoon Chong1, Sung-Hye Park3,  Jung-Eun Cheon4, and Ji Hoon Phi1 1Division of Pediatric Neurosurgery, Seoul National  University Children’s Hospital; 2Department of  Parasitology and Tropical Medicine, 3Department of  Pathology, 4Department of Diagnostic Radiology,  Seoul National University College of Medicine,  Seoul, Korea Received: 21 December 201 1 Accepted: 5 July 2012 Address for Correspondence: Ji Hoon Phi, MD Division of Pediatric Neurosurgery, Seoul National University  Children’s Hospital, 101 Daehak-ro, Jongno-gu, Seoul 1 10-744,  Korea Tel: +82.2-2072-3639, Fax: +82.2-744-8459 E-mail: phi.jihoon@gmail.comhttp://dx.doi.org/10.3346/jkms.2012.27.11.1428   •  J Korean Med Sci 2012; 27: 1428-1432CASE REPORT Infectious Diseases, Microbiology & Parasitology INTRODUCTION Paragonimiasis is a parasitic disease caused by ingesting crus - taceans, such as crabs or crayfish, that are infested with the meta - cercariae of Paragonimus (1).",Non-OADS,/arxiv_data1/oa_pdf/23/3d/jkms-27-1428.PMC3492682.pdf
"• The Return of an Old Worm http://jkms.org   1429  http://dx.doi.org/10.3346/jkms.2012.27.11.1428angiography was performed, but it did not reveal any vascular  abnormalities.",Non-OADS,/arxiv_data1/oa_pdf/23/3d/jkms-27-1428.PMC3492682.pdf
• The Return of an Old Worm 1430   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1428rological deficits.,Non-OADS,/arxiv_data1/oa_pdf/23/3d/jkms-27-1428.PMC3492682.pdf
• The Return of an Old Worm http://jkms.org   1431  http://dx.doi.org/10.3346/jkms.2012.27.11.1428lesion (Fig.,Non-OADS,/arxiv_data1/oa_pdf/23/3d/jkms-27-1428.PMC3492682.pdf
• The Return of an Old Worm 1432   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1428chest imaging findings.,Non-OADS,/arxiv_data1/oa_pdf/23/3d/jkms-27-1428.PMC3492682.pdf
Available at http://legacy.www.hani.co.kr/section-005100033/2004/07/  005100033200407011953640.html.,Non-OADS,/arxiv_data1/oa_pdf/23/3d/jkms-27-1428.PMC3492682.pdf
Available  at http://news.naver.com/main/read.nhn?mode=LSD&mid=sec&sid1= 103&oid=005&aid=0000249546.,Non-OADS,/arxiv_data1/oa_pdf/23/3d/jkms-27-1428.PMC3492682.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 First Case of Bartonella quintana  Endocarditis in Korea Since microbial gene sequencing was utilized for etiologic diagnosis of culture-negative  endocarditis, cases of Bartonella  endocarditis have been reported in various countries.",Non-OADS,/arxiv_data1/oa_pdf/cc/94/jkms-27-1433.PMC3492683.pdf
"Key Words:  Infective Endocarditis; Bartonella quintana ; 16S rRNA; Gene SequencingMin Hee Lim1, Doo Ryeon Chung1,  Wook-Sung Kim2, Kyung Sun Park3,  Chang-Seok Ki3, Nam Yong Lee3,  and Sang Min Kim4 1Division of Infectious Diseases, Department of  Internal Medicine; 2Department of Thoracic and  Cardiovascular Surgery; 3Department of Laboratory  Medicine and Genetics, Samsung Medical Center,  Sungkyunkwan University School of Medicine,  Seoul; 4Division of Cardiology, Department of  Internal Medicine, Chungbuk National University  Hospital, Cheongju, Korea Received: 1 1 April 2012 Accepted: 3 July 2012 Address for Correspondence: Doo Ryeon Chung, MD Division of Infectious Diseases, Department of Internal Medicine,  Samsung Medical Center, Sungkyunkwan University School of  Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea Tel: +82.2-3410-0323, Fax: +82.2-3410-0064 E-mail: drchung@skku.eduhttp://dx.doi.org/10.3346/jkms.2012.27.11.1433   •  J Korean Med Sci 2012; 27: 1433-1435CASE REPORT Infectious Diseases, Microbiology & Parasitology INTRODUCTION Etiologic diagnosis of infective endocarditis is very important  for appropriate treatment, however culture-negative endocar - ditis has accounted for a substantial proportion of all endocar - ditis cases (1).",Non-OADS,/arxiv_data1/oa_pdf/cc/94/jkms-27-1433.PMC3492683.pdf
"• Bartonella Endocarditis in Korea 1434   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1433 Bacterial DNA was extracted from surgically excised valve  tissue and vegetation, directly.",Non-OADS,/arxiv_data1/oa_pdf/cc/94/jkms-27-1433.PMC3492683.pdf
B. quintana  was also only the best-matched  strain in the BIBI database (http://pbil.univ-lyon1.fr/bibi/).,Non-OADS,/arxiv_data1/oa_pdf/cc/94/jkms-27-1433.PMC3492683.pdf
• Bartonella Endocarditis in Korea http://jkms.org   1435  http://dx.doi.org/10.3346/jkms.2012.27.11.1433(13).,Non-OADS,/arxiv_data1/oa_pdf/cc/94/jkms-27-1433.PMC3492683.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Membranous Nephropathy in a 13-Year-Old Boy with Common  Variable Immunodeficiency  Various forms of hypogammaglobulinemia can occur in patients with autoimmune diseases  and vice versa.",Non-OADS,/arxiv_data1/oa_pdf/01/d4/jkms-27-1436.PMC3492684.pdf
"Key Words:  Autoimmunity; Common Variable Immunodeficiency; Immunoglobulins;  Membranous GlomerulonephritisHyung Eun Yim and Kee Hwan Yoo Department of Pediatrics, Korea University Medical  Center, Seoul, Korea Received: 13 April 2012 Accepted: 3 July 2012 Address for Correspondence: Kee Hwan Yoo, MD Department of Pediatrics, Korea University Guro Hospital,   148 Gurodong-ro, Guro-gu, Seoul 152-703, Korea  Tel: +82.2-2626-3152, Fax: +82.2-2626-1249 E-mail: guroped@korea.ac.krhttp://dx.doi.org/10.3346/jkms.2012.27.11.1436   •  J Korean Med Sci 2012; 27: 1436-1438CASE REPORT Nephrology INTRODUCTION It is becoming widely accepted that membranous nephropathy  (MN) is an organ-specific autoimmune glomerular disease (1).",Non-OADS,/arxiv_data1/oa_pdf/01/d4/jkms-27-1436.PMC3492684.pdf
• Membranous Nephropathy and Immunodeficiency http://jkms.org   1437  http://dx.doi.org/10.3346/jkms.2012.27.11.1436lobe.,Non-OADS,/arxiv_data1/oa_pdf/01/d4/jkms-27-1436.PMC3492684.pdf
• Membranous Nephropathy and Immunodeficiency 1438   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1436antigens in our patient with hypogammaglobulinemia may lead  to chronic immunological activation and the development of  autoimmunity with MN.,Non-OADS,/arxiv_data1/oa_pdf/01/d4/jkms-27-1436.PMC3492684.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 A Case of Congenital Adrenal Hyperplasia Mimicking Cushing’s  Syndrome Congenital adrenal hyperplasia (CAH) is characterized by decreased adrenal hormone  production due to enzymatic defects and subsequent rise of adrenocorticotrophic hormone  that stimulates the adrenal cortex to become hyperplastic, and sometimes tumorous.",Non-OADS,/arxiv_data1/oa_pdf/09/a4/jkms-27-1439.PMC3492685.pdf
"Received: 29 November 201 1 Accepted: 30 July 2012 Address for Correspondence: Myung-Shik Lee, MD Division of Endocrinology and Metabolism, Department of  Medicine, Samsung Medical Center, Sungkyunkwan University  School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul   135-710, Korea Tel: +82.2-3410-3436, Fax: +82.2-3410-3849 E-mail: mslee0923@skku.eduhttp://dx.doi.org/10.3346/jkms.2012.27.11.1439   •  J Korean Med Sci 2012; 27: 1439-1443CASE REPORT Endocrinology, Nutrition & Metabolism INTRODUCTION Congenital adrenal hyperplasia (CAH) is a common autosomal  recessive disorder.",Non-OADS,/arxiv_data1/oa_pdf/09/a4/jkms-27-1439.PMC3492685.pdf
• Congenital Adrenal Hyperplasia Mimicking Cushing’s Syndrome 1440   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1439agnosed with acute hepatitis A.,Non-OADS,/arxiv_data1/oa_pdf/09/a4/jkms-27-1439.PMC3492685.pdf
• Congenital Adrenal Hyperplasia Mimicking Cushing’s Syndrome http://jkms.org   1441  http://dx.doi.org/10.3346/jkms.2012.27.11.1439noted in 2 independent measurements (226.4 μg/24 hr; 122.1  μg/24 hr).,Non-OADS,/arxiv_data1/oa_pdf/09/a4/jkms-27-1439.PMC3492685.pdf
• Congenital Adrenal Hyperplasia Mimicking Cushing’s Syndrome 1442   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.143921-hydroxylase reserve.,Non-OADS,/arxiv_data1/oa_pdf/09/a4/jkms-27-1439.PMC3492685.pdf
• Congenital Adrenal Hyperplasia Mimicking Cushing’s Syndrome http://jkms.org   1443  http://dx.doi.org/10.3346/jkms.2012.27.11.1439Braz J Med Biol Res 2003; 36: 1311-8.,Non-OADS,/arxiv_data1/oa_pdf/09/a4/jkms-27-1439.PMC3492685.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 Phacomatosis Pigmentokeratotica without Extracutaneous  Abnormalities: A Case Study Involving a Preterm Baby Phacomatosis pigmentokeratotica (PPK) is a rare syndrome defined by the association of an  organoid nevus occasionally with sebaceous differentiation, a speckled lentiginous nevus,  and other extracutaneous anomalies.",Non-OADS,/arxiv_data1/oa_pdf/5f/e5/jkms-27-1444.PMC3492686.pdf
"Key Words:  Epidermal Nevus Syndromes; Phacomatosis Pigmentokeratotica; Preterm  BabyGa Na Oh, Jong Yeob Kim, Jae Eun Choi,  Hyo Hyun Ahn, Young Chul Kye,   and Soo Hong Seo  Department of Dermatology, Korea University  College of Medicine, Seoul, Korea Received: 30 April 2012 Accepted: 27 July 2012 Address for Correspondence: Soo Hong Seo, MD Department of Dermatology, Korea University College of  Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul 136-705, Korea Tel: +82.2-920-5470, Fax: +82.2-928-7540 E-mail: drsshong@hanmail.nethttp://dx.doi.org/10.3346/jkms.2012.27.11.1444   •  J Korean Med Sci 2012; 27: 1444-1446CASE REPORT    Dermatology INTRODUCTION Happle et al.",Non-OADS,/arxiv_data1/oa_pdf/5f/e5/jkms-27-1444.PMC3492686.pdf
"• Phacomatosis Pigmentokeratotica  http://jkms.org   1445  http://dx.doi.org/10.3346/jkms.2012.27.11.1444entiation and certain neurologic, ophthalmologic, and skeletal  anomalies.",Non-OADS,/arxiv_data1/oa_pdf/5f/e5/jkms-27-1444.PMC3492686.pdf
"• Phacomatosis Pigmentokeratotica  1446   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.1444strabismus, and ptosis) and skeletal disorders (postural devia - tion with the appearance of kyphosis/scoliosis) (5).",Non-OADS,/arxiv_data1/oa_pdf/5f/e5/jkms-27-1444.PMC3492686.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 http://dx.doi.org/10.3346/jkms.2012.27.11.1447   •  J Korean Med Sci 2012; 27: 1447-1448CORRESPONDENCE Letter to the Editor Visceral Fat and Liver Fat as Risk Factors of Metabolic   Syndrome Ju-Hye Chung1, Sang-Wook Song1, and Se-Hong Kim1,2 1Department of Family Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea; 2Department of Radiology, Keck School of Medicine,  University of Southern California, Los Angeles, USA We have read with great interest the article “Comparison of Vis - ceral Fat and Liver Fat as Risk Factors of Metabolic Syndrome”  in a recent issue of the Journal of Korean Medical Science by  Kang et al.",Non-OADS,/arxiv_data1/oa_pdf/8e/1a/jkms-27-1447.PMC3492687.pdf
Correspondence: To the Editor 1448   http://jkms.org  http://dx.doi.org/10.3346/jkms.2012.27.11.14472006; 239: 105-12.,Non-OADS,/arxiv_data1/oa_pdf/8e/1a/jkms-27-1447.PMC3492687.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1011-8934 eISSN 1598-6357 http://dx.doi.org/10.3346/jkms.2012.27.11.1449   •  J Korean Med Sci 2012; 27: 1449CORRESPONDENCE The Author Response Comparison of Visceral Fat and Liver Fat as Risk Factors of  Metabolic Syndrome Jeongseob Lee, Dae-Sung Chung, Jee-Hyun Kang, and Byung-Yeon Yu Department of Family Medicine, Konyang University Hospital, Daejeon, Korea We appreciate the detailed and valuable comments on our arti - cle (1).",Non-OADS,/arxiv_data1/oa_pdf/a5/bf/jkms-27-1449.PMC3492688.pdf
"Interactions betweenmitochondria and ER were calculated using Image J software(http://rsbweb.nih.gov/ij/), determining the area occupied by oneorganelle and using its signal as a mask for the other one.",OADS,/arxiv_data1/oa_pdf/d1/38/emboj2012202a.PMC3492725.pdf
"Supplementary data Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).Acknowledgements We thank Kristy Brown for assistance with the electron microscopy;Bart de Strooper for providing the Ps-mutant MEFs; David Chan forproviding the Mfn2-mutant MEFS; Mariska te Lindert and Be ´ Wieringa for assisting in establishing the Ps1-KD MEFs; Tae-Wan Kim for providing PS1 constructs; Karen Duff, Ellen Steinbart, Gary Gibson, and Richard Cowburn for providing patient cells; and Salvatore DiMauro, Robert W Gilkerson, Michio Hirano, LarryHonig, and Serge Przedborski for comments.",Non-OADS,/arxiv_data1/oa_pdf/d1/38/emboj2012202a.PMC3492725.pdf
[http://creativecommons.org/licenses/by-nc-nd/3.0]Upregulated function of MAM in AD E Area-Gomez et al 4123 &2012 European Molecular Biology Organization The EMBO Journal VOL 31 |NO 21 |2012,Non-OADS,/arxiv_data1/oa_pdf/d1/38/emboj2012202a.PMC3492725.pdf
Supplementary data Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).,OADS,/arxiv_data1/oa_pdf/22/f2/emboj2012262a.PMC3492727.pdf
"2012, 8      http://www.biolsci.org  1291  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(10):1291-1309. doi: 10.7150/ ijbs.4966  Research Paper   Multiple Sodium Channel Variants in the Mosquito Culex quinquefasciatus   Lin He1,2,*, Ting Li1,*, Lee Zhang3, Nannan Liu1,  1.",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1292  itive discharges and prevents the repolarization phase  of action potentials [5 -7].",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1293  Quantitative real -time PCR (qRT -PCR)   The total RNA (0.5 µg/sample) from each mo s- quito sample was reverse -transcribed using Supe r- Script II reverse transcriptase (Stratagene) in a total  v o l u m e  o f  2 0  μ l .",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1294  tively)  with ~6.5 kb and clones (2, 7, and 2 clones for  S-lab, HAmCqG0, and HAmCqG8, respectively )  with~4.0 kb PCR amplified products from each strain  indicated that all the cDNA clones were indeed the  sodium channel transcripts.",OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1295  (Accession numbers: JN695779 and JX424548) , ident i- fied in HAmCqG8 were both full l ength sodium cha n- nel transcripts encoding entire ORFs of sodium  channels proteins (Figs.",OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8      http://www.biolsci.org  1296",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1297",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1298    Figure 2.",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1299",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1300",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1301",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1302    Figure 3.",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1303",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1304",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1305    Figure 4.",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1306    Figure 5.",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1307    Figure 6.",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1308  Xenopus oocytes, the alternative splicing varian ts  could exhibit different gating properties and generate  sodium channel proteins with differing sensitivities to  pyrethroids [18 -19].",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8    http://www.biolsci.org  1309  26.",Non-OADS,/arxiv_data1/oa_pdf/16/f2/ijbsv08p1291.PMC3492789.pdf
"2012, 8      http://www.biolsci.org  1310  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(10):1310-1322. doi: 10.7150/ ijbs.5136  Research Paper   Collagen XXIV (Col24 α1) Promotes Osteoblastic Differentiation and Mine r- alization through TGF -β/Smads Signaling Pathway    Weizhuo Wang1,3, Douglas Olson1, Gang Liang1, Renny T Franceschi4, Chunyi Li1, Bingyan Wang5, Shuen  Shiuan Wang1, Shuying Yang1,2  1.",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8    http://www.biolsci.org  1311  proteins that have collagen -like domains [1].",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8    http://www.biolsci.org  1312  National Research Council).",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8    http://www.biolsci.org  1313  4.",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8    http://www.biolsci.org  1314  protease inhibitors ( Sigma ).",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8    http://www.biolsci.org  1315  for 14 days, following which A lizarin red and V on  Kossa staining assays we re performed.",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8    http://www.biolsci.org  1316    Fig.",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8    http://www.biolsci.org  1317    Fig.",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8    http://www.biolsci.org  1318    Fig.",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8    http://www.biolsci.org  1319  with Col24α1.",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8      http://www.biolsci.org  1320  Discussion   Col24α1 is predominantly expressed in the  forming bone elements of the mouse embryo [24] as  well as in the trabecular bone and periosteum of the  newborn mouse [48] .",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8    http://www.biolsci.org  1321  Acknowledgments   We thank Drs.",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8    http://www.biolsci.org  1322  PTH/PTHrP receptor mRNA levels in MC3T3 -E1 cells.",Non-OADS,/arxiv_data1/oa_pdf/ce/40/ijbsv08p1310.PMC3492790.pdf
"2012, 8      http://www.biolsci.org  1323  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(10):1323-1334. doi: 10.7150/ ijbs.4189  Research Paper   Characterization of a Chitin Synthase Encoding Gene and Effect of  Diflubenzuron in Soybean Aphid, Aphis Glycines    Raman Bansal1, M. A. Rouf Mian2, Omprakash Mittapalli1, Andy P. Michel1  1.",Non-OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8    http://www.biolsci.org  1324  In insects, two chitin synthases occur which are  encoded by two different genes: CHS1  and CHS2  [4].",Non-OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8    http://www.biolsci.org  1325  A. glycines , sequences of T. casteneum  CHS (TcCHS1:  NP_001034491.1 and TcCHS2: NP_001034492.1) were  used as query in a tblastn search of A. glycines  tran- scriptomic database [24, R. Bansal, unpublished data].",OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8    http://www.biolsci.org  1326  plates, sealed with optical sealing tape (Bio -Rad L a- boratories, Hercules, CA).",Non-OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8    http://www.biolsci.org  1327  supposed to  play a role in chitin translocation [3] was  found in domain C. Multiple sequence alignment of  the region encompassing the catalytic domain of ch i- tin synthases in different hemipteran insects shows 90% identity and 97% similarity in amino acid resi- dues (Fig.",OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8    http://www.biolsci.org  1328    Figure 1.",Non-OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8    http://www.biolsci.org  1329    Figure 3.",Non-OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8    http://www.biolsci.org  1330  Effect of DFB on A. glycines  survival and AyCHS   expression   Results on the effect of DFB on A. glycines  sur- vival, as determined through  leaf dip bioassay, are  shown in Fig.",Non-OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8      http://www.biolsci.org  1331  Discussion   Chitin synthase is a  key enzyme for the ch i- tin-synthesis pathway in insects.",Non-OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8    http://www.biolsci.org  1332  [17].",Non-OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"http://www.biolsci.org/v0 8p1323s1.pdf     Abbreviations   CHS, Chitin synthase; DFB, Diflubenzuron; PM,  Peritrophic  membrane; RNAi, RNA interference.",OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8    http://www.biolsci.org  1333  genes in Manduca sexta: Characterization of a gut -specific transcript.",Non-OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8    http://www.biolsci.org  1334  58.",Non-OADS,/arxiv_data1/oa_pdf/58/11/ijbsv08p1323.PMC3492791.pdf
"2012, 8      http://www.biolsci.org  1335  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(10):1335-1344. doi: 10.7150/ ijbs.4654  Research Paper   Stem Cell Transplantation Increases  Antioxidant Effects in Diabetic Mice    Ming Li 1, Luca Vanella 2, Yuming Zhang 3, Ming Shi 1, Takashi Takaki4, Joseph I Shapiro2,                         Susumu Ikehara1  1.",Non-OADS,/arxiv_data1/oa_pdf/dd/1c/ijbsv08p1335.PMC3492792.pdf
This is an open -access  article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/dd/1c/ijbsv08p1335.PMC3492792.pdf
"2012, 8    http://www.biolsci.org  1336  vascular dysfunction in diabetic nephropathy (DN).",Non-OADS,/arxiv_data1/oa_pdf/dd/1c/ijbsv08p1335.PMC3492792.pdf
"2012, 8    http://www.biolsci.org  1337  Western blot analysis of kidney HO -1, peNOS,  AKT, pA KT, and iNOS   At sacrifice, kidneys were dissected, then pooled  for each mouse in order t o measure signaling mole- cules.",Non-OADS,/arxiv_data1/oa_pdf/dd/1c/ijbsv08p1335.PMC3492792.pdf
"2012, 8      http://www.biolsci.org  1338    Figure 1.",Non-OADS,/arxiv_data1/oa_pdf/dd/1c/ijbsv08p1335.PMC3492792.pdf
"2012, 8      http://www.biolsci.org  1339  Improved body weight, blood glucose and  plasma adiponectin, and insulin levels  6 weeks  after treatment with IBM -BMT  +TT  As seen in Fig.",Non-OADS,/arxiv_data1/oa_pdf/dd/1c/ijbsv08p1335.PMC3492792.pdf
"2012, 8    http://www.biolsci.org  1340    Figure 3.",Non-OADS,/arxiv_data1/oa_pdf/dd/1c/ijbsv08p1335.PMC3492792.pdf
"2012, 8      http://www.biolsci.org  1341    Figure 4.",Non-OADS,/arxiv_data1/oa_pdf/dd/1c/ijbsv08p1335.PMC3492792.pdf
"2012, 8      http://www.biolsci.org  1342  The expression of peNOS, pAKT and iNOS was  confirmed by immunochemistry staining  (Fig.",Non-OADS,/arxiv_data1/oa_pdf/dd/1c/ijbsv08p1335.PMC3492792.pdf
"2012, 8    http://www.biolsci.org  1343  37].",Non-OADS,/arxiv_data1/oa_pdf/dd/1c/ijbsv08p1335.PMC3492792.pdf
"2012, 8    http://www.biolsci.org  1344  antibody in db/db diabetic mice.",Non-OADS,/arxiv_data1/oa_pdf/dd/1c/ijbsv08p1335.PMC3492792.pdf
"2012, 8      http://www.biolsci.org  1345  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(10):1345-1362. doi: 10.7150/ ijbs.4699  Research Paper   Protect ive Effect of Grape Seed Proanthocyanidins against Liver Ischemic  Reperfusion Injury : Particularly in Diet -Induced Obese Mice   Xiaoyu Song, Hongde Xu, Yanling Feng, Xiaoman Li, Meina Lin, Liu Cao  Key Laboratory of Medical Cell Biology, China Medical University, Shen Yang  City , LiaoNing Province,  China, 110001.",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
This is an open -access article distributed under the terms of the Creative Comm ons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1346  dysfunction.",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1347  wick, NJ) and the standard chow diet containing  13.5% kcal from fat.",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8      http://www.biolsci.org  1348  Hepa tocellular Injury Assay  Aspartase aminotransferase (AST) and alanine  aminotransferase (ALT) in serum were used as ind i- cators of hepatocyte function.",OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1349  Ischemic postconditioning reduce hepatic i s- chemic reperfusion injury   In the first set of experiments, ALT and AST a c- tivities were used as markers to evaluate the effects of  various ischemic postconditioning strategies against  hepatic ischemic reperfusion injury.",OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1350      Figure  3.",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1351  TNF -α and IL -1β levels reduced in GSP pr e- conditioning and postconditioning groups   Compared to IR control samples, the concentr a- tion of TNF -α and IL -1β in serum were dramatically  decreased in IpostC -2, GSP -2 and GSP -2/ IpostC -2 groups ( P<0.01) (Figure 5A).",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1352    Figure 5.",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1353  (P<0.01) (Figure 6B and C ).",OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1354    Figure 7.",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8      http://www.biolsci.org  1355  GSP preconditioning decreased the marker of  hepatocyte injury and the sensitivity of ste a- totic liver to IRI   GSP  preconditioning decreased the marker of  hepatocyte injury: as showed in Figure  8B, the plasma  activities of ALT and AST significantly decreased in  GSP -2 and GSP -3 groups ( P<0.01) compared to  IRI  control group .",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1356",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1357",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1358    Figure 9.",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1359  group) .",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1360  Science fewer reports demonstrated the  effects of GSP  on hepatic ischemic and reperfusion injury , we are the  first to evaluate the protective effect of GSP and  postconditioning  against hepatic IRI and select the  optimum dose of  GSP for using .",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1361  livers against  warm IRI.",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8    http://www.biolsci.org  1362  33.",Non-OADS,/arxiv_data1/oa_pdf/6a/a2/ijbsv08p1345.PMC3492793.pdf
"2012, 8      http://www.biolsci.org  1363  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(10):1363-1374. doi: 10.7150/ ijbs.5106  Research Paper   Identification of Metastamirs as Metastasis -associated MicroRNAs in Clear  Cell Renal Cell Carcinomas    Zofia Wotschofsky1,2*, Julia Liep1,2*, Hellmuth -Alexander Meyer1,3, Monika Jung1, Ina Wagner4, Alexander  C. Disch5, Klaus D. Schaser5, Ingo Melcher5, Ergin Kilic6, Jonas Busch1, Steffen W eikert1, Kurt Miller1, An- dreas Erbersdobler7, Hans -Joachim Mollenkopf4, Klaus Jung1,2,8  1.",Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8    http://www.biolsci.org  1364  time of initial diagnosis,  approximately 60% of the  patients have a l ocalized carcinoma, and nearly 20%  are identified with regional or distant metastases [2].",Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"As of July 2012 , a  total of 1921 mature human miRNAs have been an- notated in the miRBase release 18.0  (http://www.mirbase.org).",Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8    http://www.biolsci.org  1365  conditions (37°C, 5% CO 2) recommended by the  American Type Culture Collection (Manassas, VA,  USA).",Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
Prediction of M icroRNA Targets   Target prediction was performed using  miRecords (http://mirecords.umn.edu/miRecords)  which integrates several miRNA target prediction  programs [25].,OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
The web -based software  DIANA -mirPath (http://diana.cslab.ece.ntua.gr) was  applied to identify genes that are affected by diffe r- entially expressed miRNAs in the renal cell carcinoma  pathway provided by the KEGG database [27] .,OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8    http://www.biolsci.org  1366  Microarray -based Selection of Metastamirs   The normalized data and the quality flags (pr e- sent and absent calls) generated from GeneSpring  software were used to identify differentially e x- pressed miRNA genes between sample groups.",OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8    http://www.biolsci.org  1367  Table 2.  miRNAs included in the RT- qPCR analysis regarding their metastatic associatio n.†  Selected miRNAs by microarray analysis      Microarray‡ RT-qPCR‡  No.",Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8    http://www.biolsci.org  1368     Figure  1.",Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8    http://www.biolsci.org  1369   No significant association was found between  the expression of any miRNA and age (r S with P va l- ues 0.061 to 0.974).",Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8    http://www.biolsci.org  1370  Table 3.",Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8    http://www.biolsci.org  1371  miR-29b 284 PDGFB, PIK3R1, VEGFA, CDC42, PIK3R2, AKT3   miR-29c 315 PDGFB, PIK3R1, VEGFA, CDC42, PIK3R2, ARNT, AKT3, TGFB3   miR-100 15 -  miR-101 188 TCEB1, MAPK1, RAC1, PAK2, RAP1B, AKT2, PAK7   miR-126 4 CRK   miR-127 4 -  miR-130a  233 MET, EGLN3, SOS1, PAK6, EP300   miR-141 168 HGF, CDC42, GRB2, TGFB2, GAB1   miR-143 74 KRAS, PTPN11, EGLN1   miR-145 101 PAK7   miR-148a  166 MET, SLC2A1, EPAS1, SOS1, EP300, PIK3R3   miR-155 96 PIK3CA, HIF1A, KRAS, SOS1, RAP1B, ETS1   miR-192 19 -  miR-194 74 HIF1A, MAPK1, RAP1B, AKT2   miR-200c  289 TCEB1, CRKL, SOS1, PTPN11, VEGFA, RAC1, RAP1B, ETS1, PAK7, EP300, EGLN1, JUN   miR-210 4 -  miR-215 19 RAP1B   miR-223 58 PAK7   miR-224 82 ETS1   miR-296 1050  -  miR-370 132 PIK3CA, SOS1   miR-514 550 RBX1, SLC2A1, JUN, AKT3   miR-638 254 -  †Number of predicted targets according to the algorithms explained in Materials and Methods.",Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
‡Validated targets indicated by t he software DIANA -mirPath (http://diana.cslab.ece.ntua.gr) corresponding to the genes that were provided to be affected in  the renal cell carcinoma pathway as shown in the KEGG database [27].,Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8    http://www.biolsci.org  1372  as differentially expressed in these reports  [19-23].",OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8    http://www.biolsci.org  1373  co-regulation/co -expression, characteristic constell a- tions were observed.",OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"For certain miRNAs, a higher number of targ ets  presented in the TarBase 6.0 of the DIANA lab (http://diana.cslab.ece.ntua.gr) compared with the  predicted targets were observed (data not shown).",OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
http://www.biolsci.org/v0 8p1363s1.pdf   Abbreviations    ccRCC: clear cell renal cell carcinoma; Cq:  quantification cycles; KEGG: Kyoto Encyclopedia  of  Genes and Genomes; miRNA: microRNA; RIN: RNA  integrity number; RT -qPCR: quantitative  RT-PCR .,Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8    http://www.biolsci.org  1374  References   1.",Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
http://seer.cancer.gov/csr/1975_2009_pops09/.,Non-OADS,/arxiv_data1/oa_pdf/b5/54/ijbsv08p1363.PMC3492794.pdf
"2012, 8      http://www.biolsci.org  1375  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(10):1375-1384. doi: 10.7150/ ijbs.4575  Research Paper   Rhein Protects against Obesity a nd Related Metabolic Disorders t hrough  Liver X Receptor -Mediated Uncoupling Protein 1 Upregulation i n Brown  Adipose Tissue    Xiaoyan Sheng1,*, Xuehua Zhu2,*, Yuebo Zhang1, Guoliang Cui1, Linling Peng3, Xiong Lu4, and Ying Qin  Zang1,  1.",Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
"2012, 8    http://www.biolsci.org  1376  and type 2 diabetes  (2-5).",Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
"2012, 8    http://www.biolsci.org  1377  sion of LXR target genes via LXR antagonism, we  used two cell models,  3T3-L1 adipocytes different i- ated for 7 days  and high level LXR -expressing HepG2  cells.",Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
"2012, 8    http://www.biolsci.org  1378    Figure 2 Rhein decreases liver X receptor ( LXR ) target gene expression in vitro .",Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
"2012, 8    http://www.biolsci.org  1379  UCP1  mRNA levels by almost 3 -fold, but  did not a f- fect th e expression of β3 -AR (Figure  4A).",Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
"2012, 8    http://www.biolsci.org  1380    Figure 4 Rhein activates uncoupling protein 1 ( UCP1 ) gene expression in brown adipose tissue (BAT) through LXR antag o- nism.",Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
"2012, 8    http://www.biolsci.org  1381  creased the expression of LXR target genes in WAT,  muscle and liver  in DIO mice.",Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
"2012, 8    http://www.biolsci.org  1382  acute and partial inhibition of LXRs differ  from those  of lifelong absence of LXRs and that there may be  some compensatory mechanisms in this phenotype.",Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
"2012, 8    http://www.biolsci.org  1383  formed using Lipofectamine 2000 (Invitrogen, Carl s- bad, CA) with the indicated plasmids or control ve c- tors.",Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
http://www.biolsci.org/v0 8p1375s1.pdf   Acknowledgments   We thank Dr. David J. Mangelsdorf (Southwes t- ern Medical Center) for the LXRα/β knockout mice  and for advice on the discussion.,Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
"2012, 8    http://www.biolsci.org  1384  24.",Non-OADS,/arxiv_data1/oa_pdf/f2/e9/ijbsv08p1375.PMC3492795.pdf
"2012, 8      http://www.biolsci.org  1385  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(10):1385-1397. doi: 10.7150/ ijbs.5141  Review   Regulation of the Src Family Kinases by Csk   Masato Okada  Department of Oncogene Research, Research Institute for Microbial Diseases, Osaka University, 3 -1 Yamada-oka, Suita,  Osaka 565- 0871, JAPAN.",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8    http://www.biolsci.org  1386  causes of SFK dysregulation in the diseases remain  unclear.",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8    http://www.biolsci.org  1387  cells, SFKs are mostly phosphorylated at Tyr -527, and  adopt the inactive conformation, which is stabilized  by two intramolecular interactions: 1) binding of  phosphorylated Tyr -527 to its own SH2 domain, and  2) binding of the SH2 -kinase linker to the SH3 d o- main.",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8      http://www.biolsci.org  1388  Although the molecular mechanisms of SFK a c- tivation may vary depending upon cell types and e x- tracellular cues, it is now believed that in general, full  activation of SFK is achieved in the following order  (Fig.2B): 1) the activated receptors, adaptors, or ef- fectors interact with the SH2/3 domains of inactive  SFKs to open up the closed conformation, and harbor  SFKs at appropriate intracellular locations such as  focal adhesions; and 2) tyrosine phosphatases  dephosphorylate the exposed pTyr -527 to stabilize the  active conformation; and 3) the activated SFKs u n- dergo intermolecular auto -phosphory lation on  Tyr-416 to lock the catalytic pocket into the fully a c- tive conformation.",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8    http://www.biolsci.org  1389  Function of Csk   The function of Csk as a negative  regulator of SFKs in vivo  was demo n- strated by the phenotypes of mice lac k- ing Csk [41, 42]  (Fig.4A).",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8    http://www.biolsci.org  1390  To further verify the functional connections b e- tween Csk and SFKs, we investigated homologs of  SFKs and Csk in two prim itive animals; a  unicellular choanoflagellate  M. ovate  and a fresh -water sponge E.  fluviatilis  (Fig.5).",OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8      http://www.biolsci.org  1391  Sequence alignment of invertebrate and vert e- brate genes reveal that Csk is highly conserve d across  the animal kingdom, from the unicellular  choanoflagellate to humans, as are the SFKs [49] , con- firming the intimate relationship between Csk and  SFKs.",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8    http://www.biolsci.org  1392  of the active site of Csk [59] .",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8    http://www.biolsci.org  1393    Fig.7.",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8    http://www.biolsci.org  1394  regulated by the redox state within the cells [93] .",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8    http://www.biolsci.org  1395    Fig.9.",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8    http://www.biolsci.org  1396  23.",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8    http://www.biolsci.org  1397  71.",Non-OADS,/arxiv_data1/oa_pdf/ad/12/ijbsv08p1385.PMC3492796.pdf
"2012, 8      http://www.biolsci.org  1398  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  BBiioollooggiiccaall  SScciieenncceess   2012; 8(10):1398-1407. doi: 10.7150/ ijbs.5079  Research Paper   TRAF Family Member -Associated NF-κB Activator   (TANK) Induced by RANKL  Negatively Regulates   Osteoclasts Survival and Function    Mengrui Wu1,2, Yiping Wang1,2, Lianfu Deng3, Wei Chen1, Yi-Ping Li1,2  1.",Non-OADS,/arxiv_data1/oa_pdf/c3/23/ijbsv08p1398.PMC3492797.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/c3/23/ijbsv08p1398.PMC3492797.pdf
"2012, 8    http://www.biolsci.org  1399  genesis.",Non-OADS,/arxiv_data1/oa_pdf/c3/23/ijbsv08p1398.PMC3492797.pdf
"2012, 8    http://www.biolsci.org  1400  sistent number of B MM cells were cultured on bovine  cortical bone slices in 24 -well plates (2X105cells/well) .",Non-OADS,/arxiv_data1/oa_pdf/c3/23/ijbsv08p1398.PMC3492797.pdf
"2012, 8      http://www.biolsci.org  1401    Figure 1.",Non-OADS,/arxiv_data1/oa_pdf/c3/23/ijbsv08p1398.PMC3492797.pdf
"2012, 8    http://www.biolsci.org  1402  ested in the role of Tank in NF-κB activation in oste o- clasts.",Non-OADS,/arxiv_data1/oa_pdf/c3/23/ijbsv08p1398.PMC3492797.pdf
"2012, 8    http://www.biolsci.org  1403    Figure 3.",Non-OADS,/arxiv_data1/oa_pdf/c3/23/ijbsv08p1398.PMC3492797.pdf
"2012, 8    http://www.biolsci.org  1404    Figure 4.",Non-OADS,/arxiv_data1/oa_pdf/c3/23/ijbsv08p1398.PMC3492797.pdf
"2012, 8    http://www.biolsci.org  1405    Figure 5.",Non-OADS,/arxiv_data1/oa_pdf/c3/23/ijbsv08p1398.PMC3492797.pdf
"2012, 8    http://www.biolsci.org  1406  pression pattern of Tank in vivo and in vitro impl i- cates the possibility that Tank may have a function in  bone resorption .",Non-OADS,/arxiv_data1/oa_pdf/c3/23/ijbsv08p1398.PMC3492797.pdf
"2012, 8    http://www.biolsci.org  1407  References   1.",Non-OADS,/arxiv_data1/oa_pdf/c3/23/ijbsv08p1398.PMC3492797.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/a3/f4/srep00819.PMC3492843.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Ishii, N., Kato, T. & Abe, J.",Non-OADS,/arxiv_data1/oa_pdf/a3/f4/srep00819.PMC3492843.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Mathiesen, J., Yde, P. & Jensen, M.H.",Non-OADS,/arxiv_data1/oa_pdf/a1/d1/srep00814.PMC3492865.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/ff/69/srep00815.PMC3492866.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Radicchi, F. In science ‘‘there is no bad publicity’’: Papers criticized in comments have high scientific impact.",Non-OADS,/arxiv_data1/oa_pdf/ff/69/srep00815.PMC3492866.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Lin, C. et al.",Non-OADS,/arxiv_data1/oa_pdf/41/49/srep00785.PMC3492867.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/66/f7/srep00822.PMC3492868.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Kuo, M.-L. et al.",Non-OADS,/arxiv_data1/oa_pdf/66/f7/srep00822.PMC3492868.pdf
These profiles wereanalyzed by hierarchical clustering (using the method of Ward’s linkage based onEuclidean distance) and visualized using a heat map using the R Project package (http://www.R-project.org).,OADS,/arxiv_data1/oa_pdf/08/bc/srep00823.PMC3492869.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Magi, S., Tashiro, E. & Imoto, M. A chemical genomic study identifying diversity in cell migration signaling in cancer cells.",Non-OADS,/arxiv_data1/oa_pdf/08/bc/srep00823.PMC3492869.pdf
Sources :Wikipedia : various pages on GDP http://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal) and http://en.wikipedia.org/wiki/ List_of_regions_by_past_GDP_(PPP).www.nature.com/ scientificreports SCIENTIFIC REPORTS | 2 : 812 | DOI: 10.1038/srep00812 2,Non-OADS,/arxiv_data1/oa_pdf/4a/b5/srep00812.PMC3492871.pdf
( Source : Forbes List http://www.forbes.com/).www.nature.com/ scientificreports SCIENTIFIC REPORTS | 2 : 812 | DOI: 10.1038/srep00812 3,Non-OADS,/arxiv_data1/oa_pdf/4a/b5/srep00812.PMC3492871.pdf
2; the top 50 continental European city populations from http://www.citymayors.com/features/euro_cities.html; the top 161 river lengths from Wikipedia http://en.wiki pedia.org/wiki/ List_of_rivers_by_length; top 2000 COCA words from http://corpus.byu.edu/coca/; GDP from Wikipedia http://en.wikipedia.org/wiki/ List_of_countries_by_GDP_(nominal); the frequency of Python module usage from http://www.algorithm.co.il/blogs/math/python-module-usage -statistics/www.nature.com/ scientificreports SCIENTIFIC REPORTS | 2 : 812 | DOI: 10.1038/srep00812 5,Non-OADS,/arxiv_data1/oa_pdf/4a/b5/srep00812.PMC3492871.pdf
"Krugman, P. The great illusion, The New York Times , August 15, A17 (2008), available at http://www.nytimes.com/2008/08/15/opinion/ 15krugman.html?_r 50 accessed 5/10/2012.",Non-OADS,/arxiv_data1/oa_pdf/4a/b5/srep00812.PMC3492871.pdf
http://www.forbes.com/wealth/forbes-400 accessed 28/9/2010.,Non-OADS,/arxiv_data1/oa_pdf/4a/b5/srep00812.PMC3492871.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Cristelli, M., Batty, M. & Pietronero, L. There is More than a Power Law in Zipf.",Non-OADS,/arxiv_data1/oa_pdf/4a/b5/srep00812.PMC3492871.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Zajac, P. & Ahmadian, A.",Non-OADS,/arxiv_data1/oa_pdf/52/77/srep00821.PMC3492873.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/5c/f2/srep00809.PMC3492875.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Barcia, C. et al.",Non-OADS,/arxiv_data1/oa_pdf/5c/f2/srep00809.PMC3492875.pdf
Additional information Supplementary Information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/9c/53/srep00824.PMC3492876.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Simonsson, L., Kurczy, M.E., Trouillon, R., Hook, F. & Cans, A.",Non-OADS,/arxiv_data1/oa_pdf/9c/53/srep00824.PMC3492876.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society Biochemical Journal    www.biochemj.org © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/e2/bj4480213.PMC3492919.pdf
Structure ﬁgures were generated using PyMOL (version 1.5.0.2; http://www.pymol.org).,OADS,/arxiv_data1/oa_pdf/82/e2/bj4480213.PMC3492919.pdf
"There is additional density close to the N-terminus c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/e2/bj4480213.PMC3492919.pdf
"In addition to occluding the ATP-binding site like c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/e2/bj4480213.PMC3492919.pdf
"In Met, the Tyr 1234side chain (equivalent to IRK Tyr1162) contacts αC directly, and its phosphorylation is required for Met activation c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/e2/bj4480213.PMC3492919.pdf
"Within the Ror2 monomer, all of the structural features described in the present paper are maintainedin 3ZZW, with the exception that molecule B in 3ZZW has a different DLG motif conﬁguration and position, slightly closer to the ‘DFG-out’ conformation seen in inactive IRK, so that the c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/e2/bj4480213.PMC3492919.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/e2/bj4480213.PMC3492919.pdf
"Sites at which mutations have been reported in cancer patients, in the literature or COSMIC (http://www.sanger.ac.uk/genetics/CGP/cosmic/) database [40], are represent ed as spheres, coloured red if the mutations lie in the activation loop or αC helix.",Non-OADS,/arxiv_data1/oa_pdf/82/e2/bj4480213.PMC3492919.pdf
"Activating mutations in IRK family TKDs Figure 6 summarizes mutations found in the TKDs of IRK family RTKs in cancer patients, from the COSMIC (CatalogueOf Somatic Mutations In Cancer) database (http://www.sanger.",OADS,/arxiv_data1/oa_pdf/82/e2/bj4480213.PMC3492919.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/e2/bj4480213.PMC3492919.pdf
"16, 5572–5581 Received 29 August 2012/18 September 2012; accepted 20 September 2012 Published as BJ Immediate Publication 20 September 2012, doi:10.1042/BJ20121365 c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/e2/bj4480213.PMC3492919.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society Biochemical Journal    www.biochemj.org © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
In experiments involving pre-treatment with 2-APB or loperamidetransient peak and plateau values were corrected for /Delta1F (or/Delta1F mean) immediately before progesterone application (Supplementary Figure S1 at http://www.BiochemJ.org/bj/448/ bj4480189add.htm).,Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"To test the c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
In the three other experiments the 2-APBpre-treatment resulted in a bi-modal or ‘smeared’ amplitude dis- tribution (Supplementary Figure S2 at http://www.BiochemJ.org/ bj/448/bj4480189add.htm).,Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"Pre-treatment with 50 μM or 100 μM 2-APB enhanced [Ca 2+]i transient amplitude in some experiments (Supplementary Figure S3 at http://www.BiochemJ.org/bj/448/bj4480189add.htm andFigure 3d), but this effect was not signiﬁcant ( P>0.2; paired ttest, n=4 sets of experiments).",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"Transient amplitudes in the two regions were correlated ( R=0.74; Supplementary Figure S4 at http://www.BiochemJ.org/bj/ 448/bj4480189add.htm), but /Delta1Fmean at the peak was ∼25% smaller in the midpiece ( P<0.002; n=11 pairs of experiments).",OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
When a sustained [Ca2+]iincrease occurred in the midpiece there was often a clear inﬂexion in the rising phase after 10– 30 s (Figures 5f and 5g; Supplementary Movies S1 and S2 at http://www.BiochemJ.org/bj/448/bj4480189add.htm).,Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"When 50 μM 2-APB was applied in this way there was an immediate but transient fall in [Ca2+]i.The [Ca2+]iplateau (‘b’ in Supplementary Figure S1) was reduced by 62 +−13% c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"Antibody c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
TRPV3 could not be detected in human sperm (Supplementary Figure S5 at http://www.BiochemJ.org/bj/448/bj4480189add.htm).,Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"Bis-phenol caused sustained[Ca 2+]ielevation within 4 min ( /Delta1Fmean=48.7+−3.4%;n=17; Supplementary Figure S6a at http://www.BiochemJ.org/bj/ 448/bj4480189add.htm), an effect that was abolished in EGTA-buffered saline ([Ca 2+]≈3×10−7M).",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"Inward monovalent c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
CatSper currents were insensitive to loperamide and outward currents were semi-reversibly inhibited (Supplementary FigureS7 at http://www.BiochemJ.org/bj/448/bj4480189add.htm).,Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"536,3 – 1 9 c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"131, 4027–4030 Received 24 February 2012/22 August 2012; accepted 3 September 2012 Published as BJ Immediate Publication 3 September 2012, doi:10.1042/BJ20120339 c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"1To whom correspondence should be addressed (email s.j.publicover@bham.ac.uk c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"Nature 471, 387–391 Received 24 February 2012/22 August 2012; accepted 3 September 2012 Published as BJ Immediate Publication 3 September 2012, doi:10.1042/BJ20120339 c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/bj4480189.PMC3492921.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society Biochemical Journal    www.biochemj.org © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/9d/bj4470363.PMC3492928.pdf
"Neutrophil activation Freshly isolated PMNs (107cells in 700 μl) were placed in low- binding microtubes and activated by incubation with 20 μM c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/9d/bj4470363.PMC3492928.pdf
"c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/9d/bj4470363.PMC3492928.pdf
"This suggests that the speciﬁcities of pig NSPs are similar to c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/9d/bj4470363.PMC3492928.pdf
"Figure 5(A) shows a representative immunostain obtained with anti-Pr3 antibodies, but the same result was obtained with all c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/9d/bj4470363.PMC3492928.pdf
"This clearly differs c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/9d/bj4470363.PMC3492928.pdf
"Drug Discovery Today 3, 251–259 c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/9d/bj4470363.PMC3492928.pdf
"104, 131–144 Received 16 May 2012/30 July 2012; accepted 6 August 2012 Published as BJ Immediate Publication 6 August 2012, doi:10.1042/BJ20120818 c/circlecopyrtThe Authors Journal compilation c/circlecopyrt2012 Biochemical Society © 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/9d/bj4470363.PMC3492928.pdf
"Mark Brown; Email: mabrown@wakehealth.edu Submitted: 02/21/12; Revised: 03/14/12; Accepted: 03/14/12 http://dx.doi.org/10.4161/adip.20035MINI-REVIEW Adipocyte 1:3, 123 –131; July/August/September 2012; G2012 Landes Bioscience www.landesbioscience.com Adipocyte 123",Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Diabetes 2012; 61:355-63; PMID:22228714; http://dx.doi.org/10.2337/db11-0994 2.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Lipid Res 2010; 51:3306-15; PMID: 20802159; http://dx.doi.org/10.1194/jlr.M010256 3.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2004; 279:47066-75; PMID:15337759; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2004; 279:48968-75; PMID:15364929; http://dx.doi.org/10.1074/jbc.M407841200 5.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Lipid Res 2009; 50 (Suppl):S63-8; PMID:19029121; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2006; 281:26465-72; PMID: 16818490; http://dx.doi.org/10.1074/jbc.M604660200 7.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2006; 281:40236-41; PMID:17074755; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2010; 285:7300-11; PMID:20023287; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2008; 283:24525- 33; PMID:18606822; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Lipid Res 2010; 51:709-19; PMID: 19801371; http://dx.doi.org/10.1194/jlr.M001917 12.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Pediatr Gastroenterol Nutr 1997; 25:541-7; PMID:9360211; http://dx.doi.org/10.1097/00005176-199711000-00011 13.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Am J Hum Genet 2001; 69:1002-12; PMID:11590543; http://dx.doi.org/ 10.1086/324121 15.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Nat Genet 2007; 39:28- 30; PMID:17187067; http://dx.doi.org/10.1038/ng1951 16.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 1996; 271:16644-51; PMID:8663220; http://dx.doi.org/10.1074/jbc.271.28.16644 17.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Science 2006; 312:734-7; PMID: 16675698; http://dx.doi.org/10.1126/science.1123965 19.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Nat Genet 2012; 44:140-7; PMID: 22246504; http://dx.doi.org/10.1038/ng.1056 20.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Lipid Res 2007; 48:2295-305; PMID: 17664529; http://dx.doi.org/10.1194/jlr.M700279- JLR200 21.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2002; 277:4806-15; PMID:11717312; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2004; 279:42062-71; PMID: 15292255; http://dx.doi.org/10.1074/jbc.M407462200 24.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2004; 279:30490-7; PMID:15136565; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Science 2004; 306:1383-6; PMID:15550674; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
"C R Biol 2006; 329:598-607, discussion 653-5; PMID:16860278; http://dx.doi.org/ 10.1016/j.crvi.2005.10.008 28.",OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Lipid Res 2007; 48:2547-59; PMID: 17878492; http://dx.doi.org/10.1194/jlr.R700014- JLR200 29.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Am J Physiol Gastrointest Liver Physiol 2007; 293:G1-4; PMID:17218471; http://dx.doi.org/10.1152/ajpgi.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Biochem Soc Trans 2003; 31:1120-4; PMID:14641008; http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Diabetes 2009; 58: 855-66; PMID:19136649; http://dx.doi.org/10.2337/ db08-1644 34.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
FEBS Lett 2010; 584: 903-10; PMID:20083112; http://dx.doi.org/10.1016/ j.febslet.2009.12.058 35.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2007; 282:996-1002; PMID: 17114792; http://dx.doi.org/10.1074/jbc.M605770200 36.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Lipid Res 2011; 52: 2032-42; PMID:21885429; http://dx.doi.org/10.1194/ jlr.M019117 37.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Mol Cell Biochem 2006; 284: 167-73; PMID:16532261; http://dx.doi.org/10.1007/ s11010-005-9045-y 38.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2009; 284:3049-57; PMID:19064991; http://dx.doi.org/10.1074/jbc.M808251200 39.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2011; 286:5126-35; PMID:21148142; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Endocrinology 2011; 152:48-58; PMID: 21106876; http://dx.doi.org/10.1210/en.2010-0661 41.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Hepatology 2011; 54:122-32; PMID:21465509; http://dx.doi.org/10.1002/hep.24338 42.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Hepatology 2011; 53:116- 26; PMID:20967758; http://dx.doi.org/10.1002/hep.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Diabetologia 2011; 54:146-56; PMID:20842343; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2009; 284:30218-29; PMID: 19723629; http://dx.doi.org/10.1074/jbc.M109.047787 46.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2009; 284:16848-59; PMID: 19389712; http://dx.doi.org/10.1074/jbc.M109.006650 47.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Science 2001; 294:1942-5; PMID:11729323; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Cell Cycle 2008; 7:3118-23; PMID:18927511; http://dx.doi.org/10.4161/cc.7.20.6881 50.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Proc Natl Acad Sci U S A 2008; 105:8286-91; PMID:18550814; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Am J Physiol Gastrointest Liver Physiol 2005; 289: G592-8; PMID:15817811; http://dx.doi.org/10.1152/ ajpgi.00063.2005 54.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
J Biol Chem 2001; 276:27855-63; PMID:11285257; http://dx.doi.org/10.1074/jbc.M008885200 55.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Hepatology 2012; 56:270-80; PMID:22271167; http://dx.doi.org/10.1002/hep.25601 59.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Arterioscler Thromb Vasc Biol 2011; 31:67-73; PMID:21030715; http://dx.doi.org/10.1161/ ATVBAHA.110.215814 60.,Non-OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Nat Med 2011; 17:1076-85; PMID:21857651; http://dx.doi.org/10.1038/nm.2439 61.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
Cell 2009; 138:476-88; PMID:19646743; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f3/e5/adip-1-123.PMC3492958.pdf
We compared all identified germline variants to those listed in the PKD foundation da- tabase at http://pkdb.mayo.edu/cgi-bin/mutations.cgi.,Non-OADS,/arxiv_data1/oa_pdf/a0/80/cee-0002-0071.PMC3492998.pdf
"In addition, we checked whether the sequences containing the variant were highly conserved using the website http://www.en-sembl.org.",Non-OADS,/arxiv_data1/oa_pdf/a0/80/cee-0002-0071.PMC3492998.pdf
"Of the mutations described  here, 7 have never been described (http://pkdb.mayo.edu/cgi-bin/mutations.cgi).",Non-OADS,/arxiv_data1/oa_pdf/a0/80/cee-0002-0071.PMC3492998.pdf
"http://www.alzforum.org/new/detail.asp?id=2999 (last accessed March 20, 2012).",OADS,/arxiv_data1/oa_pdf/7c/a4/dee-0002-0433.PMC3493003.pdf
"http://www.prnewswire.com/news-releases/us-adults-fear-alzheimers-more-than-heart- disease-diabetes-or-stroke-but-few-prepare-56323872.html (last accessed March 20, 2012).",Non-OADS,/arxiv_data1/oa_pdf/7c/a4/dee-0002-0433.PMC3493003.pdf
"42 Department of Statistics of Singapore: Key Household Characteristics and Household Income  Trends, 2011. http://www.singstat.gov.sg/pubn/papers/people.html#householdincome (last accessed March 20, 2012).",OADS,/arxiv_data1/oa_pdf/7c/a4/dee-0002-0433.PMC3493003.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreportsCompeting financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/fc/b5/srep00795.PMC3493010.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Thakur, M., Sinsabaugh, S., Isaacson, M.J., Wong, M.S.",Non-OADS,/arxiv_data1/oa_pdf/fc/b5/srep00795.PMC3493010.pdf
"The pressure monitors were connected to an analog-to-digital converter, fitted into a com-puter running a dedicated software (http://www.neurosurg.cam.ac.uk/icmplus, Cambridge University, UK)  [9] .",Non-OADS,/arxiv_data1/oa_pdf/68/25/cee-0002-0052.PMC3493014.pdf
": Cerebral Hemodynamic Changes Induced by a Lumbar Puncture inGood-Grade Subarachnoid Hemorrhage www.karger.com/cee  © 2012 S. Karger AG, Basel   The first descriptive analysis was performed using the raw signal, normalized to mean  cerebral activity and we applied a Brodmann mask [http://www.cabiatl.com/mricro/mri-cro/mricro.html] on the images.",Non-OADS,/arxiv_data1/oa_pdf/68/25/cee-0002-0052.PMC3493014.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/99/d4/srep00786.PMC3493074.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Liu, M. et al.",Non-OADS,/arxiv_data1/oa_pdf/99/d4/srep00786.PMC3493074.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/90/e5/srep00779.PMC3493116.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Hiblot, J., Gotthard, G., Chabriere, E. & Elias, M. Characterisation of the organophosphate hydrolase catalytic activity of SsoPox.",Non-OADS,/arxiv_data1/oa_pdf/90/e5/srep00779.PMC3493116.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by- nc/3.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/72/a5/ezs492.PMC3493131.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/84/37/thnov02p0976.PMC3493199.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/9c/c3/thnov02p1020.PMC3493200.pdf
Cancer facts and figures  2012. http://www.cancer.org/ acs/groups/content/   @epidemiologysurveilance/documents/document/acspc -031941.pdf    78.,Non-OADS,/arxiv_data1/oa_pdf/9c/c3/thnov02p1020.PMC3493200.pdf
This  is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/0b/42/thnov02p0999.PMC3493201.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/e0/d2/thnov02p0967.PMC3493202.pdf
This is an open -access article distributed under the terms of th e Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/4a/d1/thnov02p1010.PMC3493203.pdf
http://www.planta.at/hyper/   hyper.htm ) has a purity > 98 %.,Non-OADS,/arxiv_data1/oa_pdf/4a/d1/thnov02p1010.PMC3493203.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by -nc-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/af/c5/thnov02p0988.PMC3493204.pdf
"M. Rodriguez -Porcel, J. Wu, and S.  Gambhir , “Molecular imaging of stem cells,” in StemBook  [Intern et]  (Harvard Stem Cell Institute,Cambridge, MA, 2008 ), available from  http://www.ncbi.nlm.nih.gov/books/NBK27079/   4.",OADS,/arxiv_data1/oa_pdf/10/31/2916.PMC3493215.pdf
http://www.cso.nato.int/Pubs/rdp.asp?RDP=RTO -TR-SET-098  4.,OADS,/arxiv_data1/oa_pdf/4a/f2/2964.PMC3493216.pdf
"X. Guo, A. Mandelis , and B.  Zinman , “Applications of ultrasensitive wavelength -modulated differential  photothermal radiometry to noninvasive glucose detection in blood serum,” J. Biophotonics,  http://onlinelibrary.wiley.com/doi/10.1002/jbio.201200103/abstract .",Non-OADS,/arxiv_data1/oa_pdf/a1/30/3012.PMC3493219.pdf
"A. Cytometry , “VenturiOne cell cyc le analysis,” Application Note,  http://www.appliedcytometry.com/pdfs/VenturiOne_DNA_Cell_Cycle_Application_Note_low_res.pdf .",OADS,/arxiv_data1/oa_pdf/3f/b9/2784.PMC3493222.pdf
"Moxtek, “Pixelated polarizers” (Moxtek, Inc, 2010 ), retrieved 22 Aug, 2012, http://www.moxtek.com/optics - products/pixelated -polarizers.html .",OADS,/arxiv_data1/oa_pdf/d1/d4/2866.PMC3493224.pdf
"“Step height standards (quartz)” (VLSI Standards, Inc, 2011 ), retrieved 22 Aug, 2012,  http://vlsistandards.com/products/dimensional/step.asp?SID=100 .",OADS,/arxiv_data1/oa_pdf/d1/d4/2866.PMC3493224.pdf
"“Pond life identification kit” (Mi croscopy -UK, 2012), retrieved 22 Aug, 2012, http://www.microscopy - uk.org.uk/index.html?http://www.microscopy -uk.org.uk/pond/protozoa.html .",Non-OADS,/arxiv_data1/oa_pdf/d1/d4/2866.PMC3493224.pdf
"120(8), 1465– 1478  (2009 ), http://www.opticsinfobase.org/abstract.cfm?uri=BIOMED -2010 - BSuD110p .",Non-OADS,/arxiv_data1/oa_pdf/60/93/2700.PMC3493229.pdf
"“Biomedical Optics (BIOMED),”  http://www.osa.org/osaorg/media/osa.media/Meetings/Archives/2012/BIOMED -2012 -Archive.pdf .",Non-OADS,/arxiv_data1/oa_pdf/e5/4f/2771.PMC3493230.pdf
"“ORMOCERs,” http://www.ormocer.de/EN/index.jsp   34.",Non-OADS,/arxiv_data1/oa_pdf/f3/72/2842.PMC3493232.pdf
"J. Pekar , “Multispectral bioluminescence tomography with x -ray CT spatial priors” Ph.D. thesis (McMaster  University, Hamilton, 2011 ), Open Access Dissertations and Theses, Paper 4329,  http://digitalcommons.mcmaster.ca/opendissertations/4329 .",Non-OADS,/arxiv_data1/oa_pdf/c1/8c/2794.PMC3493244.pdf
"S. A.  Prahl , “Optical properties spectra,” (Oregon Medical Laser Clinic, 2001 ),  http://omlc.ogi.edu/spectra/index.html .",OADS,/arxiv_data1/oa_pdf/c1/8c/2794.PMC3493244.pdf
"www.landesbioscience.com  P lant Signaling & Behavior  1209P lant Signaling & Behavior 7:10, 1209-1211; October 2012; © 2012 Landes BioscienceShOrt C O mmuni Ca ti O n *Correspondence to: Dominique Van Der Straeten; Email: Dominique.VanDerStraeten@ugent.be Submitted: 05/24/12; Revised: 07/05/12; Accepted: 07/10/12http://dx.doi.org/10.4161/psb.21430Pentatricopeptide repeat (PPR) protein family which is charac - terized by tandem arrays of a degenerate 35-amino-acid repeat, is  mainly involved in the RNA metabolism, including RNA splic - ing and editing,2 Based on the protein domains, this family is  divided into the P and PLS families.",Non-OADS,/arxiv_data1/oa_pdf/97/1e/psb-7-1209.PMC3493397.pdf
Plant J 2012; PMID:22540321; http://dx.doi.org/10.1111/j.1365-313X.2012.05036.x.,OADS,/arxiv_data1/oa_pdf/97/1e/psb-7-1209.PMC3493397.pdf
Plant Cell 2004; 16:2089-103; PMID:15269332; http://dx.doi.org/10.1105/tpc.104.022236.,OADS,/arxiv_data1/oa_pdf/97/1e/psb-7-1209.PMC3493397.pdf
Nucleic Acids Res 2009; 37:e13; PMID:19059998; http://dx.doi.org/10.1093/nar/gkn975.,Non-OADS,/arxiv_data1/oa_pdf/97/1e/psb-7-1209.PMC3493397.pdf
Plant J 2010; 61:456-66; PMID:19929879; http://dx.doi.org/10.1111/j.1365-313X.2009.04082.x.5.,OADS,/arxiv_data1/oa_pdf/97/1e/psb-7-1209.PMC3493397.pdf
Plant J 2010; 63:499-511; PMID:20497377; http://dx.doi.org/10.1111/j.1365-313X.2010.04258.x.,OADS,/arxiv_data1/oa_pdf/97/1e/psb-7-1209.PMC3493397.pdf
Plant J 2010; 61:446-55; PMID:19919573; http://dx.doi.org/10.1111/j.1365-313X.2009.04076.x.,OADS,/arxiv_data1/oa_pdf/97/1e/psb-7-1209.PMC3493397.pdf
Plant Cell 2009; 21:3686-99; PMID:19934379; http://dx.doi.org/10.1105/tpc.109.071472.9.,OADS,/arxiv_data1/oa_pdf/97/1e/psb-7-1209.PMC3493397.pdf
Plant Physiol 2009; 151:603-19; PMID:19675153; http://dx.doi.org/10.1104/pp.109.141770.,Non-OADS,/arxiv_data1/oa_pdf/97/1e/psb-7-1209.PMC3493397.pdf
J Biol Chem 2010; 285:32192-9; PMID:20682769; http://dx.doi.org/10.1074/jbc.M110.147603.,OADS,/arxiv_data1/oa_pdf/97/1e/psb-7-1209.PMC3493397.pdf
Annu Rev Plant Physiol Plant Mol Biol 2001; 52:561-91; PMID:11337409; http://dx.doi.org/10.1146/annurev.arplant.52.1.561.,OADS,/arxiv_data1/oa_pdf/97/1e/psb-7-1209.PMC3493397.pdf
"Plant Signaling & Behavior 7:10, 1212-1214; October 2012; © 2012 Landes Bioscience 1212  P lant Signaling & Behavior  V olume 7 Issue 10*Correspondence to: Marcel Wiermer; Email: wiermer@uni-goettingen.de Submitted: 06/29/12; Accepted: 07/10/12http://dx.doi.org/10.4161/psb.21426Plants use sophisticated defense systems against pathogen infec - tion.",Non-OADS,/arxiv_data1/oa_pdf/af/66/psb-7-1212.PMC3493398.pdf
Plant Cell 2004; 16:1060-71; PMID:15031411; http://dx.doi.org/10.1105/tpc.020479.,OADS,/arxiv_data1/oa_pdf/af/66/psb-7-1212.PMC3493398.pdf
Mol Cell Biol 2006; 26:9533-43; PMID:17030626; http://dx.doi.org/10.1128/MCB.01063-06.5.,Non-OADS,/arxiv_data1/oa_pdf/af/66/psb-7-1212.PMC3493398.pdf
Plant Cell 2003; 15:2636-46; PMID:14576290; http://dx.doi.org/10.1105/tpc.015842.,OADS,/arxiv_data1/oa_pdf/af/66/psb-7-1212.PMC3493398.pdf
PLoS Pathog 2010; 6:e1000970; PMID:20617163; http://dx.doi.org/10.1371/journal.ppat.1000970.,Non-OADS,/arxiv_data1/oa_pdf/af/66/psb-7-1212.PMC3493398.pdf
Curr Opin Plant Biol 2005; 8:383-9; PMID:15939664; http://dx.doi.org/10.1016/j.pbi.2005.05.010.,OADS,/arxiv_data1/oa_pdf/af/66/psb-7-1212.PMC3493398.pdf
Nature 2007; 450:695-701; PMID:18046406; http://dx.doi.org/10.1038/nature06405.,OADS,/arxiv_data1/oa_pdf/af/66/psb-7-1212.PMC3493398.pdf
Plant Cell 2005; 17:1306-16; PMID:15772285; http://dx.doi.org/10.1105/tpc.104.029926.,OADS,/arxiv_data1/oa_pdf/af/66/psb-7-1212.PMC3493398.pdf
Plant J 2012; 70:796-808; PMID:22288649; http://dx.doi.org/10.1111/j.1365-313X.2012.04928.x.,OADS,/arxiv_data1/oa_pdf/af/66/psb-7-1212.PMC3493398.pdf
Mol Plant Microbe Interact 2001; 14:1131-9; PMID:11605952; http://dx.doi.org/10.1094/MPMI.2001.14.10.1131.,OADS,/arxiv_data1/oa_pdf/af/66/psb-7-1212.PMC3493398.pdf
"www.landesbioscience.com  P lant Signaling & Behavior  1215P lant Signaling & Behavior 7:10, 1215-1218; October 2012; © 2012 Landes BioscienceShOrt C O mmuni Ca ti O n *Correspondence to: Hyung-Taeg Cho; Email: htcho@snu.ac.kr Submitted: 07/04/12; Accepted: 07/10/12http://dx.doi.org/10.4161/psb.21432Protein phosphorylation is generally operational in determina - tion of subcellular polarity both in prokaryotes and eukary - otes.1 In animals, PAR (partition defective) proteins mediate  cell polarity and bilateral symmetry, and the phosphorylation  of PARs or their targets directly determines polar localization of the target proteins.",Non-OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Nature 2009; 459:583-6; PMID:19478783; http://dx.doi.org/10.1038/nature07875.,Non-OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Science 2006; 312:883; PMID:16601151; http://dx.doi.org/10.1126/science.1121356.,OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Plant Cell 2010; 22:1812-25; PMID:20525850; http://dx.doi.org/10.1105/tpc.110.074211.,OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Plant J 1997; 11:605-12; PMID:9107046; http://dx.doi.org/10.1046/j.1365-313X.1997.11030605.x.,OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Plant Cell 2006; 18:1604-16; PMID:16731587; http://dx.doi.org/10.1105/tpc.105.035972.,OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Plant Physiol 2010; 153:1046-61; PMID:20439545; http://dx.doi.org/10.1104/pp.110.156505.8.,Non-OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Plant Cell 2010; 22:1129-42; PMID:20407025; http://dx.doi.org/10.1105/tpc.109.072678.,OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Nat Cell Biol 2011; 13:447-52; PMID:21394084; http://dx.doi.org/10.1038/ncb2208.,OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
"Plant J 2012; http://dx.doi.org/10.1111/j.1365-313X.2012.05030.x, In press; PMID:22519832.",OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Nature 2008; 456:962-6; PMID:18953331; http://dx.doi.org/10.1038/nature07409.References 1.,Non-OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Mol Cells 2012; 33:423-30; PMID:22453777; http://dx.doi.org/10.1007/s10059-012-0039-9.,Non-OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Dev Cell 2007; 13:609-22; PMID:17981131; http://dx.doi.org/10.1016/j.devcel.2007.10.007.,OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Development 2011; 138:799-809; PMID:21303844; http://dx.doi.org/10.1242/dev.053538.,OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
EMBO J 2010; 29:2700-14; PMID:20717140; http://dx.doi.org/10.1038/emboj.2010.181.,OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Cell 2007; 130:1044-56; PMID:17889649; http://dx.doi.org/10.1016/j.cell.2007.07.033.,OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Development 2009; 136:627-36; PMID:19168677; http://dx.doi.org/10.1242/dev.028365.,Non-OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
Development 2010; 137:3245-55; PMID:20823065; http://dx.doi.org/10.1242/dev.052456.,OADS,/arxiv_data1/oa_pdf/54/48/psb-7-1215.PMC3493399.pdf
"*Correspondence to: Zhengguang Zhang; Email: zhgzhang@njau.edu.cn Submitted: 05/30/12; Revised: 07/05/12; Accepted: 07/10/12http://dx.doi.org/10.4161/psb.21431Heterotrimeric G-proteins play an important regulatory  role in multiple physiological processes, including the plant immune response, and substantial progress has been made in elucidating the G-protein-mediated defense-signaling network.",Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Curr Opin Plant Biol  2009; 12:406-13; PMID:19616468; http://dx.doi.org/10.1016/j.pbi.2009.06.007.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Mol Plant Microbe Interact 2006; 19:711-24; PMID:16838784; http://dx.doi.org/10.1094/MPMI-19-0711.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Annu Rev Phytopathol 2008; 46:189-215; PMID:18422429; http://dx.doi.org/10.1146/annurev.phyto.46.120407.110050.5.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Cell 2006; 124:803-14; PMID:16497589; http://dx.doi.org/10.1016/j.cell.2006.02.008.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Nature  2006; 444:323-9; PMID:17108957; http://dx.doi.org/10.1038/nature05286.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Mol Plant Microbe Interact 2010; 23:1253-9; PMID:20636104; http://dx.doi.org/10.1094/MPMI-04-10-0103.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Curr Opin Biotechnol 2010; 21:599-603; PMID:20189376; http://dx.doi.org/10.1016/j.copbio.2010.05.006.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Annu Rev Biochem 1997; 66:639-78; PMID:9242920; http://dx.doi.org/10.1146/annurev.biochem.66.1.639.10.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Signal Behav 2011; 6:1079-86; PMID:21778827; http://dx.doi.org/10.4161/psb.6.8.15771.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Signal Behav 2009; 4:942-7; PMID:19826234; http://dx.doi.org/10.4161/psb.4.10.9530.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
PLoS Comput Biol 2010; 6:e1000962; PMID:20976244; http://dx.doi.org/10.1371/journal.pcbi.1000962.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
EMBO Rep 2004; 5:572-8; PMID:15170476; http://dx.doi.org/10.1038/sj.embor.7400174.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Curr Opin Plant Biol 2009; 12:29- 35; PMID:19042149; http://dx.doi.org/10.1016/j.pbi.2008.10.006.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
FEBS Lett 2007; 581:2325-36.; PMID:17462636; http://dx.doi.org/10.1016/j.febslet.2007.04.008 44.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Cell 2006; 126:969-80; PMID:16959575; http://dx.doi.org/10.1016/j.cell.2006.06.054.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Annu Rev Phytopathol 2008; 46:101-22; PMID:18422426; http://dx.doi.org/10.1146/annurev.phyto.121107.104959.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Physiol 2010; 153:1188-98; PMID:20457804; http://dx.doi.org/10.1104/pp.110.157016.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Mol Plant Microbe Interact 2009; 22:977-86; PMID:19589073; http://dx.doi.org/10.1094/MPMI-22-8-0977.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Physiol 2004; 136:3703-11; PMID:15502012; http://dx.doi.org/10.1104/pp.104.049650.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
New Phytol 2007; 173:832-40; PMID:17286831; http://dx.doi.org/10.1111/j.1469-8137.2006.01959.x.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Int J Plant Sci 1994; 155:3-14; http://dx.doi.org/10.1086/297142.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Science 2001; 292:2070-2; PMID:11408655; http://dx.doi.org/10.1126/sci-ence.1059046.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Cell Rep 2007; 26:1469-80; PMID:17492287; http://dx.doi.org/10.1007/s00299-007-0356-1.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Biochim Biophys Acta 2001; 1520:147-53; PMID:11513956; http://dx.doi.org/10.1016/S0167-4781(01)00262-7.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
BMC Genomics 2011; 12:216; PMID:21554708; http://dx.doi.org/10.1186/1471-2164-12-216.28.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Cell Environ 2012; 35:72-85; PMID:21895695; http://dx.doi.org/10.1111/j.1365-3040.2011.02417.x.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Cell 2005; 17:957-70; PMID:15705948; http://dx.doi.org/10.1105/tpc.104.029603.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant J 2005; 43:165-80; PMID:15998304; http://dx.doi.org/10.1111/j.1365-313X.2005.02440.x.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Physiol 2006; 140:210-20; PMID:16339801; http://dx.doi.org/10.1104/pp.105.069625.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Cell 2007; 19:1235-50; PMID:17468261; http://dx.doi.org/10.1105/tpc.107.050096.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Signal Behav 2011; 6:287-92; PMID:21350337; http://dx.doi.org/10.4161/psb.6.2.14971.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Physiol Biochem 2012; 58C:1-5.; PMID:22750791; http://dx.doi.org/10.1016/j.plaphy.2012.06.005 37.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant J 2008; 56:984-96; PMID:18702674; http://dx.doi.org/10.1111/j.1365-313X.2008.03657.x.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Cell Res 2008; 18:949-60; PMID:19160542; http://dx.doi.org/10.1038/cr.2008.271.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
J Proteome Res 2010; 9:1637-47; PMID:20166762; http://dx.doi.org/10.1021/pr901011h.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Physiol 2009; 151:732-40; PMID:19656904; http://dx.doi.org/10.1104/pp.109.142133.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Curr Opin Plant Biol 2004; 7:537-46; PMID:15337096; http://dx.doi.org/10.1016/j.pbi.2004.07.009.14.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
EMBO J 2004; 23:3072-82; PMID:15272302; http://dx.doi.org/10.1038/sj.emboj.7600283.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
New Phytol 2009; 181:127-46; PMID:19076721; http://dx.doi.org/10.1111/j.1469-8137.2008.02642.x.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Physiol 2011; 155:447-63; PMID:21205632; http://dx.doi.org/10.1104/pp.110.164848.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Mol Plant Microbe Interact 2006; 19:747-57; PMID:16838787; http://dx.doi.org/10.1094/MPMI-19-0747.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant J 2011; 66:642-55; PMID:21299658; http://dx.doi.org/10.1111/j.1365-313X.2011.04525.x.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Physiol 2011; 156:2011-25; PMID:21628629; http://dx.doi.org/10.1104/pp.111.177568.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
EMBO J 2003; 22:5690-9; PMID:14592968; http://dx.doi.org/10.1093/emboj/cdg546.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant J 2011; 68:777-87; PMID:21793954; http://dx.doi.org/10.1111/j.1365-313X.2011.04728.x.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Cell 2010; 22:260-72; PMID:20061552; http://dx.doi.org/10.1105/tpc.109.070664.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Physiol 2010; 154:245-61; PMID:20643759; http://dx.doi.org/10.1104/pp.110.162339.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant J 2007; 49:1030-40; PMID:17319846; http://dx.doi.org/10.1111/j.1365-313X.2006.03022.x.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Science 2002; 296:1636-9; PMID:12040175; http://dx.doi.org/10.1126/science.1071550.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
J Plant  Physiol 2012; 169:542-5; PMID:22209167; http://dx.doi.org/10.1016/j.jplph.2011.11.010.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Signal Behav 2012; 7: In press; PMID:22751322; http://dx.doi.org/10.4161/psb.20356.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
Plant Signal  Behav 2010; 5:1565-7; PMID:21139432; http://dx.doi.org/10.4161/psb.5.12.13809.61.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
J Exp Bot 2009; 60:3109-22; PMID:19454596; http://dx.doi.org/10.1093/jxb/erp146.,Non-OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
J Exp Bot 2010; 61:3799-812; PMID:20603283; http://dx.doi.org/10.1093/jxb/erq189.58.,OADS,/arxiv_data1/oa_pdf/7f/8c/psb-7-1284.PMC3493415.pdf
"www.landesbioscience.com Cancer Biology & Therapy 1235Cancer Biology & Therapy 13:13, 1235–1243; November 2012; © 2012 Landes BioscienceCLiNiC aL STudy  CLiNiC aL STudy *Correspondence to: Rafał Stec; Email: drrafals@wp.pl Submitted: 05/15/12; Revised: 08/10/12; Accepted: 08/10/12http://dx.doi.org/10.4161/cbt.21813Introduction Colorectal cancer (CRC) is the third most common cancer in men  (663,000 cases) and second in women (571,000) in the world, with more than one million newly diagnosed cases reported annu - ally.",Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
http://globocan.iarc.fr/ 2.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Nature 1993; 366:643-54; PMID:8259209;  http://dx.doi.org/10.1038/366643a0.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Leukemia 2003; 17:1263-93; PMID:12835716; http://dx.doi.org/10.1038/ sj.leu.2402945.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Cell Cycle 2009; 8:1168- 75; PMID:19282669; http://dx.doi.org/10.4161/ cc.8.8.8147.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Nat Rev Cancer 2003; 3:11-22;  PMID:12509763; http://dx.doi.org/10.1038/nrc969.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Cancer Biol Ther  2006; 5:928-32; PMID:16969076; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Nature  1984; 312:71-5; PMID:6092966; http://dx.doi.org/10.1038/312071a0.12.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Semin Oncol 2007; 34:546-54;  PMID:18083378; http://dx.doi.org/10.1053/j.semi - noncol.2007.09.011.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Curr Colorectal Cancer Rep 2011; 7:113-20;  PMID:21625338; http://dx.doi.org/10.1007/s11888- 011-0086-1.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Cell Cycle 2009; 8:731- 5; PMID:19221485; http://dx.doi.org/10.4161/ cc.8.5.7848.,OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Adv Anat Pathol 2011;  18:90-7; PMID:21169742; http://dx.doi.org/10.1097/ PAP .0b013e3182026da6.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Cell 2004; 116:855-67; PMID:15035987; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Nature 2002; 417:949-54; PMID:12068308;  http://dx.doi.org/10.1038/nature00766.,OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Pathobiology 2011; 78:76-89; PMID:21677471;  http://dx.doi.org/10.1159/000315535.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
BMC Cancer 2009; 9:179;  PMID:19515263; http://dx.doi.org/10.1186/1471-2407-9-179.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Clin Cancer Res 2010; 16:790-9;  PMID:20103678; http://dx.doi.org/10.1158/1078- 0432.CCR-09-2446.21.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Lancet Oncol 2010; 11:753-62;  PMID:20619739; http://dx.doi.org/10.1016/S1470- 2045(10)70130-3.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
J Clin Oncol 2009; 27:5924-30; PMID:19884556; http://dx.doi.org/10.1200/JCO.2008.21.6796.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
J Clin Oncol 2009; 27:5931-7; PMID:19884549;  http://dx.doi.org/10.1200/JCO.2009.22.4295.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
N Engl J Med 2007; 357:2040-8; PMID:18003960; http://dx.doi.org/10.1056/ NEJMoa071834.,OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10.1056/ NEJMoa0804385.,OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
J  Clin Oncol 2010; 28:4697-705; PMID:20921465;  http://dx.doi.org/10.1200/JCO.2009.27.4860.wild-type codon 12 sequence that are amplified during the  second PCR round will contain two BstOI restriction sites—one identical to that in the mutant molecules and the second overlapping with the codon 12 sequence (introduced by the K1 primer).,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
J Clin Oncol 2010; 28:4706- 13; PMID:20921462; http://dx.doi.org/10.1200/ JCO.2009.27.6055.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Nat Rev Clin Oncol  2009; 6:528-34; PMID:19597509; http://dx.doi.org/10.1038/nrclinonc.2009.106.33.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
J Clin Oncol 2008; 26:1443-51; PMID:18349394;  http://dx.doi.org/10.1200/JCO.2007.14.0509.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Dis  Colon Rectum 2009; 52:1359-66; PMID:19617745;  http://dx.doi.org/10.1007/DCR.0b013e3181a7b7de.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
"Ann Surg 1999; 230:309-18, discussion 318-21; PMID:10493478; http://dx.doi.",OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
J Clin Oncol  2008; 26:5705-12; PMID:19001320; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Int J Colorectal  Dis 2011; 26:823-33; PMID:21286919; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Eur J Cancer 2010; 46:1997- 2009; PMID:20413299; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
Ann Oncol 2010; 21:2396-402;  PMID:20501503; http://dx.doi.org/10.1093/annonc/ mdq258.,OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
N Engl J Med 2000; 343:905- 14; PMID:11006366; http://dx.doi.org/10.1056/ NEJM200009283431302.,OADS,/arxiv_data1/oa_pdf/23/dc/cbt-13-1235.PMC3493430.pdf
"www.landesbioscience.com Cancer Biology & Therapy 1255Cancer Biology & Therapy 13:13, 1255–1261; November 2012; © 2012 Landes Bioscience ReseaRCh papeR ReseaRCh papeR *Correspondence to: Richard Jove; Email: rjove@coh.org Submitted: 02/18/12; Revised: 07/30/12; Accepted: 08/08/12http://dx.doi.org/10.4161/cbt.21781Introduction Melanoma is the sixth most common cancer in the United States  and it is the most malignant type of skin cancer.",Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
CA Cancer J Clin  2009; 59:225-49; PMID:19474385; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Ann N Y Acad Sci 2005; 1059:16-25; PMID:16382039; http://dx.doi.org/10.1196/ annals.1339.005.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Cancer Res 2011; 71:7137-40;  PMID:22131348; http://dx.doi.org/10.1158/0008- 5472.CAN-11-1243.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
PLoS One 2011; 6:e28973; PMID:22194965;  http://dx.doi.org/10.1371/journal.pone.0028973.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Nat Rev Cancer 2004; 4:97-105;  PMID:14964307; http://dx.doi.org/10.1038/nrc1275.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Nat Rev Cancer  2010; 10:342-52; PMID:20414202; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
J Cell Sci 2004; 117:989- 98; PMID:14996930; http://dx.doi.org/10.1242/ jcs.01111.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Oncogene  2002; 21:7001-10; PMID:12370822; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Oncogene 2000; 19:5419-27; PMID:11114718;  http://dx.doi.org/10.1038/sj.onc.1203947.16.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Science  1994; 264:1415-21; PMID:8197455; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Oncogene 2006; 25:2773-84; PMID:16407846; http://dx.doi.org/10.1038/ sj.onc.1209306.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Mol Cancer 2007; 6:69;  PMID:17967179; http://dx.doi.org/10.1186/1476- 4598-6-69.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Immunol Rev 2009; 228:273- 87; PMID:19290934; http://dx.doi.org/10.1111/ j.1600-065X.2008.00754.x.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Cancer Metastasis Rev  2005; 24:315-27; PMID:15986140; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Cell 1997; 88:435-7;  PMID:9038334; http://dx.doi.org/10.1016/S0092- 8674(00)81883-8.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Cell 1995; 81:727-36;  PMID:7774014; http://dx.doi.org/10.1016/0092- 8674(95)90534-0.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Leuk Lymphoma 2002; 43:1763-8;  PMID:12685829; http://dx.doi.org/10.1080/1042819 021000006295.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Med Sci (Paris) 2004; 20:516- 8; PMID:15190467; http://dx.doi.org/10.1051/med- sci/2004205516.30.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Cancer Res 2011; 71:3972-9; PMID:21610112;  http://dx.doi.org/10.1158/0008-5472.CAN-10-3852.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
J Med Chem 2006; 49:4638-49; PMID:16854069; http://dx.doi.org/10.1021/ jm060314i.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
J Med Chem 2010; 53:3696- 706; PMID:20361800; http://dx.doi.org/10.1021/ jm100080z.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Oncogene  2006; 25:6304-18; PMID:16702956; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
J Biol Chem 2000; 275:10761- 6; PMID:10753867; http://dx.doi.org/10.1074/ jbc.275.15.10761.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
J Med Chem  2004; 47:935-46; PMID:14761195; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Annu Rev Cell Dev Biol  1997; 13:513-609; PMID:9442882; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
J Biol Chem 2000; 275:24935-44;  PMID:10823829; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
J Invest Dermatol  2012; 132:263-5; PMID:22241441; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
Biochem Pharmacol  2010; 80:624-37; PMID:20450891; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
org/10.1016/j.bcp.2010.04.029.Supplemental Materials Supplemental materials may be found here: http://www.landesbioscience.com/journals/cbt/article/21781/,Non-OADS,/arxiv_data1/oa_pdf/0f/5e/cbt-13-1255.PMC3493432.pdf
"www.landesbioscience.com Cancer Biology & Therapy 1307Cancer Biology & Therapy 13:13, 1307–1318; November 2012; © 2012 Landes Bioscience ReseaRCh papeR ReseaRCh papeR *Correspondence to: Sang-Gu Hwang; Email: sgh63@kcch.re.kr Submitted: 06/19/12; Revised: 07/13/12; Accepted: 08/08/12http://dx.doi.org/10.4161/cbt.21788Introduction Radiotherapy in conjunction with surgery and/or chemotherapy  is currently the standard adjuvant treatment for laryngeal cancer, which is the sixth most prevalent cancer worldwide.",Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Int J Cancer  2001; 94:153-6; PMID:11668491; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Lancet Oncol  2006; 7:747-55; PMID:16945770; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Clin Otolaryngol Allied Sci 2004; 29:105-14;  PMID:15113291; http://dx.doi.org/10.1046/j.1365-2273.2003.00796.x.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Nat Rev Cancer 2005; 5:516-25; PMID:15965493;  http://dx.doi.org/10.1038/nrc1650.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Lancet Oncol 2008; 9:288-96; PMID:18308254;  http://dx.doi.org/10.1016/S1470-2045(08)70073-1.6.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Oncogene 2003; 22:5915- 25; PMID:12947398; http://dx.doi.org/10.1038/sj.onc.1206704.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Arch Otolaryngol Head Neck Surg  2008; 134:363-9; PMID:18427001; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Cancer Res  2005; 65:10338-46; PMID:16288023; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Mol Cell Biol 2003; 23:2362- 78; PMID:12640121; http://dx.doi.org/10.1128/ MCB.23.7.2362-2378.2003.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
J Natl Cancer Inst 1990; 82:607-12; PMID:1968980;  http://dx.doi.org/10.1093/jnci/82.7.607.11.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Int J Radiat Oncol Biol Phys 2002; 54:895- 902; PMID:12377343; http://dx.doi.org/10.1016/ S0360-3016(02)03037-7.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Radiat Res 2004; 162:527-35;  PMID:15624307; http://dx.doi.org/10.1667/RR3260.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Radiat  Res 2008; 170:41-8; PMID:18582150; http://dx.doi.org/10.1667/RR0986.1.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Strahlenther Onkol 2003; 179:801-11;  PMID:14652668; http://dx.doi.org/10.1007/s00066- 003-1150-9.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Cancer Lett 2009; 285:151-6; PMID:19487072;  http://dx.doi.org/10.1016/j.canlet.2009.05.009.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Cancer Lett 2010; 298:9-15; PMID:20573444; http://dx.doi.org/10.1016/j.canlet.2010.05.020.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Neuron 2001; 32:203-12; PMID:11683991;  http://dx.doi.org/10.1016/S0896-6273(01)00468-8.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Cell 2008; 133:403-14;  PMID:18455982; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
J Biol Chem 2002; 277:6266- 72; PMID:11706019; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Cell Death Differ  2005; 12:201-12; PMID:15665819; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Oncogene  2003; 22:5885-96; PMID:12947395; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Cancer  Res 2006; 66:9601-8; PMID:17018617; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Cancer Res 2007; 67:1163-9;  PMID:17283151; http://dx.doi.org/10.1158/0008-5472.CAN-06-2037.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
J Formos  Med Assoc 2009; 108:180-94; PMID:19293033; http://dx.doi.org/10.1016/S0929-6646(09)60051-6.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Nat Rev  Cancer 2002; 2:489-501; PMID:12094235; http://dx.doi.org/10.1038/nrc839.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Nature 2006; 441:523-7; PMID:16680151;  http://dx.doi.org/10.1038/nature04809.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Nat Rev Cancer 2002; 2:48-58; PMID:11902585;  http://dx.doi.org/10.1038/nrc706.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Cancer Chemother Pharmacol  2008; 61:377-93; PMID:17520257; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
BMC Genomics 2006; 7:314;  PMID:17166261; http://dx.doi.org/10.1186/1471- 2164-7-314.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
J  Biol Chem 2007; 282:29359-67; PMID:17644814;  http://dx.doi.org/10.1074/jbc.M700965200.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Proteomics 2010; 10:2589- 604; PMID:20461716; http://dx.doi.org/10.1002/pmic.200900523.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
J Biol Chem  1997; 272:23859-64; PMID:9295334; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Cancer Cell 2009; 16:115-25; PMID:19647222;  http://dx.doi.org/10.1016/j.ccr.2009.06.006.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Nature  2006; 443:651-7; PMID:17035995; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
T rends Biochem Sci 2009; 34:115-27;  PMID:19299143; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Nat Rev Mol Cell Biol 2008; 9:162-76;  PMID:18216772; http://dx.doi.org/10.1038/ nrm2335.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Oncogene 2006; 25:1420-3; PMID:16247441; http://dx.doi.org/10.1038/sj.onc.1209187.,OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Cancer Res 2007; 67:5425-33; PMID:17545624; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/8f/cbt-13-1307.PMC3493439.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/b3/ed/ncomms2122.PMC3493635.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Gunther, W .R.",Non-OADS,/arxiv_data1/oa_pdf/b3/ed/ncomms2122.PMC3493635.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/b3/ed/ncomms2122.PMC3493635.pdf
The coordinates of the symmetric tetramer model are available from b.wallace@mail.cryst.bbk.ac.uk Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.,Non-OADS,/arxiv_data1/oa_pdf/d9/c5/ncomms2077.PMC3493636.pdf
"Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article: McCusker, E.C.",Non-OADS,/arxiv_data1/oa_pdf/d9/c5/ncomms2077.PMC3493636.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2077 8 NATURE COMMUNICATIONS | 3:1102 | DOI: 10.1038/ncomms2077 | www.nature.com/naturecommunications &2012 Macmillan Publishers Limited.",Non-OADS,/arxiv_data1/oa_pdf/d9/c5/ncomms2077.PMC3493636.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/1a/31/ncomms2108.PMC3493637.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Pfau, B. et al.",Non-OADS,/arxiv_data1/oa_pdf/1a/31/ncomms2108.PMC3493637.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/1a/31/ncomms2108.PMC3493637.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/b6/b0/ncomms2095.PMC3493638.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Martin, TG and Dietz, H. Magnesium-free self-assembly of  multi-layer DNA objects.",OADS,/arxiv_data1/oa_pdf/b6/b0/ncomms2095.PMC3493638.pdf
"Reprints and permission information  is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Kozlova, N.V .",Non-OADS,/arxiv_data1/oa_pdf/90/6b/ncomms2106.PMC3493639.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-sa/3.0/ 0 2 4 6 801×106 1 T2 T3 T 5 T 14 T10 TJ (A cm–2) Ex (kV cm–1)Bz = 0 T T = 4.2 Ka bLwBz 0 5 10 150300Ex = 4.0 kV cm–1 Ex = 3.0 kV cm–1 Ex = 2.0 kV cm–1 Ex = 0.5 kV cm–1 Bz (T)∆�xx/�xx (%) Figure 4 | Linear transverse MR at high electric fields.",Non-OADS,/arxiv_data1/oa_pdf/90/6b/ncomms2106.PMC3493639.pdf
"The gene  predictions were also implemented using the Augustus software with the assistance  of RNA-seq (http://augustus.gobics.de/binaries/readme.rnaseq.html), and all data  were visualized and manually curated using the Argo software (http://www.broa - dinstitute.org/annotation/argo/).",OADS,/arxiv_data1/oa_pdf/0b/e1/ncomms2112.PMC3493640.pdf
uniprot.org/) and KEGG genes database (http://www.genome.jp/kegg/genes.html).,OADS,/arxiv_data1/oa_pdf/0b/e1/ncomms2112.PMC3493640.pdf
"The domain and family of each protein was annotated via searching the InterPro  database at EBI using InterProScan (http://www.ebi.ac.uk/Tools/pfa/iprscan/), and  Gene Ontology annotations were assigned using Blast2GO (http://www.blast2go.",OADS,/arxiv_data1/oa_pdf/0b/e1/ncomms2112.PMC3493640.pdf
"Gene function was classified by the eukaryotic orthologous   group (KOG, http://www.ncbi.nlm.nih.gov/COG/), and the automatic assignment  of metabolic pathway was implemented by KAAS (http://www.genome.jp/   tools/kaas/).",OADS,/arxiv_data1/oa_pdf/0b/e1/ncomms2112.PMC3493640.pdf
All  data are also available at http://www.bioconversion.dicp.ac.cn/EWEB/ZZW-data.html.,OADS,/arxiv_data1/oa_pdf/0b/e1/ncomms2112.PMC3493640.pdf
Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/0b/e1/ncomms2112.PMC3493640.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Zhu, Z et al.",Non-OADS,/arxiv_data1/oa_pdf/0b/e1/ncomms2112.PMC3493640.pdf
"To view a copy of this   license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/0b/e1/ncomms2112.PMC3493640.pdf
"and A.C. Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  R.H. is co-founder of Neaspec GmbH, a company  producing s-SNOM systems, such as the one used in this study.",Non-OADS,/arxiv_data1/oa_pdf/52/f4/ncomms2118.PMC3493641.pdf
Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Stiegler J. M. et al.,Non-OADS,/arxiv_data1/oa_pdf/52/f4/ncomms2118.PMC3493641.pdf
"To view a copy of this   license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/52/f4/ncomms2118.PMC3493641.pdf
Additional information Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunicationsCompeting ﬁnancial interests: The authors declare no competing ﬁnancial interests.,Non-OADS,/arxiv_data1/oa_pdf/a2/f1/ncomms2183.PMC3493642.pdf
"Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article: Xiao, J. et al.",Non-OADS,/arxiv_data1/oa_pdf/a2/f1/ncomms2183.PMC3493642.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2183 ARTICLE NATURE COMMUNICATIONS | 3:1170 | DOI: 10.1038/ncomms2183 | www.nature.com/naturecommunications 7 &2012 Macmillan Publishers Limited.",Non-OADS,/arxiv_data1/oa_pdf/a2/f1/ncomms2183.PMC3493642.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/09/25/ncomms2073.PMC3493643.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Kim, Y .-K. et al.",Non-OADS,/arxiv_data1/oa_pdf/09/25/ncomms2073.PMC3493643.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/09/25/ncomms2073.PMC3493643.pdf
Presentation at (http://www.research.ibm.com/ people/b/bennetc) (2005).44.,Non-OADS,/arxiv_data1/oa_pdf/56/39/ncomms2076.PMC3493644.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/56/39/ncomms2076.PMC3493644.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Oreshkov, O. et al.",Non-OADS,/arxiv_data1/oa_pdf/56/39/ncomms2076.PMC3493644.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial   interests.,Non-OADS,/arxiv_data1/oa_pdf/18/05/ncomms2136.PMC3493645.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Pastuhov, S. I. et al.",Non-OADS,/arxiv_data1/oa_pdf/18/05/ncomms2136.PMC3493645.pdf
"To view a copy of this   license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/18/05/ncomms2136.PMC3493645.pdf
Preprint at http://arxiv.org/abs/quant-ph/0105032 (2001).,OADS,/arxiv_data1/oa_pdf/74/85/ncomms2172.PMC3493646.pdf
Preprint at http://arxiv.org/abs/0903.5156v3 (2011).,Non-OADS,/arxiv_data1/oa_pdf/74/85/ncomms2172.PMC3493646.pdf
Additional information Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.,Non-OADS,/arxiv_data1/oa_pdf/74/85/ncomms2172.PMC3493646.pdf
"Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article: Clarke, P.J.",Non-OADS,/arxiv_data1/oa_pdf/74/85/ncomms2172.PMC3493646.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2172 8 NATURE COMMUNICATIONS | 3:1174 | DOI: 10.1038/ncomms2172 | www.nature.com/naturecommunications &2012 Macmillan Publishers Limited.",Non-OADS,/arxiv_data1/oa_pdf/74/85/ncomms2172.PMC3493646.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/54/13/ncomms2140.PMC3493647.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Pickrell, J. K. et al.",Non-OADS,/arxiv_data1/oa_pdf/54/13/ncomms2140.PMC3493647.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/54/13/ncomms2140.PMC3493647.pdf
Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests : The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/20/0c/ncomms2146.PMC3493648.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article : Hu, H.Y .",Non-OADS,/arxiv_data1/oa_pdf/20/0c/ncomms2146.PMC3493648.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/20/0c/ncomms2146.PMC3493648.pdf
"Additional information Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article: Ikawa, M. et al.",Non-OADS,/arxiv_data1/oa_pdf/ab/bc/ncomms2190.PMC3493649.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2190 8 NATURE COMMUNICATIONS | 3:1176 | DOI: 10.1038/ncomms2190 | www.nature.com/naturecommunications &2012 Macmillan Publishers Limited.",Non-OADS,/arxiv_data1/oa_pdf/ab/bc/ncomms2190.PMC3493649.pdf
Additional information Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.,Non-OADS,/arxiv_data1/oa_pdf/08/34/ncomms2177.PMC3493650.pdf
"Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/How to cite this article: Jose, P. P. & Andricioaei, I.",Non-OADS,/arxiv_data1/oa_pdf/08/34/ncomms2177.PMC3493650.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2177 8 NATURE COMMUNICATIONS | 3:1161 | DOI: 10.1038/ncomms2177 | www.nature.com/naturecommunications &2012 Macmillan Publishers Limited.",Non-OADS,/arxiv_data1/oa_pdf/08/34/ncomms2177.PMC3493650.pdf
"Additional information Accession codes:  The atomic coordinates and structure factor amplitudes have been  deposited with the Protein Data Bank (http://www.pdb.org; PDB ID codes are—4AOH  for hANG atomic resolution structure; 4AHD, 4AHE, 4AHF, 4AHG, 4AHH, 4AHI,  4AHJ, 4AHK, 4AHL, 4AHM, 4AHN for Q12L, K17E, K17I, S28N, R31K, K40I, I46V ,  K54E, P112L, V113I, R121H for hANG-ALS variants, respectively).",Non-OADS,/arxiv_data1/oa_pdf/ca/8a/ncomms2126.PMC3493651.pdf
Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/ca/8a/ncomms2126.PMC3493651.pdf
Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Thiyagarajan N. et al.,Non-OADS,/arxiv_data1/oa_pdf/ca/8a/ncomms2126.PMC3493651.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/ca/8a/ncomms2126.PMC3493651.pdf
Additional information Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.,Non-OADS,/arxiv_data1/oa_pdf/71/50/ncomms2160.PMC3493652.pdf
"Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article: Dubrovinsky, L. et al.",Non-OADS,/arxiv_data1/oa_pdf/71/50/ncomms2160.PMC3493652.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2160 ARTICLE NATURE COMMUNICATIONS | 3:1163 | DOI: 10.1038/ncomms2160 | www.nature.com/naturecommunications 7 &2012 Macmillan Publishers Limited.",Non-OADS,/arxiv_data1/oa_pdf/71/50/ncomms2160.PMC3493652.pdf
"Assembling of expressed sequence tag sequences was carried out using  CAP3, and the resulting consensus sequences were translated using the OrfPre - dictor web server (http://proteomics.ysu.edu/tools/OrfPredictor.html).",OADS,/arxiv_data1/oa_pdf/f8/71/ncomms2148.PMC3493653.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/f8/71/ncomms2148.PMC3493653.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Yue, J. et al.",Non-OADS,/arxiv_data1/oa_pdf/f8/71/ncomms2148.PMC3493653.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/f8/71/ncomms2148.PMC3493653.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial   interests.,Non-OADS,/arxiv_data1/oa_pdf/1e/cc/ncomms2137.PMC3493654.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Kim, Y .-H. et al.",Non-OADS,/arxiv_data1/oa_pdf/1e/cc/ncomms2137.PMC3493654.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/1e/cc/ncomms2137.PMC3493654.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial   interests.,Non-OADS,/arxiv_data1/oa_pdf/b5/bf/ncomms2135.PMC3493655.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Watt, N.T.",Non-OADS,/arxiv_data1/oa_pdf/b5/bf/ncomms2135.PMC3493655.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/b5/bf/ncomms2135.PMC3493655.pdf
Additional information Supplementary Information  accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests:  The authors declare no competing financial   interests.,Non-OADS,/arxiv_data1/oa_pdf/5b/7a/ncomms2151.PMC3493656.pdf
"Reprints and permission  information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article:  Zamfir, M. & Lutz, J.-F. Ultra-precise Insertion of   functional monomers in chain-growth polymerizations.",Non-OADS,/arxiv_data1/oa_pdf/5b/7a/ncomms2151.PMC3493656.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/5b/7a/ncomms2151.PMC3493656.pdf
"Published online on August 7, 2012.  pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.405  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.dispersed throughout the gastrointestinal tract and have diverse  biologic behavior.",Non-OADS,/arxiv_data1/oa_pdf/d7/c3/gnl-6-405.PMC3493717.pdf
"Published online on August 7, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.411  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.also part of the gut microflora.",Non-OADS,/arxiv_data1/oa_pdf/dd/0f/gnl-6-411.PMC3493718.pdf
DOI: http://dx.doi.org/10.1017/ S0007114511006362.,Non-OADS,/arxiv_data1/oa_pdf/dd/0f/gnl-6-411.PMC3493718.pdf
"Published online on August 7, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.417  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.formation, and infiltration of inflammatory cells into the pan - creas,9,10 which are observed in human pancreatitis.",Non-OADS,/arxiv_data1/oa_pdf/57/af/gnl-6-417.PMC3493719.pdf
"Published online on August 7, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.423  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.hemostasis INTRODUCTION Increasing numbers of patients are given antithrombotic  agents for vascular protection.",Non-OADS,/arxiv_data1/oa_pdf/20/95/gnl-6-423.PMC3493720.pdf
"Accepted on February 1, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.427  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.the major phenotypes of the idiopathic inflammatory bowel dis - ease (IBD), which afflicts millions of individuals throughout the  world with symptoms that impair quality of life and ability to  function.1 Currently, the etiology of UC is not well understood,  but mucosal tissue edema, increased gut epithelial cell perme - ability, and extensive infiltration of the colonic mucosa by  leucocytes of the myeloid lineage are major pathologic features  of this immune disorder.",Non-OADS,/arxiv_data1/oa_pdf/6b/b8/gnl-6-427.PMC3493721.pdf
"Accepted on February 6, 2011. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.434  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d3/63/gnl-6-434.PMC3493722.pdf
"Accepted on February 28, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.440  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Esophageal motility disturbance has been regarded as main  pathophysiologic mechanism of gastroesophageal reflux disease  (GERD),1 however, manometry findings were often normal in  patients with GERD.",Non-OADS,/arxiv_data1/oa_pdf/e7/8d/gnl-6-440.PMC3493723.pdf
"Accepted on March 5, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.446  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.particular, a diagnosis of high-grade dysplasia (HGD, category  4 according to the Vienna classification) with forceps biopsy  strongly suggests the presence of invasive carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/53/69/gnl-6-446.PMC3493724.pdf
"Accepted on March 11, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.452  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.The survival capability of this organism within the stomach  makes it difficult to eradicate and requires multi-drug regimens  consisting of two antibiotics and a strong acid suppressant.1  Several guidelines suggest the use of 7-day triple therapy,  comprising a proton pump inhibitor (PPI), clarithromycin and  amoxicillin, as the first line therapy, whereas the 7-day quadru - ple therapy includes bismuth salts, and is indicated for eradica - tion in patients who failed first line therapy.2-6 Nowadays, the prevalence of H. pylori  resistance to antibiot - ics is increasing, which is the major cause of treatment failure.7  Standard triple therapy had failed to eradicate H. pylori  in up  to 25% of patients.2,8 Concomitant and sequential therapy have  been attempted to overcome the treatment failure.9,10 New antibiotics have also been applied to increase the eradi - cation rate.",Non-OADS,/arxiv_data1/oa_pdf/ad/a3/gnl-6-452.PMC3493725.pdf
"Accepted on March 16, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.457  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Natural orifice transluminal endoscopic surgery (NOTES) is a  minimally invasive surgery technique that was recently devised  and whose application areas are gradually expanding.1-3 An  incision is made in the esophagus, stomach, colon, or vagina in - stead of skin, and an endoscope is inserted through the incision  site into the thoracic cavity or peritoneal cavity.4 According to  the literature, Kalloo et al.1 in 2004 first inserted an endoscope  into the peritoneal cavity of a pig to observe organs in the peri - toneal cavity.",Non-OADS,/arxiv_data1/oa_pdf/5e/70/gnl-6-457.PMC3493726.pdf
"Accepted on June 22, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.464  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.creased substantially over the last decade.",Non-OADS,/arxiv_data1/oa_pdf/94/8a/gnl-6-464.PMC3493727.pdf
"Published online on August 7, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.471  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.were incompletely treated because RFA failed to induce a large  enough ablation zone to cover the entire tumor with an appro - priate tumor free ablative margin.3-5 Sequentially overlapping  single electrode ablation has been attempted for large hepatic  tumors.6 However, repositioning of the electrode to an untreated  tumor portion is difficult, which takes a long time for procedure.",Non-OADS,/arxiv_data1/oa_pdf/b2/21/gnl-6-471.PMC3493728.pdf
"Accepted on January 31, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.476  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.the first variceal bleeding is over 30% in cirrhotic patients.2 In  addition, any deaths occurring within 6 weeks of admission due  to variceal bleeding is considered as bleeding-related mortality,  because the risk of rebleeding and mortality is the highest dur - ing the first 6 weeks.3 The risk of rebleeding decreased to similar  level of the previous bleeding risk,1 and about 30% of variceal  bleeding patients are known to have died within 12 months af - ter bleeding.4 Though many treatment modalities for variceal bleedings are  available in clinical practice and improved outcomes in variceal  bleeding in cirrhotic patients have been reported over decades,4-6  little is known about the recent changes in clinical outcomes  and characteristics of cirrhotic patients with variceal bleeding in  South Korea.",Non-OADS,/arxiv_data1/oa_pdf/b1/aa/gnl-6-476.PMC3493729.pdf
"Accepted on April 18, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.482  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.ic patients has not been well established.",Non-OADS,/arxiv_data1/oa_pdf/81/1e/gnl-6-482.PMC3493730.pdf
"Accepted on May 14, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.486  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Clevudine (1-[2-deoxy-2-fluoro- β-arabinofuranosyl] thy - mine) (CLV) is a pyrimidine analog with potent antiviral activity  against hepatitis B virus (HBV).1 CLV inhibits DNA-dependent  DNA reverse transcription and priming by HBV polymerase.2  Phase III clinical trial results showed that 24 weeks of CLV  therapy had a potent and sustained antiviral effect without  clinical evidence of viral resistance during the treatment period  in both HBeAg-positive and HBeAg-negative chronic hepatitis  B (CHB) patients.3,4 The ability to maintain antiviral activity in a  significant portion of patients following the discontinuation of  therapy is a unique characteristic of CLV.",Non-OADS,/arxiv_data1/oa_pdf/cb/4b/gnl-6-486.PMC3493731.pdf
"Published online on May 22, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.493 Dong-Won Ahn and Sang Hyub Lee contributed equally to this work as first authors.",Non-OADS,/arxiv_data1/oa_pdf/df/54/gnl-6-493.PMC3493732.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.being incidentally recognized due to the improvements in high  resolution abdominal imaging and an increasing frequency of  the use of this tool.1,2 Some investigators3,4 have advocated ag - gressive surgical resection showing their data of the relatively  high incidence of premalignant and malignant CLPs.",Non-OADS,/arxiv_data1/oa_pdf/df/54/gnl-6-493.PMC3493732.pdf
"Accepted on February 4, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.501  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.irregular narrowing of the main pancreatic duct; serologically  by elevation of serum IgG4 levels; pathologically by lympho - plasmacytic sclerosing pancreatitis; and clinically by respon - siveness to steroid.1,2 Diabetes mellitus (DM) is sometimes associated with AIP.",Non-OADS,/arxiv_data1/oa_pdf/44/53/gnl-6-501.PMC3493733.pdf
"Accepted on February 6, 2012. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.505  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.among internal organs.",Non-OADS,/arxiv_data1/oa_pdf/44/f8/gnl-6-505.PMC3493734.pdf
"Accepted on December 31, 2010. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.512  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.CASE REPORT A 19-year-old woman was admitted with impaired con - sciousness.",Non-OADS,/arxiv_data1/oa_pdf/26/fe/gnl-6-512.PMC3493735.pdf
"Accepted on December 28, 2010. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.516  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.CASE REPORT A 70-year-old malnourished male patient visited because of  anemia and hematochezia.",Non-OADS,/arxiv_data1/oa_pdf/a3/c5/gnl-6-516.PMC3493736.pdf
"Accepted on February 18, 2011. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.520  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.duration.",Non-OADS,/arxiv_data1/oa_pdf/31/b8/gnl-6-520.PMC3493737.pdf
"Accepted on December 24, 2011. pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2012.6.4.524 Yun Jeong Lim and Jae Hyeuk Choi contributed equally to this work as first authors.",Non-OADS,/arxiv_data1/oa_pdf/01/88/gnl-6-524.PMC3493738.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.they can diffusely involve the colon.",Non-OADS,/arxiv_data1/oa_pdf/01/88/gnl-6-524.PMC3493738.pdf
"Health Stat Q 2: 7–15; http://www.statistics.gov.uk/do wnloads/theme_health/HSQ2Book.pdf Fear NT, Roman E, Reeves G, Pannett B (1998) Childhood cancer and paternal employment in agriculture: the role of pesticides.",Non-OADS,/arxiv_data1/oa_pdf/ed/c6/bjc2012359a.PMC3493752.pdf
"MATERIALS AND METHODS Design A matched case–control study was conducted, using routinelycollected primary care data (http://www.abdn.ac.uk/pcciu/PCCIU.htm).",Non-OADS,/arxiv_data1/oa_pdf/11/ef/bjc2012364a.PMC3493753.pdf
READ codes are a coded thesaurus of clinical terms(http://www.connectingforhealth.nhs.uk/systemsandservices/data/uktc/readcodes).,OADS,/arxiv_data1/oa_pdf/11/ef/bjc2012364a.PMC3493753.pdf
The data contained herein were provided by the Primary Care Clinical Informatics Unit (http://www.abdn.ac.uk/pcciu/PCCIU.htm) at the University of Aberdeen.,OADS,/arxiv_data1/oa_pdf/11/ef/bjc2012364a.PMC3493753.pdf
http://info.cancerresearchuk.org/cancerstats/incidence/ commoncancers/.,Non-OADS,/arxiv_data1/oa_pdf/11/ef/bjc2012364a.PMC3493753.pdf
"Cancer J 16(5): 493–499 WHO (2010) Anatomical Therapeutic Chemical classification –Defined Daily Doses Index 2011. http://www.whocc.no/atc_ddd_index/ (last accessedon 25 May 2011) Yung KC, Piccirillo JF (2008) The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer.",Non-OADS,/arxiv_data1/oa_pdf/11/ef/bjc2012364a.PMC3493753.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Abe R, Peng T, Sailors J, Bucala R, Metz CN (2001) Regulation of the CTL response by macrophage migration inhibitory factor.",Non-OADS,/arxiv_data1/oa_pdf/ea/fb/bjc2012392a.PMC3493755.pdf
"Logistic regression analysis was then performed using all available potential predictors of high-risk disease in thelearning cohort, and a nomogram of the resulting equationgenerated using Orange (http://orange.biolab.si V2.0b, accessed 5 August 2011).",OADS,/arxiv_data1/oa_pdf/9f/87/bjc2012400a.PMC3493756.pdf
"Available from: http://www.jrocfit.org Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.",Non-OADS,/arxiv_data1/oa_pdf/9f/87/bjc2012400a.PMC3493756.pdf
"Available from: http://www.ncbi.nlm.nih.gov/books/NBK82303/ Melia J (2005) Part 1: The burden of pros tate cancer, its natural history, information on the outcome of screening and estimates of ad hoc screeningwith particular reference to England and Wales.",Non-OADS,/arxiv_data1/oa_pdf/9f/87/bjc2012400a.PMC3493756.pdf
"Available from http://www.nice.org.uk/nicemedia/pdf/CG58NICEGuideline.pdf O’Brien BA, Cohen RJ, Ryan A, Sengupta S, Mills J (2011) A new preoperative nomogram to predict minimal prostate cancer: accuracyand error rates compared to other tools to select patients for active surveillance.",Non-OADS,/arxiv_data1/oa_pdf/9f/87/bjc2012400a.PMC3493756.pdf
"Available at http://www.oralcancerfoundation.org/hpv/pdf/02-4-hpv.pdfHPV vaccination in low-resource countries V Tsu et al 1449 &2012 Cancer Research UK British Journal of Cancer (2012) 107(9), 1445 – 1450",Non-OADS,/arxiv_data1/oa_pdf/7e/aa/bjc2012404a.PMC3493757.pdf
"International Agency for Research on Cancer: Lyon, France, Available at http://globocan.iarc.fr Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, QiaoYL, Rajkumar R, Ronco G, de SS, Shin HR, Sukvirach S, Thomas JO,Meijer CJ, Munoz N (2006) Variations in the age-specific curves ofhuman papillomavirus prevalence in women worldwide.",Non-OADS,/arxiv_data1/oa_pdf/7e/aa/bjc2012404a.PMC3493757.pdf
"Available at http://www.fda.gov/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm Rodriguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, Solomon D, Guillen D, Alfaro M, Morales J, Hutchinson M,Katki H, Cheung L, Wacholder S, Burk RD (2010) Longitudinal study ofhuman papillomavirus persistence and cervical intraepithelial neoplasiagrade 2/3: critical role of duration of infection.",Non-OADS,/arxiv_data1/oa_pdf/7e/aa/bjc2012404a.PMC3493757.pdf
"Published reports in peer-reviewed journals were obtained from the following databasesusing validated search strategies: Ovid MEDLINE database, ISIWeb of Science, Science Citation Index Expanded and PUBMED (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi).",OADS,/arxiv_data1/oa_pdf/a5/08/bjc2012414a.PMC3493760.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Cohn AL, Bekaii-Saab TS, Bendell JC, Hurwitz H, Kozloff M, Roach N, Tezcan H, Feng S, Sing AP, Grothey A (2010) Clinical outcomes inbevacizumab (BV) treated patients (pts) with metastatic colorectalcancer (mCRC): results from ARIES observational cohort study (OCS)and confirmation of BRiTE data beyond progression (BBP).",Non-OADS,/arxiv_data1/oa_pdf/10/eb/bjc2012415a.PMC3493761.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)tCK18 cCK18 (n = 24)Progressive disease (n = 32)Clinical benefit (n = 24)Progressive disease 30(n = 32)Clinical benefit 20 1030 01020 –10–20–300 –20–10 Baseline median = 383 U l–1 –50–40Baselinemedian = 225 U l–1Baselinemedian = 999 U l–1Baselinemedian = 389 U l–1 –50–40 Days after first treatment–60 040 80120 040 80120 040 80120–60 040 80120–3030 01020 –20–10 –50–40 –60–3030 01020 –20–10 –50–40 –60–30% Change in tCK18 % Change in tCK18 Figure 4 PD monitoring of tCK18 and cCK18 in 56 patients with metastatic CRC undergoing conventional chemotherapy, categorised by treatment response.",Non-OADS,/arxiv_data1/oa_pdf/91/dd/bjc2012416a.PMC3493762.pdf
"Eur J Cancer 46: 1464–1473 Cancer Research UK Glossary (2011) http://science.cancerresearchuk.org/ funding/find-grant/all-funding-schemes/biomarkers-imaging-discovery-development-project-grants/definitions-glossary/ In Edition (access 2November 2012) Cummings J, Hodgkinson C, Odedra R, Sini P, Heaton SP, Mundt KE, Ward TH, Wilkinson RW, Growcott J, Hughes A, Dive C (2008) Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.",Non-OADS,/arxiv_data1/oa_pdf/91/dd/bjc2012416a.PMC3493762.pdf
Box plots of expression data were drawn using the online R programme (http://www.r-project.org/).,OADS,/arxiv_data1/oa_pdf/81/fb/bjc2012429a.PMC3493767.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P,Nowis D, Piette J, Wilson BC, Golab J (2011) Photodynamic therapy of cancer: an update.",Non-OADS,/arxiv_data1/oa_pdf/81/fb/bjc2012429a.PMC3493767.pdf
"http://www.pssru.ac.uk/pdf/ uc/uc2010/uc2010.pdf Department of Health Cancer Reform Strategy (2007) Kelly RS, Patnick J, Kitchener HC, Moss SM, NHSCSP HPV Special Interest Group (2011) HPV testing as a triage for borderline or mild dyskaryosison cervical cytology: results from the Sentinel Sites study.",Non-OADS,/arxiv_data1/oa_pdf/b8/35/bjc2012435a.PMC3493770.pdf
"http://www.nhsemployers.org/Aboutus/Publications/PayCirculars/Pages/PayCircularAfC12006.aspx Sherlaw-Johnson C, Philipps Z (2004) An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervicalcancer screening programme.",Non-OADS,/arxiv_data1/oa_pdf/b8/35/bjc2012435a.PMC3493770.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN (2003)Platelet and osteoclast beta3 integrins are critical for bone metastasis.",Non-OADS,/arxiv_data1/oa_pdf/e1/dd/bjc2012439a.PMC3493774.pdf
"Available from http://globocan.iarc.fr Firnhaber C, Van Le H, Pettifor A, Schulze D, Michelow P, Sanne IM, Lewis DA, Williamson AL, Allan B, Williams S, Rinas A, Levin S, Smith JS(2010) Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa.",Non-OADS,/arxiv_data1/oa_pdf/ce/86/bjc2012441a.PMC3493776.pdf
Available at http://www.who.int/hiv/pub/progress_ report2011/regional_facts/en/index.html.,Non-OADS,/arxiv_data1/oa_pdf/ce/86/bjc2012441a.PMC3493776.pdf
"http://www.hpa.org.uk/ Brown T, Darnton A, Fortunato L, Rushton L (2012a) Occupational cancer in Britain – respiratory cancer sites: larynx, lung and mesothelioma.",Non-OADS,/arxiv_data1/oa_pdf/13/5b/bjc2012446a.PMC3493780.pdf
http://www.hse.gov.uk/pubns/cidi2.pdfHSE (2012) The burden of occupational cancer in Great Britain: Technical report: Methodology: RR927.,Non-OADS,/arxiv_data1/oa_pdf/13/5b/bjc2012446a.PMC3493780.pdf
"http://www.hse.gov.uk/research/ Hutchings SJ, Rushton L (2012) Occupational cancer in Britain – statistical methodology.",Non-OADS,/arxiv_data1/oa_pdf/13/5b/bjc2012446a.PMC3493780.pdf
"http://monographs.iarc.fr/ENG/ Monographs/vol100D/index.php Muirhead CR, O’Hagan JA, Haylock RGE, Phillipson MA, Willcock T, Berridge GLC, Zhang W (2009a) Mortality and cancer incidencefollowing occupational radiation exposure: third analysis of the National Registry for Radiation Workers.",Non-OADS,/arxiv_data1/oa_pdf/13/5b/bjc2012446a.PMC3493780.pdf
http://www.hpa.org.uk/ United Nations Scientific Committee on the Effects of Atomic Radiation (2008) Effects of Ionising Radiation: UNSCEAR 2006 .,Non-OADS,/arxiv_data1/oa_pdf/13/5b/bjc2012446a.PMC3493780.pdf
"1, Report to the General Assembly, Annex A. http://www.unscear.org/Letter to the Editor 1661 &2012 Cancer Research UK British Journal of Cancer (2012) 107(9), 1660 – 1661",Non-OADS,/arxiv_data1/oa_pdf/13/5b/bjc2012446a.PMC3493780.pdf
"http://monographs.iarc.fr/ENG/ Monographs/vol100D/index.php Muirhead CR, Haylock R (2012) Ionising radiation and occupational cancer in Britain.",Non-OADS,/arxiv_data1/oa_pdf/56/19/bjc2012447a.PMC3493781.pdf
"1, Report to the General Assembly, Annex A. http://www.unscear.org/ *Correspondence: Dr L Rushton; E-mail: l.rushton@imperial.ac.uk Published online 2 October 2012British Journal of Cancer (2012) 107, 1662 &2012 Cancer Research UK All rights reserved 0007 – 0920/12 www.bjcancer.com",Non-OADS,/arxiv_data1/oa_pdf/56/19/bjc2012447a.PMC3493781.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Andreassen KE, Grotmol T, Cvancarova MS, Johannesen TB, Fossa ˚SD (2011) Risk of metachronous contralateral testicular germ cell tumors: apopulation-based study of 7,102 Norwegian patients (1953–2007).",Non-OADS,/arxiv_data1/oa_pdf/20/a4/bjc2012448a.PMC3493782.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Abedi-Ardekani B, Kamangar F, Hewitt SM, Hainaut P, Sotoudeh M, Abnet CC, Taylor PR, Boffetta P, Malekzadeh R, Dawsey SM (2010) Polycyclicaromatic hydrocarbon exposure in oesophageal tissue and risk ofoesophageal squamous cell carcinoma in north-eastern Iran.",Non-OADS,/arxiv_data1/oa_pdf/39/81/bjc2012449a.PMC3493783.pdf
"The KCJ needs the support and love of its members.Message From the Editor-in-Chief http://dx.doi.org/10.4070/kcj.2012.42.10.651 Print ISSN 1738-5520 • On-line ISSN 1738-5555 A Message From the Editor-in-Chief Ho-Joong Youn, MD, PhD Editor-in-Chief, Korean Circulation Journal   Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea",Non-OADS,/arxiv_data1/oa_pdf/9a/99/kcj-42-651.PMC3493799.pdf
"1-3) reported the first percutaneous pulmo - nary valve implantation in humans, many patients received this pro -Review http://dx.doi.org/10.4070/kcj.2012.42.10.652 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Percutaneous Pulmonary Valve Implantation Young-Seok Lee, MD1 and Hyoung-Doo Lee, MD2 1Division of Pediatric Cardiology, Department of Pediatrics, Dong-A University Hospital, Busan,  2Heart Center, Pusan National University Children’s Hospital, Yangsan, Korea Pulmonary regurgitation (PR) is a frequent sequelae after repair of tetralogy of Fallot, pulmonary atresia, truncus arteriosus, Rastelli and  Ross operation.",Non-OADS,/arxiv_data1/oa_pdf/ed/d9/kcj-42-652.PMC3493800.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.cedure and has been an attractive alternative method of conduit  replacement.",Non-OADS,/arxiv_data1/oa_pdf/ed/d9/kcj-42-652.PMC3493800.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.652 www.e-kcj.org being too late for restoration of the RV function.,Non-OADS,/arxiv_data1/oa_pdf/ed/d9/kcj-42-652.PMC3493800.pdf
654 Percutaneous Pulmonary Valve Implantation    http://dx.doi.org/10.4070/kcj.2012.42.10.652 www.e-kcj.org MRI should be done before catheterization.,Non-OADS,/arxiv_data1/oa_pdf/ed/d9/kcj-42-652.PMC3493800.pdf
"http://dx.doi.org/10.4070/kcj.2012.42.10.652 www.e-kcj.org tery compression, which was demonstrated by balloon inflation  within homograft to maximum diameter and simultaneous selec - tive coronary angiography.",Non-OADS,/arxiv_data1/oa_pdf/ed/d9/kcj-42-652.PMC3493800.pdf
656 Percutaneous Pulmonary Valve Implantation    http://dx.doi.org/10.4070/kcj.2012.42.10.652 www.e-kcj.org 2012;163:280-7.,Non-OADS,/arxiv_data1/oa_pdf/ed/d9/kcj-42-652.PMC3493800.pdf
"1)6)7) Potential benefits of us - ing prognostic models are to enable patients and families to have a Editorial http://dx.doi.org/10.4070/kcj.2012.42.10.657 Print ISSN 1738-5520 • On-line ISSN 1738-5555 The Risk Model for Prediction of Survival in Heart Failure Dong Heon Yang, MD Division of Cardiology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea Correspondence: Dong Heon Yang, MD, Division of Cardiology, Department  of Internal Medicine, Kyungpook National University School of Medicine,  680 Gukchaebosang-ro, Jung-gu, Daegu 700-842, KoreaTel: 82-53-200-6587, Fax: 82-53-426-2046E-mail: ddhyang@knu.ac.kr • The author has no financial conflicts of interest.",Non-OADS,/arxiv_data1/oa_pdf/d1/3e/kcj-42-657.PMC3493801.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.realistic expectation of the prognosis, to enable selection of appro - priate therapies, including cardiac resynchronization therapy (CRT),  implantable defibrillators, mechanical circulatory assist devices, and transplantation, as well as to promote open communication be - tween clinicians, patients, and their families to define the goals of th-erapy.",Non-OADS,/arxiv_data1/oa_pdf/d1/3e/kcj-42-657.PMC3493801.pdf
658 Risk Model of Heart Failure  Survival http://dx.doi.org/10.4070/kcj.2012.42.10.657  www.e-kcj.orgimpact.,Non-OADS,/arxiv_data1/oa_pdf/d1/3e/kcj-42-657.PMC3493801.pdf
"659 Copyright © 2012 The Korean Society of CardiologyKorean Circulation Journal Introduction Despite advances in pharmacotherapeutic strategies, congestive  heart failure (HF) is a chronic disease and a major public health con - cern because of its high morbidity and mortality.1) In advanced HF  with severe systolic dysfunction {left ventricular ejection fraction Original Article http://dx.doi.org/10.4070/kcj.2012.42.10.659 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Prognostic Estimation of Advanced Heart Failure   With Low Left Ventricular Ejection Fraction and Wide QRS Interval Changmyung Oh, MD1, Hyuk-Jae Chang, MD1, Ji Min Sung, PhD2, Ji Ye Kim, MD1, Wooin Yang, MD1,  Jiyoung Shim, MD1, Seok-Min Kang, MD1, Jongwon Ha, MD1, Se-Joong Rim, MD1, and Namsik Chung, MD1 1Departments of Internal Medicine and 2Research Affairs, Yonsei University College of Medicine, Seoul, Korea Background and Objectives:  Cardiac resynchronization therapy (CRT) has been known to improve the outcome of advanced heart failure  (HF) but is still underutilized in clinical practice.",Non-OADS,/arxiv_data1/oa_pdf/d7/82/kcj-42-659.PMC3493802.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d7/82/kcj-42-659.PMC3493802.pdf
660 Prognosis of Advanced Heart Failure http://dx.doi.org/10.4070/kcj.2012.42.10.659 www.e-kcj.org patients.,Non-OADS,/arxiv_data1/oa_pdf/d7/82/kcj-42-659.PMC3493802.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.659 www.e-kcj.org Table 1.,OADS,/arxiv_data1/oa_pdf/d7/82/kcj-42-659.PMC3493802.pdf
"662 Prognosis of Advanced Heart Failure http://dx.doi.org/10.4070/kcj.2012.42.10.659 www.e-kcj.org ables had significant correlations with all-cause death: NYHA class  (III, IV vs. II) {hazard ratio (HR) 4.2; 95% confidence interval (CI): 1.81  to 9.87; p<0.001 }, body mass index ( ≥25 kg/m2) (1.7; 95% CI: 1.01  to 3.04; p=0.05), the presence of hypertension (0.5; 95% CI: 0.23 to 0.98; p=0.04), CKD (2.1; 95% CI: 1.17 to 3.75; p=0.01), prior stroke (2.1; 95% CI: 1.00 to 4.47; p=0.05), LVEF ( ≤25%) (2.7; 95% CI: 1.55  to 4.68; p<0.001), LVEDD ( ≥55 mm) (0.4; 95% CI: 0.21 to 0.65; p<  0.001), heart rate (>90 bpm) (6.3; 95% CI: 3.7 to 10.6; p<0.001), se -rum Hb (2.7; 95% CI: 1.30 to 4.14; p<0.001), serum Na ( ≤135 mEq/L)  (2.74; 95% CI: 1.62 to 4.63; p<0.001), and serum creatinine ( ≥1.5  mg/dL) (3.3; 95% CI: 1.96 to 5.69; p<0.001).",Non-OADS,/arxiv_data1/oa_pdf/d7/82/kcj-42-659.PMC3493802.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.659 www.e-kcj.org as significant predictors (Table 3).,OADS,/arxiv_data1/oa_pdf/d7/82/kcj-42-659.PMC3493802.pdf
"664 Prognosis of Advanced Heart Failure http://dx.doi.org/10.4070/kcj.2012.42.10.659 www.e-kcj.org hort according to their risk score resulted in the assignment of 36  patients (55%) to the low-, 20 patients (30%) to the intermediate- and 10 patients (15%) to the high-risk groups.",Non-OADS,/arxiv_data1/oa_pdf/d7/82/kcj-42-659.PMC3493802.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.659 www.e-kcj.org This discrepancy is possibly due to the prolonged QRS interval (>120  ms) in all enrolled patients.,Non-OADS,/arxiv_data1/oa_pdf/d7/82/kcj-42-659.PMC3493802.pdf
666 Prognosis of Advanced Heart Failure http://dx.doi.org/10.4070/kcj.2012.42.10.659 www.e-kcj.org tients.24)25)  These two prediction models are more accurate predictors of sur- vival of advanced HF patients than our prediction model.,Non-OADS,/arxiv_data1/oa_pdf/d7/82/kcj-42-659.PMC3493802.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.659 www.e-kcj.org tack and ischemic stroke: a systematic review and meta-analysis.,Non-OADS,/arxiv_data1/oa_pdf/d7/82/kcj-42-659.PMC3493802.pdf
"1) Multiple factors are involved in the etiology of AF, including st-Original Article http://dx.doi.org/10.4070/kcj.2012.42.10.668 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Hypoadiponectinemia in Patients With Paroxysmal Atrial Fibrillation Byung Joo Choi, MD, Jung Ho Heo, MD, In-Soo Choi, MD, Si-Won Lee, MD,   Hyun-Soo Kim, MD, Jae Woo Lee, MD, and Tae-Joon Cha, MD Division of Cardiology, Department of Internal Medicine, Kosin University School of Medicine, Busan, Korea Background and Objectives:  Adiponectin is an adipose tissue-derived hormone that has beneficial effects on cardiac function and has  been reported to be associated with lipid metabolism, glucose metabolism, and insulin resistance.",Non-OADS,/arxiv_data1/oa_pdf/e1/02/kcj-42-668.PMC3493803.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.retching, autonomic imbalance, hyperthyroidism, and inflamma - tion.2-4) Among these, obesity and metabolic syndrome are associ - ated with AF: patients with metabolic syndrome have a larger left  atrial (LA) size than those without metabolic syndrome.5) Obesity is  also a strong risk factor for the occurrence of post-operative AF in patients older than 50 years.",Non-OADS,/arxiv_data1/oa_pdf/e1/02/kcj-42-668.PMC3493803.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.668 www.e-kcj.org of adiponectin in AF has not been extensively evaluated.,Non-OADS,/arxiv_data1/oa_pdf/e1/02/kcj-42-668.PMC3493803.pdf
"670 Association Between Adiponectin and Atrial Fibrillation http://dx.doi.org/10.4070/kcj.2012.42.10.668 www.e-kcj.org with ACE inhibitor or an angiotensin II antagonist, and 6.5% were tr- eated with a β-blocker.",Non-OADS,/arxiv_data1/oa_pdf/e1/02/kcj-42-668.PMC3493803.pdf
"http://dx.doi.org/10.4070/kcj.2012.42.10.668 www.e-kcj.org may play a key role in the development of insulin resistance.1 1) In  contrast, high adiponectin levels are observed in HF patients12-15)  and in dialysis patients.16)17) In our study, low adiponectin levels  were observed in paroxysmal AF, but not in chronic AF, indicating  that the role of adiponectin is different in terms of AF disease pro - gression.18) Our report is not fully in line with other studies.",Non-OADS,/arxiv_data1/oa_pdf/e1/02/kcj-42-668.PMC3493803.pdf
"672 Association Between Adiponectin and Atrial Fibrillation http://dx.doi.org/10.4070/kcj.2012.42.10.668 www.e-kcj.org possess a functional RAS, and both undifferentiated preadipocytes  and immature adipocytes secrete Angiotensin II.",Non-OADS,/arxiv_data1/oa_pdf/e1/02/kcj-42-668.PMC3493803.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.668 www.e-kcj.org 13.,Non-OADS,/arxiv_data1/oa_pdf/e1/02/kcj-42-668.PMC3493803.pdf
"674 Copyright © 2012 The Korean Society of CardiologyKorean Circulation Journal Introduction Fragmented QRS complexes (fQRS) are frequently seen on the  surface electrocardiograms (ECGs) with a narrow or wide QRS com -Original Article http://dx.doi.org/10.4070/kcj.2012.42.10.674 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Absence and Resolution of Fragmented QRS Predict Reversible   Myocardial Ischemia With Higher Probability of ST Segment   Resolution in Patients With ST Segment Elevation   Myocardial Infarction Mustafa Cetin, MD1, Sinan Altan Kocaman, MD1, Tuncay Kiris, MD2, Turan Erdogan, MD3, Aytun Canga, MD1,  Murtaza Emre Durakoglugil, MD3, Yüksel Çiçek, MD3, Sitki Dogan, MD1, and Omer Satiroglu, MD3 1Department of Cardiology, Rize Education and Research Hospital, Rize, 2Department of Cardiology, Ordu State Hospital, Ordu, 3Department of Cardiology, Rize University, Faculty of Medicine, Rize, Turkey  Background and Objectives:  Fragmented QRS complexes (fQRS) are associated with increased morbidity and mortality.",Non-OADS,/arxiv_data1/oa_pdf/41/f8/kcj-42-674.PMC3493804.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/  by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.plex, which includes paced rhythm, bundle branch block or ventric - ular premature beats.1) These fragmentations on surface ECG were  associated with increased adverse cardiovascular events (CVEs) in  previous studies.2-5) fQRS may be important to determine people at",Non-OADS,/arxiv_data1/oa_pdf/41/f8/kcj-42-674.PMC3493804.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.674 www.e-kcj.org high risk for CVEs on admission and after ST elevation myocardial  infarction (STEMI).,Non-OADS,/arxiv_data1/oa_pdf/41/f8/kcj-42-674.PMC3493804.pdf
"676 Fragmented QRS and ST Segment Resolution http://dx.doi.org/10.4070/kcj.2012.42.10.674 www.e-kcj.org (QRS duration <120 ms) with or without a Q wave, which included  an additional R wave (R’ prime), notching of the R wave or S wave, or the presence of more than one R prime (fragmentation) without a typical bundle branch block in two contiguous leads correspond - ing to a major lead set for major coronary artery territory (Fig.",Non-OADS,/arxiv_data1/oa_pdf/41/f8/kcj-42-674.PMC3493804.pdf
"http://dx.doi.org/10.4070/kcj.2012.42.10.674 www.e-kcj.org Pathologic Q wave: Any Q wave in lead V2 or V3 ≥0.02 seconds or  the QS complex in leads V2 and V3 with a Q wave ≥0.03 seconds  and ≥0.1 mV deep or QS complex in lead I, II, aVL, aVF, or V4 to V6 in  any 2 leads of a contiguous lead grouping (I, aVL, and V6; V4 to V6;  and II, III, and aVF) was considered as pathologic.",OADS,/arxiv_data1/oa_pdf/41/f8/kcj-42-674.PMC3493804.pdf
"678 Fragmented QRS and ST Segment Resolution http://dx.doi.org/10.4070/kcj.2012.42.10.674 www.e-kcj.org dial coronary arteries (1 for 1-25% stenosis, 2 for 26-50% stenosis,  4 for 51-75% stenosis, 8 for 76-90% stenosis, 16 for 91-99% ste - nosis, and 32 for total occlusion) and multiplies this number by a constant number determined according to the anatomical position of the lesion.",Non-OADS,/arxiv_data1/oa_pdf/41/f8/kcj-42-674.PMC3493804.pdf
"http://dx.doi.org/10.4070/kcj.2012.42.10.674 www.e-kcj.org which is a widely adopted scoring system, grades 0-3 referring to  the levels of coronary blood flow assessed during percutaneous coronary angioplasty 18) was used to score coronary flow as previ - ously defined.",Non-OADS,/arxiv_data1/oa_pdf/41/f8/kcj-42-674.PMC3493804.pdf
680 Fragmented QRS and ST Segment Resolution http://dx.doi.org/10.4070/kcj.2012.42.10.674 www.e-kcj.org perfusion parameters were presented in Table 4.,OADS,/arxiv_data1/oa_pdf/41/f8/kcj-42-674.PMC3493804.pdf
"http://dx.doi.org/10.4070/kcj.2012.42.10.674 www.e-kcj.org al scar.1 1)12) fQRS was also found to be a marker of a prior MI, defined  by regional perfusion abnormalities, which has a substantially higher  sensitivity and negative predictive value compared with the Q wave.6)26)  It has been shown that regional fQRS patterns denote the pres - ence of a greater corresponding focal regional myocardial scar on stress myocardial perfusion imaging.",OADS,/arxiv_data1/oa_pdf/41/f8/kcj-42-674.PMC3493804.pdf
682 Fragmented QRS and ST Segment Resolution http://dx.doi.org/10.4070/kcj.2012.42.10.674 www.e-kcj.org um at admission.,Non-OADS,/arxiv_data1/oa_pdf/41/f8/kcj-42-674.PMC3493804.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.674 www.e-kcj.org 16.,Non-OADS,/arxiv_data1/oa_pdf/41/f8/kcj-42-674.PMC3493804.pdf
"The incidence of AS is on the rise as a result of Original Article http://dx.doi.org/10.4070/kcj.2012.42.10.684 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Transcatheter Aortic Valve Implantation: Early Experience in Korea Won-Jang Kim, MD1, Young-Hak Kim, MD1, Jong-Young Lee, MD1, Duk-Woo Park, MD1, Soo-Jin Kang, MD1,  Seung-Whan Lee, MD1, Cheol Whan Lee, MD1, Dae-Hee Kim, MD1, Jong-Min Song, MD1, Duk-Hyun Kang, MD1,  Jae-Kwan Song, MD1, Joon Bum Kim, MD2, Sung Ho Jung, MD2, Suk Jung Choo, MD2, Cheol Hyun Chung, MD2, Jae Won Lee, MD2, Ji-Yeon Sim, MD3, In-Cheol Choi, MD3, Seong-Wook Park, MD1, and Seung-Jung Park, MD1 1Departments of Cardiology, 2Thoracic and Cardiovascular Surgery and 3Anesthesiology and Pain Medicine, University of Ulsan College of Medicine,  Asan Medical Center, Seoul, Korea Background and Objectives:  Transcatheter aortic valve implantation (TAVI) was recently introduced in Korea.",Non-OADS,/arxiv_data1/oa_pdf/47/df/kcj-42-684.PMC3493805.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.the aging population.",Non-OADS,/arxiv_data1/oa_pdf/47/df/kcj-42-684.PMC3493805.pdf
"http://dx.doi.org/10.4070/kcj.2012.42.10.684 www.e-kcj.org diac symptoms compared with the standard procedures including  balloon aortic valvuloplasty.7) The Edward SAPIENTM (Edwards Life - sciences LLC, Irvine, CA, USA)8) and CoreValve ReValving® System (Me- dtronic LLC, Irvine, CA, USA) prosthetic heart valve obtained Confor - mité Européenne mark approval in August and April 2007, respec-tively.",Non-OADS,/arxiv_data1/oa_pdf/47/df/kcj-42-684.PMC3493805.pdf
686 Transcatheter Aortic Valve Implantation http://dx.doi.org/10.4070/kcj.2012.42.10.684 www.e-kcj.org which is a center with extensive experience of TAVI.,Non-OADS,/arxiv_data1/oa_pdf/47/df/kcj-42-684.PMC3493805.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.684 www.e-kcj.org formed with general anesthesia.,Non-OADS,/arxiv_data1/oa_pdf/47/df/kcj-42-684.PMC3493805.pdf
688 Transcatheter Aortic Valve Implantation http://dx.doi.org/10.4070/kcj.2012.42.10.684 www.e-kcj.org only and the prosthetic valve spilled out to the left ventricle (Fig.,Non-OADS,/arxiv_data1/oa_pdf/47/df/kcj-42-684.PMC3493805.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.684 www.e-kcj.org Fig.,OADS,/arxiv_data1/oa_pdf/47/df/kcj-42-684.PMC3493805.pdf
690 Transcatheter Aortic Valve Implantation http://dx.doi.org/10.4070/kcj.2012.42.10.684 www.e-kcj.org cess site complications or hematomas occurred.,Non-OADS,/arxiv_data1/oa_pdf/47/df/kcj-42-684.PMC3493805.pdf
"http://dx.doi.org/10.4070/kcj.2012.42.10.684 www.e-kcj.org lection, correct sizing,17-19) positioning, 20 coaxial alignment, timely  reduction of cardiac output, operator techniques,15)16) and organized  team approach.20) In the present cohort, the team approach ensured  reduction, early detection, and treatment of complications.",Non-OADS,/arxiv_data1/oa_pdf/47/df/kcj-42-684.PMC3493805.pdf
"692 Copyright © 2012 The Korean Society of CardiologyKorean Circulation Journal Introduction In Korea, the prevalence of acute coronary syndrome (ACS) pa -Original Article http://dx.doi.org/10.4070/kcj.2012.42.10.692 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Predictors of Long-Term Survival in Acute Coronary Syndrome   Patients With Left Ventricular Dysfunction   After Percutaneous Coronary Intervention Doo Hwan Lee, RT1,2, Myung Ho Jeong, MD1,2, Jung Ae Rhee, MD3, Jin Su Choi, MD3, Ki Hong Lee, MD1,2,  Min Goo Lee, MD1,2, Doo Sun Sim, MD1,2, Keun-Ho Park, MD1,2, Nam Sik Yoon, MD1,2, Hyun Ju Yoon, MD1,2,  Kye Hun Kim, MD1,2, Hyung Wook Park, MD1,2, Young Joon Hong, MD1,2, Ju Han Kim, MD1,2, Youngkeun Ahn, MD1,2,  Jeong Gwan Cho, MD1,2, Jong Chun Park, MD1,2, and Jung Chaee Kang, MD1,2 1The Heart Center of Chonnam National University Hospital, Gwangju, 2The Heart Research Center Nominated by Korea Ministry of Health and Welfare, Gwangju,  3Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Korea Background and Objectives:  Predictive factors of mortality in acute coronary syndrome (ACS) patients with left ventricular dysfunction  were analyzed during 5-year clinical follow-up after percutaneous coronary intervention (PCI).",Non-OADS,/arxiv_data1/oa_pdf/e5/2b/kcj-42-692.PMC3493806.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.tients is increasing, as is resultant mortality.1) High-risk ACS pa - tients require active treatment because of very high mortality.",Non-OADS,/arxiv_data1/oa_pdf/e5/2b/kcj-42-692.PMC3493806.pdf
"http://dx.doi.org/10.4070/kcj.2012.42.10.692 www.e-kcj.org also affect short-term survival rate of patients with AMI undergo - ing PCI.6) In a study investigating mortality after PCI in patients with  left ventricular dysfunction, the survival rate tended to be lower in  patients with low LVEF than in those with normal LVEF.7) However,  there has been no established definite predictor of long-term sur - vival after PCI in patients with ACS accompanied by left ventricular dysfunction.",Non-OADS,/arxiv_data1/oa_pdf/e5/2b/kcj-42-692.PMC3493806.pdf
694 Left Ventricular Dysfunction After Acute Coronary Syndrome http://dx.doi.org/10.4070/kcj.2012.42.10.692 www.e-kcj.org two groups (p=0.052).,Non-OADS,/arxiv_data1/oa_pdf/e5/2b/kcj-42-692.PMC3493806.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.692 www.e-kcj.org Independent predictors of 5-year mortality after  percutaneous coronary intervention Cox regression survival analysis was used to identify independent  predictors affecting 5-year mortality.,OADS,/arxiv_data1/oa_pdf/e5/2b/kcj-42-692.PMC3493806.pdf
"696 Left Ventricular Dysfunction After Acute Coronary Syndrome http://dx.doi.org/10.4070/kcj.2012.42.10.692 www.e-kcj.org 754 patients admitted for AMI and found that women had higher  than men in short-term (relative odds=1.74, 95% CI: 1.17-2.60) and long-term mortality (51% vs. 35.9%, log rank p=0.002).",Non-OADS,/arxiv_data1/oa_pdf/e5/2b/kcj-42-692.PMC3493806.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.692 www.e-kcj.org beck EF.,OADS,/arxiv_data1/oa_pdf/e5/2b/kcj-42-692.PMC3493806.pdf
"A brief review of the literature has been included.Case Report http://dx.doi.org/10.4070/kcj.2012.42.10.698 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Exercise-Induced Intranodal Atrioventricular Block Mi-Youn Park, MD1, Woo-Seung Shin, MD2, Byung-Ju Shim, MD1, Seung-Jae Lee, MD1, Jae-Hong Park, MD2, Yoon-Seok Koh, MD2, and Jong-Min Lee, MD2 1Division of Cardiology, Department of Internal Medicine, Pohang St. Mary’s Hospital, Pohang, 2Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea School of Medicine, Uijeongbu St. Mary’s Hospital, Uijeongbu, Korea Exercise-induced atrioventricular (AV) block in patients with normal AV conduction at rest is rare.",Non-OADS,/arxiv_data1/oa_pdf/10/b9/kcj-42-698.PMC3493807.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Case A 67-year-old woman complained of a 3-month history of effort- related dizziness and dyspnea.",Non-OADS,/arxiv_data1/oa_pdf/10/b9/kcj-42-698.PMC3493807.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.698 www.e-kcj.org Fig.,OADS,/arxiv_data1/oa_pdf/10/b9/kcj-42-698.PMC3493807.pdf
"700 Exercise-Induced Atrioventricular Block http://dx.doi.org/10.4070/kcj.2012.42.10.698 www.e-kcj.org Electrophysiological studies were performed on the patient, while  she was in a non-sedated state.",Non-OADS,/arxiv_data1/oa_pdf/10/b9/kcj-42-698.PMC3493807.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.698 www.e-kcj.org when sinus tachycardia is induced by administration of atropine.3)7)8)  The precise mechanisms for rate-dependent intranodal AV block  remain to be explained.,Non-OADS,/arxiv_data1/oa_pdf/10/b9/kcj-42-698.PMC3493807.pdf
"Case  A 60-year-old man was a smoker and drinker with no history of co- ronary artery disease, hypertension and hyperlipidemia except dia -Case Report http://dx.doi.org/10.4070/kcj.2012.42.10.702 Print ISSN 1738-5520 • On-line ISSN 1738-5555 An Unusual Case of Left Ventricular Free Wall Rupture   Caused by a Silent Myocardial Infarction Xin Jin, MD1, Sang-Hoon Seol, MD2, Seung-Hyeon Park, MD2, Joo-Won Lee, MD2, Bo-Min Park, MD2,  Dong-Kie Kim, MD2, Ki-Hun Kim, MD2, Doo-Il Kim, MD2, Ho-Ki Min, MD3, and Yeon-Mee Kim, MD4 1Division of Cardiology, Department of Internal Medicine, YanBian Second People’s Hospital, YanBian, China 2Division of Cardiology, Department of Internal Medicine , 3Division of Chest Surgery and 4Pathology, Haeundae Paik Hospital, Inje University College of Medicine,  Busan, Korea Left ventricular free wall rupture (LVFWR) is a serious complication of myocardial infarction.",Non-OADS,/arxiv_data1/oa_pdf/9b/36/kcj-42-702.PMC3493808.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.betes, which was diagnosed several years ago.",Non-OADS,/arxiv_data1/oa_pdf/9b/36/kcj-42-702.PMC3493808.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.702 www.e-kcj.org tion necrosis and abscess presented with blood clots and fibrin clots.,Non-OADS,/arxiv_data1/oa_pdf/9b/36/kcj-42-702.PMC3493808.pdf
704 Ventricular Free Wall Rupture Caused by Silent MI http://dx.doi.org/10.4070/kcj.2012.42.10.702 www.e-kcj.org diography.1 1) Echocardiography provides invaluable diagnostic infor - mation and indicates the possible extent and location of a rupture  prior to surgery.,Non-OADS,/arxiv_data1/oa_pdf/9b/36/kcj-42-702.PMC3493808.pdf
"1) In this report, we describe an  unusual case of LVHT that was accompanied by severe mitral regur - gitation, a fasciculo-ventricular accessory pathway, and atrial flutter Case Report http://dx.doi.org/10.4070/kcj.2012.42.10.705 Print ISSN 1738-5520 • On-line ISSN 1738-5555 A Case of Left Ventricular Noncompaction Accompanying   Fasciculo-Ventricular Accessory Pathway and Atrial Flutter Sun Mie Yim, MD, Sung-Won Jang, MD, Hyun Ji Chun, MD, Su Jung Kim, MD,   Kyu Young Choi, MD, Beom-June Kwon, MD, Dong-Bin Kim, MD, Eun Joo Cho, MD,   Man-Young Lee, MD, Tai-Ho Rho, MD, and Jae-Hyung Kim, MD Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea Left ventricular hypertrabeculation/noncompaction (LVHT) is an uncommon type of genetic cardiomyopathy characterized by trabecula - tions and recesses within the ventricular myocardium.",Non-OADS,/arxiv_data1/oa_pdf/59/23/kcj-42-705.PMC3493809.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.(AFL).",Non-OADS,/arxiv_data1/oa_pdf/59/23/kcj-42-705.PMC3493809.pdf
706 LV Noncompaction With Fasciculo-Ventricular Accessory Pathway and Atrial Flutter http://dx.doi.org/10.4070/kcj.2012.42.10.705 www.e-kcj.org regurgitation.,Non-OADS,/arxiv_data1/oa_pdf/59/23/kcj-42-705.PMC3493809.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.705 www.e-kcj.org late atrial activation on the opposite side.,Non-OADS,/arxiv_data1/oa_pdf/59/23/kcj-42-705.PMC3493809.pdf
708 LV Noncompaction With Fasciculo-Ventricular Accessory Pathway and Atrial Flutter http://dx.doi.org/10.4070/kcj.2012.42.10.705 www.e-kcj.org also showed some difference.,Non-OADS,/arxiv_data1/oa_pdf/59/23/kcj-42-705.PMC3493809.pdf
"1) Community outbreaks largely spread through contact in  schools; however, up to 40% of household members of the infect - ed student also develop Mycoplasma  infection.2)  M. pneumoniae  is a common pathogen that causes upper and lo-Case Report http://dx.doi.org/10.4070/kcj.2012.42.10.709 Print ISSN 1738-5520 • On-line ISSN 1738-5555 A Case of Acute Myopericarditis Associated   With Mycoplasma Pneumoniae  Infection in a Child In Ho Park, MD, Du Young Choi, MD, Yeon Kyun Oh, MD, Jong Duck Kim, MD, and Seung Taek Yu, MD  Department of Pediatrics, Wonkwang University School of Medicine, Iksan, Korea Mycoplasma pneumoniae (M. pneumoniae)  primarily causes respiratory tract infections in persons aged 5-20 years.",Non-OADS,/arxiv_data1/oa_pdf/81/2f/kcj-42-709.PMC3493810.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.wer respiratory tract infections, manifesting as pharyngitis, bronch- itis, and atypical pneumonia in children and adolescents.3) Patients with or without respiratory symptoms can manifest ill - ness involving the skin, central nervous system (CNS), blood, heart, gastrointestinal tract, and joints.",Non-OADS,/arxiv_data1/oa_pdf/81/2f/kcj-42-709.PMC3493810.pdf
710 Myopericarditis Caused by M. Pneumoniae http://dx.doi.org/10.4070/kcj.2012.42.10.709 www.e-kcj.org with oral azithromycin in a private pediatric clinic for five days.,Non-OADS,/arxiv_data1/oa_pdf/81/2f/kcj-42-709.PMC3493810.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.709 www.e-kcj.org chain reaction (PCR) test of the M. pneumoniae -containing sputum  were positive.,Non-OADS,/arxiv_data1/oa_pdf/81/2f/kcj-42-709.PMC3493810.pdf
712 Myopericarditis Caused by M. Pneumoniae http://dx.doi.org/10.4070/kcj.2012.42.10.709 www.e-kcj.org with the development of carditis.,Non-OADS,/arxiv_data1/oa_pdf/81/2f/kcj-42-709.PMC3493810.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.709 www.e-kcj.org Acta Med Scand  1979;206:77-86.,OADS,/arxiv_data1/oa_pdf/81/2f/kcj-42-709.PMC3493810.pdf
"1)2) There have been many  reported cases of coronary artery fistulas,3-5) but only few reports  of Thebesian veins in Korea.6)7) Here, we presented a unique case of Case Report http://dx.doi.org/10.4070/kcj.2012.42.10.714 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Severe Form of Persistent Thebesian Veins Presenting   as Ischemic Heart Disease Younghee Jung, MD1, Hyun-Jin Kim, MD1, and Chang-Hwan Yoon, MD1,2  1Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, 2Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea Coronary artery fistula is a rare congenital anomaly.",Non-OADS,/arxiv_data1/oa_pdf/76/e6/kcj-42-714.PMC3493811.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.extensive persistent Thebesian veins in an old patient presenting as  acute coronary syndrome.",Non-OADS,/arxiv_data1/oa_pdf/76/e6/kcj-42-714.PMC3493811.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.714 www.e-kcj.org without the regional wall motion abnormality.,Non-OADS,/arxiv_data1/oa_pdf/76/e6/kcj-42-714.PMC3493811.pdf
716 Thebesian Veins Presenting as Ischemia http://dx.doi.org/10.4070/kcj.2012.42.10.714 www.e-kcj.org due to the coronary fistula.,Non-OADS,/arxiv_data1/oa_pdf/76/e6/kcj-42-714.PMC3493811.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.714 www.e-kcj.org diol 1998;63:47-52.,Non-OADS,/arxiv_data1/oa_pdf/76/e6/kcj-42-714.PMC3493811.pdf
"1) In addition, familial lone atrial fibrillation belongs to the Case Report http://dx.doi.org/10.4070/kcj.2012.42.10.718 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Familial Occurrence of Atrioventricular Nodal Reentrant Tachycardia in a Mother and Her Son June Namgung, MD, Jae-Jin Kwak, MD, Hyunmin Choe, MD, Sung Uk Kwon, MD,   Joon Hyung Doh, MD, Sung Yun Lee, MD, and Won Ro Lee, MD Division of Cardiology, Department of Internal Medicine, Inje University College of Medicine, Ilsan Paik Hospital, Goyang, Korea Atrioventricular nodal reentrant tachycardia (AVNRT), caused by a reentry circuit involving fast and slow atrioventricular nodal pathways,  is one of the most common types of paroxysmal supraventricular tachycardias.",Non-OADS,/arxiv_data1/oa_pdf/9b/7f/kcj-42-718.PMC3493812.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.family of “channelopathies” and is characterized by autosomal do- minant inheritance, corresponding to a locus on chromosome 10.2)  However, whether a genetic mechanism also contributes to the de-velopment of AVNRT has not been well known.",Non-OADS,/arxiv_data1/oa_pdf/9b/7f/kcj-42-718.PMC3493812.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.718 www.e-kcj.org USA) was placed at the coronary sinus (CS) and the right atrium (RA)  simultaneously via the right femoral vein.,Non-OADS,/arxiv_data1/oa_pdf/9b/7f/kcj-42-718.PMC3493812.pdf
"720 Familial AVNRT http://dx.doi.org/10.4070/kcj.2012.42.10.718 www.e-kcj.org tion pathways through the AV node, referred to as the fast and slow  pathways.",Non-OADS,/arxiv_data1/oa_pdf/9b/7f/kcj-42-718.PMC3493812.pdf
"http://dx.doi.org/10.4070/kcj.2012.42.10.718 www.e-kcj.org mily, and two sisters in the other family.",Non-OADS,/arxiv_data1/oa_pdf/9b/7f/kcj-42-718.PMC3493812.pdf
"2).Images in Cardiovascular Medicine http://dx.doi.org/10.4070/kcj.2012.42.10.722 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Alternating Ventricular Preexcitation Jun Kim, MD, Dongcheul Han, MD, Changbae Sohn, MD, Jeong Su Kim, MD, and Yong Hyun Park, MD Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea Received:  December 24, 201 1 / Revision Received: March 1, 2012 / Accepted: March 5, 2012 Correspondence: Jun Kim, MD, Department of Internal Medicine, Pusan National University Yangsan Hospital, 20 Geumo-ro, Mulgeum-eup, Yangsan 626- 770, KoreaTel: 82-55-360-2357, Fax: 82-55-360-2204, E-mail: mdjunkim@gmail.com • The authors have no financial conflicts of interest.",Non-OADS,/arxiv_data1/oa_pdf/4a/ec/kcj-42-722.PMC3493813.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/  by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Intermittent ventricular preexcitation is associated with a long  antegrade RP of the AP and a prolonged preexcited RR interval dur - ing atrial fibrillation.4) Twave inversion in the inferior leads occurs be- cause of the memory effect.5) Alternating ventricular preexcitation  is a rare electrocardiographic phenomenon associated with RP of  the AP greater than the length of the sinus cycle.",Non-OADS,/arxiv_data1/oa_pdf/4a/ec/kcj-42-722.PMC3493813.pdf
http://dx.doi.org/10.4070/kcj.2012.42.10.722  www.e-kcj.org Fig.,OADS,/arxiv_data1/oa_pdf/4a/ec/kcj-42-722.PMC3493813.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/c1/9d/JHRS-5-154.PMC3493829.pdf
The application can be downloaded from https://market.android.com/details?id=comm.app.medknow.,Non-OADS,/arxiv_data1/oa_pdf/51/25/JHRS-5-166.PMC3493830.pdf
"Slides were scanned using Nanozoomer (HamamatsuÒ, Japan) and images were analyzed with Image J (http://rsbweb.nih.gov/ij).",OADS,/arxiv_data1/oa_pdf/6a/72/JHRS-5-175.PMC3493832.pdf
Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)P=0.64 P=0.17 P=0.38 P=0.29 P=0.68Exon 19 deletionExon 19 deletionExon 21 point mutation Exon 21 point mutationExon 19 deletionExon 21 point mutationExon 19 deletionExon 21 point mutationExon 19 deletionExon 21 point mutationCEACAM580 60 4020 0100 80 60 40 20 0100CEACAM6 80 60 40 20 0100CEACAM380 6040 20 0100CEACAM780 60 40 20 0100CEACAM19 Figure 6 Box-plot of positive rate of each CEACAM according to the response to mutation site in EGFR mutation-positive lung adenocarcinoma.,Non-OADS,/arxiv_data1/oa_pdf/fa/2d/bjc2012422a.PMC3493859.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/FOXM1/PLK1 and oesophageal adenocarcinoma M Dibb et al 1775 &2012 Cancer Research UK British Journal of Cancer (2012) 107(10), 1766 – 1775 Genetics and Genomics",Non-OADS,/arxiv_data1/oa_pdf/cd/a7/bjc2012424a.PMC3493860.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint,inducing resistance to Taxol.",Non-OADS,/arxiv_data1/oa_pdf/45/65/bjc2012450a.PMC3493865.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/Paclitaxel and CYC3 in pancreatic cancer and BM cells Y Lin et al 1701 &2012 Cancer Research UK British Journal of Cancer (2012) 107(10), 1692 – 1701 Translational Therapeutics",Non-OADS,/arxiv_data1/oa_pdf/45/65/bjc2012450a.PMC3493865.pdf
"Magee-Womens Hospital ofUPMC (Pittsburgh, PA, USA) provided 2 : 53 late-stage serousovarian tumours and 3: 435 serous EOC samples for which complete information was available from The Cancer Genome Atlas Network web site (2011; http://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm?diseaseType=OV).",OADS,/arxiv_data1/oa_pdf/d5/f7/bjc2012451a.PMC3493866.pdf
"The STR profileswere compared with known ATCC fingerprints (ATCC.org), and to the Cell Line Integrated Molecular Authentication database (CLIMA) version 0.1.200808 (http://bioinformatics.istge.it/clima/)(Nucleic Acids Research 37:D925-D932 PMCID: PMC2686526).",OADS,/arxiv_data1/oa_pdf/d5/f7/bjc2012451a.PMC3493866.pdf
Additional information can be found at theDSMZ website (http://old.dsmz.de/human_and_animal_cell_lines/ main.php?content_id=86) and in Durkin and Reid (1998).,OADS,/arxiv_data1/oa_pdf/d5/f7/bjc2012451a.PMC3493866.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Beaudet AL, Tsui LCA (1993) A suggested nomenclature for designating mutations.",Non-OADS,/arxiv_data1/oa_pdf/d5/f7/bjc2012451a.PMC3493866.pdf
All sequences were compared withthe related NCBI (http://www.ncbi.nlm.nih.gov) reference sequences for variant detection.,OADS,/arxiv_data1/oa_pdf/c9/86/bjc2012452a.PMC3493867.pdf
"We considered a missense variant as a predictedpathogenic if two of the three in silico tools (Align-GVGD, PolyPhen-2 and SIFT) predicted it as pathogenic and the carrier frequency of that mutation was less than 1% among 6481 studysubjects of the NHLBI Exome Sequencing Project (ESP6500)(http://evs.gs.washington.edu/EVS/).",Non-OADS,/arxiv_data1/oa_pdf/c9/86/bjc2012452a.PMC3493867.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR (2010) A method and server for predictingdamaging missense mutations.",Non-OADS,/arxiv_data1/oa_pdf/c9/86/bjc2012452a.PMC3493867.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E,Stein GS, Lian JB (2010) RUNX2 association with progression of prostatecancer in patients: mechanisms mediating bone osteolysis andosteoblastic metastatic lesions.",Non-OADS,/arxiv_data1/oa_pdf/28/0a/bjc2012455a.PMC3493869.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)Serum cytokine profile in colorectal cancer T Kantola et al 1734 British Journal of Cancer (2012) 107(10), 1729 – 1736 &2012 Cancer Research UK Molecular Diagnostics",Non-OADS,/arxiv_data1/oa_pdf/47/44/bjc2012456a.PMC3493870.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Aronson WJ, Barnard RJ, Freedland SJ, Henning S, Elashoff D, Jardack PM, Cohen P, Heber D, Kobayashi N (2010) Growth inhibitory effect of low fatdiet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer.",Non-OADS,/arxiv_data1/oa_pdf/50/15/bjc2012457a.PMC3493871.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Barresi V, Tuccari G (2010) Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas.",Non-OADS,/arxiv_data1/oa_pdf/be/c7/bjc2012459a.PMC3493872.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/b9/5e/bjc2012461a.PMC3493873.pdf
"R package version 2.35-8. http://CRAN.R-project.org/package=survival Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY, van Dam PA (2009) The VEGF pathway and the AKT/mTOR/p70S6K1 signallingpathway in human epithelial ovarian cancer.",Non-OADS,/arxiv_data1/oa_pdf/b9/5e/bjc2012461a.PMC3493873.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Albanese C, D’Amico M, Reutens AT, Fu M, Watanabe G, Lee RJ, Kitsis RN, Henglein B, Avantaggiati M, Somasundaram K, Thimmapaya B, PestellRG (1999) Activation of the cyclin D1 gene by the E1A-associated proteinp300 through AP-1 inhibits cellular apoptosis.",Non-OADS,/arxiv_data1/oa_pdf/4d/e5/bjc2012463a.PMC3493874.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Cantarini MC, Trevisani F, Morselli-Labate AM, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F, Bernardi M (2006) Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/7b/19/bjc2012466a.PMC3493875.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/miR-371-3 as biomarkers in testicular germ cell tumours K-P Dieckmann et al 1760 British Journal of Cancer (2012) 107(10), 1754 – 1760 &2012 Cancer Research UK Molecular Diagnostics",Non-OADS,/arxiv_data1/oa_pdf/11/8b/bjc2012469a.PMC3493876.pdf
"The image acquisition and analysis software package, ImageJ,was used for image processing (http://rsbweb.nih.gov/ij/).The macro routine ‘Transform’ (published in DeFazio et al, 2011) was used to convert raw images into LSC images.",OADS,/arxiv_data1/oa_pdf/95/8f/jcbfm2012102a.PMC3493990.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies the paper on the Journal of Cerebral Blood Flow & Metabolism website (http:// www.nature.com/jcbfm)Albumin therapy enhances collateral perfusion RA DeFazio et al 2022 Journal of Cerebral Blood Flow & Metabolism (2012) 32, 2012–2022",Non-OADS,/arxiv_data1/oa_pdf/95/8f/jcbfm2012102a.PMC3493990.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Dashti, M. et al.",Non-OADS,/arxiv_data1/oa_pdf/9f/eb/srep00787.PMC3494008.pdf
"Environmental Research , http://dx.doi.org/10.1016/j.envres.2012.1009.1001 (2012).",OADS,/arxiv_data1/oa_pdf/34/68/srep00830.PMC3494010.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/34/68/srep00830.PMC3494010.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/How to cite this article: Guo, Y., Barnett, A.G. & Tong, S. High temperatures-related elderly mortality varied greatly from year to year: important information for heat-warning systems.Sci.",Non-OADS,/arxiv_data1/oa_pdf/34/68/srep00830.PMC3494010.pdf
To view these ﬁles please visit the journal online (http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/36/jmedgenet-2012-101203.PMC3494011.pdf
"(A) Rearrangements are schematically pinpointed with reddish bars while grey bars and striated blocks indicate intervals of recurrent polymorphisms reported in the Database of Genomic Variants (http://projects.tcag.ca/variat ion) and common sequence stretches, respectively.",OADS,/arxiv_data1/oa_pdf/eb/36/jmedgenet-2012-101203.PMC3494011.pdf
The grey area speci ﬁes the interval between the 3rd and 97th centile as deﬁned by the WHO data (http://www.who.int/childgrowth/en) between 0 –2 years and the Centre for Disease Control and Prevention data above 2 years of age.,Non-OADS,/arxiv_data1/oa_pdf/eb/36/jmedgenet-2012-101203.PMC3494011.pdf
Approved researchers can obtain the SSC population dataset described in thisstudy by applying at https://base.sfari.org Collaborators List of contributors to the 16p11.2 European Consortium: Marie Claude Addor; Benoit Arveiler; Marco Bel ﬁore; Frédérique Bena; Laura Bernardini; Patricia Blanchet; Dominique Bonneau; Odile Boute; Patrick Callier; DominiqueCampion; Jean Chiesa; Marie Pierre Cordier; Jean Marie Cuisset; Albert David; Nicole de Leeuw; Bert de Vries; Gérard Didelot; Martine Doco-Fenzy; Bénédicte Duban Bedu; Christèle Dubourg; Sophie Dupuis-Girod; Christina R. Fagerberg; LaurenceFaivre; Florence Fellmann; Bridget A. Fernandez; Richard Fisher; Elisabeth Flori; AliceGoldenberg; Delphine Heron; Muriel Holder; Juliane Hoyer; Bertrand Isidor; Sylvie Jaillard; Philippe Jonveaux; Sylvie Joriot; Hubert Journel; Frank Kooy; Cédric le Caignec; Bruno Leheup; Marie-Pierre Lemaitre; Suzanne Lewis; Valérie Malan;Michèle Mathieu-Dramard; Andres Metspalu; Fanny Morice-Picard; Mafalda Mucciolo;Eve Oiglane-Shlik; Katrin Ounap; Laurent Pasquier; Florence Petit; Anne Philippe; Ghislaine Plessis; Fabienne Prieur; Jacques Puechberty; Evica Rajcan-Separovic; Anita Rauch; Alessandra Renieri; Claudine Rieubland; Caroline Rooryck; KatharinaMagdalena Rötzer; Mariken Ruiter; Damien Sanlaville; Stéphanie Selmoni; YipingShen; Vanessa Siffredi; Jacques Thonney; Louis Vallée; Ellen van Binsbergen; Nathalie Van der Aa; Mieke M. van Haelst; Jacqueline Vigneron; Catherine Vincent-Delorme; Disciglio Vittoria; Anneke T Vulto-van Silfhout; Robert M Witwicki; SimonA.,Non-OADS,/arxiv_data1/oa_pdf/eb/36/jmedgenet-2012-101203.PMC3494011.pdf
Data sharing statement Data on the Simons VIP subjects are available through SFARI Base at https://sfari.org/resources/sfari-base.,Non-OADS,/arxiv_data1/oa_pdf/eb/36/jmedgenet-2012-101203.PMC3494011.pdf
"Images (192 3144 pixels) were obtained at a scan rate of 0.2 frames per second (fps) for 1,300 s. Images were analyzed by ImageJ 1.44o software (http://rsbweb.nih.gov/ij/) and PaintShop Pro software (COREL Corporation, Ontario, Canada).",OADS,/arxiv_data1/oa_pdf/01/0a/srep00790.PMC3494012.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/01/0a/srep00790.PMC3494012.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Iijima, M., Somiya, M., Yoshimoto, N., Niimi, T. & Kuroda, S. Nano-visualization of oriented-immobilized IgGs on immunosensors by high-speed atomic force microscopy.",OADS,/arxiv_data1/oa_pdf/01/0a/srep00790.PMC3494012.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/11/21/srep00826.PMC3494013.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Schulz, G. et al.",Non-OADS,/arxiv_data1/oa_pdf/11/21/srep00826.PMC3494013.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interest.,Non-OADS,/arxiv_data1/oa_pdf/57/3c/srep00827.PMC3494014.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Ueki, H. et al.",Non-OADS,/arxiv_data1/oa_pdf/57/3c/srep00827.PMC3494014.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/23/bf/srep00801.PMC3494015.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Xiang, G., Shi, X., Wu, Y., Zhuang, J.",Non-OADS,/arxiv_data1/oa_pdf/23/bf/srep00801.PMC3494015.pdf
"In Table 1, we analyze the enrichment with a collection of 2392 different gene sets (available at http://www.broadinstitute.org/gsea/msigdb/collections.jsp) that represents gene expression signatures of genetic and chemical perturbations (subgroup c2.cgp).",OADS,/arxiv_data1/oa_pdf/b8/b4/srep00828.PMC3494016.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/b8/b4/srep00828.PMC3494016.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ How to cite this article: Costa, C. et al.",Non-OADS,/arxiv_data1/oa_pdf/b8/b4/srep00828.PMC3494016.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/bd/fb/srep00832.PMC3494020.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Chai, G., Phuoc, N.N.",Non-OADS,/arxiv_data1/oa_pdf/bd/fb/srep00832.PMC3494020.pdf
Our implementation is available at https://github.com/kawadia/estrangement.,Non-OADS,/arxiv_data1/oa_pdf/6a/72/srep00794.PMC3494021.pdf
This was done using code publicly available at:http://netwiki.amath.unc.edu/GenLouvain/GenLouvain.,OADS,/arxiv_data1/oa_pdf/6a/72/srep00794.PMC3494021.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/6a/72/srep00794.PMC3494021.pdf
"To view a copyof this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Kawadia, V. & Sreenivasan, S. Sequential detection of temporal communities by estrangement confinement.",Non-OADS,/arxiv_data1/oa_pdf/6a/72/srep00794.PMC3494021.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/90/ea/srep00792.PMC3494035.pdf
"To view a copyof this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Shang, J. et al.",Non-OADS,/arxiv_data1/oa_pdf/90/ea/srep00792.PMC3494035.pdf
"To view a copyof this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: de las Heras, D. et al.",Non-OADS,/arxiv_data1/oa_pdf/1e/b4/srep00789.PMC3494036.pdf
"This is an Open Access article distributed under the terms of the Creative Commons AttributionNon-Commercial License (http://creativecommons.org/   licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/b5/sbs053.PMC3494044.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly c ited.",Non-OADS,/arxiv_data1/oa_pdf/6d/b5/sbs053.PMC3494044.pdf
"Image Analysis Images were corrected for head movement, eddy cur- rents, and skull-stripped using FSL (http://www.fmrib.ox.ac.uk/fsl/).",Non-OADS,/arxiv_data1/oa_pdf/6d/b5/sbs053.PMC3494044.pdf
"In order to allow for the effects of this reorientation, the local ten-sor orientation was adjusted using the ‘‘preservation of principal direction’’ algorithm implemented within Camino (http://cmic.cs.ucl.ac.uk/camino).",Non-OADS,/arxiv_data1/oa_pdf/6d/b5/sbs053.PMC3494044.pdf
"Finally, real- igned diffusion tensor images of all subjects were usedto create a population-specific template to which eachsubject’s images were then (re-)normalized; this finalstage of processing was performed with ‘‘dti-tk’’ toolkit (http://www.nitrc.org/projects/dtitk) and is described in more detail below.",Non-OADS,/arxiv_data1/oa_pdf/6d/b5/sbs053.PMC3494044.pdf
"Group Mapping Analysis The main analysis of the data was performed using XBAM v4, a software package developed at King’s College London, Institute of Psychiatry (http://brainmap.co.uk) Fig.",OADS,/arxiv_data1/oa_pdf/6d/b5/sbs053.PMC3494044.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in an y medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/62/a4/JIAS-15-17429.PMC3494159.pdf
"Journal of the International AIDS Society 2012, 15:17429 http://www.jiasociety.org/index.php/jias/article/view/17429 | http://dx.doi.org/10.7448/IAS.15.2.17429 1",Non-OADS,/arxiv_data1/oa_pdf/62/a4/JIAS-15-17429.PMC3494159.pdf
"Journal of the International AIDS Society 2012, 15:17429 http://www.jiasociety.org/index.php/jias/article/view/17429 | http://dx.doi.org/10.7448/IAS.15.2.17429 2",Non-OADS,/arxiv_data1/oa_pdf/62/a4/JIAS-15-17429.PMC3494159.pdf
"Journal of the International AIDS Society 2012, 15:17429 http://www.jiasociety.org/index.php/jias/article/view/17429 | http://dx.doi.org/10.7448/IAS.15.2.17429 3",Non-OADS,/arxiv_data1/oa_pdf/62/a4/JIAS-15-17429.PMC3494159.pdf
"Journal of the International AIDS Society 2012, 15:17429 http://www.jiasociety.org/index.php/jias/article/view/17429 | http://dx.doi.org/10.7448/IAS.15.2.17429 4",Non-OADS,/arxiv_data1/oa_pdf/62/a4/JIAS-15-17429.PMC3494159.pdf
"Journal of the International AIDS Society 2012, 15:17429 http://www.jiasociety.org/index.php/jias/article/view/17429 | http://dx.doi.org/10.7448/IAS.15.2.17429 5",Non-OADS,/arxiv_data1/oa_pdf/62/a4/JIAS-15-17429.PMC3494159.pdf
"Journal of the International AIDS Society 2012, 15:17429 http://www.jiasociety.org/index.php/jias/article/view/17429 | http://dx.doi.org/10.7448/IAS.15.2.17429 6",Non-OADS,/arxiv_data1/oa_pdf/62/a4/JIAS-15-17429.PMC3494159.pdf
"Journal of the International AIDS Society 2012, 15:17429 http://www.jiasociety.org/index.php/jias/article/view/17429 | http://dx.doi.org/10.7448/IAS.15.2.17429 7",Non-OADS,/arxiv_data1/oa_pdf/62/a4/JIAS-15-17429.PMC3494159.pdf
"Journal of the International AIDS Society 2012, 15:17429 http://www.jiasociety.org/index.php/jias/article/view/17429 | http://dx.doi.org/10.7448/IAS.15.2.17429 8",Non-OADS,/arxiv_data1/oa_pdf/62/a4/JIAS-15-17429.PMC3494159.pdf
"Journal of the International AIDS Society 2012, 15:17429 http://www.jiasociety.org/index.php/jias/article/view/17429 | http://dx.doi.org/10.7448/IAS.15.2.17429 9",Non-OADS,/arxiv_data1/oa_pdf/62/a4/JIAS-15-17429.PMC3494159.pdf
"Journal of the International AIDS Society 2012, 15:17429 http://www.jiasociety.org/index.php/jias/article/view/17429 | http://dx.doi.org/10.7448/IAS.15.2.17429 10",Non-OADS,/arxiv_data1/oa_pdf/62/a4/JIAS-15-17429.PMC3494159.pdf
"This is an open access article distributed under the terms of the Creative Commons Attributio n License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, pro vided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/28/df/JIAS-15-17352.PMC3494161.pdf
"Journal of the International AIDS Society 2012, 15:17352 http://www.jiasociety.org/index.php/jias/article/view/17352 | http://dx.doi.org/10.7448/IAS.15.2.17352 1",Non-OADS,/arxiv_data1/oa_pdf/28/df/JIAS-15-17352.PMC3494161.pdf
"Journal of the International AIDS Society 2012, 15:17352 http://www.jiasociety.org/index.php/jias/article/view/17352 | http://dx.doi.org/10.7448/IAS.15.2.17352 2",Non-OADS,/arxiv_data1/oa_pdf/28/df/JIAS-15-17352.PMC3494161.pdf
"Journal of the International AIDS Society 2012, 15:17352 http://www.jiasociety.org/index.php/jias/article/view/17352 | http://dx.doi.org/10.7448/IAS.15.2.17352 3",Non-OADS,/arxiv_data1/oa_pdf/28/df/JIAS-15-17352.PMC3494161.pdf
"Journal of the International AIDS Society 2012, 15:17352 http://www.jiasociety.org/index.php/jias/article/view/17352 | http://dx.doi.org/10.7448/IAS.15.2.17352 4",Non-OADS,/arxiv_data1/oa_pdf/28/df/JIAS-15-17352.PMC3494161.pdf
"Journal of the International AIDS Society 2012, 15:17352 http://www.jiasociety.org/index.php/jias/article/view/17352 | http://dx.doi.org/10.7448/IAS.15.2.17352 5",Non-OADS,/arxiv_data1/oa_pdf/28/df/JIAS-15-17352.PMC3494161.pdf
"Journal of the International AIDS Society 2012, 15:17352 http://www.jiasociety.org/index.php/jias/article/view/17352 | http://dx.doi.org/10.7448/IAS.15.2.17352 6",Non-OADS,/arxiv_data1/oa_pdf/28/df/JIAS-15-17352.PMC3494161.pdf
"Journal of the International AIDS Society 2012, 15:17352 http://www.jiasociety.org/index.php/jias/article/view/17352 | http://dx.doi.org/10.7448/IAS.15.2.17352 7",Non-OADS,/arxiv_data1/oa_pdf/28/df/JIAS-15-17352.PMC3494161.pdf
"Journal of the International AIDS Society 2012, 15:17352 http://www.jiasociety.org/index.php/jias/article/view/17352 | http://dx.doi.org/10.7448/IAS.15.2.17352 8",Non-OADS,/arxiv_data1/oa_pdf/28/df/JIAS-15-17352.PMC3494161.pdf
"Journal of the International AIDS Society 2012, 15:17352 http://www.jiasociety.org/index.php/jias/article/view/17352 | http://dx.doi.org/10.7448/IAS.15.2.17352 9",Non-OADS,/arxiv_data1/oa_pdf/28/df/JIAS-15-17352.PMC3494161.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in an y medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/56/3f/JIAS-15-17372.PMC3494162.pdf
"Journal of the International AIDS Society 2012, 15:17372 http://www.jiasociety.org/index.php/jias/article/view/17372 | http://dx.doi.org/10.7448/IAS.15.2.17372 1",Non-OADS,/arxiv_data1/oa_pdf/56/3f/JIAS-15-17372.PMC3494162.pdf
"Journal of the International AIDS Society 2012, 15:17372 http://www.jiasociety.org/index.php/jias/article/view/17372 | http://dx.doi.org/10.7448/IAS.15.2.17372 2",Non-OADS,/arxiv_data1/oa_pdf/56/3f/JIAS-15-17372.PMC3494162.pdf
"Journal of the International AIDS Society 2012, 15:17372 http://www.jiasociety.org/index.php/jias/article/view/17372 | http://dx.doi.org/10.7448/IAS.15.2.17372 3",Non-OADS,/arxiv_data1/oa_pdf/56/3f/JIAS-15-17372.PMC3494162.pdf
"Journal of the International AIDS Society 2012, 15:17372 http://www.jiasociety.org/index.php/jias/article/view/17372 | http://dx.doi.org/10.7448/IAS.15.2.17372 4",Non-OADS,/arxiv_data1/oa_pdf/56/3f/JIAS-15-17372.PMC3494162.pdf
Available from: http://hivrussia.ru/stat/bulletin.shtml 25.,Non-OADS,/arxiv_data1/oa_pdf/56/3f/JIAS-15-17372.PMC3494162.pdf
Available from: http://www.unaids.org/globalreport/Global_report.htm26.,Non-OADS,/arxiv_data1/oa_pdf/56/3f/JIAS-15-17372.PMC3494162.pdf
Available from: http://www.aidsjournal.ru/journal/77_7.html 32.,Non-OADS,/arxiv_data1/oa_pdf/56/3f/JIAS-15-17372.PMC3494162.pdf
Available from: http://csis.org/publication/survey-russian- doctors-hivaids 33.,Non-OADS,/arxiv_data1/oa_pdf/56/3f/JIAS-15-17372.PMC3494162.pdf
"Journal of the International AIDS Society 2012, 15:17372 http://www.jiasociety.org/index.php/jias/article/view/17372 | http://dx.doi.org/10.7448/IAS.15.2.17372 5",Non-OADS,/arxiv_data1/oa_pdf/56/3f/JIAS-15-17372.PMC3494162.pdf
"This is an open access article distributed under the terms of the Creative Commons Attributio n License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, pro vided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
"Journal of the International AIDS Society 2012, 15:17424 http://www.jiasociety.org/index.php/jias/article/view/17424 | http://dx.doi.org/10.7448/IAS.15.2.17424 1",Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
"Journal of the International AIDS Society 2012, 15:17424 http://www.jiasociety.org/index.php/jias/article/view/17424 | http://dx.doi.org/10.7448/IAS.15.2.17424 2",Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
"Journal of the International AIDS Society 2012, 15:17424 http://www.jiasociety.org/index.php/jias/article/view/17424 | http://dx.doi.org/10.7448/IAS.15.2.17424 3",Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
"Journal of the International AIDS Society 2012, 15:17424 http://www.jiasociety.org/index.php/jias/article/view/17424 | http://dx.doi.org/10.7448/IAS.15.2.17424 4",Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
"Journal of the International AIDS Society 2012, 15:17424 http://www.jiasociety.org/index.php/jias/article/view/17424 | http://dx.doi.org/10.7448/IAS.15.2.17424 5",Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
"Journal of the International AIDS Society 2012, 15:17424 http://www.jiasociety.org/index.php/jias/article/view/17424 | http://dx.doi.org/10.7448/IAS.15.2.17424 6",Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
"Journal of the International AIDS Society 2012, 15:17424 http://www.jiasociety.org/index.php/jias/article/view/17424 | http://dx.doi.org/10.7448/IAS.15.2.17424 7",Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
Available from: http://www.unaids.org/en/regionscountries/countries/nigeria/ 6.,Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
Available from: http://www.unaids.org/en/Regionscountries/Countries/Nigeria/ 9.,Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
Available from: http://www.fhi360.org/NR/rdonlyres/ek2sg7ggnq fivfajis6by747jvi2obc27at5mjng4xwkgafjqrg3dizvkjlciojcbels3os24rp4pi/GHAIN ProjectProfile1enhv.pdf 38.,Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
Available from: http://www.lamisworld.org/aboutlamis.html 39.,Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
"Journal of the International AIDS Society 2012, 15:17424 http://www.jiasociety.org/index.php/jias/article/view/17424 | http://dx.doi.org/10.7448/IAS.15.2.17424 8",Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
"Journal of the International AIDS Society 2012, 15:17424 http://www.jiasociety.org/index.php/jias/article/view/17424 | http://dx.doi.org/10.7448/IAS.15.2.17424 9",Non-OADS,/arxiv_data1/oa_pdf/61/50/JIAS-15-17424.PMC3494164.pdf
"This is an open access article distributed under the terms of the Creative Commons Attributi on License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, pro vided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"Journal of the International AIDS Society 2012, 15:17392 http://www.jiasociety.org/index.php/jias/article/view/17392 | http://dx.doi.org/10.7448/IAS.15.2.17392 1",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"Journal of the International AIDS Society 2012, 15:17392 http://www.jiasociety.org/index.php/jias/article/view/17392 | http://dx.doi.org/10.7448/IAS.15.2.17392 2",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"Journal of the International AIDS Society 2012, 15:17392 http://www.jiasociety.org/index.php/jias/article/view/17392 | http://dx.doi.org/10.7448/IAS.15.2.17392 3",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"Journal of the International AIDS Society 2012, 15:17392 http://www.jiasociety.org/index.php/jias/article/view/17392 | http://dx.doi.org/10.7448/IAS.15.2.17392 4",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"Journal of the International AIDS Society 2012, 15:17392 http://www.jiasociety.org/index.php/jias/article/view/17392 | http://dx.doi.org/10.7448/IAS.15.2.17392 5",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"Journal of the International AIDS Society 2012, 15:17392 http://www.jiasociety.org/index.php/jias/article/view/17392 | http://dx.doi.org/10.7448/IAS.15.2.17392 6",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"Journal of the International AIDS Society 2012, 15:17392 http://www.jiasociety.org/index.php/jias/article/view/17392 | http://dx.doi.org/10.7448/IAS.15.2.17392 7",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"Journal of the International AIDS Society 2012, 15:17392 http://www.jiasociety.org/index.php/jias/article/view/17392 | http://dx.doi.org/10.7448/IAS.15.2.17392 8",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"Journal of the International AIDS Society 2012, 15:17392 http://www.jiasociety.org/index.php/jias/article/view/17392 | http://dx.doi.org/10.7448/IAS.15.2.17392 9",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"Journal of the International AIDS Society 2012, 15:17392 http://www.jiasociety.org/index.php/jias/article/view/17392 | http://dx.doi.org/10.7448/IAS.15.2.17392 10",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"Journal of the International AIDS Society 2012, 15:17392 http://www.jiasociety.org/index.php/jias/article/view/17392 | http://dx.doi.org/10.7448/IAS.15.2.17392 11",Non-OADS,/arxiv_data1/oa_pdf/40/c6/JIAS-15-17392.PMC3494165.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in an y medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"[16]separate stigma from its responses and its effects andprovide a definition of stigma outside of the framework ofdiscrimination (enacted stigma) because not all stigma ideasresult in discrimination and not all discrimination arise fromAbrahams N and Jewkes R. Journal of the International AIDS Society 2012, 15:17330 http://www.jiasociety.org/index.php/jias/article/view/17330 | http://dx.doi.org/10.7448/IAS.15.2.17330 1",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"The project had two study nurses who provided psychological support to participants through a 24 hour cell phone line, and those who tested HIV-positive were also financially supported to accessAbrahams N and Jewkes R. Journal of the International AIDS Society 2012, 15:17330 http://www.jiasociety.org/index.php/jias/article/view/17330 | http://dx.doi.org/10.7448/IAS.15.2.17330 2",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"of interviews Treatment Employed ChildrenRelationship statusPartner HIV statusDisclosed to partnerDisclosed family/ friends/ othersClose family/ friends positive C1 F 28 2 ART 16/12 No Yes Dating Pos Yes Fa-S Fr-SNo E1 F 22 2 No No Yes Dating Ukn Yes Fa /C30SF r - S Y e s C2 F 34 2 ART 48/12 No Yes Broke-up C SingleEx-Ukn- Ex-Yes Full Yes E2 F 19 1 No No Yes Dating Ukn No Fa-S Fr-N No C3 M 38 3 ART 36/12 Yes Yes Dating Pos Yes Full No E3 F 24 2 No No Yes Dating Yes Yes Full No C4 F 36 2 ART 20/12 No Yes Single _ _ Fa-S Fr-SYes E4 F 23 2 No No No BF died Yes Yes Full No C5 F 39 2 ART 29/12 No Yes Cohab Ukn Yes Fa-N Fr-SYes E5 F 24 1 No No Yes Married Ukn Yes Fa-S Fr-N No C6 F 29 2 ART 15/12 No Yes Single _ _ Full Yes E6 F 20 2 ART No No BF died Yes Yes Full No C7 F 30 1 Prop Yes Yes Dating Ukn No Fa-S Fr-SNo E7 F 25 1 Tb Rx PropNo Yes Single Ukn Fa-S Fr-N No C8 F 28 2 ART 12/18 No Yes Cohab Pos Yes Fa-S Fr-SNo E8 F 25 2 Art No Yes Married Yes Yes Full No C9 F 24 2 ART 12/12 Yes No Broke-up C DatingEx-Ukn C-UknEx-Yes NoFa-S Fr-SNo E9 F 22 1 No No No Dating Yes Yes No No C10 F 22 1 ART 42/12 No Yes Married No Yes Fa-S Fr-NNo E10 F 24 2 No No Yes Dating Ukn No Fa-S Fr-S No C11 F 34 1 ART 16/12 Yes Yes Broke-up C-singleEx-Ukn Ex-Yes Fa-S Fr-SYes E11 F 22 2 No No Yes Married Ukn Yes Fa-S Fr-N No C12 F 32 2 ART 13/12 Yes Yes Dating Ukn No Fa-S Fr-NNo E12 F 21 2 No No Yes Dating Ukn Yes Fa-S Fr-N No C13 F 25 3 ART 33/12 No Yes Dating Ukn No Fa-S Fr-SYes E13 F 21 1 No No Yes Married Yes Yes Fa-S Fr-N No C14 F 30 1 Prop No No Single Ukn Yes Fa-S Fr-SYes E14 F 25 2 Prop No Yes Single Yes Yes Fa-S Fr-N No C15 F 30 1 ART 21/12 No yes Dating Pos Yes Full Yes E15 F 23 1 Prop No Yes Dating Ukn No Fa-S Fr-N No C16 M 33 2 ART 30/12 No Yes Cohab Pos Yes Fa-S Fr-SYes E16 M 25 2 No No No Dating Ukn No No No C17 F 33 1 Prop Yes Yes Cohat Ukn Yes Fa-N Fr-SYes E17 M 27 2 No No No Dating No Yes Fa-S Fr-N No C20 M 29 1 TB Rx Prop Yes Yes Dating Pos Yes Fa-S Fr-SYes E18 M 24 1 No No No Dating Ukn No Fa-N Fr-S No C21 F 28 2 Prop Yes No Divorce C-DatingEx-Pos C-UknEx-Yes C-NoFa-S Fr-SYes E19 M 23 2 Prop Yes No Dating Ukn Yes Full No C22 F 32 1 ART 35/12 No Yes Cohab Yes Yes Fa-N Fr-SYes E20 M 23 1 Prop No No Single No No C23 F 27 1 Prop No Yes Broke-up C-DatingEx-Pos C-UknEx-Yes C-NoFa-S Fr-SYes E21 M 21 1 No No No Dating Ukn No No No C1/C1C23/C30Cape Town participant; E1 /C1E21/C30Eastern Cape participant; M /C30Male; F /C30Female; ART /C30AntiRetroviral Therapy; C /C30current; Ukn /C30Unknown; Pos /C30Positive; Neg /C30Negative; Cohab/C30Cohabiting; Prop /C30prophylaxsis; TBRx /C30TB treatment; S /C30Selective; Full /C30Full disclosure; N /C30No; BF/C30Boyfriend; GF /C30Girlfriend; Fa /C30Family; Fr /C30Friend.Abrahams N and Jewkes R. Journal of the International AIDS Society 2012, 15:17330 http://www.jiasociety.org/index.php/jias/article/view/17330 | http://dx.doi.org/10.7448/IAS.15.2.17330 3",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"A young man from Mthatha described observing his friend being insulted saying ‘‘His mother always insulted him about his status and said, hey Nompuku, this thing that has got AIDS ...’’.Abrahams N and Jewkes R. Journal of the International AIDS Society 2012, 15:17330 http://www.jiasociety.org/index.php/jias/article/view/17330 | http://dx.doi.org/10.7448/IAS.15.2.17330 4",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"Social and HIV network of a Cape Town-based participant.Abrahams N and Jewkes R. Journal of the International AIDS Society 2012, 15:17330 http://www.jiasociety.org/index.php/jias/article/view/17330 | http://dx.doi.org/10.7448/IAS.15.2.17330 5",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"Their concern being that HIV positivity would be read as a sign of weakness, and used as a way of trying to contain their behaviour and thus reduce their independence, both would make them feelAbrahams N and Jewkes R. Journal of the International AIDS Society 2012, 15:17330 http://www.jiasociety.org/index.php/jias/article/view/17330 | http://dx.doi.org/10.7448/IAS.15.2.17330 6",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"For the four married women in Mthatha, their HIV status seemed to have solidified the marriage with one of the husband’s deciding to ‘‘dump hisgirlfriends’’ another wife saying ‘‘it’s been still between us’’ referring to the absence of conflict and the third saying ‘‘Marriage has got its own ups and downs but I never eventhink that those things are happening because I am HIVAbrahams N and Jewkes R. Journal of the International AIDS Society 2012, 15:17330 http://www.jiasociety.org/index.php/jias/article/view/17330 | http://dx.doi.org/10.7448/IAS.15.2.17330 7",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"Few participants in this study had personal experiences of discrimination, and the most harmful actions taken against them included insults and gossips which they could manage and deal with by opposing and resisting such labelling andAbrahams N and Jewkes R. Journal of the International AIDS Society 2012, 15:17330 http://www.jiasociety.org/index.php/jias/article/view/17330 | http://dx.doi.org/10.7448/IAS.15.2.17330 8",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"Almost all in the study had enlisted familyAbrahams N and Jewkes R. Journal of the International AIDS Society 2012, 15:17330 http://www.jiasociety.org/index.php/jias/article/view/17330 | http://dx.doi.org/10.7448/IAS.15.2.17330 9",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"2010;70(3):368 /C174.Abrahams N and Jewkes R. Journal of the International AIDS Society 2012, 15:17330 http://www.jiasociety.org/index.php/jias/article/view/17330 | http://dx.doi.org/10.7448/IAS.15.2.17330 10",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"J Commun Appl Soc Psychol.2006;16(6):498 /C1503.Abrahams N and Jewkes R. Journal of the International AIDS Society 2012, 15:17330 http://www.jiasociety.org/index.php/jias/article/view/17330 | http://dx.doi.org/10.7448/IAS.15.2.17330 11",Non-OADS,/arxiv_data1/oa_pdf/00/04/JIAS-15-17330.PMC3494166.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in an y medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
"Journal of the International AIDS Society 2012, 15:17334 http://www.jiasociety.org/index.php/jias/article/view/17334 | http://dx.doi.org/10.7448/IAS.15.2.17334 1",Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
"Journal of the International AIDS Society 2012, 15:17334 http://www.jiasociety.org/index.php/jias/article/view/17334 | http://dx.doi.org/10.7448/IAS.15.2.17334 2",Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
"Journal of the International AIDS Society 2012, 15:17334 http://www.jiasociety.org/index.php/jias/article/view/17334 | http://dx.doi.org/10.7448/IAS.15.2.17334 3",Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
"Journal of the International AIDS Society 2012, 15:17334 http://www.jiasociety.org/index.php/jias/article/view/17334 | http://dx.doi.org/10.7448/IAS.15.2.17334 4",Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
Available from: http://www.who.int/hiv/pub/progress_ report2011/en/index.html.,Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
Available from: http://www.unaids.org/globalreport/global_report.htm.,Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
Available from: http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2011/november/ 20111127aidsfunding/ 9.,Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
"Journal of the International AIDS Society 2012, 15:17334 http://www.jiasociety.org/index.php/jias/article/view/17334 | http://dx.doi.org/10.7448/IAS.15.2.17334 5",Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
2011. accessed 2011 July 17.Available from: http://utw.msfaccess.org.,Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
"Journal of the International AIDS Society 2012, 15:17334 http://www.jiasociety.org/index.php/jias/article/view/17334 | http://dx.doi.org/10.7448/IAS.15.2.17334 6",Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
Available from: http://www.lemonde.fr/idees/article/2011/04/05/l- attention-aux-malades-du-sida-barometrede-l-humanite_1502634_3232.html.,Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
"Journal of the International AIDS Society 2012, 15:17334 http://www.jiasociety.org/index.php/jias/article/view/17334 | http://dx.doi.org/10.7448/IAS.15.2.17334 7",Non-OADS,/arxiv_data1/oa_pdf/56/86/JIAS-15-17334.PMC3494167.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in an y medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4b/39/JIAS-15-17986.PMC3494169.pdf
"Journal of the International AIDS Society 2012, 15:17986 http://www.jiasociety.org/index.php/jias/article/view/17986 | http://dx.doi.org/10.7448/IAS.15.2.17986 1",Non-OADS,/arxiv_data1/oa_pdf/4b/39/JIAS-15-17986.PMC3494169.pdf
"Journal of the International AIDS Society 2012, 15:17986 http://www.jiasociety.org/index.php/jias/article/view/17986 | http://dx.doi.org/10.7448/IAS.15.2.17986 2",Non-OADS,/arxiv_data1/oa_pdf/4b/39/JIAS-15-17986.PMC3494169.pdf
"Journal of the International AIDS Society 2012, 15:17986 http://www.jiasociety.org/index.php/jias/article/view/17986 | http://dx.doi.org/10.7448/IAS.15.2.17986 3",Non-OADS,/arxiv_data1/oa_pdf/4b/39/JIAS-15-17986.PMC3494169.pdf
Available from: http://www.fda.gov/ForConsumers/ ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm122951.htm4.,Non-OADS,/arxiv_data1/oa_pdf/4b/39/JIAS-15-17986.PMC3494169.pdf
Available from: http://www.msfaccess.org/content/antiretroviral-sequencing-meeting-report 6.,Non-OADS,/arxiv_data1/oa_pdf/4b/39/JIAS-15-17986.PMC3494169.pdf
Available from: http://extranet.who.int/iris/bitstream/10665/70920/1/9789241503792_eng.pdf 18.,OADS,/arxiv_data1/oa_pdf/4b/39/JIAS-15-17986.PMC3494169.pdf
"Journal of the International AIDS Society 2012, 15:17986 http://www.jiasociety.org/index.php/jias/article/view/17986 | http://dx.doi.org/10.7448/IAS.15.2.17986 4",Non-OADS,/arxiv_data1/oa_pdf/4b/39/JIAS-15-17986.PMC3494169.pdf
"This is an open access article distributed under the terms of the Creative Commons Attributi on License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, pro vided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8d/0b/JIAS-15-17427.PMC3494170.pdf
"Journal of the International AIDS Society 2012, 15:17427 http://www.jiasociety.org/index.php/jias/article/view/17427 | http://dx.doi.org/10.7448/IAS.15.2.17427",Non-OADS,/arxiv_data1/oa_pdf/8d/0b/JIAS-15-17427.PMC3494170.pdf
"Journal of the International AIDS Society 2012, 15:17427 http://www.jiasociety.org/index.php/jias/article/view/17427 | http://dx.doi.org/10.7448/IAS.15.2.17427",Non-OADS,/arxiv_data1/oa_pdf/8d/0b/JIAS-15-17427.PMC3494170.pdf
"Journal of the International AIDS Society 2012, 15:17427 http://www.jiasociety.org/index.php/jias/article/view/17427 | http://dx.doi.org/10.7448/IAS.15.2.17427",Non-OADS,/arxiv_data1/oa_pdf/8d/0b/JIAS-15-17427.PMC3494170.pdf
"Journal of the International AIDS Society 2012, 15:17427 http://www.jiasociety.org/index.php/jias/article/view/17427 | http://dx.doi.org/10.7448/IAS.15.2.17427",Non-OADS,/arxiv_data1/oa_pdf/8d/0b/JIAS-15-17427.PMC3494170.pdf
"Journal of the International AIDS Society 2012, 15:17427 http://www.jiasociety.org/index.php/jias/article/view/17427 | http://dx.doi.org/10.7448/IAS.15.2.17427",Non-OADS,/arxiv_data1/oa_pdf/8d/0b/JIAS-15-17427.PMC3494170.pdf
"Journal of the International AIDS Society 2012, 15:17427 http://www.jiasociety.org/index.php/jias/article/view/17427 | http://dx.doi.org/10.7448/IAS.15.2.17427",Non-OADS,/arxiv_data1/oa_pdf/8d/0b/JIAS-15-17427.PMC3494170.pdf
"Available from: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf Geneva, 2006.",Non-OADS,/arxiv_data1/oa_pdf/8d/0b/JIAS-15-17427.PMC3494170.pdf
"Journal of the International AIDS Society 2012, 15:17427 http://www.jiasociety.org/index.php/jias/article/view/17427 | http://dx.doi.org/10.7448/IAS.15.2.17427",Non-OADS,/arxiv_data1/oa_pdf/8d/0b/JIAS-15-17427.PMC3494170.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in an y medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/dc/1e/JIAS-15-17380.PMC3494171.pdf
"Journal of the International AIDS Society 2012, 15:17380 http://www.jiasociety.org/content/15/2/17380 | http://dx.doi.org/10.7448/IAS.15.2.17380 1",Non-OADS,/arxiv_data1/oa_pdf/dc/1e/JIAS-15-17380.PMC3494171.pdf
"Journal of the International AIDS Society 2012, 15:17380 http://www.jiasociety.org/content/15/2/17380 | http://dx.doi.org/10.7448/IAS.15.2.17380 2",Non-OADS,/arxiv_data1/oa_pdf/dc/1e/JIAS-15-17380.PMC3494171.pdf
"Journal of the International AIDS Society 2012, 15:17380 http://www.jiasociety.org/content/15/2/17380 | http://dx.doi.org/10.7448/IAS.15.2.17380 3",Non-OADS,/arxiv_data1/oa_pdf/dc/1e/JIAS-15-17380.PMC3494171.pdf
"Journal of the International AIDS Society 2012, 15:17380 http://www.jiasociety.org/content/15/2/17380 | http://dx.doi.org/10.7448/IAS.15.2.17380 4",Non-OADS,/arxiv_data1/oa_pdf/dc/1e/JIAS-15-17380.PMC3494171.pdf
Available from: http://www.who.int/hiv/pub/mtct/guidelines/en/.4.,Non-OADS,/arxiv_data1/oa_pdf/dc/1e/JIAS-15-17380.PMC3494171.pdf
Available from: http://www.who.int/hiv/pub/2010progressreport/report/en/index.html.5.,OADS,/arxiv_data1/oa_pdf/dc/1e/JIAS-15-17380.PMC3494171.pdf
Available from: http://www.who.int/hiv/events/mtct/en/index.html.,OADS,/arxiv_data1/oa_pdf/dc/1e/JIAS-15-17380.PMC3494171.pdf
Available from: http://www.who.int/hiv/pub/vct/hiv_re_testing/en/index.html.,OADS,/arxiv_data1/oa_pdf/dc/1e/JIAS-15-17380.PMC3494171.pdf
Available from: http://www.cdc.gov/hiv/topics/testing/ressources/guidelines/rt-labor&delivery.htm.,Non-OADS,/arxiv_data1/oa_pdf/dc/1e/JIAS-15-17380.PMC3494171.pdf
"Journal of the International AIDS Society 2012, 15:17380 http://www.jiasociety.org/content/15/2/17380 | http://dx.doi.org/10.7448/IAS.15.2.17380 5",Non-OADS,/arxiv_data1/oa_pdf/dc/1e/JIAS-15-17380.PMC3494171.pdf
"This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduct ion in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d8/8f/JIAS-15-17376.PMC3494172.pdf
"Journal of the International AIDS Society 2012, 15:17376 http://www.jiasociety.org/index.php/jias/article/view/17376 | http://dx.doi.org/10.7448/IAS.15.2.17376 1",Non-OADS,/arxiv_data1/oa_pdf/d8/8f/JIAS-15-17376.PMC3494172.pdf
"Journal of the International AIDS Society 2012, 15:17376 http://www.jiasociety.org/index.php/jias/article/view/17376 | http://dx.doi.org/10.7448/IAS.15.2.17376 2",Non-OADS,/arxiv_data1/oa_pdf/d8/8f/JIAS-15-17376.PMC3494172.pdf
"Journal of the International AIDS Society 2012, 15:17376 http://www.jiasociety.org/index.php/jias/article/view/17376 | http://dx.doi.org/10.7448/IAS.15.2.17376 3",Non-OADS,/arxiv_data1/oa_pdf/d8/8f/JIAS-15-17376.PMC3494172.pdf
"Journal of the International AIDS Society 2012, 15:17376 http://www.jiasociety.org/index.php/jias/article/view/17376 | http://dx.doi.org/10.7448/IAS.15.2.17376 4",Non-OADS,/arxiv_data1/oa_pdf/d8/8f/JIAS-15-17376.PMC3494172.pdf
"Journal of the International AIDS Society 2012, 15:17376 http://www.jiasociety.org/index.php/jias/article/view/17376 | http://dx.doi.org/10.7448/IAS.15.2.17376 5",Non-OADS,/arxiv_data1/oa_pdf/d8/8f/JIAS-15-17376.PMC3494172.pdf
"Journal of the International AIDS Society 2012, 15:17376 http://www.jiasociety.org/index.php/jias/article/view/17376 | http://dx.doi.org/10.7448/IAS.15.2.17376 6",Non-OADS,/arxiv_data1/oa_pdf/d8/8f/JIAS-15-17376.PMC3494172.pdf
Available from: http://www.who.int/ reproductive-health/publications/conrad who/Conrad.doc 15.,Non-OADS,/arxiv_data1/oa_pdf/d8/8f/JIAS-15-17376.PMC3494172.pdf
Available from: http://www.amstat.org/publications/jse/secure/v8n2/levin.cfm 16.,OADS,/arxiv_data1/oa_pdf/d8/8f/JIAS-15-17376.PMC3494172.pdf
"Journal of the International AIDS Society 2012, 15:17376 http://www.jiasociety.org/index.php/jias/article/view/17376 | http://dx.doi.org/10.7448/IAS.15.2.17376 7",Non-OADS,/arxiv_data1/oa_pdf/d8/8f/JIAS-15-17376.PMC3494172.pdf
"Journal of the International AIDS Society 2012, 15:17376 http://www.jiasociety.org/index.php/jias/article/view/17376 | http://dx.doi.org/10.7448/IAS.15.2.17376 8",Non-OADS,/arxiv_data1/oa_pdf/d8/8f/JIAS-15-17376.PMC3494172.pdf
"This is an open access article distributed under the terms of the Creative Commons Attributi on License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, pro vided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
"Journal of the International AIDS Society 2012, 15:17432 http://www.jiasociety.org/index.php/jias/article/view/17432 | http://dx.doi.org/10.7448/IAS.15.2.17432 1",Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
"Journal of the International AIDS Society 2012, 15:17432 http://www.jiasociety.org/index.php/jias/article/view/17432 | http://dx.doi.org/10.7448/IAS.15.2.17432 2",Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
"Journal of the International AIDS Society 2012, 15:17432 http://www.jiasociety.org/index.php/jias/article/view/17432 | http://dx.doi.org/10.7448/IAS.15.2.17432 3",Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
"Journal of the International AIDS Society 2012, 15:17432 http://www.jiasociety.org/index.php/jias/article/view/17432 | http://dx.doi.org/10.7448/IAS.15.2.17432 4",Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
"Journal of the International AIDS Society 2012, 15:17432 http://www.jiasociety.org/index.php/jias/article/view/17432 | http://dx.doi.org/10.7448/IAS.15.2.17432 5",Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
"Journal of the International AIDS Society 2012, 15:17432 http://www.jiasociety.org/index.php/jias/article/view/17432 | http://dx.doi.org/10.7448/IAS.15.2.17432 6",Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
"Journal of the International AIDS Society 2012, 15:17432 http://www.jiasociety.org/index.php/jias/article/view/17432 | http://dx.doi.org/10.7448/IAS.15.2.17432 7",Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
Available from: http://www.hivunitmohmw.org/uploads/Main/Malawi%20ART%20Guidelines%203rd%20Edition.17.,Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
Available from: http://www.who.int/hiv/ events/paediatricmeetingreport.pdf.18.,Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
Available from: http://www.who.int/hiv/paediatric/generictool/en/.19.,Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
Available from: http://www.who.int/healthsystems/task_shifting_ booklet.pdf.23.,Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
Available from:http://www.hivunitmohmw.org/Main/AntiretroviralTherapy.30.,Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194149/?tool=pubmed.35.,Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
Available from:http://www.doctorswithoutborders.org/publications/reports/2010/MSF-No-Time-to-Quit-HIV-AIDS.pdf.36.,Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
Available from: http://www.docstoc.,Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
"Journal of the International AIDS Society 2012, 15:17432 http://www.jiasociety.org/index.php/jias/article/view/17432 | http://dx.doi.org/10.7448/IAS.15.2.17432 8",Non-OADS,/arxiv_data1/oa_pdf/ae/56/JIAS-15-17432.PMC3494175.pdf
This paper is available on line at http://www.mcponline.org 1500 Molecular & Cellular Proteomics 11.11,OADS,/arxiv_data1/oa_pdf/bb/ca/zjw1500.PMC3494176.pdf
The webserver is located athttp://www.biochem.mpg.de/mann/tools/and its graphical in-terface is shown in Fig.,OADS,/arxiv_data1/oa_pdf/bb/ca/zjw1500.PMC3494176.pdf
This paper is available on line at http://www.mcponline.org Molecular & Cellular Proteomics 11.11 1289,Non-OADS,/arxiv_data1/oa_pdf/77/d0/zjw1289.PMC3494187.pdf
This paper is available on line at http://www.mcponline.org 1510 Molecular & Cellular Proteomics 11.11,OADS,/arxiv_data1/oa_pdf/28/62/zjw1510.PMC3494197.pdf
"velopment version 1.2.7.1, http://www.maxquant.org/) ( 38, 39).",Non-OADS,/arxiv_data1/oa_pdf/28/62/zjw1510.PMC3494197.pdf
Pep - tide ion masses and fragment spectra were searched against theSaccharomyces Genome Database (SGD) ( 40) release 63 containing 6717 putative protein sequences (http://downloads.yeastgenome.,OADS,/arxiv_data1/oa_pdf/28/62/zjw1510.PMC3494197.pdf
The miss - ing regions/loops in the crystal structure were modeled using modeler(49) via the MODWEB (http://salilab.org/modweb) and MODLOOP (http://salilab.org/modloop) servers.,OADS,/arxiv_data1/oa_pdf/28/62/zjw1510.PMC3494197.pdf
This paper is available on line at http://www.mcponline.org Molecular & Cellular Proteomics 11.11 1489,Non-OADS,/arxiv_data1/oa_pdf/2f/dd/zjw1489.PMC3494207.pdf
Eluted peptides were dried and sent to the PNACfacility in Cambridge (http://www.bioc.cam.ac.uk/pnac/aaa.hml) foramino acid analysis on a Biochrome 30 Analyzer.,OADS,/arxiv_data1/oa_pdf/2f/dd/zjw1489.PMC3494207.pdf
Datawas uploaded to the central proteomics facilities pipeline (CPFPat: https://cpfp-master.molbiol.ox.ac.uk/cpfp_demo/auth/login) ( 29).,OADS,/arxiv_data1/oa_pdf/2f/dd/zjw1489.PMC3494207.pdf
Mass spectrometry data are available athttp://www.peptideatlas.org/PASS/PASS00081.,OADS,/arxiv_data1/oa_pdf/2f/dd/zjw1489.PMC3494207.pdf
"4 1, No.9,Sep2012, pp.1-9 Review Article 1 Available at: http://ijph.tums.ac.ir The Iranian Health Insurance System; Past Experiences, Present Challenges And Future Strategies *M Davari1, A Haycox2, T Walley3 1.Health Management & Economics Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran 2.Regional and International Economic Development, University of Liverpool, Liverpool, UK 3.Dept.",Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
":The Iranian Health Insurance System … Available at: http://ijph.tums.ac.ir 2Due to the limited p ublished materials, much of the evidence concerning delivery of health care services was obtained through these face -to-face interviews.",Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
"4 1, No.9,Sep2012, pp.1-9 3 Available at: http://ijph.tums.ac.iremphasise the importance of the health insurance services.",Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
":The Iranian Health Insurance System … Available at: http://ijph.tums.ac.ir 4Governmental em ployees, those in rural areas and specific groups such as students receive govern - ment subsidies.",Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
"4 1, No.9,Sep2012, pp.1-9 5 Available at: http://ijph.tums.ac.irdecade.",Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
:The Iranian Health Insurance System … Available at: http://ijph.tums.ac.ir 6Considering simply affordability as the sole criteria for accepting or rejecting new health technologies may lead HIOs to avoid the introduction of potentially cost-effective health technologies or to introduce others that are managed inefficiently.,Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
"4 1, No.9,Sep2012, pp.1-9 7 Available at: http://ijph.tums.ac.irrevenue of every HIOs with the exception of SSIO and consequently on their services.",Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
:The Iranian Health Insurance System … Available at: http://ijph.tums.ac.ir 8might be because such changes mainly originated from political pressure rather than evidence based policy.,Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
Available from: http://www.tamin.ir/ 5.Anonymous (201 0).,Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
"Retrieved Dec. 2010, Available from: http://www.emdad.ir.",Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
Available from : http://msio.org.ir/ 8.Anonymous (2006).,Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
"Available from : http://www.sci.org.ir/portal/faces/public/ sci_en 9.Davari M, Maraci MR, Bakhshizade Z, Aslani A.",Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
"Fars news agency .Available from: http://farsnews.com/ 12.Davari M, Haycox A, Walley T (2012).",Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
"4 1, No.9,Sep2012, pp.1-9 9 Available at: http://ijph.tums.ac.ir13.Davari M, Haycox A, Walley T (2012).",Non-OADS,/arxiv_data1/oa_pdf/1a/c1/ijph-41-1.PMC3494208.pdf
"4 1, No.9,Sep2012, pp.10-17 ReviewArticle 1 Available at: http://ijph.tums.ac.ir Molecular Epidemiology of Human Intestinal Amoebas in Iran * H Hooshyar1, P Rostamkhani1, M Rezaian2 1.Dept.",Non-OADS,/arxiv_data1/oa_pdf/e3/5f/ijph-41-10.PMC3494209.pdf
:Molecular Epidemiology of Human Intestinal Amoebas … 11 Available at: http://ijph.tums.ac.irin different parts of the Iran (5 -7).,Non-OADS,/arxiv_data1/oa_pdf/e3/5f/ijph-41-10.PMC3494209.pdf
"4 1, No.9,Sep2012, pp.10-17 Available at: http://ijph.tums.ac.ir 12PCR technique showed that all the isolates were E. dispar(14).",Non-OADS,/arxiv_data1/oa_pdf/e3/5f/ijph-41-10.PMC3494209.pdf
:Molecular Epidemiology of Human Intestinal Amoebas … 13 Available at: http://ijph.tums.ac.irTable 1:Prevalence of E. histolytica andE.,Non-OADS,/arxiv_data1/oa_pdf/e3/5f/ijph-41-10.PMC3494209.pdf
"4 1, No.9,Sep2012, pp.10-17 Available at: http://ijph.tums.ac.ir 14Isoenzyme analysis of 23 isolate of Entamoeba in south of Iran, cultured in Robinson's medium by Sahebani et al.",Non-OADS,/arxiv_data1/oa_pdf/e3/5f/ijph-41-10.PMC3494209.pdf
:Molecular Epidemiology of Human Intestinal Amoebas … 15 Available at: http://ijph.tums.ac.irDiscussion Intestinal protozoan infections (e.g.,Non-OADS,/arxiv_data1/oa_pdf/e3/5f/ijph-41-10.PMC3494209.pdf
"4 1, No.9,Sep2012, pp.10-17 Available at: http://ijph.tums.ac.ir 164.John TD, Petri WA (2006).",Non-OADS,/arxiv_data1/oa_pdf/e3/5f/ijph-41-10.PMC3494209.pdf
":Molecular Epidemiology of Human Intestinal Amoebas … 17 Available at: http://ijph.tums.ac.irPCR-RFLP (Isolate of Tehran, Iran).",Non-OADS,/arxiv_data1/oa_pdf/e3/5f/ijph-41-10.PMC3494209.pdf
"4 1, No.9,Sep2012, pp.18-24 Original Article 18 Available at: http://ijph.tums.ac.ir Life Expectancy at Birth in Rural Areas Based on Corrected Data of the Iranian Vital Horoscope ME Motlagh1, R Safari2, M Karami3, *A Khosravi4 1.Dept.",Non-OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
":Life Expectancy at Birth in Rural Areas … Available at: http://ijph.tums.ac.ir 19Health and Medical Education (MoH&ME), Deputy of Health operated a na tional program for death registration science 1999.",Non-OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
"4 1, No.9,Sep2012, pp.18-24 20 Available at: http://ijph.tums.ac.irand 2 represent the life table sfor males and fe - malesinrural area sforIran 2008, respectively.",Non-OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
"4 1, No.9,Sep2012, pp.18-24 20 Available at: http://ijph.tums.ac.irand 2 represent the life table sfor males and fe - malesinrural area sforIran 2008, respectively.",Non-OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
"4 1, No.9,Sep2012, pp.18-24 20 Available at: http://ijph.tums.ac.irand 2 represent the life table sfor males and fe - malesinrural area sforIran 2008, respectively.",Non-OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
":Life Expectancy at Birth in Rural Areas … Available at: http://ijph.tums.ac.ir 21Table2:Lifetable for females ,rural population ,Iran, 2008Age group Years in Interval National Population Adjusted Deaths Mortality Rate Linearity Adjustment Probability of Dying Probability of Surviving Individuals Surviving Deaths in Interval x Years Lived in Interval x Cumulative Years Lived Expectancy of Life at Age x n nNx nDxnMxax nqx npxlx ndx nLxTx ex 01178948 35330.0197 0.3 0.019 0.981 100,000 1,94798,637 7,439,118 74.39 1-44661279 7420.0011 0.4 0.004 0.996 98,053 439391,158 7,340,481 74.86 5-95770046 3860.0005 0.5 0.003 0.997 97,892 245488,846 6,969,094 71.19 10-145949206 3620.0004 0.5 0.002 0.998 97,646 186487,767 6,480,249 66.36 15-1951255395 7870.0006 0.5 0.003 0.997 97,460 305486,539 5,992,482 61.49 20-2451207907 9290.0008 0.5 0.004 0.996 97,155 373484,844 5,505,942 56.67 25-295957477 7540.0008 0.5 0.004 0.996 96,782 380482,962 5,021,098 51.88 30-345741392 6580.0009 0.5 0.004 0.996 96,402 427480,943 4,538,136 47.08 35-395614787 7330.0012 0.5 0.006 0.994 95,975 571478,448 4,057,193 42.27 40-445479294 8080.0017 0.5 0.008 0.992 95,404 801475,018 3,578,745 37.51 45-495441068 12600.0029 0.5 0.014 0.986 94,603 1,341469,662 3,103,726 32.81 50-545388817 16880.0043 0.5 0.021 0.979 93,262 2,003461,302 2,634,064 28.24 55-595310791 23440.0075 0.5 0.037 0.963 91,259 3,378447,851 2,172,762 23.81 60-645232518 29170.0125 0.5 0.061 0.939 87,881 5,345426,044 1,724,911 19.63 65-695192883 42050.0218 0.5 0.103 0.897 82,536 8,531391,353 1,298,866 15.74 70-745185401 66490.0359 0.5 0.165 0.835 74,005 12,178339,578 907,513 12.26 75-795132144 82670.0626 0.5 0.271 0.729 61,826 16,724267,321 567,935 9.19 80-84574680 85070.1139 0.5 0.443 0.557 45,102 19,995175,522 300,614 6.67 85+534731 69710.2007 1 0.000 25,107 25,107125,092 125,092 4.98 Discussion This study primarily designed to estimate life e x- pectanciesat birth for Iranian rural population, also to assess the application of Vital Horoscope system as a source of mortality information.",Non-OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
"4 1, No.9,Sep2012, pp.18-24 22 Available at: http://ijph.tums.ac.irto calculate the health indices incl uding mortality indices but there were no adjustment for death underreporting this may result in over estimation of the life expectancy in the previous studies.",Non-OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
":Life Expectancy at Birth in Rural Areas … Available at: http://ijph.tums.ac.ir 23tors, it is strongly recommended to investigate the accuracy of data from this system.",Non-OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
"Available from: http://www.statistics.gov.uk/hub/search/i n- x.html?newquery=Life+expectancy+at+bir th%3A+metho dological+options+for+sm all+ 8.Silcocks PB, Jenner DA, Reza R (2001).",OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
Summary Measures of Pop u- lation Health reports on finding and met h- odological and data issue CDC .Available from: http://www.cdc.gov/nchs/data/misc/po - phealth.pdf 11.Byass P (2007).,OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
"Available from: http://www.who.int/healthmetrics/docu - ments/hm nassessment_irn.pdf 13.Mehryar AH, Naghavi M,  Ahmad -Nia S, Kazemipour S (2008).",OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
"4 1, No.9,Sep2012, pp.18-24 24 Available at: http://ijph.tums.ac.ir18.Ghaffarian Shirazi HR, Chaman R, Ghorbani A, Hatami Pour E, Zadeh Bagheri Gh, Ja bar Nejad(2005).",Non-OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
Available from : http://www.who.int/gho/publications/wo rld_health_statistics/WHS2012_Indicator - Compendium.pdf 24.WHO (2010).,Non-OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
Millennium Develop - ment Goals .Available from: http://msja.anu.edu.au/archive/issue/01/ mdgs.php 27.WHO (1983).,Non-OADS,/arxiv_data1/oa_pdf/f0/e0/ijph-41-18.PMC3494210.pdf
"4 1, No.9,Sep2012, pp.25-30 Original Article 25 Available at: http://ijph.tums.ac.ir Preoperative Informed Consent: Is It Truly Informed?",Non-OADS,/arxiv_data1/oa_pdf/4e/cc/ijph-41-25.PMC3494211.pdf
":Preoperative Informed Consent … Available at: http://ijph.tums.ac.ir 26establish this, the patient’s right to autonomy must be respected, even if their decision results in harm or death.",Non-OADS,/arxiv_data1/oa_pdf/4e/cc/ijph-41-25.PMC3494211.pdf
"4 1, No.9,Sep2012, pp.25-30 27 Available at: http://ijph.tums.ac.ircomplications.",Non-OADS,/arxiv_data1/oa_pdf/4e/cc/ijph-41-25.PMC3494211.pdf
":Preoperative Informed Consent … Available at: http://ijph.tums.ac.ir 28importantly, it is a process of a detailed discussion between the doctor and the patient.",Non-OADS,/arxiv_data1/oa_pdf/4e/cc/ijph-41-25.PMC3494211.pdf
"4 1, No.9,Sep2012, pp.25-30 29 Available at: http://ijph.tums.ac.irpatient clinic and final consent for surgery when admitted to the ward (16).Most patients in this study gave pre -operative consent in less than per - fect circumstances, as they had already been through the admission process and were within 24 hours of surgery and even in few instances on the operating table.",Non-OADS,/arxiv_data1/oa_pdf/4e/cc/ijph-41-25.PMC3494211.pdf
:Preoperative Informed Consent … Available at: http://ijph.tums.ac.ir 30Acknowledgements The authors declare that there is no conflict of interest.,Non-OADS,/arxiv_data1/oa_pdf/4e/cc/ijph-41-25.PMC3494211.pdf
"4 1, No.9,Sep2012, pp.31-35 Original Article 31 Available at: http://ijph.tums.ac.ir Publication Rates of Public Health Theses in International and National Peer -Review Journals in Turkey *H Sipahi1, R Durusoy2, I Ergin2, H Hassoy2, A Davas2, AO Karababa2 1.Bornova Community Health Center, 35040 Izmir, Turkey 2.Dept.of Public Health, Faculty of Medicine ,Ege University, 35040, Izmir, Turkey *Corresponding Author: Tel:+9090 505 8162209 ,E-mail address: hilalsipahi@mail.ege.edu.tr (Received 11May2012; accepted 20Jul2012) Introduction Scientific research is an integral part of postgradu - ate studies, aimed at teaching future scientists how to formulate a research question, to choose the proper scientific method, to carry out the research, to present research data and to achieve clear and simple conclusions.",Non-OADS,/arxiv_data1/oa_pdf/f4/c9/ijph-41-31.PMC3494212.pdf
:Publication Rates of Public Health Theses … Available at: http://ijph.tums.ac.ir 32of the theses disseminates new knowledge and completes the scientific study process (3).,Non-OADS,/arxiv_data1/oa_pdf/f4/c9/ijph-41-31.PMC3494212.pdf
"Between 31 March and 5 May 2010, the publica tion status of these theses was searched in Pub Med, Science Citation Index -Expanded (SCI -E) database, Turkish Academic Network and Informa tion Center (ULAKBIM) Turkish Medical Database, an d Turkish Medline ( http://www.medline.pleksus.com.tr )for authorandmentor of the thesis.",Non-OADS,/arxiv_data1/oa_pdf/f4/c9/ijph-41-31.PMC3494212.pdf
"4 1, No.9,Sep2012, pp.31-35 33 Available at: http://ijph.tums.ac.irTable 1:Distribution of theses and publications according to research areas Research areasDoctorate Theses Specialization Theses TOTAL nPublication nPublicationTheses (%n/Total theses)Publica- tion (%)National (%n/Docto rate theses)International (%n/Docto - rate theses)National (%n/Speciali - zation Theses)International (%n/Speciali - zation Theses) Occupational health5210 (19) 6 (12) 29 4 (14) 2 (7) 81 22 (27) Reproductive health295 (17) 3 (10) 4711 (23) 5 (11) 76 24 (32) Infectious dis - eases and im - munization284 (14) 1 (4) 36 7 (19) 8 (22) 64 20 (31) Health admin - istration254 (16) 1 (4) 24 5 (21) 1 (4) 49 11 (23) Chronic dis - eases193 (16) 1 (5) 28 7 (25) 4 (14) 47 15 (32) Child and ado - lescent health – school health131 (8) 4(31) 33 5 (15) 11 (33) 46 21 (46) Other areas 182 (11) 2 (11) 13 2 (15) 1 (8) 31 6 (19) Environmental heath111 (9) 021 3 (14) 2 (10) 32 2 (6) Health eco - nomics70 1 (14) 12 0 1 (8) 19 2 (11) Psychiatry 81 (13) 4 (50) 10 1 (10) 1 (10) 18 7 (39) Smoking-alco- hol-drugs81 (13) 1 (13) 86 (75) 2 (25) 16 10 (63) Health educa - tion90 0 72 (29) 1 (14) 16 3 (19) Nutrition 30 012 5 (42) 0 15 5 (33) Geriatrics 64 (67) 0 92 (22) 0 15 6 (40) Medical educa - tion50 0 3 0 1 (33) 8 1 (13) Emergencies and accidents20 0 31 (33) 0 5 1 (20) TOTAL24 336 (14.8) 24 (9.9)29 561 (20.7) 40 (13.6) 538161 (29.9) Type of thesis (doctorate / specialization) did not have a significant effect on publication rates, nei - ther nationally, nor internationally w hereas theses after 2001 and later had significantly higher international publication rates when compared with theses before (15 / 302 vs. 45 / 236, Chi - square = 25.18, P:0.0001) but similar national publication rate s(51 / 302 vs. 38 / 236, Chi - square = 0.016, P:0.89).",Non-OADS,/arxiv_data1/oa_pdf/f4/c9/ijph-41-31.PMC3494212.pdf
":Publication Rates of Public Health Theses … Available at: http://ijph.tums.ac.ir 34usually available in the university libraries in the language where the thesis is performed but not in international databases (2,3).Thesis is an impor - tant part of specialization and doctorate education and requires intense work.",Non-OADS,/arxiv_data1/oa_pdf/f4/c9/ijph-41-31.PMC3494212.pdf
"4 1, No.9,Sep2012, pp.31-35 35 Available at: http://ijph.tums.ac.irbases.",Non-OADS,/arxiv_data1/oa_pdf/f4/c9/ijph-41-31.PMC3494212.pdf
Available from: http://www.yok.gov.tr/uak/temelalanlar/tablo1 0.pdf,Non-OADS,/arxiv_data1/oa_pdf/f4/c9/ijph-41-31.PMC3494212.pdf
"4 1, No.9,Sep2012, pp.36-41 Original Article 36 Available at: http://ijph.tums.ac.ir The Effect of Aerobic Exercise on Serum C -Reactive Protein and Leptin Levels in Untrained Middle -Aged Women N Bijeh1, SR Attarzadeh Hosseini2, *K Hejazi1 1.Faculty of Physical Education and Sport Sciences, Ferdowsi University of Mashhad, Mashhad, Iran 2.Dept.",Non-OADS,/arxiv_data1/oa_pdf/1b/92/ijph-41-36.PMC3494213.pdf
":The Effect of Aerobic Exercise on Serum C … 37 Available at: http://ijph.tums.ac.irwhite fat, plays a key role in controlling cen tral me- tabolism of the body and its weight.",Non-OADS,/arxiv_data1/oa_pdf/1b/92/ijph-41-36.PMC3494213.pdf
"4 1, No.9,Sep2012, pp.36-41 Available at: http://ijph.tums.ac.ir 38vice.",Non-OADS,/arxiv_data1/oa_pdf/1b/92/ijph-41-36.PMC3494213.pdf
":The Effect of Aerobic Exercise on Serum C … 39 Available at: http://ijph.tums.ac.irAlso, there were no significant differences be - tweengroups in the levels of CRP and leptin.",Non-OADS,/arxiv_data1/oa_pdf/1b/92/ijph-41-36.PMC3494213.pdf
"4 1, No.9,Sep2012, pp.36-41 Available at: http://ijph.tums.ac.ir 40redundancy, etc) have been completely ob served by the authors.",Non-OADS,/arxiv_data1/oa_pdf/1b/92/ijph-41-36.PMC3494213.pdf
":The Effect of Aerobic Exercise on Serum C … 41 Available at: http://ijph.tums.ac.irinflammatory cytokines and C -reactive protein.Med Sci Sports Exerc, 39 (10):1714 -9.",Non-OADS,/arxiv_data1/oa_pdf/1b/92/ijph-41-36.PMC3494213.pdf
"4 1, No.9,Sep2012, pp.42-47 Original Article 42 Available at: http://ijph.tums.ac.ir Aflatoxin Contamination in Wheat Flour Samples from Golestan Province, Northeast of Iran N Taheri1, S Semnani1, G Roshandel1, M Namjoo2, H Keshavarzian3, AG Chogan3, F Ghasemi Kebria1,*H Joshaghani1 1.Golestan Research center of Gastroenterology and Hepatology, Golestan University of Medical Sciences;.",Non-OADS,/arxiv_data1/oa_pdf/ab/d5/ijph-41-42.PMC3494214.pdf
":Aflatoxin Contamination in Wheat Flour Samples … 43 Available at: http://ijph.tums.ac.irmycotoxins that a re known to cause human diseases, aflatoxins have been studied most (2).",Non-OADS,/arxiv_data1/oa_pdf/ab/d5/ijph-41-42.PMC3494214.pdf
"4 1, No.9,Sep2012, pp.42-47 Available at: http://ijph.tums.ac.ir 44qualitative and q uantitative variables theStudentt- test was used .",Non-OADS,/arxiv_data1/oa_pdf/ab/d5/ijph-41-42.PMC3494214.pdf
:Aflatoxin Contamination in Wheat Flour Samples … 45 Available at: http://ijph.tums.ac.irTable 3: relationships between aflatoxin levels and characteristics of silos in two seasons* Types of aflatoxin G1 G2 B1 B2 Total Temperaturesummer0.12 (0.22)0.21 (0.36)0.22 (0.02)0.21 (0.04)0.21 (0.03) winter0.11 (0.28)0.10 (0.33)0.16 (0.10)0.02 (0.79)0.08 (0.41) Humiditysummer0.07 (0.49)0.24 (0.01)0.21 (0.03)0.20 (0.04)0.21 (0.03) winter0.13 (0.18)0.13 (0.20)0.33 (0.00)0.01 (0.85)0.24 (0.01) Storage duration of wheatsummer0.12 (0.21)0.05 (0.62)0.04 (0.63)0.08 (0.42)0.06 (0.50) winter0.26 (0.00)0.13 (0.21)0.15 (0.14)0.15 (0.13)0.15 (0.12) Storage duration of floursummer0.12 (0.21)0.05 (0.62)0.04 (0.63)0.08 (0.42)0.06 (0.50) winter0.26 (0.00)0.13 (0.21)0.15 (0.14)0.15 (0.13)0.15 (0.12) *Each cell represents Pearson correlation coefficient (P -value) Discussion The results showed that the incidences of afla toxin in wheat flour in winter and summer were respectively about 99% and 70%.,OADS,/arxiv_data1/oa_pdf/ab/d5/ijph-41-42.PMC3494214.pdf
"4 1, No.9,Sep2012, pp.42-47 Available at: http://ijph.tums.ac.ir 46in winter was higher than summer.",Non-OADS,/arxiv_data1/oa_pdf/ab/d5/ijph-41-42.PMC3494214.pdf
:Aflatoxin Contamination in Wheat Flour Samples … 47 Available at: http://ijph.tums.ac.irmycotoxins in staple cereals from Ethiopia.,Non-OADS,/arxiv_data1/oa_pdf/ab/d5/ijph-41-42.PMC3494214.pdf
"4 1, No.9,Sep2012, pp.48-55 Original Article 48 Available at: http://ijph.tums.ac.ir Community Capacity Assessment in Preventing Substance Abuse: A Participatory Approach KH Shahandeh1, R Majdzadeh1,2,*E Jamshidi1, N Loori1 1.Center for Community Based Participatory Research, Tehran University of Medical Sciences, Tehran, Iran 2.Dept.",Non-OADS,/arxiv_data1/oa_pdf/e4/4c/ijph-41-48.PMC3494215.pdf
":Community Capacity Assessment in Preventing Substance Abuse … 49 Available at: http://ijph.tums.ac.irknowledge about resources and allowed them to explain in detail the problem in their community (5).Manyauthors argue that it is appropriate to assess capacity in relation to a specific object or objective of change; that is, ‘capacity for what’.",Non-OADS,/arxiv_data1/oa_pdf/e4/4c/ijph-41-48.PMC3494215.pdf
"4 1, No.9,Sep2012, pp.48-55 Available at: http://ijph.tums.ac.ir 50est matrix diagram.",Non-OADS,/arxiv_data1/oa_pdf/e4/4c/ijph-41-48.PMC3494215.pdf
":Community Capacity Assessment in Preventing Substance Abuse … 51 Available at: http://ijph.tums.ac.irTable 1:Stakeholders' expectations, benefits and their impact on prevention drug abuse Type of stakeholder Expectations and Benefits ImpactPrimary stake holdersTrustees/ informed citizens Clergy-Increase Social capital and quality of social interactions -Opportunities for engagement, action to facilitate social change, -religious influence-/+ + + Local NGOs Alanan & Naranan-Increase Social capital and quality of social interactions -Quality of engagement, social and civic participation,+ -/+ Parent-teacher associa - tion TeachersInvolve local community members in decision –making?",Non-OADS,/arxiv_data1/oa_pdf/e4/4c/ijph-41-48.PMC3494215.pdf
"4 1, No.9,Sep2012, pp.48-55 Available at: http://ijph.tums.ac.ir 52Table 2:Stakeholders' importance and power/ influence Power / influence 1-Low, 2-Mediums, 3-HighImportance 1-Low, 2-Mediums, 3-HighKey Stakeholders 3 3 Trustees/ inform citizen 2 3Narcotics Anonymous (NA)/ local NGO (Ala - nan, Naranan) 1 3 Family /Friends/ Neighbors 1 3 Adolescents 1 3 Youth 1 3 Men/ parent 1 3 Women/Parent/ Female headed households 2 1 Academics/ Research center 3 3 Community -based Organization CBO 3 2 Police 2 1 Religious Leader/ Clergy 2 2 Teachers 2 1 Service providers 1 1 The Media Table 3:Participation Matrix -level of participation based on stage of community -based participatory research Stage Inform Consult Partnership Control Needs assessmentyouth, adoles - cents parent, clergy, school personnelclergy, parent, school personnel, teacher, social worker, police,Trustees.",Non-OADS,/arxiv_data1/oa_pdf/e4/4c/ijph-41-48.PMC3494215.pdf
":Community Capacity Assessment in Preventing Substance Abuse … 53 Available at: http://ijph.tums.ac.irTable 4:Percentage of participants agreeing with 7 statements about level of participatory on drug preven - tion statementPercentage agreeing Passive participation : People are told what is going to happen 90 Nominal Participation: Participation by giving information, Questions asked by outsiders are ans - wered70 Participation by consultation: People are consulted but have no part in decision -making.",Non-OADS,/arxiv_data1/oa_pdf/e4/4c/ijph-41-48.PMC3494215.pdf
"4 1, No.9,Sep2012, pp.48-55 Available at: http://ijph.tums.ac.ir 54institutional function with two subcategories of management and program delivery, and institu - tional condition with subcategories of leadership.",Non-OADS,/arxiv_data1/oa_pdf/e4/4c/ijph-41-48.PMC3494215.pdf
:Community Capacity Assessment in Preventing Substance Abuse … 55 Available at: http://ijph.tums.ac.ir& health Services grant No 4283-62-03-86.The au- thors declare that there is no conflict of interest .,Non-OADS,/arxiv_data1/oa_pdf/e4/4c/ijph-41-48.PMC3494215.pdf
"4 1, No.9,Sep2012, pp.56-61 Original Article 56 Available at: http://ijph.tums.ac.ir Prevalence of Hepatitis C Virus Genotypes in Mashhad, Northeast Iran H Vossughinia1, LA Goshayeshi1, H Rafatpanah Bayegi2, H Sima1, A Kazemi1, S Erfani1, S Abedini1, LEGoshayeshi3,K Ghaffarzadegan4,H Nomani3, *S Amel Jamehdar3 1.Dept.",Non-OADS,/arxiv_data1/oa_pdf/4b/84/ijph-41-56.PMC3494216.pdf
:Prevalence of Hepatitis C Virus Genotypes … 57 Available at: http://ijph.tums.ac.irassessment to plan primary prevention actions in any given population is essential (1).,Non-OADS,/arxiv_data1/oa_pdf/4b/84/ijph-41-56.PMC3494216.pdf
"4 1, No.9,Sep2012, pp.56-61 Available at: http://ijph.tums.ac.ir 58Table1:oligonucleotide primers used for genotyping of Hepatitis C Primer Nucleotide posi - tionSequence (5 -3) S2 core protein GGGAGGTCTCGTAGACCGTGCACCATG A2 core protein GAG(AC)GG(GT)AT(AG)TACCCCATGAG(AG)TCGGC S7 core protein AGACCGTGCACCATGAGCAC S2a core protein AACACTAACCGTCGCCCACAA G1a core protein GGATAGGCTGACGTCTACCT G1b core protein CCTGCCCTCGGGTTGGCTA(AG) G2a core protein CACGTGGCTGGGATCGCTCC G2b core protein GGCCCCAATTAGGACGAGAC G3a core protein GCCCAGGACCGGCCTTCGCT G3b core protein CGCTCGGAAGTCTTACGTAC G4 core protein CCCGGGAACTTAACGTCCAT G5a core protein GAACCTCGGGGGGAGAGCAA G6a core protein GGTCATTGGGGCCCCAATGT Then, 0.5 µl of ﬁrst-round PCR product was used and two PCR reactions were carried out for each sample, one with primer mix 1 and the other with mix 2.",Non-OADS,/arxiv_data1/oa_pdf/4b/84/ijph-41-56.PMC3494216.pdf
":Prevalence of Hepatitis C Virus Genotypes … 59 Available at: http://ijph.tums.ac.irDistribution of HCV genotypes Inthis study, genotype 3a showed the highest frequency with 150 (40%) of subjects.",Non-OADS,/arxiv_data1/oa_pdf/4b/84/ijph-41-56.PMC3494216.pdf
"4 1, No.9,Sep2012, pp.56-61 Available at: http://ijph.tums.ac.ir 60are relatively more common in young individuals with a history of int ravenous drug use.",Non-OADS,/arxiv_data1/oa_pdf/4b/84/ijph-41-56.PMC3494216.pdf
":Prevalence of Hepatitis C Virus Genotypes … 61 Available at: http://ijph.tums.ac.ir6.Omrani MD, Khadem Ansari MH (2009).",Non-OADS,/arxiv_data1/oa_pdf/4b/84/ijph-41-56.PMC3494216.pdf
"4 1, No.9,Sep2012, pp.62-70 Original Article 62 Available at: http://ijph.tums.ac.ir Iranian Household Financial Protection against Catastrophic HealthCare Expenditures M Nekoei Moghadam1, M Banshi2,MAkbari Javar3, *M Amiresmaili4, S Ganjavi3 1.Research Centre for Health Services Management, Kerman University of Medical Sciences, Kerman, Iran 2.Research Center for Modeling in Health, Kerman University of Medical Sciences, Kerman, Iran 3.Students’ Research Committee, Kerman University of Medical Sciences, Kerman, Iran 4.Medical Informatics Research Center, Kerman University of Medical Sciences, Haftbagh Highway, Kerman, Iran *Corresponding Author: Tel: 0098 341 3205158, E -mail address: amiresmaili@kmu.ac.ir (Received 12Dec2011; accepted 14Aug2012) Introduction Health expenditures are among issues which have always been discussed by researchers in the fields of economics and public health (1).",Non-OADS,/arxiv_data1/oa_pdf/60/d7/ijph-41-62.PMC3494217.pdf
:Iranian Household Financial Protection … 63 Available at: http://ijph.tums.ac.irPeople get sick all over the world and resources are used to cure them (4).,Non-OADS,/arxiv_data1/oa_pdf/60/d7/ijph-41-62.PMC3494217.pdf
"4 1, No.9,Sep2012, pp.62-70 Available at: http://ijph.tums.ac.ir 64had announced their food expenditures less than their subsistence expenditures, we calculated abil - ity to pay of the household considering the effec - tive income minus food expenditures.",Non-OADS,/arxiv_data1/oa_pdf/60/d7/ijph-41-62.PMC3494217.pdf
:Iranian Household Financial Protection … 65 Available at: http://ijph.tums.ac.irHousehold’s expenditure data The average of food expenditure for each house - hold was 174.7 USD monthly (The first and third percentile were 90.8 and 220.4 USD respectively).,Non-OADS,/arxiv_data1/oa_pdf/60/d7/ijph-41-62.PMC3494217.pdf
"4 1, No.9,Sep2012, pp.62-70 Available at: http://ijph.tums.ac.ir 66More than half of the households have used ou t- patient services.",Non-OADS,/arxiv_data1/oa_pdf/60/d7/ijph-41-62.PMC3494217.pdf
:Iranian Household Financial Protection … 67 Available at: http://ijph.tums.ac.ir Fig.,Non-OADS,/arxiv_data1/oa_pdf/60/d7/ijph-41-62.PMC3494217.pdf
"4 1, No.9,Sep2012, pp.62-70 Available at: http://ijph.tums.ac.ir 68with the studies carried out in developing coun - tries (15-17).",Non-OADS,/arxiv_data1/oa_pdf/60/d7/ijph-41-62.PMC3494217.pdf
":Iranian Household Financial Protection … 69 Available at: http://ijph.tums.ac.irusing health services due to lack of financial ability, household s who reduce their food expenses to provide health expenditures and also the opportu - nity costs (travel costs, the loss of income, etc) due to using health services, will be omitted in this manner.",Non-OADS,/arxiv_data1/oa_pdf/60/d7/ijph-41-62.PMC3494217.pdf
"4 1, No.9,Sep2012, pp.62-70 Available at: http://ijph.tums.ac.ir 70and then are divided into 100 equal groups.",Non-OADS,/arxiv_data1/oa_pdf/60/d7/ijph-41-62.PMC3494217.pdf
"Paying out - of-pocket for health care in Korea: change in catastrophic and poverty impact over a decade, Available: http://www.hsph.harva rd.edu/research/ta - kemi/files/RP254_takemi_journal1_lee.pdf10.Mohammadalizadeh Hanjani H, Fazaeli AA (2008).",Non-OADS,/arxiv_data1/oa_pdf/60/d7/ijph-41-62.PMC3494217.pdf
"4 1, No.9,Sep2012, pp.71-77 Original Article 71 Available at: http://ijph.tums.ac.ir The Effect of Service Quality on Patientloyalty: a Study of Private Hospitals in Tehran, Iran M Arab1, SM Ghazi Tabatabaei2, A Rashidian1, A Rahimi Forushani3, *E Zarei1 1.Dept.",Non-OADS,/arxiv_data1/oa_pdf/65/0e/ijph-41-71.PMC3494218.pdf
:The Effect of Service Quality on Patient loyalty … Available at:http://ijph.tums.ac.ir 72increasingly focusing their strategic activities on customer loyalty (6).,Non-OADS,/arxiv_data1/oa_pdf/65/0e/ijph-41-71.PMC3494218.pdf
"4 1, No.9,Sep2012, pp.71-77 73 Available at: http://ijph.tums.ac.iremployed to establish the factor loadings on the various dimensions of quality (i.e.",Non-OADS,/arxiv_data1/oa_pdf/65/0e/ijph-41-71.PMC3494218.pdf
:The Effect of Service Quality on Patient loyalty … Available at:http://ijph.tums.ac.ir 74dimensions (Table 2).,Non-OADS,/arxiv_data1/oa_pdf/65/0e/ijph-41-71.PMC3494218.pdf
"4 1, No.9,Sep2012, pp.71-77 75 Available at: http://ijph.tums.ac.irDiscussion This study provided the opportunity to consider the question that whether the quality perceived by thepatients had any influence on their loyalty towards the hospital.",Non-OADS,/arxiv_data1/oa_pdf/65/0e/ijph-41-71.PMC3494218.pdf
:The Effect of Service Quality on Patient loyalty … Available at:http://ijph.tums.ac.ir 76patient’s loyalty in the private hospitals in Tehran.,Non-OADS,/arxiv_data1/oa_pdf/65/0e/ijph-41-71.PMC3494218.pdf
"4 1, No.9,Sep2012, pp.71-77 77 Available at: http://ijph.tums.ac.ir18.Kessler DP,Mylod D(2011).Does patient satisfaction affect patient loyalty?",Non-OADS,/arxiv_data1/oa_pdf/65/0e/ijph-41-71.PMC3494218.pdf
"78-83 Original Article 78   Available at:    http://ijph.tums.ac.ir Quality of Working Life on Residents Working in Hospitals    MHosseini Zare, B Ahmadi, *A Akbari Sari, M Arab, E Movahed Kor    Dept.",Non-OADS,/arxiv_data1/oa_pdf/ef/e7/ijph-41-78.PMC3494219.pdf
: Quality of Working Life on Residents Working  … 79   Available at:    http://ijph.tums.ac.irmain factors responsible for the majority of ad- verse events and medical errors in healthcare (4).,Non-OADS,/arxiv_data1/oa_pdf/ef/e7/ijph-41-78.PMC3494219.pdf
"78-83   Available at:    http://ijph.tums.ac.ir 80 0.95 for education and research, 0.95 for manage- ment support, 0.85 for amount of salary and type  of payment, 0.82 for assessment and monitoring  and 0.80 for organizational and cultural issues .",Non-OADS,/arxiv_data1/oa_pdf/ef/e7/ijph-41-78.PMC3494219.pdf
: Quality of Working Life on Residents Working  … 81   Available at:    http://ijph.tums.ac.irpediatrics and women wards and the lowest QWL was in the emergency departments (Table 4).,Non-OADS,/arxiv_data1/oa_pdf/ef/e7/ijph-41-78.PMC3494219.pdf
78-83   Available at:    http://ijph.tums.ac.ir 82 low quality of working life.,Non-OADS,/arxiv_data1/oa_pdf/ef/e7/ijph-41-78.PMC3494219.pdf
: Quality of Working Life on Residents Working  … 83   Available at:    http://ijph.tums.ac.irthe residents’ quality of working life could be im- proved.,Non-OADS,/arxiv_data1/oa_pdf/ef/e7/ijph-41-78.PMC3494219.pdf
"4 1, No.9,Sep2012, p. 84 Letter to The Editor 84 Available at: http://ijph.tums.ac.ir Aposthia -A Motive of Circumcision Origin M  Amin ud din Dept.",Non-OADS,/arxiv_data1/oa_pdf/aa/10/ijph-41-84.PMC3494220.pdf
"4 1, No.9,Sep2012, p. 85 Letter to the Editor 85 Available at: http://ijph.tums.ac.ir Disaster And Evacuation Guide: Is It Sufficient To Foreigners?",Non-OADS,/arxiv_data1/oa_pdf/53/63/ijph-41-85.PMC3494221.pdf
2.Available from http://www.pref.miyagi.jp/english/index.h tm[cited 2012 July 10th] 3.Available from http://www.bousai.pref.chiba.lg.jp/portal_ eng/index.html [cited 2012 July 7th],Non-OADS,/arxiv_data1/oa_pdf/53/63/ijph-41-85.PMC3494221.pdf
"4 1,No.9,Sep2012, pp.86-92 Report A rticle 86 Available at: http://ijph.tums.ac.ir Coronary Artery Disease Risk Factors in an Urban and Peri -urban Setting, Kerman, Southeastern Iran (KERCADR Study): Methodol ogy and Preliminary Report H Najafipour1, *A Mirzazadeh2,11, AA Haghdoost2,1, M Shadkam1, M Afshari2, M Moazen zadeh3, HR Nasri3, M Masoomi3, F Mirzaiepour3, BSarvarAzimzadeh3, A Forood3, F Bahreini4, MR Mahmoudi4, M Sanjari5,T Malek Mohamadi6, GH Banivaheb7, MA Naderi7, GH Moshtaghi Kashanian8, R Malekpour Afshar9, Z Ghazanfari10, S Navadeh1,11,AShah Esmaeili1,12 1.Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran 2.Dept.",Non-OADS,/arxiv_data1/oa_pdf/5d/67/ijph-41-86.PMC3494222.pdf
:Coronary Artery Disease Risk F actors in an Urban and Peri -urban… 87 Available at: http://ijph.tums.ac.irHow did the study come about?,Non-OADS,/arxiv_data1/oa_pdf/5d/67/ijph-41-86.PMC3494222.pdf
"4 1, No.9,Sep2012, pp.86-92 Available at: http://ijph.tums.ac.ir 88What does the KERCADR cover?",Non-OADS,/arxiv_data1/oa_pdf/5d/67/ijph-41-86.PMC3494222.pdf
":Coronary Artery Disease Risk F actors in an Urban and Peri -urban… 89 Available at: http://ijph.tums.ac.ir Fig.3:The age distribution in the sample and target population, (N=5900) Kerman, Iran, 2009 -11 The standardized estimates (based on age and sex subgroups) for the key measures of clinical and para-clinical findings were presented separately for men and women in Table 1.",Non-OADS,/arxiv_data1/oa_pdf/5d/67/ijph-41-86.PMC3494222.pdf
"4 1, No.9,Sep2012, pp.86-92 Available at: http://ijph.tums.ac.ir 90recorded to the nearest 0.1 cm), blood pressure (standard mercury manometer – Model RISHTER, Germany) and pulse rate, fasting blood glucose (KIMIA Kit, Code 890410, Iran) (HbA1C -NYCO- CARD Kit, Code 1042184, Austria) -for known diabetic cases and those with high fasting blood glucose after two subsequent measurements), Triglyceride (KIMIA Kit,Code 890201, Iran), Total cholesterol (KI - MIA Kit, Code 890303, Iran) (HDL – PARS Kit, Code 89022, Iran) -and LDL was calculated based on Frieldwald  for - mula  [LDL = Total chol.",Non-OADS,/arxiv_data1/oa_pdf/5d/67/ijph-41-86.PMC3494222.pdf
:Coronary Artery Disease Risk F actors in an Urban and Peri -urban… 91 Available at: http://ijph.tums.ac.irleast 10 minutes at rest.,Non-OADS,/arxiv_data1/oa_pdf/5d/67/ijph-41-86.PMC3494222.pdf
"4 1, No.9,Sep2012, pp.86-92 Available at: http://ijph.tums.ac.ir 92serial exams, the results will be in the range of ±0.5.",Non-OADS,/arxiv_data1/oa_pdf/5d/67/ijph-41-86.PMC3494222.pdf
"Population Estimates for 2010, avaliable via http://www.amar.org.ir.",Non-OADS,/arxiv_data1/oa_pdf/5d/67/ijph-41-86.PMC3494222.pdf
"1-14                                                                       Review Article   1   Available at:    http://ijph.tums.ac.ir         Health Aspects of Organophosphorous Pesticides in A sian   Countries    * M Balali-Mood 1, K Balali-Mood 2, M Moodi 3, B Balali-Mood 4    1.",Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
": Health Aspects of Organophospho rous Pesticides  …    Available at:    http://ijph.tums.ac.ir   2 phosphate, pesticides, insecticides and search  terms including human exposure, org- anophosphorous pesticides poisoning and its  complications.",Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
"1-14   3   Available at:    http://ijph.tums.ac.ir  phates are usually esters, amides or thiol deriva- tives of phosphoric, phosphonic or phosphinic  acids.",Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
: Health Aspects of Organophospho rous Pesticides  …    Available at:    http://ijph.tums.ac.ir   4 to be transformed in the body to become active  (22).,Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
"1-14   5   Available at:    http://ijph.tums.ac.ir    Clinical Effects  The lipophilic diethyl phosphoryl pesticides such  as azinophos-ethyl, bromophos-ethyl, chlorpyri- phos, coumaphos, diazinon, parathion, phosalone  and sulfotep may remain in the body for many  days in severe cases.",Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
": Health Aspects of Organophospho rous Pesticides  …    Available at:    http://ijph.tums.ac.ir   6 sion, mydriasis, twitching and fasciculation of  muscles, and in more severe cases; paralysis of  diaphragm and respiratory muscles (2, 16, 22).",Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
"1-14   7   Available at:    http://ijph.tums.ac.ir  The severity of OP poisoning may be divided into  three groups according to their cholinesterase ac- tivities as shown in Table 3 (2, 16, 22).",Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
": Health Aspects of Organophospho rous Pesticides  …    Available at:    http://ijph.tums.ac.ir   8 earlier, but it is not specific and may be low natu- rally in some people due to genetic variations (40).",Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
1-14   9   Available at:    http://ijph.tums.ac.ir  moved before decontamination.,Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
": Health Aspects of Organophospho rous Pesticides  …    Available at:    http://ijph.tums.ac.ir   10 plant food contamination were reported in Mo- rocco, Egypt, Iraq, Saudi Arabia, Sudan, Syria,  Jordan, UAE, Pakistan and Yemen in the past  years.",Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
1-14   11   Available at:    http://ijph.tums.ac.ir  intentional ingestion are common and induced  health problems.,Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
: Health Aspects of Organophospho rous Pesticides  …    Available at:    http://ijph.tums.ac.ir   12 treatment of organophosphate poisoning.,Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
1-14   13   Available at:    http://ijph.tums.ac.ir  Pesticide Poisoning.,Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
: Health Aspects of Organophospho rous Pesticides  …    Available at:    http://ijph.tums.ac.ir   14 59.,Non-OADS,/arxiv_data1/oa_pdf/bb/82/ijph-41-1.PMC3494223.pdf
"41, No.10, Oct 2012, p.  102                                                    Letter to the Editor   102   Available at:    http://ijph.tums.ac.ir         Methods of Prophylaxis and Therapy for Emporiatrics : New or  Ancient    *MB Siahpoosh, F Nejatbakhsh    School of Iranian Traditional Medicine, Tehran Univ ersity of Medical Sciences, Tehran, Iran    *Corresponding Author:  Tel: +98-21-55693520 .",Non-OADS,/arxiv_data1/oa_pdf/2d/71/ijph-41-102.PMC3494224.pdf
"41, No.10, Oct 2012, pp .103-104                                                   Letter to the Editor    103   Available at:    http://ijph.tums.ac.ir         Ancient Theory about Public Health through Physical  Activity     against Hyperlipidemia and Ischemic Heart Disease    *MB Siahpoosh 1, M Ebadiani  1, GhR Shah Hosseini 2, F Nejatbakhsh 1    1.",Non-OADS,/arxiv_data1/oa_pdf/a2/5a/ijph-41-103.PMC3494225.pdf
: Ancient Theory about Public Healt h through Physical Activity  …    Available at:    http://ijph.tums.ac.ir   104 through producing normal humors and using  them.,Non-OADS,/arxiv_data1/oa_pdf/a2/5a/ijph-41-103.PMC3494225.pdf
"15-23                                                          Original Article   15   Available at:    http://ijph.tums.ac.ir         The Opportunities of Crises and Emergency Risk Comm unication in  Activities of Serbian Public Health Workforce in Em ergencies    *V Radović, L Ćurčić     Faculty of Environmental Governance and Corporate R esponsibility, EDUCONS University, Sremska Kamenica , Serbia     *Corresponding Author:  Tel: +38169 1995 172   Email: veselaradovic@yahoo.com    (Received 21 Jun 2012; accepted 05 Sep 2012)        Introduction     The communication issues in history of civiliza- tions always attract the attention of researchers.",Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
Radović & Ćur čić: The Opportunities of Crises and Emergency Risk …    Available at:    http://ijph.tums.ac.ir   16 not accept the experiences from developed coun- tries like United State of America (USA) as well as  similar from European country.,Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
"15-23   17   Available at:    http://ijph.tums.ac.ir  part of literature has been used from the courses  of risk communication and disaster management,  which Dr Radovic attended at the Tulane School  of Public Health and Tropical Medicine at Tulane  University in New Orleans, Louisiana and lectures  from the experts from the Center of the Disease  control and distinguished professors who were the  founders of the CERC (Barbara Reynolds, LuAnn  White, and Maureen Lichtveld).",Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
Radović & Ćur čić: The Opportunities of Crises and Emergency Risk …    Available at:    http://ijph.tums.ac.ir   18 plaining public health role in joint efforts with  other emergency response partners.,Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
Having in mind the presence of significant num- ber of cases of viral meningitis (55 within only one   month according to data provided from the  Health Secretariat of APV available at web- site  http://www.zdravstvo.vojvodina.gov.rs) panic  increased.,Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
15-23   19   Available at:    http://ijph.tums.ac.ir  The consequences of inappropriate communica- tions could lead to the loss of credibility.,Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
Radović & Ćur čić: The Opportunities of Crises and Emergency Risk …    Available at:    http://ijph.tums.ac.ir   20 implemented in Serbia.,Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
15-23   21   Available at:    http://ijph.tums.ac.ir  Be First:  You have to provide information from  authority as soon as it is possible.,Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
Radović & Ćur čić: The Opportunities of Crises and Emergency Risk …    Available at:    http://ijph.tums.ac.ir   22 The person who is in charge to communicate has  to know how to translate technical and scientific  concept into understandable messages.,Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
Available at URL:  http://www.petersandman.com  6.,Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
Available at URL:   http://www.cdc.gov/communications/emergency/  cerc.htm,OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
15-23   23   Available at:    http://ijph.tums.ac.ir  7.,Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
Available at URL:  http://www.atsdr.cdc.gov/HEC/primer.ht  ml.,OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
Available at URL:   http://www.riskcommunication.samhsa.gov  /index.htm  9.,Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
Available at URL:   http://www.slu.edu/centers/heartland.,Non-OADS,/arxiv_data1/oa_pdf/fc/f2/ijph-41-15.PMC3494226.pdf
"24-28                                                            Original Article   24   Available at:    http://ijph.tums.ac.ir         Effect of Mindfulness Based Stress Management on Re duction of  Generalized Anxiety Disorder    S Asmaee Majid 1,*T Seghatoleslam 1, 2 , HA Homan 3, A Akhvast 3, H Habil 2    1.",Non-OADS,/arxiv_data1/oa_pdf/a1/69/ijph-41-24.PMC3494227.pdf
": Effect of Mindfulness Based St ress Management …    25   Available at:    http://ijph.tums.ac.ir  One rationale for introducing new interventions  for GAD is related to the fact that despite effec7 tive therapies, the persistence of residual GAD  symptoms in treatment responders is a problem.",Non-OADS,/arxiv_data1/oa_pdf/a1/69/ijph-41-24.PMC3494227.pdf
"24-28     Available at:    http://ijph.tums.ac.ir   26 vioral, and biological symptoms of depression and  has acceptable psychometric properties (13,14).",Non-OADS,/arxiv_data1/oa_pdf/a1/69/ijph-41-24.PMC3494227.pdf
: Effect of Mindfulness Based St ress Management …    27   Available at:    http://ijph.tums.ac.ir  The effectiveness of the intervention was examined  using analysis of covariance.,Non-OADS,/arxiv_data1/oa_pdf/a1/69/ijph-41-24.PMC3494227.pdf
24-28     Available at:    http://ijph.tums.ac.ir   28 Acknowledgements    The authors declare that this study was not sup7 port by any financial source.,Non-OADS,/arxiv_data1/oa_pdf/a1/69/ijph-41-24.PMC3494227.pdf
"41, No.10, Oct 2012, pp .29-35                                                          Original Article   29   Available at:    http://ijph.tums.ac.ir        Sensitization to Aeroallergens in Patients with Resp iratory   Allergies Based on Skin-Prick Test Results    *V Lokaj-Berisha 1, N Berisha 2, B Lumezi 1, L Ahmetaj 1, G Bejtullahu 1, N Karahoda 1,   H Pupovci 1    1.",Non-OADS,/arxiv_data1/oa_pdf/5c/e0/ijph-41-29.PMC3494228.pdf
: Sensitization to Aeroallergen s in Patients …  Available at:    http://ijph.tums.ac.ir   30 station of allergic symptoms (6-10).,Non-OADS,/arxiv_data1/oa_pdf/5c/e0/ijph-41-29.PMC3494228.pdf
"29-35   31   Available at:    http://ijph.tums.ac.ir  tract was placed on to the volar surface of forearm   and introduced into the epidermis with sterile lan- cet (1 mm depth), new for each allergen.",Non-OADS,/arxiv_data1/oa_pdf/5c/e0/ijph-41-29.PMC3494228.pdf
: Sensitization to Aeroallergen s in Patients …  Available at:    http://ijph.tums.ac.ir   32 Table 2:  Comparison of  IgE level and eosinophils in allergic and control g roup     Allergic subjects   (n = 64)  (%)   Controls  (n = 38)  (%) Asthma  (n = 15)  Asthma/rhinitis  (n = 8)  Rhinitis  (n = 41     IgE level (IU/ml)  < 100 IU/ml 3 (20.,Non-OADS,/arxiv_data1/oa_pdf/5c/e0/ijph-41-29.PMC3494228.pdf
"29-35   33   Available at:    http://ijph.tums.ac.ir  (20), it varies throughout the world and is asso-  ciated with the ‘westernized’ lifestyle (1, 21).",Non-OADS,/arxiv_data1/oa_pdf/5c/e0/ijph-41-29.PMC3494228.pdf
": Sensitization to Aeroallergen s in Patients …  Available at:    http://ijph.tums.ac.ir   34   Ethical considerations    Ethical issues (Including plagiarism, Informed Con- sent, misconduct, data fabrication and/or falsifica tion,  double publication and/or submission, redundancy,  etc) have been completely observed by the authors    Acknowledgment     This study was part of first author magistracy re-  search, so no financial source to declare).",Non-OADS,/arxiv_data1/oa_pdf/5c/e0/ijph-41-29.PMC3494228.pdf
29-35   35   Available at:    http://ijph.tums.ac.ir  19.,Non-OADS,/arxiv_data1/oa_pdf/5c/e0/ijph-41-29.PMC3494228.pdf
"36-42                                                             Original Article   36   Available at:    http://ijph.tums.ac.ir        Association between Physical Inactivity and Academi c Record in  Korean Adolescents    *YijSoo Shin 1, WijYoung So 2    1.",Non-OADS,/arxiv_data1/oa_pdf/22/c7/ijph-41-36.PMC3494229.pdf
"Soo Shin & Young So: Association between Physical I nactivity and Academic Record …    37   Available at:    http://ijph.tums.ac.ir  fects on academic activities through increased brai n  activity has been studied extensively, whether  sedentary activity and physical inactivity is assox ciated with academic outcomes has not been a rex search focus.",Non-OADS,/arxiv_data1/oa_pdf/22/c7/ijph-41-36.PMC3494229.pdf
"36-42     Available at:    http://ijph.tums.ac.ir   38 Table 1:  The characteristics of the subjects    Variable Boys   (n = 39,612) Girls   (n = 35,454) Total   (n = 75,066)  Age ( yr ) 15.00 ± 1.73  15.12 ± 1.77  15.06 ± 1.75   Height (cm)  169.58 ± 8.19  160.08 ± 5.39  165.09 ± 8.46   Weight (kg)  60.14 ± 11.72  51.47 ± 7.67  56.04 ± 10.91   Body mass index (kg/m 2) 20.80 ± 3.21  20.05 ± 2.58  20.45 ± 2.95   Family’s socioecox nomic status,  N (%) Very rich  2,923 (7.4)  1,434 (4.0)  4,357 (5.8)   Rich  8,985 (22.7)  6,908 (19.6)  15,893 (21.2)   Average  17,743 (44.7)  17,706 (49.9)  35,449 (47.2)   Poor  7,150 (18.1)  7,090 (20.0)  14,240 (19.0)   Very poor  2,811 (7.1)  2,316 (6.5)  5,127 (6.8)   Father’s education  level  N (%) Unknown  7,297 (18.4)  5,321 (15.0)  12,618 (16.8)   Middle school or lower  2,707 (6.8)  2,483 (7.0)  5,190 (6.9)   High school  14,294 (36.1)  13,915 (39.2)  28,209 (37.6)   College or higher  15,314 (38.7)  13,735 (38.8)  29,049 (38.7)   Mother’s educax tion level  N (%) Unknown  8,069 (20.4)  5,059 (14.3)  13,128 (17.5)   Middle school or lower  2,447 (6.2)  2,490 (7.0)  4,937 (6.6)   High school  17,745 (44.7)  18,212 (51.4)  35,957 (47.9)   College or higher  11,351 (28.7)  9,693 (27.3)  21,044 (28.0)   Academic record  N (%) Very high  4,958 (12.5)  3,454 (9.7)  8,412 (11.2)   High  9,172 (23.2)  8,411 (23.7)  17,583 (23.4)   Average  10,544 (26.6)  9,675 (27.3)  20,219 (26.9)   Low  9,661 (24.4)  9,477 (26.7)  19,138 (25.5)   Very low  5,277 (13.3)  4,437 (12.5)  9,714 (12.9)   Sedentary lifestyle  during weekdays  N (%) <1 hour per day  9,748 (24.6)  8,948 (25.2)  18,696 (24.9)   ≥1 to <2 hours per day  11,661 (29.4)  10,084 (28.4)  21,745 (29.0)   ≥2 to <3 hours per day  8,852 (22.3)  7,437 (21.0)  16,289 (21.7)   ≥3 to <4 hours per day  4,159 (10.5)  3,888 (11.0)  8,047 (10.7)   ≥4 hours per day  5,192 (13.1)  5,097 (14.4)  10,289 (13.7)   Sedentary lifestyle  during the weekx end  N (%) <1 hour per day  4,662 (11.8)  4,304 (12.1)  8,966 (11.9)   ≥1 to <2 hours per day  7,536 (19.0)  6,463 (18.2)  13,999 (18.6)   ≥2 to <3 hours per day  9,432 (23.8)  7,937 (22.4)  17,369 (23.1)   ≥3 to <4 hours per day  6,640 (16.8)  6,262 (17.7)  12,902 (17.2)   ≥4 hours per day  11,342 (28.6)  10,488 (29.6)  21,830 (29.1)   Grade  N (%) 7th  grade  6,933 (17.5)  5,781 (16.3)  12,714 (16.9)   8th  grade  6,965 (17.6)  5,903 (16.6)  12,868 (17.1)   9th  grade  7,035 (17.7)  5,792 (16.3)  12,827 (17.1)   10 th  grade  6,890 (17.4)  5,587 (15.8)  12,477 (16.6)   11 th  grade  6,104 (15.4)  6,323 (17.9)  12,427 (16.6)   12 th  grade  5,685 (14.4)  6,068 (17.1)  11,753 (15.7)   Data are presented as mean ± SD or N (%)",Non-OADS,/arxiv_data1/oa_pdf/22/c7/ijph-41-36.PMC3494229.pdf
Soo Shin & Young So: Association between Physical I nactivity and Academic Record …    39   Available at:    http://ijph.tums.ac.ir  Covariate variables  Gender  The 2 response options were (i) male and (ii) fex male.,OADS,/arxiv_data1/oa_pdf/22/c7/ijph-41-36.PMC3494229.pdf
"36-42     Available at:    http://ijph.tums.ac.ir   40 During weekdays, the odds ratios (OR) (95%  confidence interval [CI]) for reporting a higher  than average academic record, as compared with  <1 hour of physical inactivity per day, was 0.796  (0.761–0.832, for ≥1 to <2 hours, 0.632 (0.603– 0.663, for ≥2 to <3 hours, 0.567 (0.535–0.601, for  ≥3 to 4 hours, and 0.494 (0.468–0.522) for ≥4  hours of physical inactivity per day.",Non-OADS,/arxiv_data1/oa_pdf/22/c7/ijph-41-36.PMC3494229.pdf
Soo Shin & Young So: Association between Physical I nactivity and Academic Record …    41   Available at:    http://ijph.tums.ac.ir  to academic record.,Non-OADS,/arxiv_data1/oa_pdf/22/c7/ijph-41-36.PMC3494229.pdf
http://www.cdc.gov/physicalactivity/every  one/health/index.html  8.,Non-OADS,/arxiv_data1/oa_pdf/22/c7/ijph-41-36.PMC3494229.pdf
36-42     Available at:    http://ijph.tums.ac.ir   42 13.,Non-OADS,/arxiv_data1/oa_pdf/22/c7/ijph-41-36.PMC3494229.pdf
http://yhs.cdc.go.kr/   14.,Non-OADS,/arxiv_data1/oa_pdf/22/c7/ijph-41-36.PMC3494229.pdf
"41, No.10, Oct 2012, pp .43-51                                                            Original Article   43   Available at:    http://ijph.tums.ac.ir        E-Health Readiness Assessment Framework in Iran    *M Rezai-Rad 1, R Vaezi 2, F Nattagh 3    1.",Non-OADS,/arxiv_data1/oa_pdf/f3/ea/ijph-41-43.PMC3494230.pdf
": E-Health Readiness Assessment …    Available at:    http://ijph.tums.ac.ir   44 A WHO meeting on e-Health on 2004, recom- mended that WHO should adopt e-Health activi- ties that would support information for 1) health  promotion and awareness, medical education,  health and biomedical research, evidence-based  medicine and e-learning; 2) health information  systems (disease surveillance, health statistics,  management information systems, financial, logis- tical, and geographic information systems),  monitoring and evaluation; and 3) health-care deli- very: diagnostics, treatment, consultation  (telemedicine applications) and electronic patient  records (3).",Non-OADS,/arxiv_data1/oa_pdf/f3/ea/ijph-41-43.PMC3494230.pdf
"43-51  45   Available at:    http://ijph.tums.ac.ir  Group (30), Heeks (31), Wickramasinghe (1),  Khoja & Ramzan (10), Jennett et al.",Non-OADS,/arxiv_data1/oa_pdf/f3/ea/ijph-41-43.PMC3494230.pdf
": E-Health Readiness Assessment …    Available at:    http://ijph.tums.ac.ir   46 Strategies and Legal and  Financial Support of ICT  Clear strategies and policies in government programs for the ICT development  (18), enough control for ensuring the implementation  of ICT projects (14), legal  framework in support of ICT development in the organ ization (17), financial sup- port in forms of budgets for ICT development in the organization (38), support  of rights of clients and consumers of ICT in the org anization (38), supporting and  encouraging information security in providing ICT-ba sed services to citizens (17)  (1)  Societal Readiness   Societal Readiness  Communication links of healthcare organizations with  other institutions (i.e.",Non-OADS,/arxiv_data1/oa_pdf/f3/ea/ijph-41-43.PMC3494230.pdf
43-51  47   Available at:    http://ijph.tums.ac.ir  Table 2:  Mean of the Indices of Readiness in the first Delph i phase    Dimension  Component  Index with high Priority (Mean) *  Technological  Readiness Availability and Affordability of  Hardware and Software/ ICT Availability of hardware and software (4.71)   Infrastructure Quality  Internet connection bandwidth (4.50)   ICT quality support (4.50)   Using Network  Using LAN and WAN for doing different tasks  (4.29)  ICT Support Personnel  Presence of ICT experts with relevant degrees (4.21 )   Access to ICT expert consultants (4.21)   IT Security  Utilization rate of security systems in the organiz a - tion (e.g.,OADS,/arxiv_data1/oa_pdf/f3/ea/ijph-41-43.PMC3494230.pdf
Rezai  Available at:    http://ijph.tums.ac.ir 1.,Non-OADS,/arxiv_data1/oa_pdf/f3/ea/ijph-41-43.PMC3494230.pdf
: E-Health Readiness Assessment …    http://ijph.tums.ac.ir   The relative weight of the indices of  technological readiness indicated that  ‘utilization rate of security systems in the  organization’ had the highest and  ‘telephone mainlines per emp loyee’ had  the lowest weight: among the indices of  engagement readiness indicated that  ‘efficient medical practice’ had the highest  and ‘time cost’ had the lowest weight;  among the indices of societal readiness  showed that ‘communication links of  e organizations with other  institutions (i.e.,OADS,/arxiv_data1/oa_pdf/f3/ea/ijph-41-43.PMC3494230.pdf
"43-51  49   Available at:    http://ijph.tums.ac.ir  components, and 58 indices were finalized; and  the prioritization of the framework showed that  technical, core, societal, and engagement readiness  had the relative impact, respectively.",OADS,/arxiv_data1/oa_pdf/f3/ea/ijph-41-43.PMC3494230.pdf
[HTML]: WHO;  [cited 2012 05/25/2012]; Available from:  http://www.who.int/trade/glossary/story021  /en/  3. WHO (2008).,Non-OADS,/arxiv_data1/oa_pdf/f3/ea/ijph-41-43.PMC3494230.pdf
: E-Health Readiness Assessment …    Available at:    http://ijph.tums.ac.ir   50 8.,Non-OADS,/arxiv_data1/oa_pdf/f3/ea/ijph-41-43.PMC3494230.pdf
43-51  51   Available at:    http://ijph.tums.ac.ir  an integrated information rich tool.,Non-OADS,/arxiv_data1/oa_pdf/f3/ea/ijph-41-43.PMC3494230.pdf
"52-59                                                            Original Article   52   Available at:    http://ijph.tums.ac.ir         Risk Factors for Spinal Osteoporosis As Compared wi th Femoral  Osteoporosis in Urban Iranian Women    *A Keramat 1, B Larigani 2, H Adibi 2    1.",Non-OADS,/arxiv_data1/oa_pdf/08/18/ijph-41-52.PMC3494231.pdf
": Risk Factors for Spinal Osteoporosi s …  53   Available at:    http://ijph.tums.ac.ir  conclude that age of attaining peak bone mass at  the hip is younger than at the spine and BMC and  BSA at the spine continue to increase through the  early thirties in female (12, 13).",Non-OADS,/arxiv_data1/oa_pdf/08/18/ijph-41-52.PMC3494231.pdf
52-59     Available at:    http://ijph.tums.ac.ir   54   Table 1:  Distribution of associated factors with osteoporosi s in two regions      Spine Femur  Variabels1   Case  (n=140) Control  (n=167) OR2 (0.95  CI) OR3  (0.95 CI) Case  (n=72) Control  (n=191) OR2 (0.95  CI) OR3 (0.95 CI)  Demographic factors   Age(mean)  58.1 ± 6.9 56.7 ±6.2   58.9 ±8.4 56.2 ±5.9      <12 yrs schooling (%) 66.1 44.2 2.5 (1.5-4.2) 2.5 (1.5-4.4) 65.2 46.2 2.7 (1.5-4.8) 1.8 (0.8-4.0)  Anthropometric charcters (%)   Weight <=60Kg (%) 36 15.3 3.1 (1.8-5.4) ---- 37.1 19.7 2.4(1.3-4.4) -----   BMI <=26 (%) 39.4 15.3 3.9 (2.3-6.7) ---- 46.2 19.8 3.6 (1.9-6.6) ----  Menopausal factors    Postmenopausal >5 yrs (%) 75.3 52.5 2.2 (1.3-3.7) 2.,Non-OADS,/arxiv_data1/oa_pdf/08/18/ijph-41-52.PMC3494231.pdf
: Risk Factors for Spinal Osteoporosi s …  55   Available at:    http://ijph.tums.ac.ir  Table 2:  Distribution of nutritional associated factors with  osteoporosis in two regions      Spine Femur  Nutritional  factors 1  Case  (n=140)  Control  (n=167)  OR 2  (0.95 CI) OR 3  (0.95 CI) Case  (n=72)  Control  (n=191)  OR 2  (0.95 CI) OR 3  (0.95 CI)   Milk    >=1 cup/ day  48.2 60.5 0.6   (0.3-0.9) 0.6   (0.3-0.9) 56 59.1 NS 2 NS 2  Yogurt   >= 3/ w  76.5 89.4 NS NS 72.5 89.5 0.3   (0.2-0.6)  0.3   (0.1-0.6)   Fish    >= 2/ w (%)  1.6 7.6 0.2   (0.04-0.5) 0.2   (0.03-0.9)  5.1 6.6 NS NS  Eggs   >=1/ w (%)  54.5 70.6 0.5   (0.3-0.8) 0.5   (0.3-0.9) 44.2 72.3 0.3   (0.2-0.6) 0.3   (0.2-0.6)  Chicken   >=2/ w (%)  58.3 72.6 0.3   (0.2-0.7) 0.4   (0.2-0.7) 57.6 72.4 0.5   (0.3-0.9)  0.4   (0.2-0.8)  Almond    No Almond  (%) 63.6 47.3 1.9   (1.2-3.2) 2.1   (1.1-3.2) 56.9 41.6 1.9   (1.-3.3) 1.9   (1.1-3.6)  Salt    Salt (%)  10 4.3 NS 3(1-8.7) 7.6 3.5 0.3 (0.2 - 0.7) 0.4   (0.2-0.9)  Fruits    Daily (%)  73.1 82.3 NS NS 58.3 83.6 0.3   (0.1-0.7) 0.3   (0.2-0.6)  Tea   >=7cup/ w  10.4 27.9 0.3   (0.2-0.6) 0.3 (0.1-0.6) 10.4 21.6 0.3   (0.2-0.8) 0.3   (0.1-0.8)  1- Variables are dichotomous.,Non-OADS,/arxiv_data1/oa_pdf/08/18/ijph-41-52.PMC3494231.pdf
52-59     Available at:    http://ijph.tums.ac.ir   56 Table 3:  Association of osteoporosis with exercises as prot ective factors in spine and femur      Spine  Femur   Variabels 1  Case   (n=140)  Control   (n=167) OR 2  (0.95 CI)  OR 3  (0.95 CI)  Case   (n=72) Control   (n=191)  OR 2  (0.95 CI) OR 3  (0.95 CI)  Walking     >3.5/w  (%) 17.5 23.5 NS NS 11.3 22.4 0.4   (0.2-0.9) NS 2  Other exercises      Yes (%)  22.2 40 0.4   (0.3-0.7) NS 16.2 42.4 0.3(0.1-0.5)  0.3(0.1-0.6)   1- Variables are dichotomous.2-Non significant.,Non-OADS,/arxiv_data1/oa_pdf/08/18/ijph-41-52.PMC3494231.pdf
: Risk Factors for Spinal Osteoporosi s …  57   Available at:    http://ijph.tums.ac.ir  osteoporosis (26).,Non-OADS,/arxiv_data1/oa_pdf/08/18/ijph-41-52.PMC3494231.pdf
52-59     Available at:    http://ijph.tums.ac.ir   58 factors as were described in previous studies.,Non-OADS,/arxiv_data1/oa_pdf/08/18/ijph-41-52.PMC3494231.pdf
: Risk Factors for Spinal Osteoporosi s …  59   Available at:    http://ijph.tums.ac.ir  Bone Mineral Density in  a Large Cohort of Pe-  rimenopausal Women from Scotland.,Non-OADS,/arxiv_data1/oa_pdf/08/18/ijph-41-52.PMC3494231.pdf
"60-64                                                            Original Article   60   Available at:    http://ijph.tums.ac.ir        Estimating the Frequency and Rate of First 50 Common  Types of  Invasive Procedures in Iran Healthcare System    A  Akbari Sari 1, * S Babashahy 1,2 , A Olyaeimanesh 1,2 , A Rashidian 1    1.",Non-OADS,/arxiv_data1/oa_pdf/b7/9c/ijph-41-60.PMC3494232.pdf
: Estimating the Frequency and Ra te of First 50  …  61   Available at:    http://ijph.tums.ac.ir  effects of any possible changes (i.e.,Non-OADS,/arxiv_data1/oa_pdf/b7/9c/ijph-41-60.PMC3494232.pdf
"60-64   Available at:    http://ijph.tums.ac.ir   62 (8.20%, 535 per 100,000 population), 260,514  coronary angiography disease (5.32%, 347 per  100,000 population), 181,836 varicocele (3.71%,  242 per 100,000 population), 144,918 appendect-omy (2.96%, 193 per 100,000 population), 134,766  rhinoplasty (2.75%, 180 per 100,000 population)  and 105,912 pilonidal cyst (2.16%, 141 per100,000  population) (Table 2).",Non-OADS,/arxiv_data1/oa_pdf/b7/9c/ijph-41-60.PMC3494232.pdf
": Estimating the Frequency and Ra te of First 50  …  63   Available at:    http://ijph.tums.ac.ir  percutaneous pinning   12 0.18 8,748 Endoscopy with biopsy collection of speci - men   37   12  0.18  8,658  Complicated  repair of forehead, cheek  38   11  0.17  8,226  Cystectomy  Ovary  39   11  0.16  7,974  Insertion and removal of Permanent Stent  40   10  0.15  7,362  Distal radial fracture of tissue of Forearm  41   9 0.14  6,768  Thempanostomy and Mastoedectomy   42   9 0.14 6,642 Reduction of closed  Dislocation  of Shoul- der   43   8 0.12  6,102  Radical resection  of tonsil   44   8 0.12  5,958  Biopsy and removal of breast mass   45   8 0.12  5,760  Fistulectomy, complicated or multiple  46   8 0.12  5,742  Excision of nail bed, complete or partial  47   7 0.11  5,544  Hemodialysis  48   7 0.11 5,490 Orchiopexy, any type, with or without her - nia repair, unilateral 49   7 0.10  5,130  Facetectomy or Foraminotomy, Lumber  50   4,649 71.32 3,486,528                        Total             Discussion      The natural vaginal delivery is the most common  invasive procedure in Iran followed by cataract,  cesarean section, coronary angiography, varicocele,   appendectomy and rhinoplasty.",Non-OADS,/arxiv_data1/oa_pdf/b7/9c/ijph-41-60.PMC3494232.pdf
"60-64   Available at:    http://ijph.tums.ac.ir   64 Ethical considerations    Ethical issues (Including plagiarism, Informed Con- sent, misconduct, data fabrication and/or falsifica tion,  double publication and/or submission, redundancy,  etc) have been completely observed by the authors.",Non-OADS,/arxiv_data1/oa_pdf/b7/9c/ijph-41-60.PMC3494232.pdf
Available at : http://www.majlis.ir/budget .,Non-OADS,/arxiv_data1/oa_pdf/b7/9c/ijph-41-60.PMC3494232.pdf
"41, No.10, Oct 2012, pp .65-71                                                         Original Article   65   Available at:    http://ijph.tums.ac.ir        Delayed Vaccination and Related Predictors among Inf ants    *J Poorolajal 1, 2 , S Khazaei 2, Z Kousehlou 2, SJ Bathaei 3, A Zahiri 3    1.",Non-OADS,/arxiv_data1/oa_pdf/e8/01/ijph-41-65.PMC3494233.pdf
Poorolajal  Available at:    http://ijph.tums.ac.ir (5).,Non-OADS,/arxiv_data1/oa_pdf/e8/01/ijph-41-65.PMC3494233.pdf
: Delayed Vaccination and Related Predictors  …    http://ijph.tums.ac.ir   elayed immunization can play a role of risk  in particular for pertussis  infections (7).,Non-OADS,/arxiv_data1/oa_pdf/e8/01/ijph-41-65.PMC3494233.pdf
65-71   67   Available at:    http://ijph.tums.ac.ir  The children population around each health cenk ter in either area was considered as a study popuk  lation.,Non-OADS,/arxiv_data1/oa_pdf/e8/01/ijph-41-65.PMC3494233.pdf
": Delayed Vaccination and Related Predictors …    Available at:    http://ijph.tums.ac.ir   68 Based on these results, 42% to 67.6% of the vack cines of various types were delivered out of the  definite deadline.",Non-OADS,/arxiv_data1/oa_pdf/e8/01/ijph-41-65.PMC3494233.pdf
65-71   69   Available at:    http://ijph.tums.ac.ir  Maternal education level       <0.001  Primary school 364  (37.1) 191  (19.5) 131  (13.4) 232  (23.7) 55  (5.6) 5 (0.5) 2 (0.2) 980   Middle school 188  (34.4) 103  (18.9) 79  (14.5) 129  (23.6) 38  (7.0) 7 (1.3) 2 (0.4) 546   High school 198  (27.3) 129  (17.8) 119  (16.4) 219  (30.1) 56  (7.7) 5 (0.7) 0 (0.0) 726   Academic 47  (22.6) 29  (13.9) 44  (21.2) 69  (33.2) 15  (7.2) 4 (1.9) 0 (0.0) 208   Vaccinators' education  level       <0.001   Primary school 70  (48.0) 23  (15.8) 20  (13.7) 26  (17.8) 7  (4.8) 0 (0.0) 0 (0.0) 146   Middle school 183  (34.9)  109  (20.8)  61  (11.6)  136  (26.0)  30  (5.7)  4 (0.8) 1 (0.2) 524   High school 418  (32.9) 244  (19.2) 202  (15.9) 324  (25.5) 69  (5.4) 11 (0.9) 2 (0.2) 1270   Academic 126  (24.2)  76  (14.6)  90  (17.3)  163  (31.4)  58  (11.2)  6 (1.2) 1 (0.2) 520   Vaccinators' work experiences (yr)       <0.001  1k10 184  (26.8) 130  (19.0) 119  (17.4) 197  (28.7) 51  (7.4) 5 (0.7) 0 (0.0) 686   11k20 378  (37.2) 182  (17.9) 139  (13.7) 235  (23.2) 68  (6.7) 9 (0.9) 4 (0.4) 1015   21k30 235  (31.0) 140  (18.5) 115  (15.2) 217  (28.6) 45  (5.9) 7 (0.9) 0 (0.0) 759   Number of monthly visits by supervisor during the l ast  year       <0.001  None 325  (24.3) 228  (17.0) 232  (17.3) 421  (31.4) 113  (8.4) 18 (1.3) 0 (0.0)  1340   Once 207  (41.5) 90  (18.0) 64  (12.8) 108  (21.6) 28  (5.6) 2  (0.4) 0 (0.0)  499   Twice 103  (40.1) 44  (17.1) 37  (14.4) 60  (23.4) 12  (4.7) 1 (0.4) 0 (0.0)  257   Thrice 125  (44.0) 70  (24.7) 35  (12.3) 42  (14.8) 11  (3.9) 0 (0.0) 1 (0.4)  284   ≥4 times 37  (46.3) 20  (25.0) 5 (6.3) 18  (22.5) 0  (0.0) 0 (0.0) 0 (0.0)  80     Discussion    Immunization Vision and Strategy 2006k2015 dek  veloped by WHO and UNICEF suggested a nak  tional vaccination coverage of at least 90% by  2010 or earlier for all countries worldwide (10).,Non-OADS,/arxiv_data1/oa_pdf/e8/01/ijph-41-65.PMC3494233.pdf
: Delayed Vaccination and Related Predictors …    Available at:    http://ijph.tums.ac.ir   70 when mothers brought their infants to the health  centers for vaccination.,Non-OADS,/arxiv_data1/oa_pdf/e8/01/ijph-41-65.PMC3494233.pdf
"65-71   71   Available at:    http://ijph.tums.ac.ir  Ethical considerations    Ethical issues (Including plagiarism, Informed Conk sent, misconduct, data fabrication and/or falsifica tion,  double publication and/or submission, redundancy,  etc) have been completely observed by the authors.",Non-OADS,/arxiv_data1/oa_pdf/e8/01/ijph-41-65.PMC3494233.pdf
"[cited 22 January, 2012]; Available from  http://www.emro.who.int/emrinfo/index.aspx  ?Ctry=ira 22 January, 2012).",OADS,/arxiv_data1/oa_pdf/e8/01/ijph-41-65.PMC3494233.pdf
"72-80                                                            Original Article   72   Available at:    http://ijph.tums.ac.ir         Candida parapsilosis  as a Potent Biocontrol Agent against  Growth and Aflatoxin Production by Aspergillus  Species    F Niknejad 1, *F Zaini 1, MA Faramarzi 2, M Amini 3, P Kordbacheh 1, M Mahmoudi 4,   M Safara 1    1.",Non-OADS,/arxiv_data1/oa_pdf/36/45/ijph-41-72.PMC3494234.pdf
": Candida parapsilosis as a Potent B iocontrol Agent …    73   Available at:    http://ijph.tums.ac.ir  The International Agency for Research on Cancer  (IARC), classifies naturally occurring aflatoxins  and aflatoxin B 1 (AFB 1) as group 1 carcinogens  for human (4).",Non-OADS,/arxiv_data1/oa_pdf/36/45/ijph-41-72.PMC3494234.pdf
"72-80   Available at:    http://ijph.tums.ac.ir   74 Growth studies   Primarily 0.5 ml of a suspension containing  1×10 6  CFU/ml of C. parapsilosis  was added to each 10  mm diameter plates with 20 ml of molten SGA  (45 ˚C) at pH values of 6.5, 7.4 and  8.0.",Non-OADS,/arxiv_data1/oa_pdf/36/45/ijph-41-72.PMC3494234.pdf
: Candida parapsilosis as a Potent B iocontrol Agent …    75   Available at:    http://ijph.tums.ac.ir  Table 1 : Inhibitory effect of Candida parapsilosis  IP1698 on mycelial growth of nine Aspergillus  spp.,Non-OADS,/arxiv_data1/oa_pdf/36/45/ijph-41-72.PMC3494234.pdf
"72-80   Available at:    http://ijph.tums.ac.ir   76 8.0  24  0 15  0 14  8 24   48  4 16  0 15  8 25   8)  A. flavus    (IP53) [+]  6.5  24  0 14  2 14  10  18   48  0 18  6 19  10  19   7.4  24  0 14  2 14  10  18   48  0 18  6 19  13  19   8.0  24  0 14  2 14  10  18   48  0 18  2 19  13  19   9)  A. flavus  (IP6641) [+]  6.5  24  0 15 0 10  3 22   48  1 17  0 12  3 22   7.4  24  0 15  0 10  3 22   48  2 17  0 12  4 22   8.0  24  0 15  0 10  3 22   48  2 17  0 12  3 22   [,]: Non,aflatoxigenic strain, [+]: Aflatoxigenic st rain, IP: Iranian patients, Ø: colony diameter milli meter, Time:  hours    Table 2:  Amount of aflatoxin produced by Aspergillus  spp.",Non-OADS,/arxiv_data1/oa_pdf/36/45/ijph-41-72.PMC3494234.pdf
: Candida parapsilosis as a Potent B iocontrol Agent …    77   Available at:    http://ijph.tums.ac.ir  Table 3:  Maximum and minimum condition for inhibition of mycelia growth in test and control Aspergillus   isolates    Aspergillus  spp.,Non-OADS,/arxiv_data1/oa_pdf/36/45/ijph-41-72.PMC3494234.pdf
"72-80   Available at:    http://ijph.tums.ac.ir   78 53.9, 52.4, 52, 51.7, 44, 38.2 and 35.4%, respec, tively (24).",Non-OADS,/arxiv_data1/oa_pdf/36/45/ijph-41-72.PMC3494234.pdf
: Candida parapsilosis as a Potent B iocontrol Agent …    79   Available at:    http://ijph.tums.ac.ir  Detection of Aflr Gene and Toxigenicity of  Aspergillus flavus Group Isolated from  Patients with Fungal Sinusitis.,Non-OADS,/arxiv_data1/oa_pdf/36/45/ijph-41-72.PMC3494234.pdf
"July 2006 (http://www.afro.who.int/des;  available at August 15, 2011).",Non-OADS,/arxiv_data1/oa_pdf/36/45/ijph-41-72.PMC3494234.pdf
72-80   Available at:    http://ijph.tums.ac.ir   80 some reference fungal strains.,Non-OADS,/arxiv_data1/oa_pdf/36/45/ijph-41-72.PMC3494234.pdf
"81-86                                                             Original Article   81   Available at:    http://ijph.tums.ac.ir        Co-Inheritance of Sickle Cell Trait and Thalassemia  Mutations in  South Central Iran    *N Saleh-gohari 1, M Mohammadi-Anaie 2    1.",Non-OADS,/arxiv_data1/oa_pdf/e4/fe/ijph-41-81.PMC3494235.pdf
"Saleh-gohari & Mohammadi-Anaie: Co-Inheritance of S ickle Cell Trait …    Available at:    http://ijph.tums.ac.ir   82 Genetic factors such as α or βqglobin gene mutaq tions can modulate the hematological diagnostic  data and clinical expression of the sickle cell, wh en  coqinherited with the βS gene (11)  .",Non-OADS,/arxiv_data1/oa_pdf/e4/fe/ijph-41-81.PMC3494235.pdf
81-86   83   Available at:    http://ijph.tums.ac.ir  amplification refractory mutations systemq polymerase chain reaction (ARMSqPCR)  technique (16).,Non-OADS,/arxiv_data1/oa_pdf/e4/fe/ijph-41-81.PMC3494235.pdf
"Saleh-gohari & Mohammadi-Anaie: Co-Inheritance of S ickle Cell Trait …    Available at:    http://ijph.tums.ac.ir   84 Table 3:  Hematologic data of sickle cell and/or thalassemia c ases from Kerman and Hormozgan Provq inces, Iran    HbS(%)  HbF(%)  HbA2(%)  HbA(%)  MCH(pg)  MCV(fL)  HCT(%)  Hb(g/dL)  Mutations   35.504  0.835  3.071  60.835  26.011  75.964  39.926  13.194  βs  72.76  18.54  4.58  5.2125  22.19  68.82  28.856  9.17  βs & βthal (het) a  34.163  0.894  3.097  63.140  24.564  73.659  39.475  13.096  βs & α thal  (het)   29.778  1.133  3.207  66.456  22.536  69.479  39.932  13.093  βs & α thal  (homo) b  a heterozygote; b homozygote    Table 4: Geographical distribution of the referred  sickle cell and/or thalassemia cases from  Hormozgan Province and Different Cities of Kerq man, Iran    % n  City  31.3  56  Hormozgan   26.8  48  Kahn oo j  23.5  42  Jiroft   9.5  17  Baft   3.9  7 Bam   3.9  7 Kerman a  1.1  2 Shahr Babak   100  179  Total   aCapital of Kerman Province, Iran     Discussion    The high coqinheritance of sickle cell trait and αq globin gene deletions (HbS/Normal, –α3.7/αα)  was predictable, since αqglobin deletion was preq viously reported as the most common globin gene  mutation in Kerman province (18), other regions  of the country (19q21) and what has been reported  in other studies around the world (22, 23).",Non-OADS,/arxiv_data1/oa_pdf/e4/fe/ijph-41-81.PMC3494235.pdf
81-86   85   Available at:    http://ijph.tums.ac.ir  the advantage of heterozygosity.,Non-OADS,/arxiv_data1/oa_pdf/e4/fe/ijph-41-81.PMC3494235.pdf
Saleh-gohari & Mohammadi-Anaie: Co-Inheritance of S ickle Cell Trait …    Available at:    http://ijph.tums.ac.ir   86 13.,OADS,/arxiv_data1/oa_pdf/e4/fe/ijph-41-81.PMC3494235.pdf
"87-96                                                            Original Article   87   Available at:    http://ijph.tums.ac.ir         Tuberculosis Surveillance Using a Hidden Markov Mod el    A Rafei 1, E Pasha 2, *R Jamshidi Orak 1    1.",Non-OADS,/arxiv_data1/oa_pdf/0d/52/ijph-41-87.PMC3494236.pdf
: Tuberculosis Surveillance Using a Hid den  …    Available at:    http://ijph.tums.ac.ir   88 ported in Iran and of these cases 246 patients  (around 2.2%) were HIV positive (21).,Non-OADS,/arxiv_data1/oa_pdf/0d/52/ijph-41-87.PMC3494236.pdf
87-96   89   Available at:    http://ijph.tums.ac.ir  nosed SS+ patients during the six-year period  2005-2011.,Non-OADS,/arxiv_data1/oa_pdf/0d/52/ijph-41-87.PMC3494236.pdf
": Tuberculosis Surveillance Using a Hid den  …    Available at:    http://ijph.tums.ac.ir   90 Let St (t=1,2,…,n)  represents a first order Markov  chain which takes on one of the m values  1,2,…,m by a transition matrix Γ=(α ij )m*m  and ini- tial probability distribution ̟=(̟ 1,…, ̟ m)T, where   αij = P(S t=j|S t}1=i)   i, j = 1,2,…,m;   t = 1,2,…,n  ̟i = P(S 1=i)   i = 1,2,…,m  Moreover, the conditional distribution of  Yt given   St=i follows a parametric form  fi(y t;θ i) where  θi is a  vector of unknown parameters.",Non-OADS,/arxiv_data1/oa_pdf/0d/52/ijph-41-87.PMC3494236.pdf
87-96   91   Available at:    http://ijph.tums.ac.ir  constant over the considered time period; that is  the time series of SS+ counts does not follows a  seasonal trend.,OADS,/arxiv_data1/oa_pdf/0d/52/ijph-41-87.PMC3494236.pdf
": Tuberculosis Surveillance Using a Hid den  …    Available at:    http://ijph.tums.ac.ir   92 Table 2:  Parameters estimation of two models with and without  seasonality for both phases of the  disease    Model  Disease  phase  Number  of states  Initial  probably  Transition proba B bility    Model parameters   Usual  Unusual   β0 β1 β2 β3  With seaso- nality  Usual 192  1 0.70  0.30   76.82  0.07  7.15  7.42   Unusual 120  0 0.45  0.55   100.26  0.07  7.15  7.42          λ     Without  seasonality  Usual 160  1 0.79  0.21   82.45      Unusual 152  0 0.21  0.79   111.24        Moreover, the shifts in the mean number of pa- tients while moving to the abnormal phase were  observed 23.44 and 28.79 in two models with and  without seasonality assumption, respectively.",Non-OADS,/arxiv_data1/oa_pdf/0d/52/ijph-41-87.PMC3494236.pdf
87-96   93   Available at:    http://ijph.tums.ac.ir        Fig.,Non-OADS,/arxiv_data1/oa_pdf/0d/52/ijph-41-87.PMC3494236.pdf
": Tuberculosis Surveillance Using a Hid den  …    Available at:    http://ijph.tums.ac.ir   94 Discussion    In this paper, a powerful statistical tool was em- ployed to monitor the routinely TB surveillance  data retrospectively, in an attempt at detecting ab- normalities and aberrations from the expected  disease incidence.",Non-OADS,/arxiv_data1/oa_pdf/0d/52/ijph-41-87.PMC3494236.pdf
"87-96   95   Available at:    http://ijph.tums.ac.ir  Ethical considerations    Ethical issues (Including plagiarism, Informed  Consent, misconduct, data fabrication and/or fal-  sification, double publication and/or submission,  redundancy, etc) have been completely observed  by the authors.",Non-OADS,/arxiv_data1/oa_pdf/0d/52/ijph-41-87.PMC3494236.pdf
: Tuberculosis Surveillance Using a Hid den  …    Available at:    http://ijph.tums.ac.ir   96 Trends of drug resistant Mycobacterium  tuberculosis in a tertiary tuberculosis center  in Iran.,Non-OADS,/arxiv_data1/oa_pdf/0d/52/ijph-41-87.PMC3494236.pdf
"Iran Ministry, Available from:  http://www.cdc.hbi.ir.",Non-OADS,/arxiv_data1/oa_pdf/0d/52/ijph-41-87.PMC3494236.pdf
"97-101                                             Short Communication   97   Available at:    http://ijph.tums.ac.ir         Determination of Aflatoxin M1 Contamination and Int egrity as  well as Credibility     *R Ataee 1, A Mehrabi Tavana 2, MH Ataee 3,4     1.",Non-OADS,/arxiv_data1/oa_pdf/6e/b2/ijph-41-97.PMC3494237.pdf
: Determination of Aflatoxin M1 Contami nation  …    Available at:    http://ijph.tums.ac.ir   98 son or not.,Non-OADS,/arxiv_data1/oa_pdf/6e/b2/ijph-41-97.PMC3494237.pdf
97-101   99   Available at:    http://ijph.tums.ac.ir  aflatoxin M1 more than European standard limit  as well 26.9% of samples had aflatoxin M1 more  than America standard limit (7).,Non-OADS,/arxiv_data1/oa_pdf/6e/b2/ijph-41-97.PMC3494237.pdf
: Determination of Aflatoxin M1 Contami nation  …    Available at:    http://ijph.tums.ac.ir   100 Table 1:  Summarized results of the researches on milk contamin ation to Aflatoxin M1in diferent seasons    Year  Authors  Region  Origin   (ng/lit)   Spring  Summer  Autumn  Winter   2007  Taj Karimi et al .,OADS,/arxiv_data1/oa_pdf/6e/b2/ijph-41-97.PMC3494237.pdf
"97-101   101   Available at:    http://ijph.tums.ac.ir  Acknowledgements    The authors would like to thank the head of Ba-  qiyatallah Research Institute, Dr. Mostafa Ghanei,  for encourage the authors, Dr. Hadi Lashini for  editing the manuscript.",Non-OADS,/arxiv_data1/oa_pdf/6e/b2/ijph-41-97.PMC3494237.pdf
This article is available online at http://www.jlr.org Supplementary key words  Nr4a  nuclear receptor  mitochondria    The mitochondrion is an indispensable component for  cellular respiration.,Non-OADS,/arxiv_data1/oa_pdf/03/36/2610.PMC3494265.pdf
"2  Current afﬁ  liation: The Center for Endocrinology, Diabetes and  Metabolism, The Saban Research Institute, Children’s Hospital Los Angeles, Los Angeles, CA   3  Current afﬁ  liation: Center for Metabolic and Degenerative Diseases,  Brown Foundation Institute of Molecular Medicine, The University of Texas Medical School at Houston, Houston, TX      The online version of this article (available at http://www.jlr.",Non-OADS,/arxiv_data1/oa_pdf/03/36/2610.PMC3494265.pdf
Supplementary Material Supplementary information and ﬁgures S1–S7 are available atMolecular Biology and Evolution online ( http://www.mbe .oxfordjournals.org/ ).,Non-OADS,/arxiv_data1/oa_pdf/b2/4c/mss179.PMC3494269.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/How to cite this article: Fanzio, P. et al.",Non-OADS,/arxiv_data1/oa_pdf/a5/84/srep00791.PMC3494361.pdf
"BJ, OS contributed to the interpretation of the data and critical reviewed themanuscript Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.",Non-OADS,/arxiv_data1/oa_pdf/cf/b1/srep00788.PMC3494377.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ How to cite this article: Bienes-Martı ´nez, R. et al.",Non-OADS,/arxiv_data1/oa_pdf/cf/b1/srep00788.PMC3494377.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0",Non-OADS,/arxiv_data1/oa_pdf/7e/32/cr2012141a.PMC3494397.pdf
"doi:10.1038/bjc.2012.410 www.bjcancer.com Published online 18 September 2012 &2012 Cancer Research UK Keywords: fibroblast growth factors; ovarian cancer; survival; chemotherapy; platinum drugs/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12/C12 Epithelial ovarian cancer, the second most common and most lethal gynaecological malignancy, frequently presents at anadvanced stage where surgery is difficult and metastatic spread common (http://www.isdscotlandarchive.scot.nhs.uk/isd/Cancer_ in_Scotland_summary.pdf).",Non-OADS,/arxiv_data1/oa_pdf/85/54/bjc2012410a.PMC3494420.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Al-Hussaini M, Stockman A, Foster H, McCluggage WG (2004) WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/85/54/bjc2012410a.PMC3494420.pdf
"Target prediction analysis To find putative target genes of miRNA-214 and build hypothesis concerning its role in RT response of NSCLC, several bio-informatics algorithms were employed, that is, miRBase predictedmRNA targets of miRNAs (http://www.mirbase.org/), Target- scan (http://www.targetscan.org/), microrna.org (http://www.",OADS,/arxiv_data1/oa_pdf/df/1c/bjc2012382a.PMC3494421.pdf
"microrna.org/microrna/home.do), microcosm (http://www.ebi.ac.uk/miRNA and radioresistance of NSCLC H Salim et al 1362 British Journal of Cancer (2012) 107(8), 1361 – 1373 &2012 Cancer Research UK Molecular Diagnostics",OADS,/arxiv_data1/oa_pdf/df/1c/bjc2012382a.PMC3494421.pdf
Protein densitometry was executed by using Image J software (http://rsbweb.nih.gov/ij/).,OADS,/arxiv_data1/oa_pdf/df/1c/bjc2012382a.PMC3494421.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Alexander K, Hinds PW (2001) Requirement for p27(KIP1) in retinoblas- toma protein-mediated senescence.",Non-OADS,/arxiv_data1/oa_pdf/df/1c/bjc2012382a.PMC3494421.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C,Pharoah P, Hiller L, Earl H, Poole CJ (2010) Predictive markers ofanthracycline benefit: a prospectively planned analysis of the UKNational Epirubicin Adjuvant Trial (NEAT/BR9601).",Non-OADS,/arxiv_data1/oa_pdf/3c/33/bjc2012370a.PMC3494422.pdf
http://www.ncin.org.uk/collecting_and_using_data/national_ cancer_data_repository/default.aspx (accessed 2 August 2012) NHS Bowel Cancer Screening Programme (2011) http://www.cancerscree- ning.nhs.uk/bowel/index.html (accessed 2 August 2012) NHS Information Centre for Health and Social Care (2011) Hospital Episode Statistics (HES) .,Non-OADS,/arxiv_data1/oa_pdf/4d/a3/bjc2012408a.PMC3494426.pdf
"http://www.hesonline.nhs.uk (accessed 2 August 2012) Parkin DM, Hakulinen T (1991) Analysis of survival.",Non-OADS,/arxiv_data1/oa_pdf/4d/a3/bjc2012408a.PMC3494426.pdf
"http://www.analyse-it.com/ Barry A, O’Cearbhaill R, Griffin D, Donnellan P, Keane M, Grimes H (2009) Evaluation of carboplatin dosage based on 4-variable modification of dietin renal disease equation.",Non-OADS,/arxiv_data1/oa_pdf/30/6c/bjc2012393a.PMC3494427.pdf
http://www.renal.org/Libraries/Other_Guidlines/NICE_73_Chronic_Kidney_Disease_2008.sflb.ashx (accessed 10 February2011) National Kidney Disease Education Program (2012) Chronic Kidney Disease and Drug Dosing: Information for Providers.,Non-OADS,/arxiv_data1/oa_pdf/30/6c/bjc2012393a.PMC3494427.pdf
"http://nkdep.nih.gov/professionals/drug-dosing-information.htm (accessed 10 January2012) National Kidney Foundation (2002) K/DOQI clinical practise guidelines for chronic kidney disease: evaluation, classification and stratification.",Non-OADS,/arxiv_data1/oa_pdf/30/6c/bjc2012393a.PMC3494427.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) 0123456 0123456701234567 01234567343536 37 38 4142 44 45 35 3436 37 3841 42 44 45N-Cad ITGA9 Hes1 Hes17BA C41Hes1 N-cad ITGA9 3734 Pearson correlation 0.771 ( P<0.05)Pearson correlation 0.584 ( P<0.1) Figure 6 The expression of Hes1, N-cadherin and a9-integrin correlate in archival RMS tumour samples.",Non-OADS,/arxiv_data1/oa_pdf/4e/28/bjc2012411a.PMC3494428.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Alric R, Cociglio M, Blayac JP, Puech R (1981) Performance evaluation of a reversed-phase, high-performance liquid chromatographic assay ofvalproic acid involving a ‘‘solvent demixing’’ extraction procedure and precolumn derivatisation.",Non-OADS,/arxiv_data1/oa_pdf/8c/99/bjc2012409a.PMC3494429.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/Gut microbiota, propionate and cancer cell growth LB Bindels et al 1344 British Journal of Cancer (2012) 107(8), 1337 – 1344 &2012 Cancer Research UK Molecular Diagnostics",Non-OADS,/arxiv_data1/oa_pdf/8c/99/bjc2012409a.PMC3494429.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Becker PD, Legrand N, van Geelen CM, Noerder M, Huntington ND, Lim A, Yasuda E, Diehl SA, Scheeren FA, Ott M, Weijer K, Wedemeyer H,Di Santo JP, Beaumont T, Guzman CA, Spits H (2010) Generation of human antigen-specific monoclonal IgM antibodies using vaccinated ‘human immune system’ mice.",Non-OADS,/arxiv_data1/oa_pdf/67/93/bjc2012394a.PMC3494430.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/3.0/Anti-HER-2 responses in humanised mice C De Giovanni et al 1309 &2012 Cancer Research UK British Journal of Cancer (2012) 107(8), 1302 – 1309 Translational Therapeutics",Non-OADS,/arxiv_data1/oa_pdf/67/93/bjc2012394a.PMC3494430.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y (1994) Radical lymph node dissection for cancer of the thoracic esophagus.",Non-OADS,/arxiv_data1/oa_pdf/1d/5e/bjc2012396a.PMC3494434.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K,Escudier B (2011) Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded-access study: a large open- label study in diverse community settings.",Non-OADS,/arxiv_data1/oa_pdf/b1/44/bjc2012327a.PMC3494435.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (2004) Tumor cells circulatein the peripheral blood of all major carcinomas but not in healthysubjects or patients with nonmalignant diseases.",Non-OADS,/arxiv_data1/oa_pdf/9c/e2/bjc2012388a.PMC3494437.pdf
The annotation and oligonucleo-tide sequences of the probes conformed to the miRBase microRNA database (http://microRNA.sanger.ac.uk/sequences/).,OADS,/arxiv_data1/oa_pdf/21/b0/bjc2012326a.PMC3494440.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Alix-Panabieres C, Riethdorf S, Pantel K (2008) Circulating tumor cells and bone marrow micrometastasis.",Non-OADS,/arxiv_data1/oa_pdf/21/b0/bjc2012326a.PMC3494440.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/Endothelial cell metabolism U Harjes et al 1212 British Journal of Cancer (2012) 107(8), 1207 – 1212 &2012 Cancer Research UK",Non-OADS,/arxiv_data1/oa_pdf/dd/2a/bjc2012398a.PMC3494441.pdf
"Access available at URL http://geoconvert.mimas.ac.uk/ (accessed July 2012) Vamos EP, Pape UJ, Bottle A, Hamilton FL, Curcin V, Ng A, Molokhia M, Car J, Majeed A, Millett C (2011) Association of practice size and pay-for-performance incentives with the quality of diabetes management in primary care.",Non-OADS,/arxiv_data1/oa_pdf/6b/38/bjc2012320a.PMC3494442.pdf
"In an ongoing clinical trial for recurrent paediatric brain tumours (Phase II), the efficacy of TMZ (alone) is being testedagainst that of intravenous carboplatin/etoposide (HIT-REZ 2005;http://clinicaltrials.gov/ct2/show/NCT00749723).",Non-OADS,/arxiv_data1/oa_pdf/26/a9/bjc2012403a.PMC3494444.pdf
Another clinical trial compares the effectiveness of the well-tested combination ofTMZ and irinotecan hydrochloride with or without bevacizumab (http://clinicaltrials.gov/ct2/show/NCT01217437) in recurrent MB.,Non-OADS,/arxiv_data1/oa_pdf/26/a9/bjc2012403a.PMC3494444.pdf
"Gene expression by microarray analysis The gene expression data of MB tumours ( n¼61), which are available from NCBI’s Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/; accession number GSE10327) and published by Kool et al (2012), were reanalysed, whereas those of the 12 MB cell lines (D341Med, D425Med, D283Med, DAOY, MHH-MED-1, D556Med, 1580WU ¨, MHH-MED-3, MEB-MED-8S, MHH- MED-4, MEB-MED-8A, and UW228-2) were newly generated.",OADS,/arxiv_data1/oa_pdf/26/a9/bjc2012403a.PMC3494444.pdf
Data analysis was performed using the R2 microarray analysisand visualisation platform (http://r2.amc.nl).,OADS,/arxiv_data1/oa_pdf/26/a9/bjc2012403a.PMC3494444.pdf
"Included as reference were the expression data of nine normal cerebellum (CB; without information about age) samples which were assessed also by Affymetrix HG U133 Plus 2.0 array by Roth et al (2006), and data were available from NCBI’s Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/; accessionnumber GSE3526).",OADS,/arxiv_data1/oa_pdf/26/a9/bjc2012403a.PMC3494444.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Baldwin P, Laskey R, Coleman N (2003) Translational approaches to improving cervical screening.",Non-OADS,/arxiv_data1/oa_pdf/d4/10/bjc2012381a.PMC3494445.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W, Sarkar FH, Raz A (2011) Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells.",Non-OADS,/arxiv_data1/oa_pdf/53/fc/bjc2012383a.PMC3494446.pdf
"stanford.edu/cgi-bin/source/sourceSearch) and EntrezGene (Homosapiens gene information database, release from 09 December2008, ftp://ftp.ncbi.nlm.nih.gov/gene/).",OADS,/arxiv_data1/oa_pdf/1d/87/bjc2012390a.PMC3494448.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Allander SV, Nupponen NN, Ringner M, Hostetter G, Maher GW, Goldberger N, Chen Y, Carpten J, Elkahloun AG, Meltzer PS (2001)Gastrointestinal stromal tumors with KIT mutations exhibit a remark-ably homogeneous gene expression profile.",Non-OADS,/arxiv_data1/oa_pdf/1d/87/bjc2012390a.PMC3494448.pdf
"Data were stored in the R2 microarray analysis and visualisation platform (AMC Amsterdam, http://r2.amc.nl, Amsterdam, The Netherlands) for explorationand visualisation.",OADS,/arxiv_data1/oa_pdf/82/c8/bjc2012391a.PMC3494449.pdf
"Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) REFERENCES Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P, Roobeek I, Weis I, Voute PA, Schwab M, Versteeg R (2001) N-mycenhances the expression of a large set of genes functioning in ribosomebiogenesis and protein synthesis.",Non-OADS,/arxiv_data1/oa_pdf/82/c8/bjc2012391a.PMC3494449.pdf
"Three C-P3Hs (nomenclature was amended according to approval by the HGNC symbols and names at http:// www.genenames.org/ and Entrez database at http://www.ncbi.nlm.nih.gov/gene) leucineproline-enriched proteoglycan (leprecan) 1 (Lepre1 ), leprecan-like 1 ( Leprel1 ), leprecan-like 2 ( Leprel2 ) and two paralogs Cartilage-Related Protein ( CRTAP ) and leprecan-like 4 (Leprel4 ) are found in humans.",Non-OADS,/arxiv_data1/oa_pdf/ad/85/bjc2012380a.PMC3494450.pdf
Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc) MU MU MU MU MMU MMMMMMMM M MMMMMMMM M MMM MMMM MMU M MMU UM UUM U M U M U M U MUMUMUMUMUMUMUMUMUMUMUMU MUMUMUMU MUMUMUMUMUMUMUMUMU BB CMCML1 L2 L3 L4 B BBBCM CM CMCM CM CMCM BB CMCM BB CMCMCU CUCU CUCML1 L1 L1L2 L2 L2L3 L4 L5L5 L6L6 L7L7 L8 L4Leprel4 L3 L2 L3 L3L4CRTA P Leprel1 P4HA1Leprel2 12345678 9 123456789 123456789P4HA2 P4HA3 Leprel1 Leprel2 Unmethylated Unmethylated Methylated Methylated Figure 6 Analysis of the CpG islands in C-P3H and C-P4H genes in clinical lymphoma cases.,Non-OADS,/arxiv_data1/oa_pdf/ad/85/bjc2012380a.PMC3494450.pdf
"DuPage and colleagues showed that loss of tumor anti - gen expression or presentation on Class I MHC molecules was necessary and T-cell dependent immunoselection Mads Hald a ndersen department of Hematology; Center for Cancer Immune t herapy (CCI t); Copenhagen University Hospital Herlev; Herlev, d enmark Correspondence to: Mads Hald Andersen; Email: mads.hald.andersen@regionh.dk Submitted: 05/24/12; Accepted: 05/30/12http://dx.doi.org/10.4161/onci.20927sufficient for immunoediting to occur.",OADS,/arxiv_data1/oa_pdf/47/56/onci-1-1003.PMC3494614.pdf
Nature 2012; 482:400-4; PMID:22318521;  http://dx.doi.org/10.1038/nature10755.,Non-OADS,/arxiv_data1/oa_pdf/47/56/onci-1-1003.PMC3494614.pdf
Nature 2012; 482:405- 9; PMID:22318517; http://dx.doi.org/10.1038/ nature10803.,Non-OADS,/arxiv_data1/oa_pdf/47/56/onci-1-1003.PMC3494614.pdf
Cancer Res 2004; 64:5456-60;  PMID:15289355; http://dx.doi.org/10.1158/0008- 5472.CAN-04-0937.4.,Non-OADS,/arxiv_data1/oa_pdf/47/56/onci-1-1003.PMC3494614.pdf
Cancer Res 2004; 64:1595-9; PMID:14996715;  http://dx.doi.org/10.1158/0008-5472.CAN-03-3231.,Non-OADS,/arxiv_data1/oa_pdf/47/56/onci-1-1003.PMC3494614.pdf
Clin Cancer Res 2006; 12:1365-72; PMID:16489095; http://dx.doi.org/10.1158/1078- 0432.CCR-05-1672.,Non-OADS,/arxiv_data1/oa_pdf/47/56/onci-1-1003.PMC3494614.pdf
Cancer Res 2006; 66:3287-93;  PMID:16540682; http://dx.doi.org/10.1158/0008- 5472.CAN-05-1932.,Non-OADS,/arxiv_data1/oa_pdf/47/56/onci-1-1003.PMC3494614.pdf
"Kaumaya; Email: Kaumaya.1@osu.edu Submitted: 05/17/12; Revised: 06/05/12; Accepted: 06/08/12http://dx.doi.org/10.4161/onci.21057Introduction ERBB2 (best known as HER-2/neu is an oncoprotein that is over - expressed in approximately 20–30% cases of breast cancers and  is associated with increased aggressiveness and poor clinical out - come.1 HER-2 is a well-established target for immunotherapy and  many different anti-HER-2 strategies have been tested, including several humanized monoclonal antibodies (such as trastuzumab and pertuzumab) and small molecule tyrosine kinase inhibitor (like lapatanib).",Non-OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Science 1987; 235:177-82;  PMID:3798106; http://dx.doi.org/10.1126/sci- ence.3798106.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
J Pediatr Surg 2001; 36:1177-81; PMID:11479851;  http://dx.doi.org/10.1053/jpsu.2001.25747.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Pharmacol Rev  2004; 56:549-80; PMID:15602010; http://dx.doi.org/10.1124/pr.56.4.3.,Non-OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Hypertension  2002; 39:1095-100; PMID:12052848; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Eur J Cancer  2006; 42:3127-39; PMID:17098419; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
J Clin Oncol 2009; 27:5270-7; PMID:19752336; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
J Biol Chem  2011; 286:13626-37; PMID:21325276; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
OncoImmunology 2012; 1: In press;  http://dx.doi.org/10.4161/onci.20708.,Non-OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Science  2005; 307:58-62; PMID:15637262; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Nihon Rinsho Meneki Gakkai Kaishi 2010; 33:24- 30; PMID:20190507; http://dx.doi.org/10.2177/ jsci.33.24.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Nat  Rev Drug Discov 2006; 5:649-59; PMID:16883303;  http://dx.doi.org/10.1038/nrd2089.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Biopolymers 2005; 80:67- 84; PMID:15729688; http://dx.doi.org/10.1002/ bip.20219.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Ann Oncol 2008; 19:1530- 9; PMID:18480068; http://dx.doi.org/10.1093/annonc/mdn292.,Non-OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Am J Pathol  2003; 163:2113-26; PMID:14578209; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Drugs 1998; 55:5-30; PMID:9463787;  http://dx.doi.org/10.2165/00003495-199855010- 00002.,Non-OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
J Clin Immunol 1991; 11:117-27; PMID:1679763; http://dx.doi.org/10.1007/ BF00918679.,Non-OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Curr Protein Pept Sci  2003; 4:339-56; PMID:14529528; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Chem Rev 1998; 98:763- 96; PMID:11848914; http://dx.doi.org/10.1021/ cr970468t.,Non-OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
J Pept Res 2005; 65:591-604; PMID:15885118; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
Ann Oncol 2002; 13:12-5;  PMID:11863092; http://dx.doi.org/10.1093/annonc/ mdf093.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
J Biol Chem 2004; 279:24141- 51; PMID:15060075; http://dx.doi.org/10.1074/jbc.M313210200.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
J Pept Sci 2000; 6:387-97; PMID:10969868; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/11/onci-1-1004.PMC3494615.pdf
"www.landesbioscience.com OncoImmunology 1017 ReseaR ch papeR ReseaR ch papeR OncoImmunology 1:7, 1017–1026; October 2012; © 2012 Landes Bioscience *Correspondence to: Firouzeh Korangy and Tim F. Greten; Email: firouzeh.korangy@nih.gov and tim.greten@nih.gov Submitted: 06/08/12; Accepted: 06/11/12http://dx.doi.org/10.4161/onci.21098Introduction Tumor cell death can control antitumor immune responses.",Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Cancer Metastasis  Rev 2011; 30:71-82; PMID:21298323; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Annu Rev Immunol 1994; 12:991-1045;  PMID:8011301; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
J Exp Med  2000; 191:423-34; PMID:10662788; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Int Immunol 2000; 12:1539-46; PMID:11058573;  http://dx.doi.org/10.1093/intimm/12.11.1539.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Nature 2002; 418:191-5; PMID:12110890;  http://dx.doi.org/10.1038/nature00858.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Nature 2003; 425:516-21; PMID:14520412;  http://dx.doi.org/10.1038/nature01991.8.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
J Biol Chem 2004; 279:12542-50; PMID:14729660;  http://dx.doi.org/10.1074/jbc.M310175200.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Immunity 2012; 36:635-45;  PMID:22483800; http://dx.doi.org/10.1016/j.immu- ni.2012.03.008.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Nat Med 2005; 11:1173-9;  PMID:16244651; http://dx.doi.org/10.1038/nm1315.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Cell Res 2000; 10:267-78; PMID:11191349; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
T rends Genet 2002; 18:142-9; PMID:11858838; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
J Exp Med  2002; 196:1091-7; PMID:12391020; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Nature 1998; 392:86-9;  PMID:9510252; http://dx.doi.org/10.1038/32183.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
J Exp Med 2005; 202:1691-701; PMID:16365148;  http://dx.doi.org/10.1084/jem.20050915.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Nat Med 2009; 15:1170- 8; PMID:19767732; http://dx.doi.org/10.1038/ nm.2028.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Nat  Med 2007; 13:54-61; PMID:17187072; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
J Immunol  2011; 186:1503-11; PMID:21187449; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
J Exp Med 2000;  191:1699-708; PMID:10811863; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Immunol Cell  Biol 2000; 78:110-7; PMID:10762410; http://dx.doi.org/10.1046/j.1440-1711.2000.00889.x.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Cell 1994; 76:17-27; PMID:8287475; http://dx.doi.org/10.1016/0092- 8674(94)90169-4.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Nature 2000; 408:740-5; PMID:11130078;  http://dx.doi.org/10.1038/35047123.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Immunity 1999; 11:443-51;  PMID:10549626; http://dx.doi.org/10.1016/S1074- 7613(00)80119-3.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Immunity 1998; 9:143-50; PMID:9697844;  http://dx.doi.org/10.1016/S1074-7613(00)80596-8.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
J Biol Chem 2007; 282:13190- 8; PMID:17353199; http://dx.doi.org/10.1074/jbc.M610340200.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Proc Natl Acad Sci U S A 2000; 97:14590- 5; PMID:11106387; http://dx.doi.org/10.1073/ pnas.260497597.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Nature 2009; 458:899-903; PMID:19219027;  http://dx.doi.org/10.1038/nature07750.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Br J Cancer 2006; 95:896- 905; PMID:16953240; http://dx.doi.org/10.1038/sj.bjc.6603341.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Cancer Res  2006; 66:7285-92; PMID:16849578; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Science  2004; 304:1318-21; PMID:15166379; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Immunity 2008; 28:787-98; PMID:18549799;  http://dx.doi.org/10.1016/j.immuni.2008.04.015.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
J Exp Med 1998; 188:409-14; PMID:9670054;  http://dx.doi.org/10.1084/jem.188.2.409.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Annu Rev Immunol  2001; 19:47-64; PMID:11244030; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Immunol Rev 2005; 207:8-18; PMID:16181323; http://dx.doi.org/10.1111/j.0105-2896.2005.00309.x.23.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Cell 2011; 147:728-41;  PMID:22078875; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Cell Death Differ  2009; 16:991-1005; PMID:19229247; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Science 2011; 334:1573- 7; PMID:22174255; http://dx.doi.org/10.1126/sci- ence.1208347.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Cell Death Differ 2003; 10:1156-64; PMID:14502239;  http://dx.doi.org/10.1038/sj.cdd.4401286.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Mol Biol Cell 2004; 15:1089-100;  PMID:14668480; http://dx.doi.org/10.1091/mbc.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
Eur J Immunol 2000; 30:705-8;  PMID:10671230; http://dx.doi.org/10.1002/1521- 4141(200002)30:2<705::AID-IMMU705>3.0.CO;2-P. 32.,Non-OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
J Biol Chem  2002; 277:20847-53; PMID:11912201; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/05/onci-1-1017.PMC3494616.pdf
"www.landesbioscience.com OncoImmunology 1027OncoImmunology 1:7, 1027-1037; October 2012; © 2012 Landes Bioscience ReseaR ch papeR ReseaR ch papeR *Correspondence to: Dagmar Stoiber; Email: dagmar.stoiber@meduniwien.ac.at Submitted: 03/29/12; Revised: 06/21/12; Accepted: 06/27/12http://dx.doi.org/10.4161/onci.21284Introduction Type I IFNs were identified and intensively studied as cytokines  induced during viral infections.",Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Blood 2011; 117:1565-73; PMID:21127177;  http://dx.doi.org/10.1182/blood-2010-06-291633.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Nature 2003; 424:516- 23; PMID:12872134; http://dx.doi.org/10.1038/ nature01850.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
J Clin Invest 2010; 120:1151- 64; PMID:20237412; http://dx.doi.org/10.1172/JCI37223.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
J Clin Invest  2009; 119:1251-63; PMID:19349689; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
J Exp Med 2008; 205:2965- 73; PMID:19029380; http://dx.doi.org/10.1084/ jem.20081752.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Nat Immunol 2000; 1:119-26;  PMID:11248803; http://dx.doi.org/10.1038/77793.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Nat  Med 1999; 5:405-11; PMID:10202929; http://dx.doi.org/10.1038/7403.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
J Exp Med 2004; 200:287-95; PMID:15289500;  http://dx.doi.org/10.1084/jem.20040370.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Immunity  2007; 26:503-17; PMID:17398124; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Science  1994; 264:1918-21; PMID:8009221; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Blood  2006; 108:3253-61; PMID:16868248; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
N Engl J Med 1999; 341:164- 72; PMID:10403855; http://dx.doi.org/10.1056/ NEJM199907153410306.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Leuk  Lymphoma 1995; 18(Suppl 1):37-42; PMID:7496353;  http://dx.doi.org/10.3109/10428199509075301.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Adv Virus Res 1988;  35:39-81; PMID:2852893; http://dx.doi.org/10.1016/ S0065-3527(08)60708-3.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Curr Opin Immunol 2003; 15:158-65;  PMID:12633665; http://dx.doi.org/10.1016/S0952- 7915(03)00012-8.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Annu Rev Immunol 2001; 19:595-621;  PMID:11244048; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Immunol Rev 2000; 175:23-32;  PMID:10933588; http://dx.doi.org/10.1111/j.1600- 065X.2000.imr017517.x.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
J Immunol 2009; 183:3229-36;  PMID:19667093; http://dx.doi.org/10.4049/jimmu-nol.0804277.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Cancer Cell 2006; 10:77-87; PMID:16843267; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Blood 2008; 112:4655-64;  PMID:18684865; http://dx.doi.org/10.1182/blood- 2008-02-139105.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Blood 2011; 117:1565-73; PMID:21127177;  http://dx.doi.org/10.1182/blood-2010-06-291633.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Blood 2009; 113:5488-96;  PMID:19234143; http://dx.doi.org/10.1182/blood- 2008-10-187179.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Eur J Immunol 1999; 29:1390- 6; PMID:10229107; http://dx.doi.org/10.1002/(SICI)1521-4141(199904)29:04<1390::AID- IMMU1390>3.0.CO;2-C.References 1.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Immunity  2000; 13:643-55; PMID:11114377; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Exp Hematol 2008; 36:255- 64; PMID:18207304; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Nat Med 2009; 15:696- 700; PMID:19483695; http://dx.doi.org/10.1038/nm.1973.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Biochimie 2007; 89:884-93;  PMID:17532550; http://dx.doi.org/10.1016/j.bio- chi.2007.04.006.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Autoimmunity 2010; 43:204-9; PMID:20187707; http://dx.doi.org/10.3109/08916930903510880.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/sci- ence.1203486.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Nat Immunol 2005; 6:646-8; PMID:15970935; http://dx.doi.org/10.1038/ni0705-646.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Nat Rev Immunol  2007; 7:703-14; PMID:17717540; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Blood  2011; 118:4635-45; PMID:21878673; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
Nature 1995; 376:352-5;  PMID:7543183; http://dx.doi.org/10.1038/376352a0.,Non-OADS,/arxiv_data1/oa_pdf/f6/73/onci-1-1027.PMC3494617.pdf
"OncoImmunology 1:7, 1038–1047; October 2012; © 2012 Landes Bioscience ReseaR ch papeR 1038 OncoImmunology Volume 1 Issue 7*Correspondence to: Guillermo Mazzolini; Email: gmazzoli@cas.austral.edu.ar Submitted: 04/10/12; Revised: 05/07/12; Accepted: 05/08/12http://dx.doi.org/10.4161/onci.20684Introduction During the last two decades, multiple immunotherapy-based  strategies against cancer have been developed, with promising results.",Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Cancer Immunol Immunother 2007; 56:1687-700; PMID:17571260; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
T rends Immunol  2001; 22:113-5; PMID:11286714; http://dx.doi.org/10.1016/S1471-4906(00)01824-X.,OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Clin Cancer Res 2009; 15:7256-65; PMID:19920110;  http://dx.doi.org/10.1158/1078-0432.CCR-09-1861.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Nat Rev Cancer  2004; 4:423-36; PMID:15170445; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Semin Immunopathol 2011; 33:369-83;  PMID:21611872; http://dx.doi.org/10.1007/s00281- 011-0245-0.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Cancer J 2010; 16:348- 53; PMID:20693846; http://dx.doi.org/10.1097/ PPO.0b013e3181eb3358.12.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
J Immunol  2009; 183:137-44; PMID:19535620; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Cancer Immunol Immunother 2002; 50:588-96;  PMID:11807622; http://dx.doi.org/10.1007/s00262- 001-0237-3.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
J Clin Oncol 2011; 29:4491-7;  PMID:22042958; http://dx.doi.org/10.1200/ JCO.2011.36.7045.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Cancer Immunol Immunother 2012; 61:353-62; PMID:21915801;  http://dx.doi.org/10.1007/s00262-011-1106-3.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Mol Ther 2011; 19:1737- 46; PMID:21673660; http://dx.doi.org/10.1038/ mt.2011.113.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Oncol Res 2010; 18:601-5;  PMID:20939436; http://dx.doi.org/10.3727/0965040 10X12777678141662.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Crit Rev Oncol Hematol 2012; 82:40-50;  PMID:21641231; http://dx.doi.org/10.1016/j.critrev-onc.2011.04.009.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Adv Exp Med Biol  2008; 622:255-60; PMID:18546633; http://dx.doi.org/10.1007/978-0-387-68969-2_20.22.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Clin Cancer Res 2007; 13:6301-11;  PMID:17975141; http://dx.doi.org/10.1158/1078- 0432.CCR-07-1403.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Cancer Immunol  Immunother 2008; 57:813-21; PMID:17962941;  http://dx.doi.org/10.1007/s00262-007-0417-x.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Cancer Immunol Immunother  2007; 56:641-8; PMID:16960692; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Cancer  Lett 1996; 104:1-5; PMID:8640735; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Int Immunopharmacol 2001; 1:307-19;  PMID:11360931; http://dx.doi.org/10.1016/S1567- 5769(00)00028-X.,OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Cancer Res 2010; 70:3052-61; PMID:20388795; http://dx.doi.org/10.1158/0008- 5472.CAN-09-3690.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Cancer Lett 2009; 278:9-16;  PMID:19185418; http://dx.doi.org/10.1016/j.can- let.2008.12.029.36.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Cancer Res 2011; 71:768-78; PMID:21156650;  http://dx.doi.org/10.1158/0008-5472.CAN-10-2788.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
J T ransl Med 2011; 9:140;  PMID:21859450; http://dx.doi.org/10.1186/1479-5876-9-140.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Cancer Gene Ther 1999; 6:514-22; PMID:10608348;  http://dx.doi.org/10.1038/sj.cgt.7700072.31.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Clin Cancer Res 2005; 11:6713-21; PMID:16166452;  http://dx.doi.org/10.1158/1078-0432.CCR-05-0883.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
Nat Rev Immunol 2002; 2:151-61;  PMID:11913066; http://dx.doi.org/10.1038/nri746.,Non-OADS,/arxiv_data1/oa_pdf/93/2b/onci-1-1038.PMC3494618.pdf
"Kaumaya; Email: kaumaya.1@osu.edu Submitted: 04/17/12; Revised: 05/09/12; Accepted: 05/10/12http://dx.doi.org/10.4161/onci.20708Introduction The oncoprotein human epidermal growth factor receptor 2  (HER-2) is an orphan member of the HER family of receptors,1  which includes HER-1, HER-3 and HER-4.",Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Science 1987; 235:177-82;  PMID:3798106; http://dx.doi.org/10.1126/sci- ence.3798106.2.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
J Biol Chem 1995; 270:9585- 9; PMID:7721889; http://dx.doi.org/10.1074/jbc.270.16.9585.3.,Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Development 2003; 130:2291- 301; PMID:12702645; http://dx.doi.org/10.1242/ dev.00447.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Proc Natl Acad Sci USA  1987; 84:7159-63; PMID:2890160; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
J Clin Oncol 2006; 24:5658- 63; PMID:17102066; http://dx.doi.org/10.1200/JCO.2006.07.0250.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Br J Cancer  2005; 92:1253-60; PMID:15785739; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
J Clin Oncol 2006; 24:2376- 85; PMID:16710036; http://dx.doi.org/10.1200/ JCO.2005.03.4827.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
J Soc Gynecol  Investig 1996; 3:99-105; PMID:8796816; http://dx.doi.org/10.1016/1071-5576(96)00001-9.,Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Mol Cell Biol  2001; 21:3995-4004; PMID:11359907; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Blood 2003; 102:964-71;  PMID:12689940; http://dx.doi.org/10.1182/blood- 2002-12-3738.,Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Prog Growth Factor Res 1994; 5:89-97;  PMID:7515293; http://dx.doi.org/10.1016/0955-2235(94)90019-1.,Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Int J Radiat Oncol Biol Phys 2006; 64:38- 46; PMID:16377414; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Oncology 2005; 69:46-56; PMID:16301835;  http://dx.doi.org/10.1159/000088483.,Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Nat Med 2000; 6:443-6;  PMID:10742152; http://dx.doi.org/10.1038/74704.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Immunity  1995; 3:21-6; PMID:7621075; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Mol Cancer 2003; 2:25;  PMID:12904264; http://dx.doi.org/10.1186/1476-4598-2-25.,Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Oncologist 2004;  9:43-9; PMID:15178815; http://dx.doi.org/10.1634/theoncologist.9-suppl_1-43.,Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Proc Natl Acad Sci USA 2002; 99:11393-8; PMID:12177445; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Blood 2003; 101:1316-23;  PMID:12406876; http://dx.doi.org/10.1182/blood- 2002-07-2184.,Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Cell 1990; 61:1339-47;  PMID:1973074; http://dx.doi.org/10.1016/0092- 8674(90)90697-D. 32.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
Br J  Cancer 2004; 90:1-7; PMID:14710197; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
J Biol Chem 2004; 279:24141- 51; PMID:15060075; http://dx.doi.org/10.1074/jbc.M313210200.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
J Pept Sci 2000; 6:387-97; PMID:10969868; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
J Biol Chem 2001; 276:22892-900;  PMID:11303022; http://dx.doi.org/10.1074/jbc.M011647200.,OADS,/arxiv_data1/oa_pdf/a6/c1/onci-1-1048.PMC3494619.pdf
"www.landesbioscience.com OncoImmunology 1061OncoImmunology 1:7, 1061–1073; October 2012; © 2012 Landes Bioscience ReseaR ch papeR ReseaR ch papeR *Correspondence to: Haidong Dong; Email: dong.haidong@mayo.edu Submitted: 03/12/12; Revised: 05/22/12; Accepted: 05/23/12http://dx.doi.org/10.4161/onci.20850Introduction The metastatic spread of tumor cells is the primary cause of  cancer related mortalities, indicating a need for therapeutic approaches capable of controlling or preventing metastasis.",Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Cell 2010; 140:883-99;  PMID:20303878; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Science  2006; 313:1960-4; PMID:17008531; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
J Immunol  2011; 186:6280-6; PMID:21525385; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
J Biol Chem 2006; 281:813- 23; PMID:16282323; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Science 2005; 307:1098-101;  PMID:15718470; http://dx.doi.org/10.1126/sci- ence.1106148.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Cell 2006; 127:125- 37; PMID:16962653; http://dx.doi.org/10.1016/j.cell.2006.08.033.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Blood 2009; 114:1537-44; PMID:19423728;  http://dx.doi.org/10.1182/blood-2008-12-195792.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Cancer  Res 2006; 66:3381-5; PMID:16585157; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Immunity  2008; 28:218-30; PMID:18275832; http://dx.doi.org/10.1016/j.immuni.2007.12.014.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Cell Immunol 2011; 269:104-14;  PMID:21481848; http://dx.doi.org/10.1016/j.cel - limm.2011.03.011.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Nat Med 2006; 12:1198- 202; PMID:16917489; http://dx.doi.org/10.1038/ nm1482.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Hepatology 2007; 45:588- 601; PMID:17326153; http://dx.doi.org/10.1002/ hep.21541.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Proc Natl Acad Sci USA  2003; 100:14175-80; PMID:14623954; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Eur J Immunol 2006; 36:1694-706; PMID:16761315; http://dx.doi.org/10.1002/eji.200635897.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Proc Natl Acad Sci USA  2004; 101:7681-6; PMID:15136728; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
"Pro-apoptotic cascade activates BID,  which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ  2000; 7:1166-73; PMID:11175253; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Proc Natl Acad Sci USA  2006; 103:18703-8; PMID:17116875; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
J Immunol 2009; 183:7672- 81; PMID:19933864; http://dx.doi.org/10.4049/jim- munol.0902874.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Blood 2010; 116:1291-8;  PMID:20472828; http://dx.doi.org/10.1182/blood- 2010-01-265975.4.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Cancer Immunol Immunother 2009; 58:449-59; PMID:18791714; http://dx.doi.org/10.1007/s00262- 008-0583-5.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Science 2001; 291:2413-7;  PMID:11264538; http://dx.doi.org/10.1126/sci- ence.1058867.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Expert Opin Biol Ther  2004; 4:1577-83; PMID:15461569; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Clin Cancer  Res 2007; 13:709-15; PMID:17255298; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Nat Med 1999; 5:1365-9; PMID:10581077; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
J Immunol  2009; 183:3634-41; PMID:19710456; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Annu Rev Immunol 2008; 26:677-704; PMID:18173375;  http://dx.doi.org/10.1146/annurev.immu- nol.26.021607.090331.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Immunity 2007; 27:111-22;  PMID:17629517; http://dx.doi.org/10.1016/j.immu- ni.2007.05.016.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Immunol Rev  2010; 236:54-67; PMID:20636808; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Immunity  1994; 1:365-71; PMID:7533645; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Int Immunol 1995; 7:1451-8; PMID:7495753; http://dx.doi.org/10.1093/ intimm/7.9.1451.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Eur J Immunol  1996; 26:1459-67; PMID:8766547; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Clin Cancer Res 2008; 14:3044-51;  PMID:18483370; http://dx.doi.org/10.1158/1078- 0432.CCR-07-4079.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Curr Opin Immunol 2012; 24:207-12;  PMID:22236695; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
J Clin Invest  2012; 122:987-99; PMID:22354169; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Science 1999; 283:1745- 8; PMID:10073942; http://dx.doi.org/10.1126/sci- ence.283.5408.1745.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Science 2009; 323:502-5; PMID:19164748; http://dx.doi.org/10.1126/science.1163612.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Science 2009; 323:505-9;  PMID:19164749; http://dx.doi.org/10.1126/sci- ence.1166831.45.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
J Immunol  2011; 187:5606-14; PMID:22025548; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Curr  Biol 1997; 7:261-9; PMID:9094314; http://dx.doi.org/10.1016/S0960-9822(06)00122-9.,OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
J Exp Med 2009; 206:3015-29;  PMID:20008522; http://dx.doi.org/10.1084/ jem.20090847.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Nat Rev Immunol 2008; 8:107-19;  PMID:18219309; http://dx.doi.org/10.1038/nri2251.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
Nature 2012; 483:227-31;  PMID:22388819; http://dx.doi.org/10.1038/ nature10851.,Non-OADS,/arxiv_data1/oa_pdf/f1/6b/onci-1-1061.PMC3494620.pdf
"OncoImmunology 1:7, 1074–1083; October 2012; © 2012 Landes Bioscience ReseaR ch papeR 1074 OncoImmunology Volume 1 Issue 7*Correspondence to: Nikola L. Vujanovic; Email: vujanovicnl@msx.upmc.edu Submitted: 12/01/11; Revised: 05/16/12; Accepted: 05/26/12http://dx.doi.org/10.4161/onci.20897Introduction Coordinated communications between cells are essential for  the life of multicellular organisms.",Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
T raffic  2002; 3:321-30; PMID:11967126; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
J Cell Physiol 1991; 147:27-36; PMID:2037622; http://dx.doi.org/10.1002/ jcp.1041470105.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Annu Rev Immunol 1991; 9:271-96;  PMID:1910679; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Immunol Today 1990; 11:206-11;  PMID:2191684; http://dx.doi.org/10.1016/0167- 5699(90)90084-M. 6.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Nature 1998; 392:245-52;  PMID:9521319; http://dx.doi.org/10.1038/32588.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Immunol Res 2011; 50:159-74;  PMID:21717067; http://dx.doi.org/10.1007/s12026- 011-8228-8.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Nat Med 1999; 5:405-11; PMID:10202929; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Cell Immunol  2001; 213:14-23; PMID:11747352; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
J Exp Med  2002; 195:335-41; PMID:11828008; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
J Exp Med  2002; 195:343-51; PMID:11828009; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
T rends Immunol 2005; 26:668-75; PMID:16198147;  http://dx.doi.org/10.1016/j.it.2005.09.008.22.,OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Nat Rev Immunol  2002; 2:957-64; PMID:12461568; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Expert Opin Biol Ther  2005; 5:1303-15; PMID:16197336; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Blood 2007; 109:3333-41;  PMID:17164346; http://dx.doi.org/10.1182/blood-2006-06-026385.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Blood 2010; 116:575-83;  PMID:20430958; http://dx.doi.org/10.1182/blood- 2009-08-240325.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
J Leukoc Biol 2006; 80:471- 8; PMID:16809645; http://dx.doi.org/10.1189/ jlb.0206094.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Blood 2004; 104:3257-66; PMID:15284116;  http://dx.doi.org/10.1182/blood-2004-03-0824.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Nat Med 1998; 4:594-600;  PMID:9585234; http://dx.doi.org/10.1038/nm0598-594.,OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Naure Immunol 2002; 3:1156-62; http://dx.doi.org/10.1038/ni854.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
Immunol Res  2006; 36:247-54; PMID:17337785; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d6/87/onci-1-1074.PMC3494621.pdf
"OncoImmunology 1:7, 1084-1094; October 2012; © 2012 Landes Bioscience ReseaR ch papeR 1084 OncoImmunology Volume 1 Issue 7*Correspondence to: Andrew Currie; Email: A.Currie@murdoch.edu.au Submitted: 04/20/12; Revised: 05/30/12; Accepted: 05/30/12http://dx.doi.org/10.4161/onci.20924Introduction There is an urgent need for novel treatment modalities for solid  tumors, and in this context antitumor immunotherapy (espe - cially tumor vaccination) has received considerable attention.",Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
Cancer  1994; 74:2460-7; PMID:7923001; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
Lung Cancer 2006; 52:189-97; PMID:16563560; http://dx.doi.org/10.1016/j.lungcan.2006.01.007.,Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
JAMA 2004; 292:97- 100; PMID:15238597; http://dx.doi.org/10.1001/ jama.292.1.97.,OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
Cancer Gene Ther 2001;  8:580-8; PMID:11571536; http://dx.doi.org/10.1038/ sj.cgt.7700347.,Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
J Urol 2004; 171:1071-6; PMID:14767273;  http://dx.doi.org/10.1097/01.ju.0000110610.61545.ae.,OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
BJU Int 2002; 89:523-5; PMID:11942956; http://dx.doi.org/10.1046/j.1464-410X.2002.02631.x.,OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
N Engl J Med 2001; 345:1655-9; PMID:11759643; http://dx.doi.org/10.1056/NEJMoa003013.14.,OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
J Urol  1997; 158:1691-5; PMID:9334580; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
J Urol  1997; 158:1675-8; PMID:9334576; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
Brain Behav  Immun 2003; 17(Suppl 1):S27-36; PMID:12615183;  http://dx.doi.org/10.1016/S0889-1591(02)00063-6.,Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
Cancer Res 2006; 66:5527-36;  PMID:16740684; http://dx.doi.org/10.1158/0008-5472.CAN-05-4128.,Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
Annu Rev Immunol 2006; 24:175-208;  PMID:16551247; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
PLoS One 2009;  4:e6982; PMID:19746156; http://dx.doi.org/10.1371/journal.pone.0006982.,Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
J Immunol Methods  1994; 171:131-7; PMID:8176234; http://dx.doi.org/10.1016/0022-1759(94)90236-4.,Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
Cancer Res 2004; 64:4024-9;  PMID:15173017; http://dx.doi.org/10.1158/0008- 5472.CAN-03-3949.,Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
Clin Dev Immunol 2010;  2010:539519; PMID:20976125; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
J Clin Invest  2008; 118:294-305; PMID:18060041; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
Nature  2006; 439:682-7; PMID:16382236; http://dx.doi.org/10.1038/nature04444.,OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
J Immunol Methods 1990; 133:87-97; PMID:2212694; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2d/e8/onci-1-1084.PMC3494622.pdf
"www.landesbioscience.com OncoImmunology 1095OncoImmunology 1:7, 1095–1103; October 2012; © 2012 Landes Bioscience ReseaR ch papeR ReseaR ch papeR *Correspondence to: Catherine J. Wu; Email: cwu@partners.org Submitted: 05/02/12; Revised: 05/25/12; Accepted: 05/30/12http://dx.doi.org/10.4161/onci.20954Introduction Chronic myeloid leukemia (CML) is characterized by the presence  of the BCR-ABL translocation,1 and is known to be particularly  immunosensitive.",Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Blood 2004; 103:1037-42;  PMID:14504104; http://dx.doi.org/10.1182/blood-2003-03-0954.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Leukemia 2008; 22:1658-64; PMID:18563174; http://dx.doi.org/10.1038/leu.2008.148.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Cancer Immunol Immunother  2008; 57:1569-77; PMID:18523771; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Blood 2009; 113:18-27; PMID:18809757;  http://dx.doi.org/10.1182/blood-2008-06-165654.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
J Clin Oncol  2003; 21:3343-50; PMID:12947071; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Clin Cancer Res 2010; 16:338-47; PMID:20048335;  http://dx.doi.org/10.1158/1078-0432.CCR-09-2046.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
J Surg Res  2005; 125:173-81; PMID:15854671; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Nature 1998; 392:86-9;  PMID:9510252; http://dx.doi.org/10.1038/32183.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
PLoS Biol 2005; 3:185; PMID:15839733;  http://dx.doi.org/10.1371/journal.pbio.0030185.,OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
J T ransl Med 2008; 6:21;  PMID:18445282; http://dx.doi.org/10.1186/1479- 5876-6-21.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Prostate Cancer Prostatic Dis 2004; 7:63-72; PMID:14999241; http://dx.doi.org/10.1038/ sj.pcan.4500694.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Vaccine 2008; 26:6422-32;  PMID:18848858; http://dx.doi.org/10.1016/j.vac- cine.2008.08.063.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Hum Immunol 2000; 61:438-52; PMID:10773346; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Blood 2008; 111:2112-21;  PMID:18063750; http://dx.doi.org/10.1182/blood- 2007-06-096586.25.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Bone Marrow T ransplant 2008; 42:569-79; PMID:18711351; http://dx.doi.org/10.1038/ bmt.2008.259.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Exp Hematol  2005; 33:1172-81; PMID:16219539; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Clin Cancer Res  2010; 16:2729-39; PMID:20460482; http://dx.doi.org/10.1158/1078-0432.CCR-10-0415.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Blood  2009; 113:2312-23; PMID:19074734; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Expert Rev Anticancer  Ther 2009; 9:67-74; PMID:19105708; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Cancer Gene Ther 2010; 17:465- 75; PMID:20168352; http://dx.doi.org/10.1038/ cgt.2010.2.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Clin Cancer Res 2011; 17:183-92; PMID:21208907;  http://dx.doi.org/10.1158/1078-0432.CCR-10-2195.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Cancer Gene Ther 2009; 16:620- 4; PMID:19287371; http://dx.doi.org/10.1038/ cgt.2009.15.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Cancer Immunol Immunother  2010; 59:379-88; PMID:19711075; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Clin Cancer Res 2009; 15:4986-92; PMID:19622576;  http://dx.doi.org/10.1158/1078-0432.CCR-08-3240.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Blood  2009; 114:1736-45; PMID:19556425; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Cancer Gene Ther 2006; 13:555-62; PMID:16410826; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
J Virol 2004; 78:5535-45; PMID:15140950; http://dx.doi.org/10.1128/ JVI.78.11.5535-45.2004.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Ann Oncol 2007; 18:226-32;  PMID:17116643; http://dx.doi.org/10.1093/annonc/ mdl158.,OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
J Clin Invest  2007; 117:1902-13; PMID:17557120; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Sci T ransl Med 2011; 3:80; PMID:21525398;  http://dx.doi.org/10.1126/scitranslmed.3002207.,OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Curr Gene Ther 2005; 5:511-21; PMID:16250891;  http://dx.doi.org/10.2174/156652305774329221.,OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Vaccine 2006; 24:2264-74;  PMID:16376465; http://dx.doi.org/10.1016/j.vac- cine.2005.11.045.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Mol Ther 2007; 15:981- 8; PMID:17375070; http://dx.doi.org/10.1038/mt.sj.6300134.36.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Clin  Cancer Res 2008; 14:3098-104; PMID:18483377;  http://dx.doi.org/10.1158/1078-0432.CCR-07-4875.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Mol Cancer Ther 2008; 7:721-9; PMID:18347157;  http://dx.doi.org/10.1158/1535-7163.MCT-07-2067.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Curr Opin Hematol  2002; 9:503-8; PMID:12394172; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
Leuk Res 1979; 3:363-70; PMID:95026; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/70/06/onci-1-1095.PMC3494623.pdf
"OncoImmunology 1:7, 1104-1110; October 2012; © 2012 Landes Bioscience ReseaR ch papeR 1104 OncoImmunology Volume 1 Issue 7*Correspondence to: Koji Kono; Email: surkoji@nus.edu.sg Submitted: 03/01/12; Revised: 06/04/12; Accepted: 06/08/12http://dx.doi.org/10.4161/onci.21056Introduction ERBB2 (best known as HER2 or neu) is a proto-oncogene  encoding a 185-kDa transmembrane glycoprotein member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases.",Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Cancer Immunol  Immunother 2008; 57:1511-21; PMID:18536917;  http://dx.doi.org/10.1007/s00262-008-0540-3.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Br J Cancer 2008; 99:1462- 7; PMID:18841157; http://dx.doi.org/10.1038/ sj.bjc.6604715.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Cancer Immunol Immunother 2008; 57:1719-26;  PMID:18408926; http://dx.doi.org/10.1007/s00262-008-0515-4.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Br J Cancer 2010; 103:552- 9; PMID:20628381; http://dx.doi.org/10.1038/ sj.bjc.6605772.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
J T ransl  Med 2010; 8:53; PMID:20529245; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Clin Cancer Res 2010; 16:1486-97;  PMID:20179226; http://dx.doi.org/10.1158/1078- 0432.CCR-09-1764.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Cancer Res 2004; 64:215-20;  PMID:14729627; http://dx.doi.org/10.1158/0008- 5472.CAN-2522-2.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Cancer Immunol Immunother  2006; 55:653-62; PMID:16151808; http://dx.doi.org/10.1007/s00262-005-0050-5.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Int J Cancer 2011; 128:390- 401; PMID:20715101; http://dx.doi.org/10.1002/ ijc.25613.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Int J Radiat  Oncol Biol Phys 2004; 58:903-13; PMID:14967450;  http://dx.doi.org/10.1016/j.ijrobp.2003.06.002.,OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Int J Cancer  2004; 108:71-7; PMID:14618618; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Ann  Oncol 2004; 15:1510-6; PMID:15367412; http://dx.doi.org/10.1093/annonc/mdh388.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Cancer  Cell 2004; 6:117-27; PMID:15324695; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Breast Cancer Res T reat  1999; 57:237-43; PMID:10617300; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
J Biol Chem 2001; 276:9817- 24; PMID:11139588; http://dx.doi.org/10.1074/jbc.M010840200.References 1.,OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Science 1985; 230:1132- 9; PMID:2999974; http://dx.doi.org/10.1126/sci- ence.2999974.,OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Br J Cancer 2005; 92:1253-60; http://dx.doi.org/10.1038/ sj.bjc.6602499; PMID:15785739.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
J Clin Pathol 2007; 60:768-72; PMID:16882699;  http://dx.doi.org/10.1136/jcp.2006.038281.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
J Clin Oncol 2009; 27:4685-92; PMID:19720923; http://dx.doi.org/10.1200/ JCO.2008.20.6789.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
J Clin Oncol  2005; 23:7536-45; PMID:16157940; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Clin Cancer Res  2009; 15:2895-904; PMID:19351776; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
Clin Cancer Res  2008; 14:797-803; PMID:18245541; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/80/onci-1-1104.PMC3494624.pdf
"www.landesbioscience.com OncoImmunology 1111OncoImmunology 1:7, 1111-1134; October 2012; © 2012 Landes BioscienceREVIEW  REVIEW *Correspondence to: Guido Kroemer; Email: kroemer@orange.fr Submitted: 07/14/12; Accepted: 07/14/12http://dx.doi.org/10.4161/onci.21494Dendritic cells (DCs) occupy a central position in the immune  system, orchestrating a wide repertoire of responses that span from the development of self-tolerance to the elicitation  of potent cellular and humoral immunity.",Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cell  2001; 106:271-4; PMID:11509176; http://dx.doi.org/10.1016/S0092-8674(01)00448-2.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunity 2003; 19:225-34;  PMID:12932356; http://dx.doi.org/10.1016/S1074- 7613(03)00208-5.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunol Rev 2007; 220:129-50; PMID:17979844;  http://dx.doi.org/10.1111/j.1600-065X.2007.00575.x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunol Rev 2007; 219:118-42;  PMID:17850486; http://dx.doi.org/10.1111/j.1600- 065X.2007.00551.x.8.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2000; 192:F39-44; PMID:11120782; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2000; 192:1535-44; PMID:11104796;  http://dx.doi.org/10.1084/jem.192.11.1535.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2012; 209:109- 21; PMID:22213806; http://dx.doi.org/10.1084/ jem.20110399.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med  2010; 207:1261-71; PMID:20479117; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunol Rev 2010; 234:18-31; PMID:20193009;  http://dx.doi.org/10.1111/j.0105-2896.2009.00870.x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Blood 2008; 112:3264-73; PMID:18669894;  http://dx.doi.org/10.1182/blood-2008-05-155176.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunol Rev  2010; 234:142-62; PMID:20193017; http://dx.doi.org/10.1111/j.0105-2896.2009.00881.x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Rev Immunol 2011; 11:558-65; PMID:21779033; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2002; 195:953- 8; PMID:11927638; http://dx.doi.org/10.1084/ jem.20020045.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2001; 194:863-9; PMID:11561001; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cell Immunol  2002; 218:74-86; PMID:12470615; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Hum Immunol 2002; 63:1126-32;  PMID:12480256; http://dx.doi.org/10.1016/S0198- 8859(02)00751-6.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunol 2010; 185:2790-9; PMID:20686126;  http://dx.doi.org/10.4049/jimmunol.0903740.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunol Rev 2010; 234:105-19;  PMID:20193015; http://dx.doi.org/10.1111/j.0105- 2896.2009.00871.x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunol Rev  2010; 234:199-212; PMID:20193020; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med  1994; 180:1263-72; PMID:7523569; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2004; 199:1607-18; PMID:15197224;  http://dx.doi.org/10.1084/jem.20040317.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cell 2010; 140:805-20;  PMID:20303872; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Rev  Immunol 2006; 6:476-83; PMID:16691244; http://dx.doi.org/10.1038/nri1845.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Annu Rev Immunol 2012; 30:1- 22; PMID:22136168; http://dx.doi.org/10.1146/annurev-immunol-100311-102839.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Proc Natl Acad Sci U S A 1999; 96:1036- 41; PMID:9927689; http://dx.doi.org/10.1073/ pnas.96.3.1036.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunity 2008; 29:497-510;  PMID:18789730; http://dx.doi.org/10.1016/j.immu-ni.2008.07.013.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Clin Invest  2012; 122:1700-11; PMID:22523067; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2010; 207:1273-81; PMID:20479115;  http://dx.doi.org/10.1084/jem.20100348.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med  2010; 207:1283-92; PMID:20479118; http://dx.doi.org/10.1084/jem.20100223.11.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunol 2009; 182:6815- 23; PMID:19454677; http://dx.doi.org/10.4049/jim- munol.0802008.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Immunol 2000; 1:510-4; PMID:11101873; http://dx.doi.org/10.1038/82763.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Rev Immunol  2005; 5:296-306; PMID:15803149; http://dx.doi.org/10.1038/nri1592.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Science 2001; 294:1540-3; PMID:11711679; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Science 2001; 293:253-6; PMID:11452116; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nature 2007; 449:419-26; PMID:17898760; http://dx.doi.org/10.1038/nature06175.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Rev Cancer 2012; 12:265-77;  PMID:22437871; http://dx.doi.org/10.1038/nrc3258.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nature 1998; 392:245-52;  PMID:9521319; http://dx.doi.org/10.1038/32588.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Annu Rev Immunol  2005; 23:975-1028; PMID:15771591; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Immunol 2003;  4:733-9; PMID:12888794; http://dx.doi.org/10.1038/ ni957.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Annu Rev Immunol  2003; 21:685-711; PMID:12615891; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Physiol  Rev 2007; 87:99-163; PMID:17237344; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunity  2007; 26:629-41; PMID:17509906; http://dx.doi.org/10.1016/j.immuni.2007.03.016.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Immunol 2005; 6:280-6; PMID:15685176;  http://dx.doi.org/10.1038/ni1165.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Med 2007; 13:1050-9;  PMID:17704786; http://dx.doi.org/10.1038/nm1622.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2005; 202:1691-701; PMID:16365148;  http://dx.doi.org/10.1084/jem.20050915.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Med 2009; 15:1170- 8; PMID:19767732; http://dx.doi.org/10.1038/ nm.2028.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat  Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Science 2011; 334:1573- 7; PMID:22174255; http://dx.doi.org/10.1126/sci- ence.1208347.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunol Res 2011; 50:248-54; PMID:21717064;  http://dx.doi.org/10.1007/s12026-011-8231-0.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Med 2011; 17:700-7; PMID:21552268;  http://dx.doi.org/10.1038/nm.2366.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Science 2004; 305:200- 5; PMID:15247469; http://dx.doi.org/10.1126/sci- ence.1100369.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2008; 31:620-32; PMID:18600182;  http://dx.doi.org/10.1097/CJI.0b013e31818213df.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Clin Invest 2007; 117:1195-203; PMID:17476349; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Expert Rev Anticancer  Ther 2009; 9:97-114; PMID:19105710; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Ther Oncol 2002; 2:337-49; PMID:12440225;  http://dx.doi.org/10.1046/j.1359-4117.2002.01050.x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2002; 196:781- 91; PMID:12235211; http://dx.doi.org/10.1084/ jem.20020186.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med  2006; 203:2473-83; PMID:17030949; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Immunol 2005; 6:769-76; PMID:15995707; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Gut 2008; 57:1480; PMID:18791123; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Sci T ransl Med 2011; 3:73ra20;  PMID:21389264; http://dx.doi.org/10.1126/scitrans- lmed.3001201.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Sci T ransl  Med 2011; 3:73ra19; PMID:21389263; http://dx.doi.org/10.1126/scitranslmed.3001180.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/sci- ence.1203486.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med  2007; 204:1037-47; PMID:17438063; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med  2005; 202:1075-85; PMID:16230475; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat  Rev Immunol 2004; 4:941-52; PMID:15573129;  http://dx.doi.org/10.1038/nri1498.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Semin Cancer Biol 2002; 12:33-42; PMID:11926410;  http://dx.doi.org/10.1006/scbi.2001.0400.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat  Rev Drug Discov 2012; 11:215-33; PMID:22301798;  http://dx.doi.org/10.1038/nrd3626.58.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Virol 2006; 80:3985-93; PMID:16571815;  http://dx.doi.org/10.1128/JVI.80.8.3985-3993.2006.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2002; 195:517-28; PMID:11854364;  http://dx.doi.org/10.1084/jem.20011672.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med  2006; 203:1805-15; PMID:16818672; http://dx.doi.org/10.1084/jem.20052545.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Virol 2003; 77:11139- 49; PMID:14512561; http://dx.doi.org/10.1128/ JVI.77.20.11139-11149.2003.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunol Cell Biol  2010; 88:716-26; PMID:20212510; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Leukoc Biol 2007; 82:1407- 19; PMID:17881511; http://dx.doi.org/10.1189/ jlb.0507268.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cell 2000; 100:587-97;  PMID:10721995; http://dx.doi.org/10.1016/S0092- 8674(00)80694-7.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Curr Opin Rheumatol 2008; 20:669- 74; PMID:18946326; http://dx.doi.org/10.1097/ BOR.0b013e3283157538.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Rev Immunol 2003; 3:630-41;  PMID:12974478; http://dx.doi.org/10.1038/nri1150.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
N Engl J Med 2008; 358:2704-15; PMID:18565863; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Annu Rev Immunol 2006; 24:175-208;  PMID:16551247; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Oncoimmunology  2012; 1:306-15; PMID:22737606; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
OncoImmunology 2012; 1: In press; http://dx.doi.org/10.4161/onci.20696.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Oncoimmunology 2012; 1:28-37; PMID:22720209; http://dx.doi.org/10.4161/ onci.1.1.17938.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
OncoImmunology 2012; 1: In press; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Oncoimmunology 2012; 1:493-506;  PMID:22754768; http://dx.doi.org/10.4161/ onci.20459.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Oncoimmunology 2012; 1:179-88; PMID:22720239;  http://dx.doi.org/10.4161/onci.1.2.19026.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Int J Cancer 1997; 70:706-15; PMID:9096653;  http://dx.doi.org/10.1002/(SICI)1097- 0215(19970317)70:6<706::AID-IJC13>3.0.CO;2-7.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Surg Oncol 1998; 68:79-91; PMID:9624036;  http://dx.doi.org/10.1002/(SICI)1096- 9098(199806)68:2<79::AID-JSO3>3.0.CO;2-H. 144.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cell Immunol  1998; 185:65-74; PMID:9636684; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Biomaterials 2012; 33:4229-39;  PMID:22410170; http://dx.doi.org/10.1016/j.bioma- terials.2012.02.036.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Blood 2012; 119:2284-92; PMID:22234694; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Blood 2011; 118:4111-9;  PMID:21860028; http://dx.doi.org/10.1182/blood- 2011-04-346957.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Eur J Immunol 2012; PMID:22653683;  http://dx.doi.org/10.1002/eji.201142258.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Blood  2011; 118:6836-44; PMID:21967977; http://dx.doi.org/10.1182/blood-2011-07-367615.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Med 1998; 4:594-600;  PMID:9585234; http://dx.doi.org/10.1038/nm0598- 594.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Cell Biol  1999; 147:599-610; PMID:10545503; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Res 2010; 70:1281-5;  PMID:20145139; http://dx.doi.org/10.1158/0008- 5472.CAN-09-3276.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Immunol Lett 2006; 107:102-8; PMID:17067686;  http://dx.doi.org/10.1016/j.imlet.2006.09.005.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Leukoc Biol 2006; 80:471- 8; PMID:16809645; http://dx.doi.org/10.1189/ jlb.0206094.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2011; 34:65-75; PMID:21150714; http://dx.doi.org/10.1097/CJI.0b013e3181fe535b.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Med 2001; 7:297-303; PMID:11231627;  http://dx.doi.org/10.1038/85438.102.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Res  2006; 66:8887-96; PMID:16951206; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Rev Immunol 2007; 7:790-802; PMID:17853902; http://dx.doi.org/10.1038/nri2173.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer  J 2010; 16:318-24; PMID:20693842; http://dx.doi.org/10.1097/PPO.0b013e3181eaca83.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
N Engl J Med 2010; 363:411-22;  PMID:20818862; http://dx.doi.org/10.1056/ NEJMoa1001294.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2011; 17:3520-6;  PMID:21471425; http://dx.doi.org/10.1158/1078- 0432.CCR-10-3126.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Eur J Immunol 2006; 36:1124- 35; PMID:16568496; http://dx.doi.org/10.1002/ eji.200535443.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med  2004; 199:815-24; PMID:15024047; http://dx.doi.org/10.1084/jem.20032220.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med  2002; 196:1627-38; PMID:12486105; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2001; 194:769-79; PMID:11560993;  http://dx.doi.org/10.1084/jem.194.6.769.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Res 2007; 67:8847-55;  PMID:17875726; http://dx.doi.org/10.1158/0008- 5472.CAN-07-0321.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J T ransl  Med 2011; 9:178; PMID:22013914; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2012;  PMID:22290073; http://dx.doi.org/10.1007/s00262- 011-1192-2.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Am J Respir Crit Care Med 2010; 181:1383-90; PMID:20167848; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2005; 28:496- 504; PMID:16113606; http://dx.doi.org/10.1097/01.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Hepatology  2009; 49:124-32; PMID:18980227; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Hepatobiliary Pancreat Sci 2012; 19:171-8; PMID:21874278; http://dx.doi.org/10.1007/s00534- 011-0437-y.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Melanoma Res  2003; 13:521-30; PMID:14512794; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2004; 53:125-34; PMID:14600790; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol  Immunother 2004; 53:651-8; PMID:14999431;  http://dx.doi.org/10.1007/s00262-003-0495-3.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Dermatol 2006; 33:462-72;  PMID:16848818; http://dx.doi.org/10.1111/j.1346-8138.2006.00110.x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother  2006; 55:819-29; PMID:16187085; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J T ransl Med 2007; 5:67; PMID:18093335;  http://dx.doi.org/10.1186/1479-5876-5-67.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Br J Cancer 2003; 89:1172-9; PMID:14520441;  http://dx.doi.org/10.1038/sj.bjc.6601268.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2005; 11:4160-7; PMID:15930352; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Res 2004; 64:4973-9;  PMID:15256471; http://dx.doi.org/10.1158/0008- 5472.CAN-03-3505.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Neurooncol 2010; 99:261-72;  PMID:20146084; http://dx.doi.org/10.1007/s11060- 010-0131-y.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2008; 14:3098-104; PMID:18483377;  http://dx.doi.org/10.1158/1078-0432.CCR-07-4875.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother  2011; 34:382-9; PMID:21499132; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cell Biochem Biophys  2012; 62:91-9; PMID:21909820; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Oncol Rep 2009; 21:1585-92; PMID:19424640; http://dx.doi.org/10.3892/ or_00000391.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Thyroid 2007; 17:53-8; PMID:17274750;  http://dx.doi.org/10.1089/thy.2006.0178.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Lung Cancer  2007; 57:365-72; PMID:17509725; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Clin Oncol  2004; 22:2808-15; PMID:15254048; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Lung Cancer 2010; 70:188-94; PMID:20223553;  http://dx.doi.org/10.1016/j.lungcan.2010.02.006.145.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Int J Cancer  2001; 93:539-48; PMID:11477558; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nature 1998; 392:86-9;  PMID:9510252; http://dx.doi.org/10.1038/32183.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Res 2010; 70:9062-72; PMID:20884630; http://dx.doi.org/10.1158/0008- 5472.CAN-10-1825.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Leukemia 2005; 19:1621- 7; PMID:15990861; http://dx.doi.org/10.1038/ sj.leu.2403860.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Leukemia 2008; 22:1007- 17; PMID:18323802; http://dx.doi.org/10.1038/ leu.2008.29.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother  2012; 61:865-79; PMID:22086161; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Blood 2003; 102:2338-44; PMID:12714511; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother  2008; 31:771-80; PMID:18779742; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2008; 31:254- 62; PMID:18317362; http://dx.doi.org/10.1097/CJI.0b013e318167b023.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2009; 15:4986-92;  PMID:19622576; http://dx.doi.org/10.1158/1078- 0432.CCR-08-3240.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Scand J Immunol 2009; 70:481-9;  PMID:19874553; http://dx.doi.org/10.1111/j.1365- 3083.2009.02322.x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
BJU Int 2004; 94:412-8; PMID:15291878; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
PLoS One 2010;  5.PMID:20824184http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cytotherapy 2007; 9:755-70; PMID:17917887;  http://dx.doi.org/10.1080/14653240701589221.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunol 2011; 187:6130-42; PMID:22048768;  http://dx.doi.org/10.4049/jimmunol.1102209.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol  Immunother 2002; 51:45-52; PMID:11845259; http://dx.doi.org/10.1007/s00262-001-0255-1.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother  2011; 60:1097-107; PMID:21547597; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res  2010; 16:5548-56; PMID:20884622; http://dx.doi.org/10.1158/1078-0432.CCR-10-2138.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Acta Oncol 2009;  48:1157-64; PMID:19863224; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2007; 56:2003-16; PMID:17333181;  http://dx.doi.org/10.1007/s00262-007-0299-y.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Urol 1999; 161:777-82; PMID:10022683;  http://dx.doi.org/10.1016/S0022-5347(01)61767-1.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Urol  Int 1999; 63:151-9; PMID:10738185; http://dx.doi.org/10.1159/000030438.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother  2002; 51:637-44; PMID:12439609; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother  2003; 26:412-9; PMID:12973030; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother  2005; 54:663-70; PMID:15918076; http://dx.doi.org/10.1007/s00262-004-0629-2.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Int J Urol 2007; 14:277-83; PMID:17470153;  http://dx.doi.org/10.1111/j.1442-2042.2006.01723.x.183.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother  2008; 31:101-12; PMID:18157017; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2008; 57:1039-51; PMID:18157724; http://dx.doi.org/10.1007/s00262- 007-0435-8.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2008; 31:591-8; PMID:18528294;  http://dx.doi.org/10.1097/CJI.0b013e31817fd90b.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J T ransl Med 2008; 6:6; PMID:18221542; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Clin Oncol 2009; 27:945-52; PMID:19139436;  http://dx.doi.org/10.1200/JCO.2008.18.0794.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Biother Radiopharm 2009; 24:311-9; PMID:19538053; http://dx.doi.org/10.1089/ cbr.2008.0599.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J T ransl  Med 2010; 8:89; PMID:20875102; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cytotherapy 2010; 12:721-34; PMID:20429791; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2011; 17:1984-97;  PMID:21355077; http://dx.doi.org/10.1158/1078- 0432.CCR-10-3421.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2012; PMID:22426890; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Br J Haematol  2007; 139:415-24; PMID:17910631; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Am J Hematol 2009; 84:799- 802; PMID:19899131; http://dx.doi.org/10.1002/ ajh.21560.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother  2011; 34:100-6; PMID:21150718; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Med Pediatr Oncol 2002; 38:158-64; PMID:11836714;  http://dx.doi.org/10.1002/mpo.1303.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Clin Oncol  2011; 29:330-6; PMID:21149657; http://dx.doi.org/10.1200/JCO.2010.30.7744.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Neurosurg  Focus 2000; 9:e8; PMID:16817691; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2005; 11:5515-25; PMID:16061868;  http://dx.doi.org/10.1158/1078-0432.CCR-05-0464.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Mol Cancer Ther 2009; 8:2773-9;  PMID:19825799; http://dx.doi.org/10.1158/1535- 7163.MCT-09-0124.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol  Immunother 2004; 53:777-85; PMID:15185007; http://dx.doi.org/10.1007/s00262-004-0520-1.233.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Hum Gene Ther 1999;  10:1151-61; PMID:10340547; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunol 2011; 186:1325- 31; PMID:21248270; http://dx.doi.org/10.4049/jim- munol.0902539.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Res 2005; 65:10041-9;  PMID:16267030; http://dx.doi.org/10.1158/0008- 5472.CAN-05-1383.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Blood Rev 2009; 23:137- 42; PMID:18951668; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2007; 13:1353-5; PMID:17332275;  http://dx.doi.org/10.1158/1078-0432.CCR-06-2650.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Jpn J Cancer Res  1999; 90:1117-29; PMID:10595741; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Leuk Res  2003; 27:795-802; PMID:12804637; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Br J Haematol  2000; 108:805-16; PMID:10792287; http://dx.doi.org/10.1046/j.1365-2141.2000.01958.x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Leuk Lymphoma  2006; 47:29-37; PMID:16321824; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Clin Oncol 2005; 23:5779- 87; PMID:16110035; http://dx.doi.org/10.1200/JCO.2005.06.478.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Natl Cancer Inst 2010; 102:1388-97; PMID:20826737; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Exp Biol Med (Maywood) 2008; 233:522-34; PMID:18375829; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2008; 14:4898-907;  PMID:18676764; http://dx.doi.org/10.1158/1078- 0432.CCR-07-4899.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 1996;  183:1357-65; PMID:8666894; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 1996; 183:317- 22; PMID:8551239; http://dx.doi.org/10.1084/ jem.183.1.317.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 1996; 183:87- 97; PMID:8551248; http://dx.doi.org/10.1084/ jem.183.1.87.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Stem Cells 1997; 15:94- 103; PMID:9090785; http://dx.doi.org/10.1002/ stem.150094.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat  Med 1999; 5:405-11; PMID:10202929; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Ann N Y Acad Sci 1996; 795:284-93; PMID:8958940; http://dx.doi.org/10.1111/j.1749-6632.1996.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Clin Oncol  2003; 21:4016-26; PMID:14581425; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Exp Med 2011; 12:173-80;  PMID:21932124; http://dx.doi.org/10.1007/s10238-011-0159-0.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol  Immunother 2004; 53:609-16; PMID:14735319;  http://dx.doi.org/10.1007/s00262-003-0491-7.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2007; 30:762-72;  PMID:17893568; http://dx.doi.org/10.1097/CJI.0b013e318133451c.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2011; 60:1565-75;  PMID:21681375; http://dx.doi.org/10.1007/s00262- 011-1051-1.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2007; 30:116- 22; PMID:17198090; http://dx.doi.org/10.1097/01.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2006; 55:63-7;  PMID:15864588; http://dx.doi.org/10.1007/s00262- 005-0673-6.270.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer 2007; 110:203- 14; PMID:17541944; http://dx.doi.org/10.1002/ cncr.22744.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Res 2006; 66:4943-51;  PMID:16651452; http://dx.doi.org/10.1158/0008- 5472.CAN-05-3396.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother  2006; 55:1209-18; PMID:16331519; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Arch Dermatol Res 2007; 299:483-6;  PMID:17934742; http://dx.doi.org/10.1007/s00403- 007-0786-1.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res  2006; 12:7380-8; PMID:17189411; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Int J Cancer 2000; 86:385-92; PMID:10760827; http://dx.doi.org/10.1002/(SICI)1097- 0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T. 277.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother  2000; 23:487-98; PMID:10916759; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Clin Oncol 2003; 21:2342- 8; PMID:12805336; http://dx.doi.org/10.1200/JCO.2003.12.144.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res  2009; 15:6267-76; PMID:19789309; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2004; 27:354-67; PMID:15314544;  http://dx.doi.org/10.1097/00002371-200409000- 00004.258.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2004; 53:633-41;  PMID:14985857; http://dx.doi.org/10.1007/s00262- 003-0493-5.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res  2004; 10:828-39; PMID:14871958; http://dx.doi.org/10.1158/1078-0432.CCR-0620-3.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother  2007; 56:1485-99; PMID:17285289; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Vaccine 2008; 26:4716-24;  PMID:18616968; http://dx.doi.org/10.1016/j.vac-cine.2008.06.085.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Proc Natl Acad Sci U S A 2001; 98:8809- 14; PMID:11427731; http://dx.doi.org/10.1073/ pnas.141226398.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J T ransl Med 2005; 3:9; PMID:15723705;  http://dx.doi.org/10.1186/1479-5876-3-9.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol  Immunother 2006; 55:268-76; PMID:16034561;  http://dx.doi.org/10.1007/s00262-005-0021-x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Clin Cancer Res 2011; 30:65; PMID:21682877; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2005; 28:505-16; PMID:16113607;  http://dx.doi.org/10.1097/01.cji.0000171292.79663.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Clin  Oncol 2003; 21:3826-35; PMID:14551301; http://dx.doi.org/10.1200/JCO.2003.04.042.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Int J Cancer 2004; 111:229- 37; PMID:15197776; http://dx.doi.org/10.1002/ ijc.20238.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med  1998; 188:1075-82; PMID:9743526; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Biotechnol 2000; 18:1273-8;  PMID:11101806; http://dx.doi.org/10.1038/82383.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 1997; 186:1247- 56; PMID:9334364; http://dx.doi.org/10.1084/ jem.186.8.1247.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Eur J Immunol  1997; 27:2702-7; PMID:9368629; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Hum Gene Ther 1997; 8:1355- 63; PMID:9295130; http://dx.doi.org/10.1089/ hum.1997.8.11-1355.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Exp Immunol 1999; 117:244-51; PMID:10444254; http://dx.doi.org/10.1046/j.1365- 2249.1999.00913.x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Gene Med 1999; 1:400-6;  PMID:10753065; http://dx.doi.org/10.1002/ (SICI)1521-2254(199911/12)1:6<400::AID- JGM68>3.0.CO;2-D. 329.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cell Immunol 1999; 198:131- 8; PMID:10648127; http://dx.doi.org/10.1006/cimm.1999.1585.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2000; 191:1699-708; PMID:10811863; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2000; 23:59-66; PMID:10687138;  http://dx.doi.org/10.1097/00002371-200001000- 00008.306.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Prostate  2006; 66:811-21; PMID:16482569; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Prostate 2007; 67:500-8; PMID:17262804; http://dx.doi.org/10.1002/pros.20539.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol  Immunother 2006; 55:1033-42; PMID:16283303;  http://dx.doi.org/10.1007/s00262-005-0090-x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Prostate 1999; 39:291- 7; PMID:10344219; http://dx.doi.org/10.1002/ (SICI)1097-0045(19990601)39:4<291::AID- PROS10>3.0.CO;2-9.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Int J  Cancer 2006; 119:2428-34; PMID:16977630; http://dx.doi.org/10.1002/ijc.22097.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol  Immunother 2006; 55:1524-33; PMID:16612599;  http://dx.doi.org/10.1007/s00262-006-0157-3.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2006; 12:869-77;  PMID:16467101; http://dx.doi.org/10.1158/1078- 0432.CCR-05-1574.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Clin Oncol  2006; 24:3089-94; PMID:16809734; http://dx.doi.org/10.1200/JCO.2005.04.5252.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer 2009; 115:3670- 9; PMID:19536890; http://dx.doi.org/10.1002/ cncr.24429.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 1996; 184:465- 72; PMID:8760800; http://dx.doi.org/10.1084/ jem.184.2.465.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Med 1996; 2:1122-8; PMID:8837611; http://dx.doi.org/10.1038/nm1096- 1122.293.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer  Res 2006; 66:5910-8; PMID:16740731; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2012; 61:629-41; PMID:22021066; http://dx.doi.org/10.1007/s00262- 011-1081-8.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother  2012; 61:373-84; PMID:21927947; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Cancer Res Clin Oncol  2003; 129:521-30; PMID:12898233; http://dx.doi.org/10.1007/s00432-003-0463-5.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Virol 2008; 82:1968-79; PMID:18057249;  http://dx.doi.org/10.1128/JVI.02343-07.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Prostate 1999; 38:73-8; PMID:9973112;  http://dx.doi.org/10.1002/(SICI)1097- 0045(19990101)38:1<73::AID-PROS9>3.0.CO;2-V. 299.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Prostate 1999; 39:54-9; PMID:10221267; http://dx.doi.org/10.1002/ (SICI)1097-0045(19990401)39:1<54::AID- PROS9>3.0.CO;2-U.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Urol Oncol 2000; 5:265-73;  PMID:11008095; http://dx.doi.org/10.1016/S1078- 1439(00)00086-7.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother  2004; 53:453-60; PMID:14760510; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Expert Opin Biol Ther  2010; 10:983-91; PMID:20420527; http://dx.doi.org/ 10.1517/14712598.2010.484801.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2004; 10:5381-90; PMID:15328176; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cell Immunol 2002; 220:1-12;  PMID:12718934; http://dx.doi.org/10.1016/S0008- 8749(03)00009-1.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cell Immunol 2003; 225:65-74;  PMID:14698141; http://dx.doi.org/10.1016/j.cel - limm.2003.09.005.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Biochem Biophys Res Commun 2006; 346:829-39; PMID:16780801; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cytotherapy 2011;  13:774-85; PMID:21299362; http://dx.doi.org/10.31 09/14653249.2011.553593.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Gene Ther 2006; 13:138-49; PMID:16136162;  http://dx.doi.org/10.1038/sj.gt.3302609.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2010; 33:155- 66; PMID:20145548; http://dx.doi.org/10.1097/ CJI.0b013e3181bed253.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Semin Oncol 2012;  39:287-95; PMID:22595051; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Invest 2003; 21:341-9;  PMID:12901279; http://dx.doi.org/10.1081/CNV- 120018224.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother  2011; 60:809-18; PMID:21365467; http://dx.doi.org/10.1007/s00262-011-0991-9.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2006; 55:1432-42;  PMID:16612595; http://dx.doi.org/10.1007/s00262- 006-0161-7.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Br J Cancer 2005; 93:749- 56; PMID:16136047; http://dx.doi.org/10.1038/ sj.bjc.6602761.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Neuro Oncol 2004; 6:236-46; PMID:15279716; http://dx.doi.org/10.1215/S1152851703000668.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol  Immunother 2003; 52:632-7; PMID:12827308;  http://dx.doi.org/10.1007/s00262-003-0408-5.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Gene Ther 2006; 13:905- 18; PMID:16710345; http://dx.doi.org/10.1038/ sj.cgt.7700961.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2002; 51:669-73; PMID:12439613; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res  2006; 12:878-87; PMID:16467102; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Med 2000; 6:1011-7;  PMID:10973321; http://dx.doi.org/10.1038/79519.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Neurosurg  2001; 94:474-81; PMID:11235953; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Gene Ther 2002; 9:787- 97; PMID:12189529; http://dx.doi.org/10.1038/ sj.cgt.7700499.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother  2003; 26:420-31; PMID:12973031; http://dx.doi.org/10.1097/00002371-200309000-00005.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Am J Hematol 2004; 75:121-7; PMID:14978690;  http://dx.doi.org/10.1002/ajh.10471.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cytotherapy 2009; 11:653-68; PMID:19530029;  http://dx.doi.org/10.1080/14653240902960411.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Proc Natl Acad Sci U S A  2010; 107:13824-9; PMID:20631300; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin  Cancer Res 2007; 13:6666-72; PMID:18006767;  http://dx.doi.org/10.1158/1078-0432.CCR-07-0504.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer 2012; 118:2476- 85; PMID:21953023; http://dx.doi.org/10.1002/cncr.26511.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Int J Cancer 2003; 104:92- 7; PMID:12532424; http://dx.doi.org/10.1002/ ijc.10915.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol  Immunother 2007; 56:1459-69; PMID:17279413;  http://dx.doi.org/10.1007/s00262-007-0286-3.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Clin Oncol  2008; 26:4410-7; PMID:18802153; http://dx.doi.org/10.1200/JCO.2007.15.0284.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Metastasis Rev 2011; 30:13-25; PMID:21271351; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2005; 11:2576-82; PMID:15814636;  http://dx.doi.org/10.1158/1078-0432.CCR-04-1448.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother  2010; 33:435-41; PMID:20386463; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol  Immunother 2011; 60:909-18; PMID:21644034; http://dx.doi.org/10.1007/s00262-011-1046-y.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer 2000; 89:2646-54;  PMID:11135227; http://dx.doi.org/10.1002/1097- 0142(20001215)89:12<2646::AID- CNCR18>3.0.CO;2-A.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother  2005; 28:129-35; PMID:15725956; http://dx.doi.org/10.1097/01.cji.0000154248.74383.5e.387.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2004; 10:6347S-52S;  PMID:15448029; http://dx.doi.org/10.1158/1078- 0432.CCR-050005.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
"Int Braz J Urol 2011; 37:180-5, discussion 185-6;  PMID:21557834; http://dx.doi.org/10.1590/S1677- 55382011000200004.",OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Hum Gene Ther 2003; 14:483-94; PMID:12691613; http://dx.doi.org/10.1089/104303403321467243.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol  Immunother 2009; 58:1587-97; PMID:19221746;  http://dx.doi.org/10.1007/s00262-009-0668-9.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Exp Immunol  2006; 144:41-7; PMID:16542363; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunol 2011; 186:1218-27;  PMID:21149605; http://dx.doi.org/10.4049/jimmu- nol.1000808.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Magn  Reson Med 2009; 62:599-606; PMID:19544372;  http://dx.doi.org/10.1002/mrm.22030.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Lett 2000; 159:103-8; PMID:10974412; http://dx.doi.org/10.1016/S0304- 3835(00)00542-5.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer 2001; 91:2136-47;  PMID:11391595; http://dx.doi.org/10.1002/1097- 0142(20010601)91:11<2136::AID- CNCR1242>3.0.CO;2-Q.374.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Br J Haematol  2005; 129:340-9; PMID:15842657; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Br  J Haematol 2004; 125:343-52; PMID:15086415;  http://dx.doi.org/10.1111/j.1365-2141.2004.04929.x.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Blood 2011; 117:393-402; PMID:21030562; http://dx.doi.org/10.1182/blood-2010-04-277137.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother  2004; 27:452-9; PMID:15534489; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Breast Cancer 2003;  3(Suppl 4):S158-63; PMID:12620154; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Cancer Res 2004; 10:4699-708;  PMID:15269142; http://dx.doi.org/10.1158/1078- 0432.CCR-04-0347.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2004; 53:1111-8;  PMID:15185011; http://dx.doi.org/10.1007/s00262- 004-0551-7.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2004; 27:147-55; PMID:14770086; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Immunother 2002; 25:421-8; PMID:12218780;  http://dx.doi.org/10.1097/00002371-200209000- 00006.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Int J Cancer 2004; 110:730-40;  PMID:15146563; http://dx.doi.org/10.1002/ ijc.20191.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Clin Endocrinol (Oxf) 2006; 65:215-22;  PMID:16886963; http://dx.doi.org/10.1111/j.1365- 2265.2006.02576.x.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
J Exp Med 2004; 199:1503- 11; PMID:15173207; http://dx.doi.org/10.1084/ jem.20032118.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Proc Natl Acad Sci U S A  2010; 107:11895-9; PMID:20547850; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Biotechnol 2012; 30:337- 43; PMID:22426030; http://dx.doi.org/10.1038/ nbt.2157.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Res 2012; 72:1081-91;  PMID:22237626; http://dx.doi.org/10.1158/0008- 5472.CAN-11-3722.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Biotechnol  2005; 23:1407-13; PMID:16258544; http://dx.doi.org/10.1038/nbt1154.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cancer Immunol Immunother 2012; PMID:22294456; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Nat Rev Cancer 2006; 6:409-14;  PMID:16633367; http://dx.doi.org/10.1038/nrc1883.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992;  http://dx.doi.org/10.1056/NEJMoa1003466.413.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Int J Radiat  Oncol Biol Phys 2012; 82:924-32; PMID:21398051;  http://dx.doi.org/10.1016/j.ijrobp.2010.12.068.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Ann N Y Acad Sci 2009; 1174:41-50; PMID:19769735; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Mol Immunol 2011; 48:810- 7; PMID:21257206; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Blood 2010; 116:564-74;  PMID:20424184; http://dx.doi.org/10.1182/blood- 2009-11-251884.,Non-OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
Cell  2012; 148:886-95; PMID:22385958; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/cd/b9/onci-1-1111.PMC3494625.pdf
"Van Ginderachter; Email: jvangind@vub.ac.be Submitted: 06/03/12; Revised: 07/20/12; Accepted: 07/20/12http://dx.doi.org/10.4161/onci.21566The versatility and plasticity of myeloid cell polarization/ differentiation has turned out to be crucial in health and disease, and has become the subject of intense investigation  during the last years.",Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res  2012; 72:2473-80; PMID:22414581; http://dx.doi.org/10.1158/0008-5472.CAN-12-0122.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Semin Cancer Biol  2011; 21:139-46; PMID:21251983; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Nat  Rev Immunol 2011; 11:702-11; PMID:21941296;  http://dx.doi.org/10.1038/nri3064.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Pathol  2002; 196:254-65; PMID:11857487; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Immunobiology 2011; 216:1192- 202; PMID:21803441; http://dx.doi.org/10.1016/j.imbio.2011.06.007.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Nat Rev Immunol  2011; 11:723-37; PMID:21997792; http://dx.doi.org/10.1038/nri3073.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Clin  Invest 2007; 117:1155-66; PMID:17476345; http://dx.doi.org/10.1172/JCI31422.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Science  2006; 313:1960-4; PMID:17008531; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Surg Res  2011; 167:e211-9; PMID:19765725; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res 2010; 70:5728-39; PMID:20570887;  http://dx.doi.org/10.1158/0008-5472.CAN-09-4672.12.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res 2012; (E-pub ahead of print);  PMID:22719068; http://dx.doi.org/10.1158/0008- 5472.CAN-11-2994.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res  2010; 70:5270-80; PMID:20530679; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Cell 2005; 8:211-26; PMID:16169466; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Immunol 2009; 182:4499-506; PMID:19342621;  http://dx.doi.org/10.4049/jimmunol.0802740.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Blood 2008; 111:4233-44; PMID:18272812;  http://dx.doi.org/10.1182/blood-2007-07-099226.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Immunol Immunother  2012; 61:255-63; PMID:22120756; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Eur J Immunol  2010; 40:22-35; PMID:19941314; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer  Res 2012; 72:876-86; PMID:22174368; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Leukoc Biol 2011; 90:31-6; PMID:21486906; http://dx.doi.org/10.1189/jlb.0111021.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Eur J Immunol 2010; 40:2089- 94; PMID:20853491; http://dx.doi.org/10.1002/ eji.201040498.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Immunol Rev  2009; 227:234-47; PMID:19120488; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Curr  Opin Immunol 2011; 23:146-52; PMID:20970973;  http://dx.doi.org/10.1016/j.coi.2010.09.008.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Cell 2012; 21:402-17; PMID:22439936;  http://dx.doi.org/10.1016/j.ccr.2012.01.008.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Nat  Med 2003; 9:562-7; PMID:12704383; http://dx.doi.org/10.1038/nm863.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
"Liu Q, Zhang C, Sun A, Zheng Y, Wang L, Cao  X. T umor-educated CD11bhighIalow regulatory den- dritic cells suppress T cell response through arginase I. J Immunol 2009; 182:6207-16; PMID:19414774;  http://dx.doi.org/10.4049/jimmunol.0803926.",Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Proc Natl Acad Sci U S A  2008; 105:17073-8; PMID:18952840; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res 2011; 71:5601-5; PMID:21846822;  http://dx.doi.org/10.1158/0008-5472.CAN-11-1316.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res 2006; 66:9290- 8; PMID:16982774; http://dx.doi.org/10.1158/0008- 5472.CAN-06-1819.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Int J Cancer 2009; 124:2621- 33; PMID:19235923; http://dx.doi.org/10.1002/ ijc.24249.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res  2008; 68:1228-35; PMID:18281500; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Exp Med 2008; 205:2235-49; PMID:18809714; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Immunol Immunother 2012; 61:223-30;  PMID:22065047; http://dx.doi.org/10.1007/s00262- 011-1138-8.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Immunol 2012; 188:21-8;  PMID:22187483; http://dx.doi.org/10.4049/jimmu- nol.1101029.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Exp Med 2005; 202:931-9; PMID:16186186;  http://dx.doi.org/10.1084/jem.20050715.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Nat Rev Immunol  2010; 10:554-67; PMID:20616810; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Immunol  Res 2011; 51:170-82; PMID:22139852; http://dx.doi.org/10.1007/s12026-011-8262-6.47.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Genes Dev  2010; 24:491-501; PMID:20194441; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Am J Pathol 2000; 157:411- 21; PMID:10934146; http://dx.doi.org/10.1016/S0002-9440(10)64554-3.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Clin Invest  2010; 120:2699-714; PMID:20644254; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
PLoS  One 2011; 6:e18534; PMID:21494556; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Exp Med 2010; 207:2439- 53; PMID:20876310; http://dx.doi.org/10.1084/ jem.20100587.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Blood 2008;  112:3723-34; PMID:18694997; http://dx.doi.org/10.1182/blood-2008-02-142091.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Immunol  2011; 187:4403-9; PMID:22013206; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Proc Natl Acad Sci U S A  2011; 108:6561-6; PMID:21464300; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cell 2006; 124:587-99;  PMID:16469704; http://dx.doi.org/10.1016/j.cell.2005.11.040.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Clin Cancer Res 2011; 17:959-64; PMID:21224375;  http://dx.doi.org/10.1158/1078-0432.CCR-10-1489.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Semin Immunopathol  2011; 33:441-54; PMID:21688197; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Gastroenterology 2011; 140:310- 21; PMID:20955708; http://dx.doi.org/10.1053/j.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Exp Med 2012; 209:495- 506; PMID:22351930; http://dx.doi.org/10.1084/jem.20111413.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
T rends Immunol 2010; 31:318-24; PMID:20620114; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res 2011; 71:2411-6; PMID:21427354; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Cell 2009; 16:183-94; PMID:19732719;  http://dx.doi.org/10.1016/j.ccr.2009.06.017.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Nat Rev Immunol 2012; 12:253-68; PMID:22437938;  http://dx.doi.org/10.1038/nri3175.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Microenviron 2012; 5:133-49;  PMID:21948460; http://dx.doi.org/10.1007/s12307- 011-0091-6.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Nat Rev Cancer 2008; 8:618-31;  PMID:18633355; http://dx.doi.org/10.1038/nrc2444.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
FASEB J 2002; 16:1151-62; PMID:12153983;  http://dx.doi.org/10.1096/fj.01-0944rev.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Cell  2008; 13:206-20; PMID:18328425; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
PLoS One 2011; 6:e17922; PMID:21423807; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
FEBS Lett 1995; 372:233- 7; PMID:7556675; http://dx.doi.org/10.1016/0014- 5793(95)00986-J.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Blood 2009; 114:844- 59; PMID:19454749; http://dx.doi.org/10.1182/ blood-2008-12-195941.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Am J Pathol 2003; 163:1233-43; PMID:14507633;  http://dx.doi.org/10.1016/S0002-9440(10)63483-9.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res 2011; 71:318-27; PMID:21224361; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Immunol  2012; 188:1592-9; PMID:22231700; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Biol Chem 2011; 286:22403-13;  PMID:21515679; http://dx.doi.org/10.1074/jbc.M110.215301.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Eur J Immunol 1998; 28:359-69;  PMID:9485215; http://dx.doi.org/10.1002/ (SICI)1521-4141(199801)28:01<359::AID- IMMU359>3.0.CO;2-4.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Blood  2012; 119:4919-27; PMID:22490680; http://dx.doi.org/10.1182/blood-2011-11-392894.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Cell 2008; 13:23- 35; PMID:18167337; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Biochem  Pharmacol 2006; 72:1622-31; PMID:16846592;  http://dx.doi.org/10.1016/j.bcp.2006.05.017.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res 2009; 69:6367-70; PMID:19654288;  http://dx.doi.org/10.1158/0008-5472.CAN-09-1918.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Blood 2010; 115:1461-71;  PMID:20008303; http://dx.doi.org/10.1182/blood- 2009-08-237412.88.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Cell  2012; 21:488-503; PMID:22516258; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res 2011; 71:7463-70; PMID:22025564;  http://dx.doi.org/10.1158/0008-5472.CAN-11-2449.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Exp Med  2011; 208:1949-62; PMID:21930770; http://dx.doi.org/10.1084/jem.20101956.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Int Immunopharmacol 2011; 11:783-8;  PMID:21406269; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res  2010; 70:3526-36; PMID:20406969; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Science 2011; 332:1284-8;  PMID:21566158; http://dx.doi.org/10.1126/sci- ence.1204351.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Science 2009; 326:867-71;  PMID:19892988; http://dx.doi.org/10.1126/sci-ence.1176056.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res  2006; 66:605-12; PMID:16423985; http://dx.doi.org/10.1158/0008-5472.CAN-05-4005.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Blood 2007; 110:587- 95; PMID:17395778; http://dx.doi.org/10.1182/ blood-2007-01-068031.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
BMC Immunol 2011; 12:43;  PMID:21813021; http://dx.doi.org/10.1186/1471- 2172-12-43.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
"Dis Model Mech  2008; 1:155-67, discussion 165; PMID:19048079;  http://dx.doi.org/10.1242/dmm.000596.",Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Res 2010; 70:10019-23; PMID:21159626; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Immunol 2010; 185:2773-82;  PMID:20675592; http://dx.doi.org/10.4049/jimmu- nol.1000772.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
J Immunol  2011; 186:4183-90; PMID:21368233; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Blood 2009; 114:901-14; PMID:19383967;  http://dx.doi.org/10.1182/blood-2009-01-200931.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Cell  2009; 16:91-102; PMID:19647220; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Genes Dev 2010; 24:241- 55; PMID:20080943; http://dx.doi.org/10.1101/ gad.1874010.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Cell 2011; 19:441-55; PMID:21481787;  http://dx.doi.org/10.1016/j.ccr.2011.03.002.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Cancer Cell 2011; 19:512-26; PMID:21481792;  http://dx.doi.org/10.1016/j.ccr.2011.02.005.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Science  1983; 220:210-2; PMID:6828888; http://dx.doi.org/10.1126/science.6828888.,OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
Blood 2008; 111:5457-66;  PMID:18375791; http://dx.doi.org/10.1182/blood- 2008-01-136895.,Non-OADS,/arxiv_data1/oa_pdf/88/f1/onci-1-1135.PMC3494626.pdf
"We review published evidence in support of cancer-sup - pressive properties of inflammatory cells and of the canonical  *Correspondence to: Alexandre Corthay; Email: alexandre.corthay@medisin.uio.no Submitted: 05/29/12; Revised: 07/17/12; Accepted: 07/19/12http://dx.doi.org/10.4161/onci.21542in oncology, inflammation is generally regarded as a cancer- promoting process only.",Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Lancet 2001; 357:539-45;  PMID:11229684; http://dx.doi.org/10.1016/S0140- 6736(00)04046-0.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Nature 2008; 454:436-44; PMID:18650914; http://dx.doi.org/10.1038/ nature07205.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Cell 2010; 140:883-99;  PMID:20303878; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Cytokine 1999;  11:80-6; PMID:10080883; http://dx.doi.org/10.1006/ cyto.1998.0398.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Nat Rev Cancer 2010; 10:403-14;  PMID:20495574; http://dx.doi.org/10.1038/nrc2857.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Arthritis Rheum  2003; 48:963-70; PMID:12687538; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Lancet  2012; 379:1602-12; PMID:22440946; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Lancet 2012; 379:1591-601;  PMID:22440947; http://dx.doi.org/10.1016/S0140- 6736(12)60209-8.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Lancet Oncol 2012; 13:518-27; PMID:22440112; http://dx.doi.org/10.1016/S1470- 2045(12)70112-2.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Proc Natl Acad Sci USA  1994; 91:5700-4; PMID:7911244; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Eur J Immunol 1995; 25:3079-86; PMID:7489746; http://dx.doi.org/10.1002/eji.1830251114.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Cancer Res 2009; 69:5901-7;  PMID:19567679; http://dx.doi.org/10.1158/0008- 5472.CAN-08-4816.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Blood  2012; 119:2176-7; PMID:22383793; http://dx.doi.org/10.1182/blood-2011-10-388892.19.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Nat Commun 2011; 2:240; PMID:21407206;  http://dx.doi.org/10.1038/ncomms1239.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
T rends Immunol 2002; 23:549-55;  PMID:12401408; http://dx.doi.org/10.1016/S1471- 4906(02)02302-5.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J  Natl Cancer Inst 1989; 81:1893-904; PMID:2593166;  http://dx.doi.org/10.1093/jnci/81.24.1893.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Eur J Cancer 2005; 41:2645- 54; PMID:16239109; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Histopathology 2006; 48:692-701; PMID:16681685;  http://dx.doi.org/10.1111/j.1365-2559.2006.02410.x.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Surg Oncol 1996;  62:78-85; PMID:8649045; http://dx.doi.org/10.1002/ (SICI)1096-9098(199606)62:2<78::AID- JSO2>3.0.CO;2-N. 57.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Exp Med 1990; 171:629-36; PMID:2307930;  http://dx.doi.org/10.1084/jem.171.3.629.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Neurooncol 1999; 45:209-18; PMID:10845391;  http://dx.doi.org/10.1023/A:1006357424124.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Immunol 2010; 185:7067-76;  PMID:21041732; http://dx.doi.org/10.4049/jimmu- nol.1001137.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Clin Invest 2011; 121:3846-59; PMID:21926464; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Proc Natl Acad Sci USA 1992; 89:9215- 9; PMID:1409627; http://dx.doi.org/10.1073/ pnas.89.19.9215.41.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Natl Cancer Inst 1991; 83:119- 23; PMID:1988686; http://dx.doi.org/10.1093/ jnci/83.2.119.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Exp Med  1988; 168:2031-43; PMID:3143799; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Exp Med  2010; 207:1045-56; PMID:20385749; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/ nm.2028.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Ann Hematol 2011; 90:1173-81; PMID:21347685;  http://dx.doi.org/10.1007/s00277-011-1194-3.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Exp Med  1987; 165:515-30; PMID:2950198; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Science  2006; 313:1960-4; PMID:17008531; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
PLoS Med 2005; 2:e284; PMID:16124834; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Cancer Cell 2006; 10:99- 111; PMID:16904609; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Clin Oncol  2005; 23:8959-67; PMID:16219934; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Clin Cancer Res 2007; 13:1472-9;  PMID:17332291; http://dx.doi.org/10.1158/1078- 0432.CCR-06-2073.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Proc Natl Acad Sci USA 2009; 106:7119- 24; PMID:19359475; http://dx.doi.org/10.1073/ pnas.0902745106.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Nature 2001;  410:1107-11; PMID:11323675; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Nature 1983; 305:239-40;  PMID:6412144; http://dx.doi.org/10.1038/305239a0.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Proc Natl Acad Sci USA 1996; 93:13791-6; PMID:8943014; http://dx.doi.org/10.1073/ pnas.93.24.13791.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Exp Med  1998; 187:129-34; PMID:9419219; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Nature 2009; 462:510- 3; PMID:19898495; http://dx.doi.org/10.1038/nature08511.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Br J Cancer 1973; 27:370-89; PMID:4713170; http://dx.doi.org/10.1038/ bjc.1973.45.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Immunotherapy  2010; 2:551-60; PMID:20636008; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Nat Immunol 2002; 3:196-200;  PMID:11812998; http://dx.doi.org/10.1038/ni758.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Am Acad  Dermatol 2002; 47:390-8; PMID:12196749; http://dx.doi.org/10.1067/mjd.2002.126215.85.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
"Ann Surg 1996; 224:756- 64, discussion 764-5; PMID:8968230; http://dx.doi.org/10.1097/00000658-199612000-00011.",Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Br J Cancer 2010; 103:837-44; PMID:20717115;  http://dx.doi.org/10.1038/sj.bjc.6605858.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Cancer Gene Ther 2011; 18:189-95; PMID:21052099; http://dx.doi.org/10.1038/ cgt.2010.69.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Proc Natl Acad Sci USA  2012; 109:7841-6; PMID:22547817; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Int J Cancer 1989; 44:1108-16; PMID:2606579; http://dx.doi.org/10.1002/ ijc.2910440629.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Oncogene 2008; 27:3780- 8; PMID:18246123; http://dx.doi.org/10.1038/ onc.2008.4.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Clin  Endocrinol Metab 1995; 80:1664-9; PMID:7745015;  http://dx.doi.org/10.1210/jc.80.5.1664.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Proc Natl Acad Sci USA  1998; 95:7556-61; PMID:9636188; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Science 2002; 296:1634-5; PMID:12040173;  http://dx.doi.org/10.1126/science.1071924.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Curr Dir Autoimmun 2010;  11:105-18; PMID:20173390; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Nat  Med 1999; 5:828-31; PMID:10395330; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Proc Natl Acad Sci USA  1975; 72:3666-70; PMID:1103152; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Exp Med 1988; 167:1067-85; PMID:3351434;  http://dx.doi.org/10.1084/jem.167.3.1067.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Nature 1975; 258:731-2; PMID:1207755;  http://dx.doi.org/10.1038/258731a0.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Exp Med 1998; 188:1611-9; PMID:9802973;  http://dx.doi.org/10.1084/jem.188.9.1611.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Proc Natl Acad Sci USA  2008; 105:652-6; PMID:18178624; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Int J Cancer 2009; 124:130-9; PMID:18839429;  http://dx.doi.org/10.1002/ijc.23886.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
Nat Med 2007; 13:1050-9;  PMID:17704786; http://dx.doi.org/10.1038/nm1622.115.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
J Am Acad Dermatol 2004; 50:714- 21; PMID:15097955; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
N  Engl J Med 2008; 358:1465-73; PMID:18385498;  http://dx.doi.org/10.1056/NEJMoa072685.,OADS,/arxiv_data1/oa_pdf/e2/3a/onci-1-1146.PMC3494627.pdf
"OncoImmunology 1:7, 1156-1158; October 2012; © 2012 Landes Bioscience Aut OphA gIc punctum 1156 OncoImmunology Volume 1 Issue 7Keywords:  breast cancer prognosis,  immunoglobulin kappa C, humoral  immune system, prognosis, prediction of chemotherapy response, lung cancer, colon cancer Submitted: 07/25/12Accepted: 07/26/12http://dx.doi.org/10.4161/onci.21653 Correspondence to: Jan G. Hengstler;   Email: hengstler@ifado.de Infiltration of plasma cells is associated  with better prognosis in breast, lung  and colon cancer.",Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Ann Oncol 2009; 20:258- 64; PMID:18824499; http://dx.doi.org/10.1093/annonc/mdn590.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Nature 2002; 415:530-6; PMID:11823860; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
BMC Bioinformatics  2011; 12:478; PMID:22177110; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
BMC Bioinformatics  2010; 11:276; PMID:20500820; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
N  Engl J Med 2004; 351:2817-26; PMID:15591335; http://dx.doi.org/10.1056/NEJMoa041588.,OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
J Natl Cancer Inst  2006; 98:262-72; PMID:16478745; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
N Engl J Med 2006; 355:560-9; PMID:16899776; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Clin Cancer Res  2010; 16:451-60; PMID:20068093; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Cancer Res  2009; 69:2695-8; PMID:19318558; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Breast Cancer  Res Treat 2011; 125:637-46; PMID:20352488;  http://dx.doi.org/10.1007/s10549-010-0856-5.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Nature 2000; 406:747-52; PMID:10963602; http://dx.doi.org/10.1038/35021093.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Proc Natl Acad Sci USA  2001; 98:10869-74; PMID:11553815; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Clin Cancer Res 2005;  11:5678-85; PMID:16115903; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Cancer Res 2008; 68:5405-13; PMID:18593943;  http://dx.doi.org/10.1158/0008-5472.CAN-07- 5206.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Clin Cancer Res 2012; 18:2695-703; PMID:22351685; http://dx.doi.org/10.1158/1078-0432.CCR-11-2210.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Clin Cancer Res 2012; 18:2417-9; PMID:22442060; http://dx.doi.org/10.1158/1078-0432.CCR-12- 0566.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Breast Cancer  Res 2010; 12:R44; PMID:20584310; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Cytoskeleton (Hoboken) 2012; 69:267- 77; PMID:22407943; http://dx.doi.org/10.1002/ cm.21023.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Curr Opin Immunol 2007; 19:209-16; PMID:17276050; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
Cancer Res 2006; 66:7741-7; PMID:16885377; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/7e/onci-1-1156.PMC3494628.pdf
"For instance, epidermal growth fac - tor (EGF)-enhanced expression of hBD3 has been reported in oral carcinoma Friend or foe A novel role of β-defensins in tumor development Johann r öhrl,1,* edward K. Geissler2 and t homas h ehlgans1 1Department of Immunology; u niversity of r egensburg; r egensburg, Germany; 2Department of s urgery; u niversity Medical Center r egensburg; r egensburg, Germany Keywords:  defensin, antimicrobial peptide, tumor growth, angiogenesis, lymphotoxin β -receptor, chemokine receptor 6 Abbreviations:  hBD, human β -defensin; LT βR, lymphotoxin β -receptor; mBD, mouse β -defensin *Correspondence to: Johann Röhrl; Email: johann.roehrl@klinik.uni-regensburg.de Submitted: 05/21/12; Accepted: 05/21/12http://dx.doi.org/10.4161/onci.20825lesions.6 Such an intratumoral hBD3  chemoattracts tumor-associated macro - phages (TAMs) into carcinoma lesions in  a CCR2-dependent manner and stimu - lates the production of tumor-promoting cytokines like interleukin-8 (IL-8), which is known to be a pro-angiogenic factor.",Non-OADS,/arxiv_data1/oa_pdf/50/9a/onci-1-1159.PMC3494629.pdf
Curr  Opin Immunol 2002; 14:96-102; PMID:11790538;  http://dx.doi.org/10.1016/S0952-7915(01)00303-X.,OADS,/arxiv_data1/oa_pdf/50/9a/onci-1-1159.PMC3494629.pdf
J Biol Chem 2010; 285:7028-34; PMID:20068036; http://dx.doi.org/10.1074/jbc.M109.091090.,OADS,/arxiv_data1/oa_pdf/50/9a/onci-1-1159.PMC3494629.pdf
Science 1999; 286:525-8; PMID:10521347;  http://dx.doi.org/10.1126/science.286.5439.525.,OADS,/arxiv_data1/oa_pdf/50/9a/onci-1-1159.PMC3494629.pdf
J Immunol 2010; 184:6688-94; PMID:20483750;  http://dx.doi.org/10.4049/jimmunol.0903984.,Non-OADS,/arxiv_data1/oa_pdf/50/9a/onci-1-1159.PMC3494629.pdf
J Biol Chem 2008; 283:5414-9;  PMID:18167348; http://dx.doi.org/10.1074/jbc.M709103200.,OADS,/arxiv_data1/oa_pdf/50/9a/onci-1-1159.PMC3494629.pdf
Oral Oncol 2009; 45:696- 702; PMID:19097930; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/50/9a/onci-1-1159.PMC3494629.pdf
PLoS  One 2010; 5:10993; PMID:20544025; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/9a/onci-1-1159.PMC3494629.pdf
Peptides 2009; 30:267-72;  PMID:19041917; http://dx.doi.org/10.1016/j.pep- tides.2008.11.001.,OADS,/arxiv_data1/oa_pdf/50/9a/onci-1-1159.PMC3494629.pdf
"Cancer Res 2008; 68:6482-5; PMID:18701469; http://dx.doi.org/10.1158/0008-5472.CAN-08-0044.that the activation of lymphotoxin- β- receptor (LT βR) on fibrosarcoma cells  by ligand-expressing activated T and B  lymphocytes results in increased expres - sion of pro-angiogenic CXCL2 (MIP-2), the functional mouse ortholog of human IL-8, and hence increased tumor growth.",Non-OADS,/arxiv_data1/oa_pdf/50/9a/onci-1-1159.PMC3494629.pdf
"Neutrophils are shown to be required for the efficacy of BCG immunotherapy in mouse models, 2 and proportionately,  neutrophils account for about 75% of Redirecting neutrophils against bladder cancer  cells by BCG and Smac mimetic combination Goodwin Jinesh G. and Ashish M. Kamat* Department of u rology, u nit 1373; t he u niversity of t exas MD Anderson Cancer Center; h ouston, t X us A Keywords:  BCG, bladder cancer, FASL, Smac mimetics, neutrophils, TNF α, TRAIL *Correspondence to: Ashish M. Kamat; Email: akamat@mdanderson.org Submitted: 05/28/12; Accepted: 05/30/12http://dx.doi.org/10.4161/onci.20928the immune cells recruited in response  to BCG immunotherapy in patients.3  Neutrophil priming/activation in this setup can be either due to the BCG lipo - polysaccharides, which enable neutrophil self-priming, or to interferon γ (IFN γ)  secreted from other immune cells (which helps neutrophil priming).",Non-OADS,/arxiv_data1/oa_pdf/bb/5f/onci-1-1161.PMC3494630.pdf
Nat Rev Immunol 2012; 12:253-68; PMID:22437938;  http://dx.doi.org/10.1038/nri3175.,Non-OADS,/arxiv_data1/oa_pdf/bb/5f/onci-1-1161.PMC3494630.pdf
Cancer Res 2006; 66:8250-7;  PMID:16912205; http://dx.doi.org/10.1158/0008- 5472.CAN-06-1416.,Non-OADS,/arxiv_data1/oa_pdf/bb/5f/onci-1-1161.PMC3494630.pdf
Urol Res 1991; 19:45-50; PMID:2028562; http://dx.doi.org/10.1007/BF00294021.,Non-OADS,/arxiv_data1/oa_pdf/bb/5f/onci-1-1161.PMC3494630.pdf
Lab Invest 2004; 84:1363-71;  PMID:15220936; http://dx.doi.org/10.1038/labin- vest.3700148.,OADS,/arxiv_data1/oa_pdf/bb/5f/onci-1-1161.PMC3494630.pdf
Blood 2005; 106:3474-82; PMID:16037389;  http://dx.doi.org/10.1182/blood-2005-03-1327.,Non-OADS,/arxiv_data1/oa_pdf/bb/5f/onci-1-1161.PMC3494630.pdf
Nat Rev Drug Discov  2012; 11:109-24; PMID:22293567; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/bb/5f/onci-1-1161.PMC3494630.pdf
"3Hunting for clues Regulatory T cells and colorectal cancer Awen Gallimore and Andrew Godkin* Institute of Infection and Immunity; Cardiff u niversity s chool of Medicine; Cardiff, u K Keywords:  T cell, colorectal cancer, regulatory T cell *Correspondence to: Andrew Godkin; Email: godkinaj@cf.ac.uk Submitted: 04/24/12; Accepted: 04/24/12http://dx.doi.org/10.4161/onci.20499Tregs express a series of markers includ - ing CD4, CD25 (high levels), and the  transcription factor Foxp3.",Non-OADS,/arxiv_data1/oa_pdf/12/e1/onci-1-1163.PMC3494631.pdf
Nat Med  2004; 10:909-15; PMID:15340416; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/12/e1/onci-1-1163.PMC3494631.pdf
Nat Immunol 2005; 6:345- 52; PMID:15785760; http://dx.doi.org/10.1038/ni1178.4.,Non-OADS,/arxiv_data1/oa_pdf/12/e1/onci-1-1163.PMC3494631.pdf
J Am  Med Assoc 1931; 96:30-3; http://dx.doi.org/10.1001/ jama.1931.02720270032009.,Non-OADS,/arxiv_data1/oa_pdf/12/e1/onci-1-1163.PMC3494631.pdf
Science  2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139.,OADS,/arxiv_data1/oa_pdf/12/e1/onci-1-1163.PMC3494631.pdf
PLoS One 2006; 1:129;  PMID:17205133; http://dx.doi.org/10.1371/journal.pone.0000129.7.,OADS,/arxiv_data1/oa_pdf/12/e1/onci-1-1163.PMC3494631.pdf
Adv Drug Deliv Rev 2006; 58:948-61; PMID:17070961; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/12/e1/onci-1-1163.PMC3494631.pdf
Cancer Immunol  Immunother 2011; 60:909-18; PMID:21644034;  http://dx.doi.org/10.1007/s00262-011-1046-y.,Non-OADS,/arxiv_data1/oa_pdf/12/e1/onci-1-1163.PMC3494631.pdf
"van den Brink tytgat Institute for Liver and Intestal r esearch and Department of Gastroenterology; Academic Medical Center; Amsterdam, the Netherlands Keywords:  rage, intestinal polyp, ApcMin, MyD88, innate immune system, colon cancer *Correspondence to: Jarom Heijmans; Email: j.heijmans@amc.nl Submitted: 05/28/12; Accepted: 05/30/12http://dx.doi.org/10.4161/onci.20929in tumor development.",Non-OADS,/arxiv_data1/oa_pdf/d6/27/onci-1-1165.PMC3494632.pdf
Science 2007; 317:121-4; PMID:17615358;  http://dx.doi.org/10.1126/science.1140485.,OADS,/arxiv_data1/oa_pdf/d6/27/onci-1-1165.PMC3494632.pdf
Cell 2004; 118:285-96; PMID:15294155;  http://dx.doi.org/10.1016/j.cell.2004.07.013.,OADS,/arxiv_data1/oa_pdf/d6/27/onci-1-1165.PMC3494632.pdf
Nat Rev Cancer 2006; 6:24-37; PMID:16397525;  http://dx.doi.org/10.1038/nrc1782.,Non-OADS,/arxiv_data1/oa_pdf/d6/27/onci-1-1165.PMC3494632.pdf
PLoS  One 2011; 6:23132; PMID:21829704; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d6/27/onci-1-1165.PMC3494632.pdf
Carcinogenesis 2008; 29:2035-43;  PMID:18689872; http://dx.doi.org/10.1093/carcin/ bgn188.,Non-OADS,/arxiv_data1/oa_pdf/d6/27/onci-1-1165.PMC3494632.pdf
Science 2007; 317:124- 7; PMID:17615359; http://dx.doi.org/10.1126/sci- ence.1140488.,OADS,/arxiv_data1/oa_pdf/d6/27/onci-1-1165.PMC3494632.pdf
Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d6/27/onci-1-1165.PMC3494632.pdf
Oncogene  2012; PMID:22469986; http://dx.doi.org/10.1038/ onc.2012.119.,OADS,/arxiv_data1/oa_pdf/d6/27/onci-1-1165.PMC3494632.pdf
J Exp Med 2008; 205:275- 85; PMID:18208974; http://dx.doi.org/10.1084/ jem.20070679.,Non-OADS,/arxiv_data1/oa_pdf/d6/27/onci-1-1165.PMC3494632.pdf
"heery and James L. Gulley* Laboratory of t umor Immunology and Biology; National Cancer Institute; Bethesda, MD us A Keywords:  PROSTVAC, PSA-TRICOM, ipilimumab, vaccine, prostate cancer *Correspondence to: James L. Gulley; Email: gulleyj@mail.nih.gov Submitted: 04/11/12; Accepted: 05/02/12http://dx.doi.org/10.4161/onci.20591directed against CTLA-4, can inhibit  such a negative regulatory signal, and potentially create more robust T-cell responses and higher-avidity antitumor T cells.",Non-OADS,/arxiv_data1/oa_pdf/09/7f/onci-1-1167.PMC3494633.pdf
N Engl J Med 2010; 363:411-22;  PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.,OADS,/arxiv_data1/oa_pdf/09/7f/onci-1-1167.PMC3494633.pdf
Clin Cancer Res 2011; 17:3884-91;  PMID:21680544; http://dx.doi.org/10.1158/1078- 0432.CCR-10-2656.4.,Non-OADS,/arxiv_data1/oa_pdf/09/7f/onci-1-1167.PMC3494633.pdf
J Clin Oncol  2010; 28:1099-105; PMID:20100959; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/09/7f/onci-1-1167.PMC3494633.pdf
Nat Immunol 2002; 3:611-8;  PMID:12087419; http://dx.doi.org/10.1038/ni0702- 611.,Non-OADS,/arxiv_data1/oa_pdf/09/7f/onci-1-1167.PMC3494633.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992;  http://dx.doi.org/10.1056/NEJMoa1003466.8.,OADS,/arxiv_data1/oa_pdf/09/7f/onci-1-1167.PMC3494633.pdf
Cancer Immunol Immunother  2010; 59:663-74; PMID:19890632; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/09/7f/onci-1-1167.PMC3494633.pdf
Clin Cancer Res 2005; 11:2416-26; PMID:15788693; http://dx.doi.org/10.1158/1078- 0432.CCR-04-1380.,Non-OADS,/arxiv_data1/oa_pdf/09/7f/onci-1-1167.PMC3494633.pdf
"In the absence of insights into the level and type of immune proficiency that must be attained for effective tumor eradication in each particular patient, it is unlikely that any “one-size-fits-all” approach will Personalizing immunotherapy Balancing predictability and precision Zvia Agur1,* and s tanimir Vuk-Pavlović2 1Institute of Medical BioMathematics; Bene Ataroth, Israel; 2College of Medicine; Mayo Clinic; r ochester, MN us A Keywords:  mathematical model, in-treatment, personalization, prostate cancer, clinical trial *Correspondence to: Zvia Agur; Email: agur@imbm.org Submitted: 05/28/12; Accepted: 05/30/12http://dx.doi.org/10.4161/onci.20955be predictably effective.",Non-OADS,/arxiv_data1/oa_pdf/ec/6d/onci-1-1169.PMC3494634.pdf
Nat Biotechnol  2011; 29:867-70; PMID:21997622; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ec/6d/onci-1-1169.PMC3494634.pdf
PLoS Comput Biol 2011; 7:1002206;  PMID:22022259; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/ec/6d/onci-1-1169.PMC3494634.pdf
Clin Cancer Res 2005; 11:4469-78; PMID:15958632;  http://dx.doi.org/10.1158/1078-0432.CCR-04-2337.,Non-OADS,/arxiv_data1/oa_pdf/ec/6d/onci-1-1169.PMC3494634.pdf
Cancer Res 2012;  72:2218-27; PMID:22422938; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ec/6d/onci-1-1169.PMC3494634.pdf
PLoS One 2010; 5:15482;  PMID:21151630; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/ec/6d/onci-1-1169.PMC3494634.pdf
"turnis,1 Alan J. Korman,2 Charles G. Drake3 and Dario A.A. Vignali1,* 1Department of Immunology; s t. Jude Children’s r esearch h ospital; Memphis, t N us A; 2Biologics Discovery California; Bristol-Myers- squibb; Milpitas, CA us A;   3Departments of Oncology, Immunology and u rology; Johns h opkins s idney Kimmel Comprehensive Cancer Center; Baltimore, MD us A Keywords:  cancer, immunotherapy, lymphocyte, synergy, PD-1, CD279, LAG-3, CD223, CTLA-4, CD152, MDX-1106,  ipilimumab Abbreviations:  PD-1, programmed death 1; LAG-3, lymphocyte activation gene 3; CTLA-4, cytotoxic T-lymphocyte-associated  protein 4 *Correspondence to: Dario A.A. Vignali; Email: dario.vignali@stjude.org Submitted: 05/01/12; Accepted: 05/02/12http://dx.doi.org/10.4161/onci.20593LAG-3 (lymphocyte activation gene,  CD223, gene name LAG3 ) is a negative  regulatory molecule expressed upon acti - vation of various lymphoid cell types.",Non-OADS,/arxiv_data1/oa_pdf/67/0a/onci-1-1172.PMC3494635.pdf
Cancer  Res 2012; 72:917-27; PMID:22186141; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/67/0a/onci-1-1172.PMC3494635.pdf
Int Immunol 2009; 21:1065-77; PMID:19651643; http://dx.doi.org/10.1093/intimm/ dxp072.,Non-OADS,/arxiv_data1/oa_pdf/67/0a/onci-1-1172.PMC3494635.pdf
J Immunol 2009; 182:6659-69;  PMID:19454660; http://dx.doi.org/10.4049/jimmu- nol.0804211.,Non-OADS,/arxiv_data1/oa_pdf/67/0a/onci-1-1172.PMC3494635.pdf
PLoS One 2012; 7:30852; PMID:22347406; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/67/0a/onci-1-1172.PMC3494635.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992;  http://dx.doi.org/10.1056/NEJMoa1003466.8.,OADS,/arxiv_data1/oa_pdf/67/0a/onci-1-1172.PMC3494635.pdf
Proc Natl Acad Sci USA  2010; 107:4275-80; PMID:20160101; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/67/0a/onci-1-1172.PMC3494635.pdf
J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/67/0a/onci-1-1172.PMC3494635.pdf
Nature  2007; 450:566-9; PMID:18033300; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/67/0a/onci-1-1172.PMC3494635.pdf
"4  Independently, in comparative gene expression profiling of invasive bladder cancer cell lines and human muscle-inva - sive urothelial cancer samples, we discov - ered that versican (VCAN), also known RhoGDI2 suppresses bladder cancer metastasis  via reduction of inflammation in the tumor  microenvironment Neveen s aid1 and Dan t heodorescu2,3,* 1Department of u rology; u niversity of Virginia; Charlottesville, VA us A; 2Department of s urgery; u niversity of Colorado Comprehensive Cancer Center; Denver, CO us A;  3Department of Pharmacology; u niversity of Colorado Comprehensive Cancer Center; Denver, CO us A Keywords:  bladder cancer, metastasis, RhoGDI2, versican, inflammation *Correspondence to: Dan Theodorescu; Email: dan.theodorescu@ucdenver.edu Submitted: 05/02/12; Accepted: 05/02/12http://dx.doi.org/10.4161/onci.20594as chondroitin sulfate proteoglycan 2  (CSPG2), is highly expressed in invasive and metastatic cancers.",Non-OADS,/arxiv_data1/oa_pdf/42/c1/onci-1-1175.PMC3494636.pdf
J Clin Invest 2011; 121:132-47; PMID:21183790;  http://dx.doi.org/10.1172/JCI42912.,Non-OADS,/arxiv_data1/oa_pdf/42/c1/onci-1-1175.PMC3494636.pdf
Cancer Metastasis Rev  2009; 28:327-33; PMID:20013033; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/42/c1/onci-1-1175.PMC3494636.pdf
Clin Cancer Res 2004; 10:3800-6; PMID:15173088;  http://dx.doi.org/10.1158/1078-0432.CCR-03-0653.,Non-OADS,/arxiv_data1/oa_pdf/42/c1/onci-1-1175.PMC3494636.pdf
Oncogene 2008; 27:6679-89; PMID:18724390;  http://dx.doi.org/10.1038/onc.2008.264.6.,Non-OADS,/arxiv_data1/oa_pdf/42/c1/onci-1-1175.PMC3494636.pdf
Curr Opin Cell Biol  2002; 14:617-23; PMID:12231358; http://dx.doi.org/10.1016/S0955-0674(02)00375-7.,OADS,/arxiv_data1/oa_pdf/42/c1/onci-1-1175.PMC3494636.pdf
Int J Cancer 2005; 114:879- 86; PMID:15645431; http://dx.doi.org/10.1002/ ijc.20813.,Non-OADS,/arxiv_data1/oa_pdf/42/c1/onci-1-1175.PMC3494636.pdf
J Clin Invest 2012; 122:1503- 18; PMID:22406535; http://dx.doi.org/10.1172/ JCI61392.9.,Non-OADS,/arxiv_data1/oa_pdf/42/c1/onci-1-1175.PMC3494636.pdf
J Natl Cancer Inst 2010; 102:522- 8; PMID:20233997; http://dx.doi.org/10.1093/jnci/ djq044.,Non-OADS,/arxiv_data1/oa_pdf/42/c1/onci-1-1175.PMC3494636.pdf
"Program; u niversity of Minnesota; Minneapolis, MN us A; 2Center for Immunology; u niversity of Minnesota;  Minneapolis, MN us A; 3Department of u rology; u niversity of Minnesota; Minneapolis, MN us A Keywords:  TRAIL, immunotherapy, adenovirus, RCC, apoptosis *Correspondence to: Thomas S. Griffith; Email: tgriffit@umn.edu Submitted: 04/27/12; Accepted: 05/04/12http://dx.doi.org/10.4161/onci.20638in using agonistic monoclonal antibod - ies (mAbs) specific for the death-induc - ing TRAIL receptors, TRAIL-R1 and  -R2.",Non-OADS,/arxiv_data1/oa_pdf/5a/c0/onci-1-1178.PMC3494637.pdf
Mol Ther 2000; 1:574-80;  PMID:10933982; http://dx.doi.org/10.1006/ mthe.2000.0074.,OADS,/arxiv_data1/oa_pdf/5a/c0/onci-1-1178.PMC3494637.pdf
Cancer BiolTher  2005; 4:1104-12; PMID:16096370; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/c0/onci-1-1178.PMC3494637.pdf
Cancer Res 2007; 67:11980-90; PMID:18089829;  http://dx.doi.org/10.1158/0008-5472.CAN-07-1526.,Non-OADS,/arxiv_data1/oa_pdf/5a/c0/onci-1-1178.PMC3494637.pdf
PLoS One 2012; 7:31085;  PMID:22312440; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/5a/c0/onci-1-1178.PMC3494637.pdf
Eur J Pharmacol 2009; 625:63-72; PMID:19836385;  http://dx.doi.org/10.1016/j.ejphar.2009.06.066.References 1.,OADS,/arxiv_data1/oa_pdf/5a/c0/onci-1-1178.PMC3494637.pdf
Immunity 1995; 3:673-82; PMID:8777713;  http://dx.doi.org/10.1016/1074-7613(95)90057-8.,OADS,/arxiv_data1/oa_pdf/5a/c0/onci-1-1178.PMC3494637.pdf
Mol Ther 2001; 4:257- 66; PMID:11545617; http://dx.doi.org/10.1006/ mthe.2001.0439.,OADS,/arxiv_data1/oa_pdf/5a/c0/onci-1-1178.PMC3494637.pdf
Cancer Immunol Immunother 2011; 60:659-69;  PMID:21318638; http://dx.doi.org/10.1007/s00262- 011-0973-y.,Non-OADS,/arxiv_data1/oa_pdf/5a/c0/onci-1-1178.PMC3494637.pdf
"3Interleukin-2 treatment of tumor patients   can expand regulatory T cells Marc Beyer Genomics and Immunoregulation; LIM es-Institute; u niversity of Bonn; Bonn, Germany Keywords:  Treg cells, immunotherapy, interleukin-2, tumor Correspondence to: Marc Beyer; Email: marc.beyer@uni-bonn.de Submitted: 04/27/12; Accepted: 05/04/12http://dx.doi.org/10.4161/onci.20639One important and yet unresolved  aspect in tumor immunology is how  and where Treg cells in tumor patients  develop.",Non-OADS,/arxiv_data1/oa_pdf/35/56/onci-1-1181.PMC3494638.pdf
Annu  Rev Immunol 2008; 26:453-79; PMID:18062768;  http://dx.doi.org/10.1146/annurev.immu- nol.26.021607.090357.,Non-OADS,/arxiv_data1/oa_pdf/35/56/onci-1-1181.PMC3494638.pdf
Annu  Rev Immunol 2012; 30:531-64; PMID:22224781;  http://dx.doi.org/10.1146/annurev.immu- nol.25.022106.141623.,Non-OADS,/arxiv_data1/oa_pdf/35/56/onci-1-1181.PMC3494638.pdf
Curr Pharm Des  2009; 15:1879-92; PMID:19519430; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/35/56/onci-1-1181.PMC3494638.pdf
Blood 2006; 107:2409-14; PMID:16304057; http://dx.doi.org/10.1182/blood- 2005-06-2399.,Non-OADS,/arxiv_data1/oa_pdf/35/56/onci-1-1181.PMC3494638.pdf
Nat Med 2005; 11:1238-43; PMID:16227988; http://dx.doi.org/10.1038/nm1312.,OADS,/arxiv_data1/oa_pdf/35/56/onci-1-1181.PMC3494638.pdf
J Clin Oncol 2008; 26:2292- 8; PMID:18467720; http://dx.doi.org/10.1200/JCO.2007.13.3165.,Non-OADS,/arxiv_data1/oa_pdf/35/56/onci-1-1181.PMC3494638.pdf
Cancer Res  2007; 67:7487-94; PMID:17671219; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/35/56/onci-1-1181.PMC3494638.pdf
J Clin Invest 2005;  115:1953-62; PMID:16007258; http://dx.doi.org/10.1172/JCI23963.,Non-OADS,/arxiv_data1/oa_pdf/35/56/onci-1-1181.PMC3494638.pdf
Immunity 2009; 30:899- 911; PMID:19464196; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/35/56/onci-1-1181.PMC3494638.pdf
"1 Cytokines  with Th1-stimulating properties such as Blocking IL-10 enhances bacillus Calmette-Guérin  induced T helper Type 1 immune responses   and anti-bladder cancer immunity Yi Luo Department of u rology; u niversity of Iowa; Iowa City, IA us A Keywords:  bladder cancer, BCG, IL-10, immunotherapy, Th1 Abbreviations:  BCG, bacillus Calmette-Guérin; DTH, delayed-type hypersensitivity; IFN, interferon; IL, interleukin; IL-10R1,  IL-10 receptor 1; mAb, monoclonal antibody; Th, T helper type Correspondence to: Yi Luo; Email: yi-luo@uiowa.edu Submitted: 04/30/12; Accepted: 05/04/12http://dx.doi.org/10.4161/onci.20639interferon (IFN) α, interleukin (IL)-2 and  IL-12 have been investigated in combina - tion with BCG in the treatment of bladder  cancer.2-4 We previously combined BCG  with intravesical IFN α and observed this  combination therapy to be safe and effec - tive, particularly in patients who failed to respond to BCG monotherapy.",Non-OADS,/arxiv_data1/oa_pdf/ef/8e/onci-1-1183.PMC3494639.pdf
World J Urol 2006; 24:481-7;  PMID:17021823; http://dx.doi.org/10.1007/s00345- 006-0112-0.,OADS,/arxiv_data1/oa_pdf/ef/8e/onci-1-1183.PMC3494639.pdf
Annu Rev Immunol 2001; 19:683-765;  PMID:11244051; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/ef/8e/onci-1-1183.PMC3494639.pdf
J Immunother 2001; 24:392-407; http://dx.doi.org/10.1097/00002371-200109000-00002.,Non-OADS,/arxiv_data1/oa_pdf/ef/8e/onci-1-1183.PMC3494639.pdf
Clin Exp Immunol  2003; 131:206-16; PMID:12562379; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ef/8e/onci-1-1183.PMC3494639.pdf
Clin Exp Immunol 2002; 127:20-6;  PMID:11882028; http://dx.doi.org/10.1046/j.1365- 2249.2002.01734.x.,Non-OADS,/arxiv_data1/oa_pdf/ef/8e/onci-1-1183.PMC3494639.pdf
J Urol 2012; 2228-35;  http://dx.doi.org/10.1016/j.juro.2012.01.030.,OADS,/arxiv_data1/oa_pdf/ef/8e/onci-1-1183.PMC3494639.pdf
"4 In this setting, tumor antigen Tumor-infiltrating B cells The ignored players in tumor immunology Michael Linnebacher* and Claudia Maletzki Division of Molecular Oncology and Immunotherapy; Department of General s urgery; u niversity of r ostock; r ostock, Germany Keywords: tumor-infiltrating lymphocytes, tumor-infiltrating B cells, tumor host interaction, B cell subtypes, tumor immunology *Correspondence to: Michael Linnebacher; Email: michael.linnebacher@med.uni-rostock.de Submitted: 05/04/12; Accepted: 05/04/12http://dx.doi.org/10.4161/onci.20641specific Ab responses have repeatedly  been found.",Non-OADS,/arxiv_data1/oa_pdf/d4/21/onci-1-1186.PMC3494640.pdf
Science  2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139.,OADS,/arxiv_data1/oa_pdf/d4/21/onci-1-1186.PMC3494640.pdf
Cancer Res 2012; 72:1070-80;  PMID:22266112; http://dx.doi.org/10.1158/0008- 5472.CAN-11-3218.,Non-OADS,/arxiv_data1/oa_pdf/d4/21/onci-1-1186.PMC3494640.pdf
Cancer Res 2008; 68:5405-13; PMID:18593943;  http://dx.doi.org/10.1158/0008-5472.CAN-07-5206.,Non-OADS,/arxiv_data1/oa_pdf/d4/21/onci-1-1186.PMC3494640.pdf
"J Immunol 2010; 185:4977-82;  PMID:20962266; http://dx.doi.org/10.4049/jimmu- nol.1001323.Be-1 and Be-2-polarized B cells differen - tiated after mutual interaction with Th1  and Th2 CD4+ T cells.10 In summary, we would like to con - clude that investigations on the natural role of TiBcs in tumor biology are an obvious task with a high pay-back poten - tial.",Non-OADS,/arxiv_data1/oa_pdf/d4/21/onci-1-1186.PMC3494640.pdf
Curr Opin Immunol  2008; 20:332-8; PMID:18417336; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d4/21/onci-1-1186.PMC3494640.pdf
Cancer Immunol  Immunother 2003; 52:715-38; PMID:12920480;  http://dx.doi.org/10.1007/s00262-003-0409-4.,Non-OADS,/arxiv_data1/oa_pdf/d4/21/onci-1-1186.PMC3494640.pdf
PLoS  One 2012; 7:32639; PMID:22393427; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d4/21/onci-1-1186.PMC3494640.pdf
"3,4 The likelihood that distinct  regimens of rapamycin administration may produce distinct functional outcomes in antigen-specific T cells implies that Rapamycin A rheostat for CD8+ T-cell-mediated tumor therapy rupesh K. s rivastava, Adam u tley and Protul A. s hrikant* Department of Immunology; r oswell Park Cancer Institute; Buffalo, NY us A Keywords:  cancer, rapamycin, mTOR, memory CD8+ T cells, vaccine *Correspondence to: Protul A. Shrikant; Email: protul.shrikant@roswellpark.org Submitted: 05/04/12; Accepted: 05/07/12http://dx.doi.org/10.4161/onci.20663rapamycin, an FDA approved drug, may  be a useful tool, if carefully applied, to generate memory CD8 + T cells.3 It is note - worthy that the potential clinical benefits of rapamycin must be carefully weighed against its immunosuppressive properties and its renal toxicity, to maximize thera - peutic index.",Non-OADS,/arxiv_data1/oa_pdf/17/a4/onci-1-1189.PMC3494641.pdf
Immunity 2010; 32:67-78;  PMID:20060330; http://dx.doi.org/10.1016/j.immu- ni.2009.10.010.3.,OADS,/arxiv_data1/oa_pdf/17/a4/onci-1-1189.PMC3494641.pdf
Nature 2009; 460:108- 12; PMID:19543266; http://dx.doi.org/10.1038/ nature08155.,OADS,/arxiv_data1/oa_pdf/17/a4/onci-1-1189.PMC3494641.pdf
Immunity 2011; 34:541-53;  PMID:21511183; http://dx.doi.org/10.1016/j.immu- ni.2011.04.006.,OADS,/arxiv_data1/oa_pdf/17/a4/onci-1-1189.PMC3494641.pdf
J Leukoc Biol 2008; 83:1230-9; PMID:18270248;  http://dx.doi.org/10.1189/jlb.1207851.,Non-OADS,/arxiv_data1/oa_pdf/17/a4/onci-1-1189.PMC3494641.pdf
Proc Natl Acad Sci USA  2012; 109:5797-802; PMID:22454499; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/a4/onci-1-1189.PMC3494641.pdf
J Immunol 2012; 188:3080-7; PMID:22379028; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/17/a4/onci-1-1189.PMC3494641.pdf
Science 2012; 335:1638- 43; PMID:22461615; http://dx.doi.org/10.1126/sci- ence.1215135.,OADS,/arxiv_data1/oa_pdf/17/a4/onci-1-1189.PMC3494641.pdf
"Lee,1,2 elizabeth M. Jaffee1,2,3,4,5 and t odd D. Armstrong1,2,* 1the s idney Kimmel Cancer Center; Johns h opkins u niversity s chool of Medicine; Baltimore, MD us A; 2Department of Oncology; Johns h opkins u niversity s chool of Medicine;  Baltimore, MD us A; 3Graduate Program in Immunology; Johns h opkins s chool of Medicine; Baltimore, MD us A; 4Graduate Programs in Cellular and Molecular Medicine and  Pharmacology; Johns h opkins s chool of Medicine; Baltimore, MD us A; 5the s kip Viragh Pancreatic Cancer Center; Johns h opkins s chool of Medicine; Baltimore, MD us A Keywords:  immunotherapy, Treg depletion, tumor vaccine, cyclophosphamide, anti-CD25, high avidity T-cells Abbreviations:  Treg, regulatory T cells; Cy, cyclophosphamide; neu-vaccine, neu-targeted whole cell GM-CSF-secreting vaccine;  neu-N, HER-2/neu transgenic *Correspondence to: Todd D. Armstrong; Email: tarmstro@jhmi.edu Submitted: 05/07/12; Accepted: 05/07/12http://dx.doi.org/10.4161/onci.20664when CD25-targeted approaches are used  to inhibit Tregs.",Non-OADS,/arxiv_data1/oa_pdf/16/37/onci-1-1191.PMC3494642.pdf
Clin Cancer Res  2010; 16:5067-78; PMID:20736326; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/37/onci-1-1191.PMC3494642.pdf
J Exp Med 2008; 205:2125-38; PMID:18725522;  http://dx.doi.org/10.1084/jem.20080099.,Non-OADS,/arxiv_data1/oa_pdf/16/37/onci-1-1191.PMC3494642.pdf
J Exp Med 2005; 201:1591-602; PMID:15883172; http://dx.doi.org/10.1084/ jem.20042167.,Non-OADS,/arxiv_data1/oa_pdf/16/37/onci-1-1191.PMC3494642.pdf
PLoS One 2012; 7:31962; PMID:22359647;  http://dx.doi.org/10.1371/journal.pone.0031962.,Non-OADS,/arxiv_data1/oa_pdf/16/37/onci-1-1191.PMC3494642.pdf
J Exp Med  2004; 199:303-13; PMID:14757740; http://dx.doi.org/10.1084/jem.20031562.,OADS,/arxiv_data1/oa_pdf/16/37/onci-1-1191.PMC3494642.pdf
J Immunol 2011; 186:3847-57;  PMID:21346233; http://dx.doi.org/10.4049/jimmu- nol.1000361.,Non-OADS,/arxiv_data1/oa_pdf/16/37/onci-1-1191.PMC3494642.pdf
Blood 2011; 118:3003-12; PMID:21768296; http://dx.doi.org/10.1182/blood-2011-02-334565.endogenous high-avidity T-cell responses  againt HER-2/neu.7 Similar results showing the ineffec - tiveness of PC61 in melanoma and pan - creas cancer models may be explained by the fact that PC61-like therapies fail to attack effector T regs that traffic with regu - lar effector CD8+ T cells into the tumor  microenvironment.,Non-OADS,/arxiv_data1/oa_pdf/16/37/onci-1-1191.PMC3494642.pdf
"In this regard, a unique class of antigens known as cancer testis (CT) Cancer testis antigens A new paradigm for cancer therapy Anil s uri,* s hikha s aini, Abhilasha s inha, s umit Agarwal, Archana Verma, Deepak Parashar, s warnendra s ingh,   Namita Gupta and Nirmala Jagadish Cancer Microarray; Genes and Proteins Laboratory; National Institute of Immunology; New Delhi, India Keywords:  cancer testis antigens, SPAG9, biomarkers, immunotherapy, cancer vaccines Abbreviations:  SPAG9, sperm-associated antigen 9; CT, cancer testis; JNK, c-Jun N-terminal kinase; CTLA4, cytotoxic  T-lymphocyte antigen 4 *Correspondence to: Anil Suri; Email: anil@nii.res.in Submitted: 05/07/12; Accepted: 05/08/12http://dx.doi.org/10.4161/onci.20686antigens, which are specifically expressed  in the normal testis and show aberrant expression in various malignancies, is the focus of an intense wave of research, both as putative biomarkers and for their poten - tial to constitute convenient targets for immunotherapeutic strategies ( Fig.",Non-OADS,/arxiv_data1/oa_pdf/7a/e3/onci-1-1194.PMC3494643.pdf
CA Cancer J Clin 2012; 62:10-29; PMID:22237781;  http://dx.doi.org/10.3322/caac.20138.,Non-OADS,/arxiv_data1/oa_pdf/7a/e3/onci-1-1194.PMC3494643.pdf
Expert Opin Biol Ther 2006;  6:379-89; PMID:16548764; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7a/e3/onci-1-1194.PMC3494643.pdf
Nat  Med 2011; 17:916-8; PMID:21818078; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7a/e3/onci-1-1194.PMC3494643.pdf
Cancer Res 2008; 68:8240-48;  PMID:18922895; http://dx.doi.org/10.1158/0008- 5472.CAN-08-1708 6.,Non-OADS,/arxiv_data1/oa_pdf/7a/e3/onci-1-1194.PMC3494643.pdf
Lancet Oncol 2012; 13:501-8;  PMID:22326924; http://dx.doi.org/10.1016/S1470- 2045(12)70006-2.9.,Non-OADS,/arxiv_data1/oa_pdf/7a/e3/onci-1-1194.PMC3494643.pdf
Clin Cancer Res  2011; 17:7164-73; PMID:22068656; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7a/e3/onci-1-1194.PMC3494643.pdf
Am J Pathol 2011; 178:1009- 20; PMID:21356354; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/7a/e3/onci-1-1194.PMC3494643.pdf
"Patients in cohort A were neurologically asymptom - atic with no systemic glucocorticosteroid Ipilimumab in a Phase II trial of melanoma  patients with brain metastases Kim Margolin university of w ashington; s eattle, w A us A Keywords: ipilimumab, brain, metastatic, metastases, melanoma Correspondence to: Kim Margolin; Email: kmargoli@seattlecca.org Submitted: 05/07/12; Accepted: 05/08/12http://dx.doi.org/10.4161/onci.20687therapy in the 10 d prior to the start of  ipilimumab therapy.",Non-OADS,/arxiv_data1/oa_pdf/34/96/onci-1-1197.PMC3494644.pdf
J Immunother  2002; 25:82-7; PMID:11924913; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/34/96/onci-1-1197.PMC3494644.pdf
J Clin Oncol 2008; 26:5233-9; PMID:18809613;  http://dx.doi.org/10.1200/JCO.2008.16.5449.4.,Non-OADS,/arxiv_data1/oa_pdf/34/96/onci-1-1197.PMC3494644.pdf
Eur J Cancer 2003; 39:476-80;  PMID:12751378; http://dx.doi.org/10.1016/S0959- 8049(02)00731-1.,Non-OADS,/arxiv_data1/oa_pdf/34/96/onci-1-1197.PMC3494644.pdf
Lancet Oncol; PMID:22456429;  http://dx.doi.org/10.1016/S1470-2045(12)70090-6.,OADS,/arxiv_data1/oa_pdf/34/96/onci-1-1197.PMC3494644.pdf
"We recently Opposing consequences of signaling through EGF  family members Escape from CTLs could be a bait for NK cells rolf Kiessling,1,* riki Okita,1 Dimitrios Mougiakakos,1,2 Yumeng Mao,1 Dhifaf s arhan,1 erik w ennerberg,1 Barbara s eliger,3  Andreas Lundqvist,1 Kousaku Mimura4 and Koji Kono4 1Department of Oncology and Pathology; Immune and Gene t herapy Laboratory; Cancer Center Karolinska; Karolinska Institutet; s tockholm, s weden; 2Department of Internal  Medicine, h ematology and Oncology; u niversity of e rlangen; e rlangen, Germany; 3Institute of Medical Immunology; Martin Luther u niversity; h alle- wittenberg; h alle,  Germany; 4Department of s urgery; National u niversity of s ingapore (N us); singapore Keywords:  EGF receptors, MICA/B, MHC Class I, NK cell, immune escape *Correspondence to: Rolf Kiessling; Email: Rolf.Kiessling@ki.se Submitted: 05/02/12; Accepted: 05/08/12http://dx.doi.org/10.4161/onci.20685confirmed the inverse correlation of HER2  and MHC Class I expression by immu - nohistochemistry (IHC) in a cohort of 70 patients affected by breast carcinomas (unpublished observations).",Non-OADS,/arxiv_data1/oa_pdf/8a/de/onci-1-1200.PMC3494645.pdf
Cancer Immunol  Immunother 2012; 61:249-54; PMID:22120755; http://dx.doi.org/10.1007/s00262-011-1153-9.,Non-OADS,/arxiv_data1/oa_pdf/8a/de/onci-1-1200.PMC3494645.pdf
Cancer Immunol  Immunother 2009; 58:653-64; PMID:18820911;  http://dx.doi.org/10.1007/s00262-008-0587-1.,Non-OADS,/arxiv_data1/oa_pdf/8a/de/onci-1-1200.PMC3494645.pdf
Cancer Res 2004; 64:215-20;  PMID:14729627; http://dx.doi.org/10.1158/0008- 5472.CAN-2522-2.5.,Non-OADS,/arxiv_data1/oa_pdf/8a/de/onci-1-1200.PMC3494645.pdf
Int J Cancer 2011; 128:390- 401; PMID:20715101; http://dx.doi.org/10.1002/ijc.25613.,Non-OADS,/arxiv_data1/oa_pdf/8a/de/onci-1-1200.PMC3494645.pdf
Clin Cancer Res  2009; 15:2895-904; PMID:19351776; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8a/de/onci-1-1200.PMC3494645.pdf
J Immunol 2012; 188:2136-45;  PMID:22301547; http://dx.doi.org/10.4049/jimmu- nol.1102237.8.,Non-OADS,/arxiv_data1/oa_pdf/8a/de/onci-1-1200.PMC3494645.pdf
Nature 2005; 436:1186-90; PMID:15995699; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8a/de/onci-1-1200.PMC3494645.pdf
"3,4  Consistent with the pro-tumorigenic role Flipping the script on macrophages   in leiomyosarcoma Badreddin e dris,1,2 Kipp w eiskopf,3 Irving L. w eissman1,3 and Matt van de r ijn1,* 1Department of Pathology; s tanford u niversity s chool of Medicine; s tanford, CA us A; 2Department of Genetics; s tanford u niversity s chool of Medicine; s tanford, CA us A;  3Institute for s tem Cell Biology and r egenerative Medicine and the Ludwig Cancer Institute; s tanford u niversity s chool of Medicine; s tanford, CA us A Keywords:  leiomyosarcoma, tumor-associated macrophages, CSF1, CD47, SIRP α, monoclonal antibody cancer therapy Abbreviations:  CSF1, colony stimulating factor 1; LMS, leiomyosarcoma; mAb, monoclonal antibody; SIRP α, signal regulatory  protein α ; TAM, tumor-associated macrophage *Correspondence to: Matt van de Rijn; Email: mrijn@stanford.edu Submitted: 05/16/12; Accepted: 05/18/12http://dx.doi.org/10.4161/onci.20799ascribed to TAMs in many cancer types,  we found that patients whose LMSs were densely infiltrated by macrophages had highly vascularized tumors and signifi - cantly worse clinical outcomes.",Non-OADS,/arxiv_data1/oa_pdf/f2/d1/onci-1-1202.PMC3494646.pdf
Cell 2010; 141:39- 51; PMID:20371344; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f2/d1/onci-1-1202.PMC3494646.pdf
Immunol Rev 2008; 222:155-61; PMID:18364000; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f2/d1/onci-1-1202.PMC3494646.pdf
Clin Cancer Res 2008; 14:1423-30; PMID:18316565;  http://dx.doi.org/10.1158/1078-0432.CCR-07-1712.,Non-OADS,/arxiv_data1/oa_pdf/f2/d1/onci-1-1202.PMC3494646.pdf
Cell 2010; 142:699- 713; PMID:20813259; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f2/d1/onci-1-1202.PMC3494646.pdf
Proc Natl Acad Sci USA  2012; 109:6662-7; PMID:22451913; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f2/d1/onci-1-1202.PMC3494646.pdf
Curr Opin Immunol  2012; 24:225-32; PMID:22310103; http://dx.doi.org/10.1016/j.coi.2012.01.010.,OADS,/arxiv_data1/oa_pdf/f2/d1/onci-1-1202.PMC3494646.pdf
Proc Natl Acad Sci USA 2012; 109:6656- 61; PMID:22451919; http://dx.doi.org/10.1073/ pnas.1121629109.4.,OADS,/arxiv_data1/oa_pdf/f2/d1/onci-1-1202.PMC3494646.pdf
Am J Pathol 2009; 174:2347-56; PMID:19443701;  http://dx.doi.org/10.2353/ajpath.2009.081037.,Non-OADS,/arxiv_data1/oa_pdf/f2/d1/onci-1-1202.PMC3494646.pdf
Am J Pathol 2011; 179:2100- 7; PMID:21854753; http://dx.doi.org/10.1016/j.ajpath.2011.06.021.,OADS,/arxiv_data1/oa_pdf/f2/d1/onci-1-1202.PMC3494646.pdf
J Exp Med 2009; 206:1089-102; PMID:19398755;  http://dx.doi.org/10.1084/jem.20081605.,Non-OADS,/arxiv_data1/oa_pdf/f2/d1/onci-1-1202.PMC3494646.pdf
"Previous data from our Stromal CEACAM1 expression regulates   colorectal cancer metastasis Azadeh Arabzadeh1 and Nicole Beauchemin1,2,* 1Goodman Cancer r esearch Centre; McGill u niversity; Montreal, QC Canada; 2Depatment of Oncology; Medicine and Biochemistry; McGill u niversity; Montreal, QC Canada Keywords:  CEACAM1, colon cancer, metastasis *Correspondence to: Nicole Beauchemin; Email: nicole.beauchemin@mcgill.ca Submitted: 05/11/12; Accepted: 05/12/12http://dx.doi.org/10.4161/onci.20735laboratory indicate that the absence of  CEACAM1 exacerbates colonic and intes - tinal tumor burden in azoxymethane-treated and Apc 1638N/+ mice, respectively.5  Interestingly, CEACAM1 re-expression often occurs in the advanced stages of mul - tiple malignancies including non-small cell lung cancer, thyroid cancer, gastric carcinoma, pancreatic cancer, malignant melanoma and even metastatic colon can - cer.",Non-OADS,/arxiv_data1/oa_pdf/a2/a7/onci-1-1205.PMC3494647.pdf
Nat Rev Immunol  2006; 6:433-46; PMID:16724098; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a2/a7/onci-1-1205.PMC3494647.pdf
Nat Genet 2002; 30:270-6; PMID:11850617;  http://dx.doi.org/10.1038/ng840.5.,OADS,/arxiv_data1/oa_pdf/a2/a7/onci-1-1205.PMC3494647.pdf
Oncogene  2008; 27:4943-53; PMID:18454175; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a2/a7/onci-1-1205.PMC3494647.pdf
Int J Cancer  2011; 129:1351-61; PMID:21413011; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a2/a7/onci-1-1205.PMC3494647.pdf
Oncogene 2012; Epub ahead of  print; PMID:22469976; http://dx.doi.org/10.1038/ onc.2012.112.8.,Non-OADS,/arxiv_data1/oa_pdf/a2/a7/onci-1-1205.PMC3494647.pdf
Cancer Res  2012; 72:2239-50; PMID:22406619; http://dx.doi.org/10.1158/0008-5472.CAN-11-3016.,Non-OADS,/arxiv_data1/oa_pdf/a2/a7/onci-1-1205.PMC3494647.pdf
Cancer Cell 2012; 21:309-22; PMID:22439926;  http://dx.doi.org/10.1016/j.ccr.2012.02.022.,Non-OADS,/arxiv_data1/oa_pdf/a2/a7/onci-1-1205.PMC3494647.pdf
"3 The authors observed that—follow - ing cytokine-based immunotherapies such as the administration of agonis - tic anti-CD40 mAbs and interleukin 2 Specificity may be overrated   in cancer immunotherapy Getting to know the nonspecific side of memory T cells Gail D. s ckisel1 and w illiam J. Murphy1,2,* 1Department of Dermatology; u niversity of California; Davis s chool of Medicine; s acramento, CA us A; 2Department of Internal Medicine; u niversity of California;   Davis s chool of Medicine; s acramento, CA us A Keywords:  bystander CD8 T cells, NKG2D, antigen non-specific T cells, LAK cells, cytokine induced killer cells, cancer  immunotherapy Abbreviations:  FDA, food and drug administration; mAbs, monoclonal antibodies; TLR, toll-like receptor; IL-2, interleukin 2;  TCR, T cell receptor; NK, natural killer; OVA, ovalbumin; PD-1, programmed death 1; PD-1L, programmed death 1 ligand *Correspondence to: William J. Murphy; Email: wmjmurphy@ucdavis.edu Submitted: 03/10/12; Accepted: 05/16/12http://dx.doi.org/10.4161/onci.20779(IL-2)—CD8+ memory T cells express - ing granzyme B and possessing elevated  lytic capability expand.",Non-OADS,/arxiv_data1/oa_pdf/e6/ff/onci-1-1208.PMC3494648.pdf
Nat Rev Immunol 2006; 6:383-93;  PMID:16622476; http://dx.doi.org/10.1038/nri1842.,Non-OADS,/arxiv_data1/oa_pdf/e6/ff/onci-1-1208.PMC3494648.pdf
Nat Rev Immunol 2010; 10:317-27; PMID:20414205;  http://dx.doi.org/10.1038/nri2744.,Non-OADS,/arxiv_data1/oa_pdf/e6/ff/onci-1-1208.PMC3494648.pdf
Blood 2012; 119:3073-83; PMID:22251483;  http://dx.doi.org/10.1182/blood-2011-07-369736.4.,Non-OADS,/arxiv_data1/oa_pdf/e6/ff/onci-1-1208.PMC3494648.pdf
Immunity 2004; 21:357-66;  PMID:15357947; http://dx.doi.org/10.1016/j.immu- ni.2004.06.020.,OADS,/arxiv_data1/oa_pdf/e6/ff/onci-1-1208.PMC3494648.pdf
Nat Immunol 2002; 3:991-8;  PMID:12407406; http://dx.doi.org/10.1038/ni1102- 991.,Non-OADS,/arxiv_data1/oa_pdf/e6/ff/onci-1-1208.PMC3494648.pdf
Blood 2009; 114:1545- 52; PMID:19417208; http://dx.doi.org/10.1182/ blood-2009-03-206672.,Non-OADS,/arxiv_data1/oa_pdf/e6/ff/onci-1-1208.PMC3494648.pdf
"The cancer relevance of these CD4+ T cells  was further emphasized by the findings that IDO-specific T-cells reacted toward CD4 responses against IDO Mads h ald Andersen Center for Cancer Immune t herapy (CCI t); Department of h ematology; Copenhagen u niversity h ospital; h erlev, Denmark Keywords:  IDO, CD4, antigen, immune regulation, Th17, Th1 Correspondence to: Mads Hald Andersen; Email: mads.hald.andersen@regionh.dk Submitted: 05/09/12; Accepted: 05/16/12http://dx.doi.org/10.4161/onci.20687dendritic cells (DCs) pulsed with IDO+  tumor lysates.",OADS,/arxiv_data1/oa_pdf/30/7d/onci-1-1211.PMC3494649.pdf
"IL-15  binds intracellularly with high affinity to IL-15R α, forming a complex that shuttles Targeted cancer immunotherapy Mimicking physiological trans-presentation of IL-15 Dafne Müller Institut für Zellbiologie und Immunologie; u niversität s tuttgart; s tuttgart, Germany Keywords:  IL-15, IL-15R α, antibody fusion protein, targeting, trans-presentation Correspondence to: Dafne Müller; Email: dafne.mueller@izi.uni-stuttgart.de Submitted: 05/18/12; Accepted: 05/21/12http://dx.doi.org/10.4161/onci.20824from the endoplasmic reticulum to the  cell surface, where IL-15R α presents IL-15  mainly in trans to IL-2/15R βγc expressing  neighbor cells, although cis-presentation is also possible.",Non-OADS,/arxiv_data1/oa_pdf/96/e6/onci-1-1213.PMC3494650.pdf
Mol Cancer Ther 2009; 8:2736-45; PMID:19723883; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/96/e6/onci-1-1213.PMC3494650.pdf
Cancer Res 2012; 72:1964- 74; PMID:22374983; http://dx.doi.org/10.1158/0008- 5472.CAN-11-3208.,Non-OADS,/arxiv_data1/oa_pdf/96/e6/onci-1-1213.PMC3494650.pdf
Cancer Res 2008; 68:2972-83; PMID:18413767;  http://dx.doi.org/10.1158/0008-5472.CAN-08-0045.,Non-OADS,/arxiv_data1/oa_pdf/96/e6/onci-1-1213.PMC3494650.pdf
Cancer Res 2007; 67:4940-8; PMID:17510424;  http://dx.doi.org/10.1158/0008-5472.CAN-07-0283.,Non-OADS,/arxiv_data1/oa_pdf/96/e6/onci-1-1213.PMC3494650.pdf
Mol Cancer Ther 2012; Epub ahead of press;  PMID:22491823; http://dx.doi.org/10.1158/1535- 7163.MCT-12-0019.approach for an improved application of  IL-15 in cancer immunotherapy.,Non-OADS,/arxiv_data1/oa_pdf/96/e6/onci-1-1213.PMC3494650.pdf
Immunol Rev 2008; 222:357-68;  PMID:18364014; http://dx.doi.org/10.1111/j.1600- 065X.2008.00604.x.,Non-OADS,/arxiv_data1/oa_pdf/96/e6/onci-1-1213.PMC3494650.pdf
T rends  Pharmacol Sci 2012; 33:35-41; PMID:22032984; http://dx.doi.org/10.1016/j.tips.2011.09.004.,OADS,/arxiv_data1/oa_pdf/96/e6/onci-1-1213.PMC3494650.pdf
Immunol Lett 2010; 127:85-92; PMID:19818367;  http://dx.doi.org/10.1016/j.imlet.2009.09.009.,Non-OADS,/arxiv_data1/oa_pdf/96/e6/onci-1-1213.PMC3494650.pdf
"2,3Production of epitope-specific antibodies using  peptide-CpG-ODN-liposome complex without  carriers and their application as a cancer vaccine  in mice Younghee Lee1 and h yung-Joo Kwon2,* 1Department of Biochemistry; College of Natural s ciences; Chungbuk National u niversity; Chungbuk, r epublic of Korea; 2Department of Microbiology; College of Medicine;  hallym u niversity; Gangwon-do, r epublic of Korea Keywords:  CpG-DNA, epitope, liposome, peptide vaccine, TM4SF5 *Correspondence to: Hyung-Joo Kwon; Email: hjookwon@hallym.ac.kr Submitted: 04/14/12; Accepted: 04/16/12http://dx.doi.org/10.4161/onci.20404CpG-DNA represents synthetic oli - godeoxynucleotides (ODNs) and bacte - rial DNA containing unmethylated CpG  dinucleotides flanked by specific base sequences.",Non-OADS,/arxiv_data1/oa_pdf/b2/a1/onci-1-1215.PMC3494651.pdf
BMB  Rep 2011; 44:607-12; PMID:21944255; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b2/a1/onci-1-1215.PMC3494651.pdf
J Clin Invest  2008; 118:1354-66; PMID:18357344; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b2/a1/onci-1-1215.PMC3494651.pdf
Biochem Biophys Res Commun 2009; 379:362-7;  PMID:19103173; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b2/a1/onci-1-1215.PMC3494651.pdf
Mol Immunol 2006; 43:2107- 18; PMID:16442622; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/b2/a1/onci-1-1215.PMC3494651.pdf
J Clin Invest 1996; 98:1119- 29; PMID:8787674; http://dx.doi.org/10.1172/JCI118894.References 1.,Non-OADS,/arxiv_data1/oa_pdf/b2/a1/onci-1-1215.PMC3494651.pdf
Expert Rev Vaccines  2007; 6:591-603; PMID:17669012; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b2/a1/onci-1-1215.PMC3494651.pdf
PLoS  One 2012; 7:33121; PMID:22427965; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b2/a1/onci-1-1215.PMC3494651.pdf
Nat Rev Drug Discov 2006; 5:471- 84; PMID:16763660; http://dx.doi.org/10.1038/ nrd2059.,Non-OADS,/arxiv_data1/oa_pdf/b2/a1/onci-1-1215.PMC3494651.pdf
"More recently, it has been reported that autophagy can play a role in the immunogenic cell death, because Activation of dendritic cells by tumor cell death Mara Cirone,* Livia Di r enzo, Lavinia V. Lotti, Valeria Conte, Pankaj t rivedi, r oberta s antarelli, r oberta Gonnella, Luigi Frati  and Alberto Faggioni Department of e xperimental Medicine; Istituto Pasteur-Fondazione Cenci Bolognetti; s apienza u niversity; rome, Italy Keywords:  DC, PEL, CD91, bortezomib, AG490 *Correspondence to: Mara Cirone; Email: Mara.Cirone@uniroma1.it Submitted: 04/17/12; Accepted: 04/18/12http://dx.doi.org/10.4161/onci.20428during the autophagic process, that may  precedes the cell death, molecules such as ATP are released to recruit and activate DC.",Non-OADS,/arxiv_data1/oa_pdf/57/b9/onci-1-1218.PMC3494652.pdf
Cancer Metastasis  Rev 2011; 30:71-82; PMID:21298323; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/57/b9/onci-1-1218.PMC3494652.pdf
Immunity 2011; 35:456-66; PMID:22035838;  http://dx.doi.org/10.1016/j.immuni.2011.08.011.,OADS,/arxiv_data1/oa_pdf/57/b9/onci-1-1218.PMC3494652.pdf
Cancer Metastasis Rev 2011; 30:61-9;  PMID:21249425; http://dx.doi.org/10.1007/s10555- 011-9273-4.5.,Non-OADS,/arxiv_data1/oa_pdf/57/b9/onci-1-1218.PMC3494652.pdf
Science 2011; 334:1573- 7; PMID:22174255; http://dx.doi.org/10.1126/sci- ence.1208347.,OADS,/arxiv_data1/oa_pdf/57/b9/onci-1-1218.PMC3494652.pdf
PLoS One 2012; 7:31732;  PMID:22412839; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/57/b9/onci-1-1218.PMC3494652.pdf
J Immunol 2010; 184:2638-45; PMID:20124100;  http://dx.doi.org/10.4049/jimmunol.0902960.8.,Non-OADS,/arxiv_data1/oa_pdf/57/b9/onci-1-1218.PMC3494652.pdf
Blood 2012; 119:2895-905; PMID:22223827; http://dx.doi.org/10.1182/blood- 2011-08-372383.,Non-OADS,/arxiv_data1/oa_pdf/57/b9/onci-1-1218.PMC3494652.pdf
Immunity  2001; 14:303-13; PMID:11290339; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/57/b9/onci-1-1218.PMC3494652.pdf
Blood 2003; 101:4000-4;  PMID:12531796; http://dx.doi.org/10.1182/blood- 2002-11-3353.,Non-OADS,/arxiv_data1/oa_pdf/57/b9/onci-1-1218.PMC3494652.pdf
"In the context of prostate cancer, pre- clinical and clinical studies have shown Opposing effects of androgen ablation   on immune function in prostate cancer shuai t ang1 and Purnima Dubey2,3,4,5,6,* 1Molecular Pathology Graduate Program; w ake Forest s chool of Medicine; w inston s alem, NC us A; 2Department of Pathology- tumor Biology; w ake Forest s chool of  Medicine; w inston s alem, NC us A; 3Department of Cancer Biology; w ake Forest s chool of Medicine; w inston s alem, NC us A; 4Department of Microbiology & Immunology;  wake Forest s chool of Medicine; w inston s alem, NC us A; 5Molecular Medicine and t ranslational s cience Program; w ake Forest s chool of Medicine; w inston s alem, NC us A;  6Comprehensive Cancer Center; w ake Forest s chool of Medicine; w inston s alem, NC us A Keywords:  prostate cancer, androgen ablation, Tregs, castration-resistant, CD8+ effector T cells *Correspondence to: Purnima Dubey; Email: pdubey@wakehealth.edu Submitted: 04/18/12; Accepted: 04/20/12http://dx.doi.org/10.4161/onci.20448that CD4+ and CD8+ T-cell responses are  increased early after androgen ablation.1  Functional CD8+ cytolytic T cells are  required for the rejection of solid tumors.",Non-OADS,/arxiv_data1/oa_pdf/31/89/onci-1-1220.PMC3494653.pdf
Cancer Res 2010; 70:3473-82;  PMID:20406970; http://dx.doi.org/10.1158/0008- 5472.CAN-09-2490.,Non-OADS,/arxiv_data1/oa_pdf/31/89/onci-1-1220.PMC3494653.pdf
Cancer Res 2012; 72:1975-85;  PMID:22374980; http://dx.doi.org/10.1158/0008- 5472.CAN-11-2499.,Non-OADS,/arxiv_data1/oa_pdf/31/89/onci-1-1220.PMC3494653.pdf
Proc Natl Acad Sci USA 2011; 108:7529- 34; PMID:21502514; http://dx.doi.org/10.1073/ pnas.1103782108.,OADS,/arxiv_data1/oa_pdf/31/89/onci-1-1220.PMC3494653.pdf
J Immunol 2011; 187:3186-97;  PMID:21849683; http://dx.doi.org/10.4049/jimmu- nol.1101649.,Non-OADS,/arxiv_data1/oa_pdf/31/89/onci-1-1220.PMC3494653.pdf
"J Clin Invest 2005; 115:3623- 33; PMID:16308572; http://dx.doi.org/10.1172/ JCI25947.were castrated alone, further strengthening  the suggestion that increased IL-2 caused the paradoxical response.",Non-OADS,/arxiv_data1/oa_pdf/31/89/onci-1-1220.PMC3494653.pdf
Proc Natl Acad Sci USA  2001; 98:14565-70; PMID:11734652; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/31/89/onci-1-1220.PMC3494653.pdf
Androgen ablation mitigates  tolerance to a prostate/prostate cancer-restricted anti- gen. Cancer Cell 2005; 7:239-49; PMID:15766662;  http://dx.doi.org/10.1016/j.ccr.2005.01.027.,Non-OADS,/arxiv_data1/oa_pdf/31/89/onci-1-1220.PMC3494653.pdf
"Front Biosci 2007; 12:4957-71; PMID:17569623;  http://dx.doi.org/10.2741/2441.Increased IL-2 produced by the acti - vated effector T cells leads to expansion  of Tregs, which then inhibit CD8+ T-cell  function.8,9 This paracrine loop is at least  partially responsible for prostate cancer progression after castration.",Non-OADS,/arxiv_data1/oa_pdf/31/89/onci-1-1220.PMC3494653.pdf
This article is distributed under the terms of an Attribution– Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub - lication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"After six months it is available under a  Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,  as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).THE JOURNAL OF CELL BIOLOGY",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1074/ jbc.M50157320 0 Barnhart, E.L., K.C.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1371/journal   .pbio.100105 9 Berry, M.F., A.J.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1152/ajpheart.01017.200 5 Breckenridge, M.T., N.G.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1091/mbc   .E08-04-037 2	d t d ttd t d ttlog( ( )) log()( )( ) log()log(),RMSD  = +αα	 	log() ,t u=	 	d t dudt tlog() ,= = 	 	   , andd R MSD t d ttd t duulog( ( )) log()( )( )= +αα	 	d R MSD t d ttlog( ( )) log()~ ( ).α	 MS sample preparation For proteomic experiments (Fig.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1083/jcb.20120112 4 Pollard, T.D.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1083/jcb.95.3   .816 Quevedo, H.C., K.E.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi   .org/10.1073/pnas.090320110 6 Rehfeldt, F., A.E.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1039/   c2ib00150 k Saitoh, T., S. Takemura, K. Ueda, H. Hosoya, M. Nagayama, H. Haga, K.  Kawabata, A. Yamagishi, and M. Takahashi.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1016/S0014-5793(01)03186- 6 Salem, H.K., and C. Thiemermann.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1074/jbc.M60534320 0 Shi, Y., G. Hu, J. Su, W. Li, Q. Chen, P. Shou, C. Xu, X. Chen, Y. Huang, Z.  Zhu, et al.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/   10.1038/cr.2010.4 4 Shin, J.W., J.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi   .org/10.1242/jcs.0309 6 Tse, J.R., and A.J.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1371/journal.pone.001597 8 Vicente-Manzanares, M., J. Zareno, L. Whitmore, C.K.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/   10.1083/jcb.20080603 0 Xu, J., F. Wang, A.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1016/S0092-8674(03)   00555- 5 Zemel, A., F. Rehfeldt, A.E.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1038/nphys161 3Burt, R.K., Y. Loh, W. Pearce, N. Beohar, W.G.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"299:925– 936. http://dx.doi.org/10.1001/jama.299.8.92 5 Cai, Y., N. Biais, G. Giannone, M. Tanase, G. Jiang, J.M.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1002/anie.20090080 7 Conti, M.A., S. Even-Ram, C. Liu, K.M.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"279:41263– 41266. http://dx.doi.org/10.1074/jbc.C40035220 0 Discher, D.E., P. Janmey, and Y.L.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi   .org/10.1126/science.111699 5 Distel, M., J.C. Hocking, K. Volkmann, and R.W.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi   .org/10.1083/jcb.20100415 4 Doyle, A.D., F.W.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1083/jcb.20081004 1 Dulyaninova, N.G., R.P.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1091/   mbc.E06-11-105 6 Engler, A.J., S. Sen, H.L.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi   .org/10.1016/j.cell.2006.06.04 4 Fischer, R.S., M. Gardel, X. Ma, R.S.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1016/j.cub.2008.12.04 5 Gray, D.S., J. Tien, and C.S.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1002/jbm.a.1058 5 Hadjipanayi, E., V. Mudera, and R.A. Brown.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1002/cm.2033 1 Isenberg, B.C., P.A.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10   .1016/j.bpj.2009.06.02 1 Johnson, C.P., H.Y.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1091/mbc   .E03-04-020 5 Lo, C.M., H.B.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1091/mbc   .E03-06-035 9 Ma, X., S.S. Jana, M.A.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1091/mbc.E10-04-029 3 Maupin, P., C.L.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1016/j.cub.2009.06.05 3 Oakes, P.W., D.C. Patel, N.A.",OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
"http://dx.doi.org/10.1182/   blood-2008-11-19144 5 Orlic, D., J. Kajstura, S. Chimenti, I. Jakoniuk, S.M.",Non-OADS,/arxiv_data1/oa_pdf/a8/5e/JCB_201205056.PMC3494847.pdf
This article is distributed under the terms of an Attribution– Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub - lication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"After six months it is available under a  Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,  as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).THE JOURNAL OF CELL BIOLOGY",Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1038/7142 9 Bouzahzah, B., C. Albanese, F. Ahmed, F. Pixley, M.P.",Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1038/ncb186 2 Cain, R.J., B.B.",Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1007/978-1-61779-207-6_1 2 Charras, G., and E. Paluch.",Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/   10.1038/nrm245 3 Charvet, C., P. Auberger, S. Tartare-Deckert, A. Bernard, and M. Deckert.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"277:15376– 15384. http://dx.doi.org/10.1074/jbc.M11162720 0 Dubin-Thaler, B.J., J.M.",Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1371/journal.pone.000373 5 Friedl, P., and S. Alexander.",Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/   10.1016/j.cell.2011.11.01 6 Gassmann, P., J. Haier, K. Schlüter, B. Domikowsky, C. Wendel, U. Wiesner,  R. Kubitza, R. Engers, S.W.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1007/s10555-008-9166- 3 Heasman, S.J., L.M.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/   10.1083/jcb.20100206 7 Hill, C.S., J. Wynne, and R. Treisman.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1016/S0092-8674(05)80020- 0 Hua, K.T., C.T.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/   10.1016/j.ccr.2010.11.01 0 Huck, L., S.M.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1042/0300-5127:028031 1 Im, J.H., W. Fu, H. Wang, S.K.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1158/0008-5472.CAN-04-207 8 Isaji, T., Y. Sato, T. Fukuda, and J. Gu.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1016/j.febslet.2008.04.03 9 Wang, H., W. Fu, J.H.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1083/   jcb.20030911 2 Wang, H.S., Y.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1016/j.yexcr.2004.10.01 5 Yang, Q., S.R.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1385/   IR:36:1:1 3 Yang, L., L. Wang, H. Geiger, J.A.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1074/jbc   .M80792020 0 Joyce, J.A., and J.W.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1038/nrc261 8 Kren, A., V. Baeriswyl, F. Lehembre, C. Wunderlin, K. Strittmatter, H.  Antoniadis, R. Fässler, U. Cavallaro, and G. Christofori.",Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10   .1038/sj.emboj.760173 8 Kusama, T., M. Mukai, M. Tatsuta, H. Nakamura, and M. Inoue.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1016/j.devcel   .2010.06.01 3 Margadant, C., M. Kreft, D.J.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1158/1541-7786   .MCR-09-055 1 Mehlen, P., and A. Puisieux.",Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1038/nrc188 6 Mierke, C.T., B. Frey, M. Fellner, M. Herrmann, and B. Fabry.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1242/jcs.07198 5 Nguyen, D.X., P.D.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1016/   j.bpj.2010.07.03 1 Olson, E.N., and A. Nordheim.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1038/nrm289 0 Phipps, L.E., S. Hino, and R.J. Muschel.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
http://dx.doi.org/10.1158/1541-7786.,Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1091/mbc.E05-03-018 6 Reymond, N., P. Riou, and A.J.",Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi   .org/10.1007/978-1-61779-442-1_ 9 Ridley, A.J.",Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi   .org/10.1016/j.cell.2011.06.01 0 Sequeira, L., C.W.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi   .org/10.1073/pnas.090422710 6 Stengel, K., and Y. Zheng.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/   10.1016/j.cellsig.2011.04.00 1 Stoletov, K., H. Kato, E. Zardouzian, J. Kelber, J. Yang, S. Shattil, and R.  Klemke.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10.1242/jcs.06944 3 van Golen, K.L., C. Ying, L. Sequeira, C.W.",Non-OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"http://dx.doi.org/10   .1002/jcb.2165 2 Vega, F.M., and A.J.",OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
http://dx.doi.org/10.1016/j.cell.2007.06.02 1,OADS,/arxiv_data1/oa_pdf/3e/b9/JCB_201205169.PMC3494849.pdf
"We propose that early, more  strategic, support of cutting-edge academic research by  industry may be more effective for translational purposes  than the current model of a late selection of community- evolved projects.Cell biology: A key driver of therapeutic innovation Oliver Hantschel1 and Giulio Superti-Furga2 1École polytechnique fédérale de Lausanne (EPFL), School of Life Sciences, Swiss Institute for Experimental Cancer Research (ISREC), CH-1015 Lausanne, Switzerland 2CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, A-1090 Vienna, Austria © 2012 Hantschel and Superti-Furga  This article is distributed under the terms of an  Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months   after the publication date (see http://www.rupress.org/terms).",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"After six months it is available  under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported  license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).THE JOURNAL OF CELL BIOLOGY",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/3500050 1 Arkin, M.R., and J.A.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nrd134 3 Bantscheff, M., D. Eberhard, Y .",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nbt132 8 Baxter, E.J., L.M.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nrd83 9 Cuatrecasas, P. 2006.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1172/JCI2999 9 Davis, R.E., V.N.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nature0863 8 Druker, B.J.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1182/   blood-2008-07-07795 8 Druker, B.J., S. Tamura, E. Buchdunger, S. Ohno, G.M.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nm0596-56 1 Filippakopoulos, P., J. Qi, S. Picaud, Y. Shen, W.B.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/   10.1038/nature0950 4 Fitzgerald, G.A.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nrd184 9 Gorre, M.E., M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1126/science.106253 8 Hantschel, O.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.3324/haematol.2012.06181 2 Hantschel, O., and G. Superti-Furga.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/   10.1038/nrm128 0 Hantschel, O., F. Grebien, and G. Superti-Furga.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1158/0008-5472.CAN-12-127 6 Heinrich, M.C.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1016/S1470-   2045(10)70225- 4 Heinrich, M.C., D.J.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/   10.1038/nature0354 6 Kralovics, R. 2008.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/leu.2008.23 3 Kralovics, R., F. Passamonti, A.S. Buser, S.S. Teo, R. Tiedt, J.R. Passweg, A.  Tichelli, M. Cazzola, and R.C.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1056/NEJMoa05111 3 Levine, R.L., M. Wadleigh, J. Cools, B.L.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"7:387– 397. http://dx.doi.org/10.1016/j.ccr.2005.03.02 3 McClain, D.A.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1016/   j.tibs.2010.01.00 6 Mesa, R.A., U. Yasothan, and P. Kirkpatrick.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nrd365 2 Mullard, A.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nrd365 7 O’Hare, T., A.S. Corbin, and B.J.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1016/j.gde.2005.11.00 2 O’Hare, T., M.S.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nrc331 7 Oltersdorf, T., S.W.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nature0357 9 Rix, U., and G. Superti-Furga.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/   10.1038/nchembio.21 6 Rowley, J.D.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1182/blood-2008-04-09793 1 Shah, N.P., C. Tran, F.Y.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1126/science.109948 0 Sheridan, C. 2012.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nbt0312-19 9 Swinney, D.C., and J. Anthony.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1038/nrd348 0 Taipale, M., I. Krykbaeva, M. Koeva, C. Kayatekin, K.D.",OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.1182/   blood-2011-11-39522 8 Van Etten, R.A. 2007.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/   10.1084/jem.2006233 5 von Bubnoff, N., S. Barwisch, M.R.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
"http://dx.doi.org/10.4161/cc.4.3.156 0 Weisberg, E., P. Manley, J. Mestan, S. Cowan-Jacob, A. Ray, and J.D.",Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
http://dx.doi.org/10.1038/sj.bjc.660317 0,Non-OADS,/arxiv_data1/oa_pdf/10/f6/JCB_201208111.PMC3494851.pdf
This article is distributed under the terms of an Attribution– Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub - lication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"After six months it is available under a  Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,  as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).THE JOURNAL OF CELL BIOLOGY",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1074/jbc   .M70157420 0 Diener, D.R., L.H.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/   10.1083/jcb.123.1.18 3 Diener, D.R., P. Yang, S. Geimer, D.G.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1083/jcb.153.2.44 3 Gaillard, A.R., L.A. Fox, J.M.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi   .org/10.1091/mbc.E06-02-009 5 Gold, M.G., B. Lygren, P. Dokurno, N. Hoshi, G. McConnachie, K. Taskén, C.R.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi   .org/10.1016/j.molcel.2006.09.00 6 Greengard, P., J. Jen, A.C. Nairn, and C.F.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1126/science   .171600 1 Gupta, A., D.R.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/   10.1083/jcb.20111104 1 Habermacher, G., and W.S.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1083/jcb.136.1.16 7 Herberg, F.W., A. Maleszka, T. Eide, L. V ossebein, and K. Tasken.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1006/jmbi.2000.366 2 Hirsch, A.H., S.B.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10   .1083/jcb.127.6.168 3 Hsu, D.R., and B.J.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1083/jcb.88.1.8 0 Jarnaess, E., A. Ruppelt, A.J.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1074/jbc   .M80480720 0 Jiang, H., A. Shukla, X. Wang, W.Y.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi   .org/10.1016/j.cell.2011.01.02 0 Kammerer, S., L.L.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1073/   pnas.262802810 0 Kinderman, F.S., C. Kim, S. von Daake, Y. Ma, B.Q.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
http://dx.doi.org/10.1016/j.molcel.2006.09.01 5with a deviated CP.,OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi   .org/10.1073/pnas.033073410 0 Angelo, R., and C.S.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi   .org/10.1074/jbc.273.23.1463 3 Banky, P., M. Roy, M.G.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1016/   S0022-2836(03)00552- 7 Barber, C.F., T. Heuser, B.I.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1091/mbc.E11-   08-069 2 Brokaw, C.J.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi   .org/10.1002/jcb.24035030 2 Burns-Hamuro, L.L., Y. Ma, S. Kammerer, U. Reineke, C. Self, C. Cook,  G.L.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1073/   pnas.262803810 0 Cao, F., Y. Chen, T. Cierpicki, Y. Liu, V. Basrur, M. Lei, and Y. Dou.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1371/journal   .pone.001410 2 Carr, D.W., R.E.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1074/jbc   .M01125220 0 Chen, Y., B. Wan, K.C.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1038/embor.2011.10 1 Cho, Y.W., T. Hong, S. Hong, H. Guo, H. Yu, D. Kim, T. Guszczynski, G.R.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1083/   jcb.153.1.6 3 South, P.F., I.M.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1074/jbc   .M109.04269 7 Wang, X., Z. Lou, X. Dong, W. Yang, Y. Peng, B. Yin, Y. Gong, J. Yuan, W.  Zhou, M. Bartlam, et al.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1016/   j.jmb.2009.05.06 1 Warner, F.D., and P. Satir.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1083/jcb.63.1.3 5 Wei, M., P. Sivadas, H.A.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
http://dx.doi.org/10.1124/mi.10.2.,Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1083/jcb.109.1.23 5 Wirschell, M., F. Zhao, C. Yang, P. Yang, D. Diener, A. Gaillard, J.L.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1002/cm.2025 7 Witman, G.B., J. Plummer, and G. Sander.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1083/jcb.76.3.72 9 Xia, B., A. Joubert, B. Groves, K. Vo, D. Ashraf, D. Djavaherian, J.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1371/journal   .pone.001177 1 Xu, Z., Q. Gong, B. Xia, B. Groves, M. Zimmermann, C. Mugler, D. Mu, B.  Matsumoto, M. Seaman, and D. Ma.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1083/jcb.20090214 6 Yang, C., and P. Yang.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1091/mbc   .E05-07-063 0 Yang, C., H.A.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi   .org/10.1083/jcb.20070506 9 Yang, P., D.R.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1083/jcb.153.6.131 5 Yang, P., D.R.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi   .org/10.1242/jcs.0281 1Kindle, K.L.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi   .org/10.1073/pnas.87.3.122 8 Klauck, T.M., M.C.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/   10.1126/science.271.5255.158 9 Kohno, T., K. Wakabayashi, D.R.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi   .org/10.1083/jcb.118.5.114 5 Mauban, J.R., M. O’Donnell, S. Warrier, S. Manni, and M. Bond.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1152/physiol.00041.200 8 Means, C.K., B. Lygren, L.K.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1083/jcb.144   .2.29 3 Morikis, D., M. Roy, M.G.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
http://dx.doi.org/10.1046/j.1432-1033.2002.02852.,Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1002/cm.2027 9 Nicastro, D., J.R. McIntosh, and W. Baumeister.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/   10.1073/pnas.050827410 2 Omoto, C.K., I.R.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"284:24242– 24256. http://dx.doi.org/10.1074/jbc.M109.01449 8 Patel-King, R.S., O. Gorbatyuk, S. Takebe, and S.M.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1091/mbc .E04-04-   0352 Pauling, L., R.B.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1083/jcb.20110612 5 Roguev, A., D. Schaft, A. Shevchenko, W.W. Pijnappel, M. Wilm, R. Aasland,  and A.F.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1093/emboj/20.24.713 7 Rual, J.F., K. Venkatesan, T. Hao, T. Hirozane-Kishikawa, A. Dricot, N. Li,  G.F. Berriz, F.D.",Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi.org/10.1038/   nature0420 9 Sarma, G.N., F.S.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
"http://dx.doi   .org/10.1016/j.str.2009.12.01 2 Satir, P. 1999.",OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
http://dx.doi.org/10.1126/science.117566 8,Non-OADS,/arxiv_data1/oa_pdf/c7/a8/JCB_201111042.PMC3494852.pdf
This article is distributed under the terms of an Attribution–Noncommercial– Share Alike–No Mirror Sites license for the first six months after the publication date (see  http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"After six months it is available under a Creative Commons  License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at  http://creativecommons.org/licenses/by-nc-sa/3.0/).THE JOURNAL OF CELL BIOLOGY",Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"Online supplemental material is  available at http://www.jcb.org/cgi/content/full/jcb.201207079/DC1.mitochondrial adaptor called Mff (Strack and Cribbs, 2012).",Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1074/jbc   .M21176120 0 Koirala, S., H.T.",Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"191:1127– 1139. http://dx.doi.org/10.1083/jcb.20100504 6 Kuravi, K., S. Nagotu, A.M. Krikken, K. Sjollema, M. Deckers, R. Erdmann, M.  Veenhuis, and I.J.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1242/jcs.0316 6 Labrousse, A.M., M.D.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/   10.1016/S1097-2765(00)80391- 3 Lackner, L.L., J.S.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1126/   science.117692 1 Li, X., and S.J.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1074/jbc   .M21203120 0 Mears, J.A., P. Ray, and J.E.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/ 10.1016/   j.str.2007.08.01 2 Mears, J.A., L.L.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/   10.1038/nsmb.194 9 Moss, T.J., C. Andreazza, A. Verma, A. Daga, and J.A.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/   10.1083/jcb.151.2.36 7 Naylor, K., E. Ingerman, V. Okreglak, M. Marino, J.E.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1074/jbc   .M50794320 0 Nishida, K., F. Yagisawa, H. Kuroiwa, Y. Yoshida, and T. Kuroiwa.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1016/0076-6879(83)01017- 4 Orso, G., D. Pendin, S. Liu, J. Tosetto, T.J. Moss, J.E.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1038/nature0828 0 Otera, H., C. Wang, M.M.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1083/jcb.20100715 2 Otsuga, D., B.R.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/   10.1038/embor.2011.5 4 Praefcke, G.J., and H.T.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1038/nrm131 3 Rapaport, D., M. Brunner, W. Neupert, and B. Westermann.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1074/jbc.273.32.2015 0 Sesaki, H., and R.E.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1083/jcb.147.4.69 9 Strack, S., and J.T.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1074/jbc.M112.34210 5We thank Jane Macfarlane for expertise in mutagenesis and plasmid construc - tion, members of the Shaw laboratory for critical discussions, and J. Nunnari  for the His-Dnm1 expression plasmid.",Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/   10.1105/tpc.108.05857 8 Bhar, D., M.A.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1074/jbc.M51353020 0 Bleazard, W., J.M.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/   10.1038/1301 4 Cerveny, K.L., and R.E.",Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1091/mbc.E03-02-009 2 Cerveny, K.L., J.M.",Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"160:189– 200. http://dx.doi.org/10.1083/jcb.20021104 6 Eura, Y., N. Ishihara, S. Yokota, and K. Mihara.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/   10.1093/jb/mvg15 0 Faelber, K., Y. Posor, S. Gao, M. Held, Y. Roske, D. Schulze, V. Haucke, F.  Noé, and O. Daumke.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1038/nature1036 9 Ford, M.G., S. Jenni, and J. Nunnari.",Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1038/nature1044 1 Gandre-Babbe, S., and A.M. van der Bliek.",Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1091/   mbc.E07-12-128 7 Gao, H., D. Kadirjan-Kalbach, J.E.",Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/   10.1083/jcb.20050314 8 Guthrie, C., and G. Fink.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"90:121– 129. http://dx.doi.org/10.1016/S0092-8674(00)80319- 0 Hermann, G.J., J.W.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/   10.1083/jcb.143.2.35 9 Hu, J., Y. Shibata, P.P.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1083/jcb.20050615 8 Kelley, L.A., and M.J. Sternberg.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
http://dx.doi.org/   10.1038/nprot.2009.,Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1083/jcb.151.2.35 3 van der Bliek, A.M. 1999.",Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1016/S0962-8924(98)01490- 1 Zhang, Y., N.C. Chan, H.B.",OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
"http://dx.doi.org/10.1074/jbc.M111.32935 9 Zhao, J., T. Liu, S. Jin, X. Wang, M. Qu, P. Uhlén, N. Tomilin, O. Shupliakov,   U. Lendahl, and M. Nistér.",Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
http://dx.doi.org/10.1038/emboj   .2011.19 8,Non-OADS,/arxiv_data1/oa_pdf/90/9a/JCB_201207079.PMC3494853.pdf
This article is distributed under the terms of an Attribution–Noncommercial– Share Alike–No Mirror Sites license for the first six months after the publication date (see  http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"After six months it is available under a Creative Commons  License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at  http://creativecommons.org/licenses/by-nc-sa/3.0/).THE JOURNAL OF CELL BIOLOGY",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
Online supplemental material is available at  http://www.jcb.org/cgi/content/full/jcb.201202105/DC1.,Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1038/nature0599 4 Amagai, M., and J.R. Stanley.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1038/   jid.2011.39 0 Angst, B.D., L.A. Nilles, and K.J.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1016/j.hrthm.2011.06.02 6 Bhuiyan, Z.A., J.D.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/   10.1161/CIRCGENETICS.108.83982 9 Bonifacino, J.S., and L.M.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1146/annurev.biochem.72.121801.16180 0 Brennan, D., Y. Hu, S. Joubeh, Y.W.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi   .org/10.1242/jcs.0339 2 Brennan, D., S. Peltonen, A. Dowling, W. Medhat, K.J.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
http://dx.doi.org/10.1038/onc.2011.34 6and 4% sucrose solutions were successively layered upon one another  with 800 µl cell lysate placed on the very top.,Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1016/j   .biocel.2008.09.02 7 Jennings, J.M., D.K.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1038/jid.2010.38 9 Jolly, P.S., P. Berkowitz, M. Bektas, H.E.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"285:8936– 8941. http://dx.doi.org/10.1074/jbc.M109.08799 9 Kami, K., M. Chidgey, T. Dafforn, and M. Overduin.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1016/j.jmb.2008.12.05 4 Klessner, J.L., B.V. Desai, E.V.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1091/mbc.E08-04-035 6 Koch, P.J., M.J. Walsh, M. Schmelz, M.D.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.4161/cam.5.4.1691 1 Nava, P., M.G.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"18:4565– 4578. http://dx.doi.org/10.1091/mbc.E07-05-042 6 Nekrasova, O.E., E.V.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi   .org/10.1083/jcb.20110605 7 Nie, Z., A. Merritt, M. Rouhi-Parkouhi, L. Tabernero, and D. Garrod.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1074/jbc.M110   .19224 5 Niessen, C.M., D. Leckband, and A.S. Yap.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/   10.1152/physrev.00004.201 0 Paterson, A.D., R.G.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1074/jbc.M30008220 0 Pokutta, S., and W.I.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1146/annurev.cellbio.22.010305.10424 1 Rutman, A.J., R.S.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1016/0014-   5793(94)01049- 8 Schäfer, S., P.J.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1006/excr.1994.110 3 Schock, F., and N. Perrimon.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/   10.1146/annurev.cellbio.18.022602.13183 8 Simons, K., and M.J. Gerl.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1038/   nrm297 7 Simpson, C.L., and K.J.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1038/nmeth94 7 Syed, S.E., B. Trinnaman, S. Martin, S. Major, J. Hutchinson, and A.I.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1042/0264-6021:362031 7Brooke, M.A., D. Nitoiu, and D.P.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1002/   path.302 7 Bryant, D.M., and J.L.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1016/j.tcb.2004   .07.00 7 Chitaev, N.A., and S.M.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1083/jcb.138.1.19 3 Choi, H.J., J.C.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1074/jbc.M109.04792 8 Christensen, A.H., M. Benn, H. Bundgaard, A. Tybjaerg-Hansen, S. Haunso,  and J.H.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1136/jmg.2010   .07789 1 Claycomb, W.C., N.A.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/   10.1073/pnas.95.6.297 9 Delva, E., J.M.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1074/jbc.M71004620 0 Doherty, G.J., and H.T.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1146/annurev.biochem   .78.081307.11054 0 Dusek, R.L., S. Getsios, F. Chen, J.K. Park, E.V.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1074/jbc   .M50825820 0 Eshkind, L., Q. Tian, A. Schmidt, W.W. Franke, R. Windoffer, and R.E.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1078/0171-9335-0027 8 Fleming, T.P., D.R.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1083/jcb   .20080904 4 Green, K.J., and C.A.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi   .org/10.1038/3504303 2 Green, K.J., and C.L.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1038/   sj.jid.570101 5 Green, K.J., S. Getsios, S. Troyanovsky, and L.M.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1101/cshperspect.a00012 5 Gustafsson, M.G.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1126/   science.108695 7 Holm, P.K., S.H.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi   .org/10.1016/S0074-7696(07)64003- 0 Hudson, T.Y., L. Fontao, L.M.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
http://dx.doi.org/10.1016/   S0091-679X(04)78026- 7,OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/   10.1093/eurheartj/ehl38 0 Tan, B.Y., R. Jain, A.D. den Haan, Y. Chen, D. Dalal, H. Tandri, N. Amat- Alarcon, A. Daly, C. Tichnell, C. James, et al.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1042/BJ2010056 7 Wang, H., Z.Y.",OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
"http://dx.doi.org/10.1083/jcb.99.6.221 1 Xiao, K., J. Garner, K.M.",Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
http://dx.doi.org/10.1091/mbc.E05-05-044 0,Non-OADS,/arxiv_data1/oa_pdf/9b/e8/JCB_201202105.PMC3494854.pdf
This article is distributed under the terms of an Attribution–Noncommercial– Share Alike–No Mirror Sites license for the first six months after the publication date (see  http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"After six months it is available under a Creative Commons  License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at  http://creativecommons.org/licenses/by-nc-sa/3.0/).THE JOURNAL OF CELL BIOLOGY",Non-OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"http://dx.doi.org/10.1146/annurev   .genom.7.080505.11561 0 Barr, M.M., and P.W.",OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"http://dx.doi.org/10.1016/   S0960-9822(01)00423- 7 Benson, M.D., Q.J.",OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"http://dx.doi.org/   10.1073/pnas.060670210 4 Blacque, O.E., E.A.",Non-OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"http://dx.doi   .org/10.1016/j.cub.2005.04.05 9 Cantagrel, V., J.L.",OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"http://dx.doi.org/   10.1016/j.ajhg.2008.06.02 3 Caspary, T., C.E.",OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"http://dx.doi.org/10.1016/j.devcel.2007.03.00 4 Castillo-Lluva, S., M.H.",OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"http://dx.doi   .org/10.1083/jcb.20090813 3 Chakarova, C.F., H. Khanna, A.Z.",Non-OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"http://dx.doi.org/10.1093/hmg/   ddq54 3 Cheng, T.S., L.K.",OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"http://dx.doi.org/10.1016/j   .lfs.2005.06.02 1 Dadke, S., S. Cotteret, S.C. Yip, Z.M.",OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"http://dx.doi   .org/10.1038/nsmb.184 2 Doherty, D. 2009.",Non-OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
"http://dx.doi.org/10.1242/dev.03635 0 Eggenschwiler, J.T., and K.V.",Non-OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
http://dx.doi.org/10.1146/   annurev.cellbio.23.090506.12324 9serum to induce cilia.,Non-OADS,/arxiv_data1/oa_pdf/74/cb/JCB_201203150.PMC3494855.pdf
